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Abstract 
 
The rare diseases atypical haemolytic uraemic syndrome (aHUS) and C3 
glomerulopathy (C3G) are associated with dysregulation of complement activation. It is 
unclear which genes most frequently predispose to aHUS or C3G. Accordingly, a six-
centre analysis of 610 rare genetic variants in 13 mostly complement genes from >3500 
patients with aHUS and C3G was performed. A new interactive Database of Complement 
Gene Variants was developed to extract allele frequencies for these 13 genes using the 
Exome Aggregation Consortium server as the reference genome. For aHUS, significantly 
more protein-altering rare variation was found in the five genes CFH, CFI, CD46, C3 and 
DGKE than in ExAC. For C3G, an association was only found for rare variants in C3 and 
the N-terminal C3b-binding or C-terminal non-surface-associated regions of factor H 
(FH). FH is the major regulator of C3b and its Tyr402His polymorphism is an age-related 
macular degeneration risk-factor. To better understand FH complement binding, the 
solution structures of both allotypes were studied. Starting from known FH short 
complement regulator domains and glycan structures, small angle X-ray scattering data 
were fitted using Monte Carlo methods to determine atomistic structures for monomeric 
FH. The analysis of 29,715 physically realistic but randomised FH conformations resulted 
in 100 similar best-fit FH structures for each allotype. Two distinct molecular structures 
resulted; an extended N-terminal domain arrangement with a folded-back C-terminus, or 
an extended C-terminus and folded-back N-terminus. To clarify FH functional roles in 
host protection, crystal structures for the FH complexes with C3b and C3dg revealed that 
the extended N-terminal conformation accounted for C3b fluid phase regulation, the 
extended C-terminal conformation accounted for C3d binding, and both conformations 
accounted for bivalent FH binding to the host cell-surface. Finally, statistical analyses 
indicated that the structural location of rare variants in complement may predict the 
occurrences of aHUS or C3G.
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Impact Statement 
 
The analyses and insights presented in this PhD thesis could be put to a number 
of beneficial uses, both outside and inside of the academic environment. The main focus 
of this thesis is on the molecular mechanisms of the complement inflammatory pathway, 
which provides rapid protection from pathogens, and its associations with genetic disease. 
Thus, disrupted complement regulation is associated with age-related macular 
degeneration (AMD), the most common cause of blindness in the West, and atypical 
haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy (C3G), two rare and fatal 
diseases. The first major analysis in this thesis confirmed the association of rare variants 
in the five complement and related genes CFH, CFI, C3, CD46 and DGKE with aHUS, 
and in CFH and C3 with C3G. The reference datasets comprised unselected individuals 
from large-scale sequencing, such as the Exome Aggregation Consortium. Overall, my 
results explain how genetic changes in the same inflammatory pathway and/or proteins 
result in the different pathologies. This work included the development of the new 
interactive Database of Complement Gene Variants, which presents and analyses genetic 
variant data for complement diseases. By this, the database facilitates the assessment of 
the impacts of rare complement variants identified in patients thus being an important 
resource. For the clinician, this informs the diagnoses, treatment and outcome for patients. 
It also facilitates research-based collaboration between researchers and clinicians at the 
international level. This work was published in the Journal of Immunology (2018). In 
addition, for both the academic and the commercial pharmaceutical sectors, the rare 
variant analyses have potential for the development of new therapies for aHUS and C3G 
which will greatly benefit patients. The second major research finding in this thesis was 
that the complement regulator factor H (FH) exists in two distinct structural 
conformations that account for its functions. Thus, the extended N-terminal conformation 
accounted for C3b fluid phase regulation, an extended C-terminal conformation 
accounted for C3d binding, and both conformations accounted for bivalent FH binding to 
the target cell surface. This provided new insights into the molecular mechanisms of the 
complement proteins in inflammation, which may appear in education resources such as 
textbooks on human inflammation. Within academia, this research finding has been 
reviewed and returned for acceptance at the Journal of Biological Chemistry. In addition, 
this research provides new methodology for analysing the structural ensembles of 
flexible, glycosylated proteins and how these may be perturbed in human disease.
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Chapter One 
 
The complement system
2 
 
This introduction chapter describes the human complement system of immunity 
and its involvement in the two rare renal diseases atypical haemolytic syndrome 
and C3 glomerulopathy, and the common eye disease age-related macular 
degeneration. More specifically, this involves the genes, proteins and molecular 
interactions of the complement alternative pathway. This theory is required for the 
analyses presented in my three results Chapters 4, 5 and 6 on genetic variants and 
molecular structures of the complement proteins and their roles in these diseases. 
 
 
1.1 The immune system 
 
The immune system protects the host from disease using many different 
biochemical components and processes. The current germ theory of disease, which was 
first proposed by Pasteur in 1861 and later confirmed in 1876 by Koch (Smith, 2012), 
attributes the onset of infectious disease to pathogens, also known as ‘germs’. Pathogens 
can take the form of either viruses, bacteria, parasitic worms, fungi, algae, prions or 
compromised host cells and their fragments. In order to remove such disease-causing 
pathogens, the immune system must first distinguish them from host cells. The immune 
system is categorised into either the innate or adaptive systems. For the innate system, a 
limited number of germline-encoded pattern-recognition receptors recognise conserved 
patterns on pathogens (Akira et al., 2006), which rapidly triggers an inflammatory 
response. In contrast, the adaptive system is highly specific to a particular pathogen. This 
specificity of the adaptive system is due to a process known as somatic hypermutation 
which creates an immunological memory that ultimately leads to an enhanced immune 
response (Chaplin, 2010). This is exploited in vaccinations against disease. For most 
organisms, an innate system is sufficient for survival. Only vertebrates appear to have 
evolved an adaptive system (Beutler, 2004). The innate system thus evolved long before 
the adaptive system. One of the oldest host defence systems with similar functions to the 
innate system is the activation of nuclear factor kappa-light-chain-enhancer of activated 
B-cells (NFκB) transcription factor by the Toll pathway. This system is found in the fruit 
fly and possibly plants. In the Toll pathway, host cells with pattern-recognition receptors 
known as Toll-like receptors bind to pathogens and activate NFκB, which leads to the 
regulation of the immune response. In addition, phagocytic cell types of the innate system 
may have originated from unicellular amoeba-like early eukaryotes (Janeway, 2001). In 
contrast, adaptive immunity is believed to have arisen in the first jawed vertebrates 
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(gnathostomes), however jawless fish were recently discovered to have similar lymphoid 
cell-based systems of adaptive immunity (Flajnik & Kasahara, 2010).  
 
The first major line of defence is epithelial skin cells which form a physical barrier 
against non-host material. If pathogens enter the host, the innate system mediates an 
inflammatory response. By this, both humoral (fluid) and cell-based components identify 
and destroy the invading pathogen. For the cell-based components, this involves white 
blood cells or leukocytes such as mast cells, natural killer cells and basophils, and 
phagocytes such as macrophages, neutrophils and dendritic cells. For pathogen 
identification, some of these cells express Toll-like receptors which bind to pathogen-
associated molecular patterns and damage-associated molecular patterns on pathogens 
and compromised host cells, respectively. Once identified, the innate cells eliminate 
pathogens via a diverse set of processes such as digestion by macrophages and the release 
of toxic substances and proteins by basophils and neutrophils.  
 
In addition to innate cells, pathogens can be destroyed via the activation of the 
adaptive system by antigen-presenting cells such as macrophages and dendritic cells. 
Thus, antigen-presenting cells digest the pathogens and present their fragments as 
antigens to adaptive system proteins. For the adaptive system, the lymphocytes known as 
B-cells and T-cells are essential for mediating each of the humoral and cell-mediated 
immune responses, respectively. For antigen specificity, both B- and T-cells possess 
genetically rearranged and highly diverse antigen receptors. These receptors are sensitive 
enough to be able to distinguish between two antigens that differ by only a single amino 
acid (Alberts, 2002). For B-cell activation, the antigens on antigen-presenting cells are 
bound. Once activated, B cells differentiate into either plasma or memory cells. For 
differentiated plasma B-cells, secreted antibody immunoglobulins (Igs) bind to specific 
pathogens that correspond to the presented antigens. Antibodies inactivate bound 
pathogens by neutralisation, agglutination, precipitation and complement activation. For 
memory B-cells, the antigen is biochemically remembered, which speeds up the immune 
response for subsequent exposures. For T-cell activation, the detection of an antigen 
presented on a host cell causes a cell-mediated reaction. For example, host cells infected 
with a virus are eliminated by T-cells before the virus can replicate. In cell-mediated 
immunity, T-cell activation causes the development of cytotoxic T-cells and engagement 
of accessory cells such as macrophages. T-cells are also involved in antibody based 
immunity. Thus, the activation of T cells increases both the antibody response via T-
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helper cells and the production of antibody by B-cells (Pross, 2007). For lymphocyte 
development in mammals, T-cells develop in the thymus whereas B-cells mature in the 
bone marrow. However, for B-cells, their name originates from the Bursa of Fabricius 
organ, which is the location of B-cell maturation in birds (Katze et al., 2016).  
 
1.2 The complement system 
 
The complement system is an important effector component of both the innate 
and adaptive immune systems (Chaplin, 2010). Complement consists of both soluble and 
membrane bound proteins and operates in plasma, on tissues, on cell surfaces and within 
cells (Merle et al., 2015b). Liver hepatocytes are the major source of plasma complement 
components, with some exceptions. However, the penetration of complement components 
into tissues can be limited by their large sizes. Thus, for compensation, complement 
components are also produced locally (Morgan & Gasque, 1997). When the complement 
system is activated, a proteolytic cascade leads to the opsonisation and clearance of 
pathogens and immune complexes, as well as B- and T-cell modulation. Complement is 
considered to be evolutionarily ancient. Thus, genomic analyses have identified a 
primitive version that consists of two complement genes corresponding to ancient C3 and 
complement factor B (CFB) which emerged in the common ancestor of Cnidaria and 
Bilateralia more than 1,300 million years ago (Nonaka & Kimura, 2006). A complement 
C3-like protein may have been present in organisms that emerged prior to sea sponges 
(Elvington et al., 2016). Complement was first discovered in 1891 as a heat-labile serum 
factor that was able to kill bacteria (Buchner, 1891). This bactericidal activity was also 
found to be dependent on a heat-stable factor which is now known as antibody (Morgan, 
1990). Later, complement was described as a heat-labile antimicrobial component which 
combined with antibody to form an enzyme that killed pathogens, as part of a theory by 
Paul Ehrlich. Next, in 1907, Ferrata and Brand separated complement into two fractions 
which are now known as the complement proteins C1 and C2. This demonstrated that 
complement was not a single substance. After this, work by Ueno, Mayer and colleagues 
showed that the sequence of the classical pathway could be unravelled in reconstitution 
assays by adding partially purified complement components to antibody-sensitised sheep 
erythrocytes. Next, in the 1960s, for the classical complement pathway, Nilsson, Muller-
Eberhard and colleagues isolated and characterised the components and discovered their 
sequence. With the development of ion-exchange chromatography and 
ultracentrifugation methods, this work led to the discovery of eleven distinct plasma 
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proteins essential for complement activation (Law & Reid, 1995; Nelson et al., 1966). In 
1968, in order to reflect the order of activation, the terminology of these complement 
components was adjusted. A second, antibody-independent activation pathway, now 
known as the alternative pathway (AP), was proposed in the 1950s by Pillemer but 
accepted in 1970 (Law & Reid, 1995; Nesargikar et al., 2012). A third complement 
activation pathway, known as the lectin pathway, was discovered in 1987 by Ikeda and 
colleagues. For the lectin pathway, activator proteins such as mannose-binding lectin 
(MBL) were identified firstly in rabbit liver and serum followed by their role in child 
immunodeficiencies (Nesargikar et al., 2012). Complement is now known to be activated 
via three distinct pathways, which merge at the activation of the complement protein C3 
(Figure 1.1). The classical pathway is activated when an antibody-antigen complex is 
formed. The lectin pathway is activated via complex carbohydrates such as bacterial 
membrane polysaccharides. In contrast, the AP is activated not by pathogens but by a 
wide variety of compounds and surfaces such as small nucleophiles, water molecules, 
serum proteases and perturbations. All of the protein complement components are 
glycoproteins. In order to protect host cells from complement attack, each of the three 
complement pathways are regulated.  
 
1.2.1 Activation of C3 
 
In order for the complement system to destroy invading pathogens, complement 
C3 is activated on their surfaces. This key step is common to the three complement 
pathways (Figure 1.1). C3 is a large protein with a molecular weight of 185 kDa that is 
present in plasma at a concentration of approximately 1 mg/ml (5.3 µM) (Law & Reid, 
1995). C3 is encoded by the C3 gene on chromosome 19 in the human genome. In the 
synthesis of C3, four Arginine residues are removed which splits the C3 polypeptide into 
a 110 kDa α-chain and a 75 kDa β-chain (Law & Reid, 1995). In mature C3, the α- and 
β-chains are linked by disulphide bonds and noncovalent forces (Bokisch et al., 1975). 
For C3, in order to transform this from an inert circulating protein with an internal 
thioester, accessible only to small nucleophiles, into an active form capable of binding to 
targets, a major conformational change is required (Law & Dodds, 1997). Thus, for the 
activation of C3, a single peptide bond in the α-chain is cleaved, which dissociates the 
first 77 amino acids, known as the anaphylatoxin C3a fragment, from the C3b fragment. 
In C3b, the previously buried thioester is exposed, which is extremely reactive with 
nucleophiles such as hydroxyl and amino groups found on surfaces (Figure 1.2). 
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Figure 1.1 Overview of the complement system.  The proteolytic activation of C3, 
which generates active C3b, is common to each of the classical, lectin and alternative 
pathways (AP). On activator surfaces, C3b binds to the C3 convertase to form a C5 
convertase. This leads to formation of the membrane attack complex (MAC). The AP 
convertases C3bBb and C3b2Bb are stabilised by properdin (P). Host surfaces are 
protected from complement attack by factor I (FI), which inactivates C3b to form iC3b 
in the presence of a cofactor. For FI, cofactor activity is carried out by each of C4 binding 
protein (C4bp), complement receptor 1 (CR1), decay-accelerating factor (DAF), factor H 
(FH) and membrane cofactor protein (MCP). In the fluid phase, FI regulates C3b and C4b 
by using FH/C4bp and C4bp as cofactors, respectively. For both C4bp and FH, decay-
acceleration activities regulate the C3 and C5 convertases of the classical and the AP, 
respectively. The AP serves as an amplification loop for the complement system thus 
C3b. 
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Figure 1.2 The activation of C3. In each of the three complement pathways, C3 (left) is 
proteolytically activated to C3b by a C3 convertase. The anaphylatoxin C3a fragment is 
also generated. In C3b (centre), a highly reactive thioester in a Cys residue is exposed 
which binds to nucleophiles such as water and hydroxyl and amine (NH) groups on 
surfaces. Thus C3b either reacts with water to form fluid phase C3b (top right) or 
covalently binds to cell surfaces via either an ester or an amide (NH) bond (bottom right).  
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However, for the thioester in plasma, its hydrolysis of C3 by water molecules into 
C3(H2O) readily occurs due to the high concentration of water at 55 M (Law & Reid, 
1995). Once C3 is cleaved to form C3b, the thioester reacts within ∼60 μs, in which 
C3b can diffuse up to 30 nm before it becomes covalently bound to a target (Sim et al., 
1981). Thus, before its hydrolysis by water, the reaction of C3b with target surfaces via 
the thioester is spatially restricted to local surfaces. For the proteolytic activation of C3 
to C3b, catalysis by the C3 convertase serine protease is required. For each of the classical 
and lectin pathways, the C3 convertase complex is C4b2a. In contrast, for the AP, the C3 
convertase complex is either C3bBb or C3(H2O)Bb. In addition, instead of using its 
thioester, C3b can bind to the cell surface by interacting with surface molecules that serve 
as platforms for C3b recruitment (Merle et al., 2015a). 
 
1.2.2 Opsonisation by C3 
 
By opsonising target surfaces with C3b, complement triggers the destruction of 
the pathogen in three major ways. Firstly, it marks the target for destruction. For example, 
C3b molecules on activator surfaces are bound by phagocytes, including antigen-
presenting cells, via their surface-expressed complement receptor 1 (CR1). The 
phagocytes either engulf the target or enhance its antigenic presentation to T cells. 
Secondly, for viral pathogens, C3b neutralises the virus by blocking their receptor-
mediated entry to host cells. Thirdly, for immune complexes, C3b eases their clearance 
from the circulation by solubilisation. Thus, for C3b-coated immune complexes, 
erythrocytes bind to C3b via CR1 and transport them to the liver and spleen for phagocytic 
disposal (Mak et al., 2014). In addition to surface binding, C3b activates the terminal 
pathway of complement by binding to a C3 convertase. This generates a C5 convertase 
in the form of either a C4bC3b2a or C3b2Bb complex. By this, C5 convertases cleave the 
complement protein C5 which generates activated C5b and the anaphylatoxin fragment 
C5a. For C5b, reaction with the complement proteins C6, C7, C8 and C9 generates the 
membrane-attack complex (MAC) C5b6789n. For the lysis of pathogens, the MAC forms 
pores in their membrane which disrupts the osmotic balance and leads to cell death. For 
the released anaphylatoxin polypeptides, such as C3a, C4a and C5a, their pro-
inflammatory functions include the activation of granulocytes, mast cells and 
macrophages (Klos et al., 2009). They also promote muscle contraction and increasing 
vascular permeability. 
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1.3 The classical pathway 
 
The activation of the classical pathway involves the recognition of IgG- and IgM-
containing immune complexes. The classical pathway is also activated independently of 
antibodies by direct interaction with C-reactive protein, serum amyloid P and apoptotic 
cells (Nauta et al., 2002). For the activation of C3 by the classical pathway, each of the 
pro-enzymes C1, C2 and C4 are activated. For C1, its multimeric C1qr2s2 complex is 
formed of a 462 kDa six-domain C1q molecule and two of each of 83 kDa C1r and C1s 
molecules. In C1, the C1q subcomponent is responsible for both recognition and binding 
whereas both C1r and C1s are pro-enzyme serine proteases. For the activation of C1, C1q 
interacts with either immune complexes, Ig activators such as IgG- or IgM-containing 
aggregates or polyanions such as bacterial liposaccharides, deoxyribonucleic acid (DNA) 
and ribonucleic acid (RNA). Upon C1 activation, both of the C1r and C1s pro-enzymes 
auto-activate. For the activation of C4, auto-activated C1s catalyses the proteolysis of the 
C4 α-chain. This generates the anaphylatoxin C4a and the active C4b fragment. For the 
activation of C2, C4b binds to the C2b domain of C2 in the presence of C1s which splits 
C2 into the fragments C2a and C2b. Next, C4b binds to C2a which forms the classical 
pathway C3 convertase C4b2a complex capable of activating C3. For C4b, in addition to 
forming part of the classical pathway C3 convertase, its exposed thioester allows it to 
bind to cell surfaces by either amide or ester bonds (Campbell et al., 1980; Law et al., 
1980) (Figure 1.2). This directs complement activation, via the formation of C4b2a 
complexes, to the target-cell surface. In addition, the opsonisation of target cells by C4b 
triggers phagocytic immune clearance via CR1 on phagocytes (Law & Reid, 1995). 
 
1.4 The lectin pathway 
 
 The lectin pathway is activated by the detection of pattern recognition molecules 
such as complex carbohydrates on the cellular surfaces of bacteria and viruses by serum 
MBL. MBL consists of both carbohydrate binding modules and C1q-like triple-helical 
collagen-like regions. In plasma, MBL is complexed with MBL-associated serine 
protease (MASP). For MASP, it was recently shown that the MASP-1 form activates the 
MASP-2 form, and thus suggested that both MASP-1 and MASP-2 are essential for 
complement activation (Garred et al., 2016). The classical pathway C1qr2s2 and lectin 
pathway MBL-MASP complexes are structurally and functionally similar to each other. 
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Upon activation, MASP cleaves C4 and C2, which leads to the generation of the C3 and 
C5 convertases C4b2a and C4b3b2a. 
 
1.5 The alternative pathway 
 
In contrast to the classical and lectin pathways, the AP is spontaneously activated 
at a low rate by the water-mediated hydrolysis of C3. In this way, the AP provides an 
important mechanism of keeping complement alert which allows the constant probing 
of cell surfaces. This is termed “tick-over” (Bexborn et al., 2008). Water molecules are 
both small and nucleophilic enough to access and subsequently react with the buried 
thioester in C3. The hydrolysed C3(H2O) (also known as C3i or C3u) complex is 
generated at a rate of 0.2-0.4% per hour (Pangburn & Muller-Eberhard, 1983), without 
the loss of the C3a fragment. C3(H2O) is also short-lived (Law & Reid, 1995). The serine 
proteases factor B (FB) and factor D (FD) and the protein properdin are all activators of 
the AP. They are not part of the classical and lectin pathways. In the AP, FB circulates as 
a zymogen until it reacts with C3(H2O) and forms a C3(H2O)B complex. Cleavage by FD 
then activates the FB zymogen which yields the active but unstable C3 convertase 
C3(H2O)Bb and the fragment Ba. The active Bb fragment (residues 235-739) is also a 
serine protease that consists of both a von Willebrand Factor type A domain and a serine 
protease domain. The Ba fragment (residues 1-234) (Fishelson et al., 1984) consists of 
three short complement regulator (SCR) domains and a linker. For FB to bind C3b or 
C3(H2O), each of the Ba fragment, the Bb Mg
2+-dependent metal ion-dependent adhesion 
site motif and Mg2+ ions are required. The C3(H2O)Bb convertase can activate a few 
molecules of C3 to C3b before the complex rapidly decays (Lindorfer et al., 2010). In 
turn, this can initiate the formation of the C3bBb convertase (Figure 1.1). In addition to 
its hydrolysis by water, C3 in the AP is also activated slowly and continuously to C3b by 
either serum proteases or non-specific perturbations. These lead to conformational 
changes in C3 that expose the thioester. As with C3(H2O), active C3b reacts with FB in 
the presence of Mg2+ ions to form C3bB, and FD reacts with C3bB to form the AP C3 
convertase C3bBb and the Ba fragment. Both of the C3 convertases C3(H2O)Bb and 
C3bBb have a short half-life of 90 s (Fishelson et al., 1984), and once Bb dissociates from 
C3b, it cannot re-associate (Pangburn & Muller-Eberhard, 1986). However, for the C3 
and C5 convertases of the AP, their binding to properdin prevents both spontaneous 
dissociation and regulator-induced decay. Thus, properdin increases the stability of the 
convertases ten-fold on target surfaces (Fearon & Austen, 1975) and also inhibits its 
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regulation (Medicus et al., 1976). Properdin is the only known naturally occurring 
positive regulator of complement. Its importance in host defence is shown by that 
approximately 50% of properdin-deficient individuals experience severe bacterial 
infections that have a fatality rate of almost 75% (Schwaeble & Reid, 1999). If a target 
surface is in close proximity, C3b generated by either a C3(H2O)Bb or C3bBb convertase 
can covalently bind to the surface and initiate AP activation. However, the probability of 
this occurring is very low because C3(H2O) in the fluid phase is short-lived and both 
C3(H2O) and C3b are regulated. These restrict both the production of C3 convertase and 
the deposition of C3b on host cells (Law & Reid, 1995). If a C3b molecule is deposited 
on the target surface, an “explosive” amplification loop of C3 activation occurs. Thus, on 
the target surface, C3b can react with FB in the presence of FD and properdin to generate 
a C3bBb C3 convertase which in turn activates more C3 to C3b. In the absence of any 
control, this leads to a positive feedback mechanism that depletes plasma C3 and leads to 
attack of the target. Interestingly, when compared to C3(H2O)Bb, the convertase activity 
of C3bBb approximately doubled but both the stability and the resistance to inactivation 
by regulation decreased (Bexborn et al., 2008). In the AP, for C3(H2O), its noncovalent 
binding to complement receptor type 2 promotes the formation of a membrane-associated 
C3 convertase C3(H2O)Bb on itself. This focusses complement AP activation on 
complement receptor type 2-expressing cells, such as immune and epithelial cells, which 
is not completely understood in physiological terms (Schwendinger et al., 1997). 
 
1.6 Regulation of complement 
 
The complement system is regulated in order to prevent unwanted complement 
activation and inflammation on host cell surfaces. Thus, a fine balance between activating 
and regulating components ensures that complement activation is firstly restricted to 
pathogenic surfaces only and then turned off once the pathogen has been destroyed. For 
the regulation of the three activated complement pathways, C3b in both the fluid phase 
and at host cellular surfaces is subject to irreversible proteolysis by the serine protease 
factor I (FI) and a cofactor. This stops the interaction of C3b with effector immune 
components that can lead to target destruction. For C3b, FI splits the α-chain of C3b at 
two sites on either side of the thioester (Figure 1.3). This yields a ~174 kDa inactive C3b 
(iC3b) and a ~2 kDa C3f fragment. iC3b consists of two polypeptides which are linked 
by two disulphide bonds and unable to bind FB (Lambris et al., 1996) in order to form an 
AP C3 convertase (Pangburn et al., 1977). Despite being a direct consequence of C3b 
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Figure 1.3 The inactivation of C3b. Surface-bound C3b on host cells is cleaved by factor 
I (FI) in the presence of one of the cofactors complement receptor 1 (CR1), decay-
accelerating factor (DAF), factor H (FH) or (MCP). The first cleavage of C3b, at two 
places on the α chain (Arg1303-Ser1304 and Arg1320-Ser1321 (Ross et al., 1983)), 
generates inactive C3b (iC3b) and C3f (residues 1304-1320). This disrupts the factor B 
binding site required for C3 convertase formation. iC3b consists of an intact β chain and 
an α chain which is in two fragments of 60 kDa and 40 kDa. Inter-chain disulphide bonds 
hold the α and β chains together. Further cleavage of the 60 kDa fragment of iC3b (at 
Arg954-Glu955) by either serum proteases or FI in association with CR1 generates C3c 
(23 kDa) and C3dg (37 kDa). C3c contains three chains: an intact β chain and two α chain-
derived fragments (of 23 kDa and 40 kDa). Further cleavage of C3dg by serum proteases 
generates C3d (32 kDa) and C3g (5 kDa). The C3d fragment harbours the thioester thus 
remains attached the surface. Adapted from (Law & Reid, 1995).
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inactivation, C3f is a 3 kDa weak spasmogen (i.e. smooth muscle contractor) with similar 
functions to the C3a anaphylatoxin (Ganu et al., 1989). Next, iC3b undergoes proteolysis 
by FI and serum proteases which generates the ~33 kDa C3dg and ~142 kDa C3c 
fragments. C3dg undergoes further proteolysis by serum proteases which generates C3d 
and C3g. At the host cell surface, C3d remains attached. A number of high-affinity 
complement receptors bind C3 fragments and generate either a pro-inflammatory 
response or tolerogenic suppression (Merle et al., 2015a), depending on the type of C3 
fragment present. For example, the membrane-bound inactivation fragments iC3b, C3dg 
and C3d are ligands for complement receptor type 2 expressed on B cells, epithelial cells, 
follicular dendritic cells, thymocytes and some T cells. The interaction between these C3 
fragments and complement receptor type 2 links the innate and the adaptive immune 
systems together and enhances the production of B cell-mediated antibodies (Holers, 
2014). iC3b is also bound by complement receptors 3 and 4 expressed on macrophages, 
phagocytes, leukocytes and follicular dendritic cells. In addition, the C3 fragments are 
bound by an Ig superfamily complement receptor expressed on liver-resident 
macrophages which leads to the critical clearance of complement-opsonised fragments 
(Helmy et al., 2006). 
 
FI and its cofactors are crucial for the regulation of the three activated complement 
pathways. FI is encoded by the CFI gene which has a genomic location of 4q25 (Shiang 
et al., 1989). CFI consists of 13 exons (Figure 1.4) and a 35 kb intron between exons 1 
and 2 (Vyse et al., 1994). For CFI, instead of a TATA box promoter, an initiator element 
TCAGCCA is responsible for promoter activity. Both the initiator element TCAGCCA 
and the twice-occurring CTGGAT motif play an important role in its constitutive 
expression. After expression by hepatocytes in the liver and other cell types, FI is secreted 
as a multi-domain 88 kDa protein which circulates in human blood at 35 µg/mL (0.39 
µM) (Nilsson et al., 2011). FI consists of a heavy 50 kDa and a light 38 kDa chain 
(Goldberger et al., 1984) linked by a disulphide bridge (Fearon, 1977). The heavy chain 
consists of a FI membrane attack complex domain, a scavenger receptor Cys-rich or CD5-
like domain, low-density lipoprotein receptor 1 and 2 domains (LDLr1 and 2) and a small 
region of unknown homology which is sometimes called the D-region. A signal peptide 
of 18 residues is cleaved after secretion. For the light chain of FI, the serine protease 
domain (Chamberlain et al., 1998) harbours the catalytic triad formed by the residues 
His362, Asp411 and Ser507 in the active site (Figure 1.4).  
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Figure 1.4 Structure of the complement factor I gene and protein. (A) For the 
complement factor I (CFI) gene, the arrangement of the 13 exons is shown. A very large 
intron of 35 kB is situated between exons 1 and 2 (not shown). (B) For the factor I (FI) 
protein, the five domains are schematically represented. The heavy chain consists of a FI 
membrane attack complex domain (FIMAC), a CD5-like or scavenger receptor Cys-rich 
domain and the low-density lipoprotein receptor 1 and 2 domains (LDLr1 and 2). The 
light chain consists of the serine protease domain which includes the active site formed 
by the catalytic triad. The arrows represent the locations of the six glycans on FI. (C) For 
the FI protein, the structural model is shown in cartoon-style and colour-coded by domain 
(Protein Data Bank code: 2XRC). The catalytic triad is shown as red spheres. Adapted 
from (Nilsson et al., 2011)
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The cofactor used by FI depends on both the complement pathway and the local 
environment. For the FI-mediated proteolysis of C3b on host cell surfaces, the cofactors 
are membrane-bound CR1 (CR1), factor H (FH; CFH) and membrane cofactor protein 
(MCP; CD46). The CR1, CFH and CD46 genes are all located within a cluster of 60 genes 
called the regulators of complement activation (RCA). The RCA cluster is located at the 
genomic location 1q32 and 15 of its 60 genes are complement-related. In the RCA cluster, 
CR1 and CD46 are in one group and CFH is in the other group, arranged in tandem 
(Rodriguez de Cordoba & Goicoechea de Jorge, 2008). The proteins encoded by RCA 
genes are not only related genetically but also structurally and functionally. Thus, the 
RCA family of proteins possess both SCR domains, which are ~60 residues in length and 
include four invariant Cys residues, and the ability to bind C3b or C4b. Overall, RCA 
proteins have major roles in the protection of host cells from complement by regulating 
complement activation, processing immune complexes, microbes and other foreign 
materials, and activating immune cells. This includes the binding, transport, and clearance 
of foreign material, endocytosis and signal transduction (Hourcade et al., 1989). 
 
For the classical and the lectin pathways, the FI-mediated proteolysis of C4b relies 
upon cofactor activity from either C4 binding protein (C4bp; C4BP) (Fujita & 
Nussenzweig, 1979), CR1 or MCP. The C4BP gene is located within the first group of 
the RCA cluster (Rodriguez de Cordoba & Goicoechea de Jorge, 2008). The major 
isoform of C4bp consists of seven identical α-chains and one β-chain, which fold as eight 
and three SCR domains, respectively. C4bp mostly circulates with the anti-coagulant 
protein S which enables it to interact with negatively charged phospholipid membranes 
and dead cells (Webb et al., 2002). However, C4bp can also bind and protect host cell 
surfaces via heparan sulphate (HS) and its analogue heparin. C4bp binds to both C4b and 
heparin via its SCR-1/3 domains in the α-chain (Blom et al., 2001; Blom et al., 1999; 
Hessing et al., 1990). For C4bp SCR-1/3, heparin binding inhibited the binding of Ig-like 
surface proteins of the pathogenic bacteria Leptospira (Breda et al., 2015). In addition, 
C4bp bound to tumour cell surfaces via heparin was functionally active for FI-mediated 
cofactor activity (Holmberg et al., 2001). As for C3b, the α-chain of C4b is cleaved by FI 
at two sites on either side of the thioester, in the presence of a cofactor. This yields the 
C4c and C4d fragments. Currently, the functions of C4c and C4d are unknown and do not 
appear to include ligand binding. In addition to FI-mediated cofactor activity, both C4bp 
and membrane-bound CR1 can accelerate the decay of the classical C3 and C5 
convertases (Ermert et al., 2013; Fujita & Nussenzweig, 1979). This is termed decay-
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accelerating activity (DAA). Membrane-bound decay-accelerating factor (DAF) (Medof 
et al., 1984) also shows DAA for the classical C3 and C5 convertases. Thus, C4bp, CR1, 
and DAF bind to C4b and either block the formation of C4b2a and C4b3b2a or accelerate 
the dissociation of C2a from C4b (Law & Reid, 1995). C4bp can also act as a co-factor 
for the FI-mediated cleavage of fluid phase C3b, but cannot inhibit the AP C3 convertase 
(Seya et al., 1985) or efficiently regulate cell-bound C3b unless at a very high 
concentration (Blom et al., 2003; Fujita & Nussenzweig, 1979). Thus, for AP activity, 
C4bp has some control but cannot replace that of the AP regulator FH (Blom et al., 2004).  
 
CR1 is a ~250 kDa membrane protein (Park et al., 2014) which regulates all three 
of the complement pathways. CR1 is composed of 30 SCR domains, a transmembrane 
and an intracytoplasmic domain. In addition to FI-mediated co-factor activity, CR1 can 
bind to either C3b or C4b thereby accelerating the dissociation of both the C3 and C5 
convertases (Java et al., 2015). For CR1 on host immune cell surfaces, binding to C3b or 
C4b on opsonised pathogenic activator surfaces also triggers downstream immune 
processes. In contrast, for CR1 on host epithelial cell surfaces, binding to C3b or C4b 
locally deposited on the same surface allows the FI-mediated proteolysis of C3b for 
protection from complement attack. Indeed, for CR1 on host immune complexes, 
attachment to C3b can also degrade C3b to iC3b (Medof et al., 1982). On CR1, SCR-1/3 
binds mainly C4b and has DAA, while SCR-8/10 and SCR-15/17 bind both C3b and C4b 
and have FI cofactor activity (Smith et al., 2002).  
 
MCP is a membrane-associated protein which is encoded by the CD46 gene. 
CD46 has a genomic location of 1q32.2 and is part of the RCA cluster. CD46 has 14 
exons and is alternatively spliced to give rise to four major transcripts for MCP. By this, 
the alternatively spliced regions of CD46 correspond to three exons which encode the O-
glycosylation region and other exons which encode the carboxyl terminal cytoplasmic 
tail. For most cell types, the expression ratio of the four proteins is very similar, including 
on peripheral blood cells (Liszewski & Atkinson, 2015). MCP is composed of four SCR 
domains, the variable O-glycosylation region, a Ser/Thr/Pro-rich region, a 
transmembrane hydrophobic domain, a cytoplasmic anchor domain and the variable 
cytoplasmic tail domain. For all three of the complement pathways, MCP possesses 
cofactor activity for the FI-mediated proteolysis of C3b or C4b, but not DAA for the C3 
or C5 convertases. 
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DAF is a ubiquitously expressed membrane-associated protein which is encoded 
by the CD55 gene also located within the RCA cluster. Structurally, DAF consists of four 
SCR domains and a serine and threonine-rich domain which is bound to the membrane 
via a glycosylphosphatidylinositol anchor (Pan et al., 2015). For all three of the 
complement pathways, DAF possesses DAA for both the C3 and C5 convertases, but not 
cofactor activity for the FI-mediated proteolysis of C3b or C4b. DAF also plays a role in 
T cell and macrophage activation (Heeger et al., 2005).  
 
Complement components other than C3b and C4b are also regulated. For the 
classical pathway, in order to prevent its activation in the absence of a C1 activator, C1 
inhibitor (C1-Inh) rapidly forms a covalent complex with each of C1r and C1s (Sim & 
Reboul, 1981). By this, C1r and C1s are removed from C1q, which stops the activation 
of C4 by C1. C1-Inh also inhibits the proteolytic activities of MASP in the lectin pathway 
(Matsushita et al., 2000). For both the classical and the lectin pathways, the activator C2 
is regulated at the cell membrane by C2 receptor inhibitor trispanning, which blocked C3 
convertase formation in vitro (Inal et al., 2005). For all three pathways, after activation 
of C3 and C5, the complement anaphylatoxins C3a and C5a generated can both be 
inhibited by serum carboxypeptidases. By this, carboxypeptidase cleaves the C-terminal 
Arg residue, which generates C3a and C5a desArg, respectively (Matthews et al., 2004). 
The formations of both C3a and C5a desArg show a rapid loss of peptide and receptor 
binding activity. This was importantly shown to downregulate inflammation in 
autoimmune arthritis (Song et al., 2011). All three of the complement pathways are also 
regulated by sushi domain-containing protein 4 which is mainly expressed in the brain. 
For the regulation of the terminal pathway, each of the proteins protectin, clusterin and 
vitronectin inhibit either the formation or the membrane insertion of the MAC (Meri et 
al., 1990). 
 
For the AP, in order to prevent host cell attack via its spontaneous activation, 
regulation is essential. Thus, FI and the cofactor FH regulate C3b in the fluid phase; and 
FI, membrane-bound FH and the three membrane proteins MCP, CR1 and DAF regulate 
C3b at the host-cell surface (Figure 1.1). FH is the main inhibitor of the AP (Rodriguez 
de Cordoba et al., 2004). FH regulates the AP in three ways. Firstly, FH is a cofactor for 
the FI-mediated degradation of either fluid phase or membrane-bound C3b, and 
C3b(H2O) in the fluid phase. Secondly, FH has DAA for both of the C3 convertases 
C3bBb and C3(H2O)Bb and also the C5 convertase C3b2Bb, which leads to their 
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dissociations. In DAA, FH rapidly dissociates the enzymatic Bb domain from the C3 
convertase. The DAA of FH is more effective for C3bBb than for C3(H2O)Bb. The 
affinity of FH for C3(H2O) is several fold weaker than for C3b (Heurich et al., 2011). 
Thirdly, FH blocks the formation of the C3bBb and C3(H2O)Bb convertases. FH provides 
targeted regulation of AP activation at host cell surfaces by recognising surface poly-
anions such as sialic acid and glycosaminoglycans. The cleavage of C3b by FI and the 
cofactor FH is inhibited by the complement activator properdin. In addition to AP 
regulation, FH can directly compete with C1q for binding to anionic phospholipids and 
act as a down-regulator of classical pathway activation (Tan et al., 2010). 
 
1.6.1 Complement factor H 
 
The complement regulator FH is encoded by the CFH gene. The genomic location 
of CFH is 1q31.3 which is within group 2 of the RCA cluster. Thus, CFH is located next 
to five homologous CFH-related (CFHR) genes that are situated in tandem (Figure 1.5). 
The CFHR1-5 genes are thought to have arisen from gene duplication events. Their 
homologous repeat regions are prone to non-allelic homologous recombination events 
which can lead to chromosomal deletions and hybrid gene products. CFH is expressed 
from exons 1-9 spliced with exons 11-23 to form a full-length 150 kDa protein consisting 
of 1,213 residues (Rodriguez de Cordoba et al., 2004). Full-length FH is composed of 20 
SCR domains which are joined by 19 flexible linker peptides of 3 to 8 residues 
(Okemefuna et al., 2009). CFH is alternatively spliced to form a truncated 42 kDa form 
which consists of 431 residues. This truncated form of FH is known as FH-like 1 protein 
(FHL-1) (Ripoche et al., 1988) and consists of the first seven SCR domains of FH plus 
four extra C terminal residues (Hellwage et al., 1997). The products of the CFHR1-5 
genes, the FH-related 1-5 (FHR1-5) proteins, are composed of different types and 
amounts of SCR domains. For example, FHR2 and one isoform of FHR4 are the shortest 
with four SCR domains, whereas FHR5 is the longest with nine SCR domains. FHR1-2 
and FHR5 circulate in the blood as dimers, via the two N-terminal SCR domains, whereas 
FHR3-4 do not (Skerka et al., 2013). 
 
 In plasma, FH occurs both in the fluid phase and attached to host cell surfaces. FH 
is present in the plasma at a concentration of 110-615 µg/mL (~ 3.2 µM). The N-terminal 
SCR-1/4 domains of FH are involved in both C3b and FI binding, which are essential for 
both its regulatory cofactor activity and DAA. FH attaches to host cells by binding to  
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Figure 1.5 Schematic representation of the complement factor H gene cluster and 
protein family. Figure legend overleaf.
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Figure 1.5 (continued) Schematic representation of the complement factor H gene 
cluster and protein family. (A) The human complement factor H (CFH) gene cluster on 
chromosome 1q32 includes the CFH and complement factor H-related (CFHR) 1-5 genes, 
in tandem. A1-C3 denote the homologous repeat regions which are involved in non-allelic 
homologous recombination events that can lead to large chromosomal rearrangements. 
For example, for B1 and B2, each of the solid and slashed black lines describes the CFH-
CFHR1 hybrid gene formation and the CFHR1-CFHR3 gene deletion, respectively. The 
CFH gene consists of 23 exons which are alternatively spliced to generate either short 
complement repeat (SCR)-1/20 factor H (FH) (exons 1-9 and 11-23) or a SCR-1/7 FH-
like (FHL-1) (exons 1-10) protein. (B) The FH protein family consists of FH, FHL-1 and 
five FHR proteins, which are all composed entirely of SCR domains. For FH and FHL-1 
but not the five FHRs, SCR-1/4 in region I are associated with regulatory functions. For 
all six proteins, the N-terminal SCRs in region II (green) are similar in sequence. FHR5 
SCR-3/7 have high sequence similarity to FH SCR-10/14 in region III. For FH and the 
five FHRs, the C-terminal SCRs in region IV (blue) share sequence homology and are 
associated with recognition functions. The FHRs in Group 1 have an N-terminal 
dimerization motif for the formation of homo-dimers whereas the FHRs in Group 2 do 
not. Adapted from (Rodriguez de Cordoba & Goicoechea de Jorge, 2008), (Jozsi & Zipfel, 
2008) and (Skerka et al., 2013). 
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sialic acid and glycosaminoglycans such as HS on host cell surfaces. FH cannot bind to 
sialic acid on host cell surfaces in the absence of C3b. On FH, these interactions are 
mediated by the C-terminal SCR-18/20 domains and the middle SCR-6/8 domains. The 
C-terminal SCR-18/20 domains of FH are also involved in C3b and C3d recognition 
(Rodriguez de Cordoba et al., 2004).  
 
In contrast, FHL-1 does not possess SCR-18/20 which are involved in host cell 
attachment and C3b and C3d recognition in FH. However, FHL-1 does possess SCR-1/4 
and part of SCR-6/8 which are involved in regulatory activities and binding to host cell 
surfaces via HS, respectively. In terms of function, FHL-1 shows both cofactor activity 
for the FI-mediated degradation of C3b (Kuhn et al., 1995) and DAA for the AP C3 
convertase (Kuhn & Zipfel, 1996). However, for DAA, FH is 100-fold more efficient 
than FHL-1. On the other hand, is has been suggested that the smaller size of FHL-1 may 
allow better tissue penetration which would affect local convertase regulation (Clark & 
Bishop, 2015). 
 
For each of the five FHRs, despite possessing fewer SCR domains than FH, the 
SCR domains showed high sequence similarity (36–100%) to some of those in FH (Figure 
1.5). For FH and the FHRs, the conservation of some of their SCR domain sequences 
suggests their related functions. For FHR1-5, the FH N-terminal SCR-1/4 domains are 
not conserved. Despite this, some of the FHRs still bind to C3b, but in a different way to 
FH. Thus, FHR1 cannot perform cofactor activity or C3 convertase (C3bBb) mediated 
DAA (Timmann et al., 1991), but can inhibit both the C5 convertase and formation of the 
terminal pathway complex (Heinen et al., 2009). In contrast FHR2 can inhibit both the 
AP amplification loop, by binding to the C3b in the C3 convertase via SCR-3/4, and the 
formation of the terminal pathway complex via SCR-1/2 (Eberhardt et al., 2011; 
Eberhardt et al., 2012). Recombinant FHR3 showed low cofactor activity for the FI-
mediated cleavage of C3b which is probably not its main function. Both FHR3 and FHR4 
may enhance the cofactor activity of FH (Hellwage et al., 1999). At high concentrations, 
FHR5 showed both cofactor activity and DAA. For all five FHRs, the N-terminal and C-
terminal SCR domains showed high sequence similarity (36-100%) to the FH SCR-6/8 
and SCR-18/20 domains, respectively. The FH SCR-6/8 and SCR-18/20 domains are 
involved in host cell recognition. Accordingly, the FHRs 1-5 can bind to C3b and C3d 
and discriminate between host and non-host surfaces (Skerka et al., 2013). For FHR5 
only, five additional middle SCR domains show high sequence similarity (36-100%) to 
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SCR-10/14 of FH. For FH, the SCR-10/14 domains are involved in C-reactive protein 
interactions. For FHR5, C-reactive protein mediates its recruitment to damaged host cells 
in order to inactivate C3b (Park & Wright, 1996). Overall, the functions of the FHRs 1-5 
encompass support for the cofactor activity of FH as well as additional complement 
regulatory activities such as inhibition of the terminal pathway. However, the FHRs can 
also compete with FH for C3b binding thus these will negatively impact FH function 
(Skerka et al., 2013). 
 
1.7 Diseases of complement  
 
Complement is a powerful surveillance system which rapidly detects and triggers 
the destruction of pathogens. However, complement can also be activated spontaneously 
by the AP, and activators themselves cannot discriminate between pathogens and the host. 
Thus, a fine balance between complement activators and regulators is essential to ensure 
that pathogens are killed whilst host cells are protected. If this balance is disrupted, 
complement will not be able to defend the host from either pathogens or itself, which can 
lead to either infectious or autoimmune diseases, respectively. Complement disease is 
classified as either primary (hereditary) or secondary (acquired) (Grumach & Kirschfink, 
2014).  
 
Secondary complement disease includes triggers of complement activation such 
as the massive influx of either pathogen-associated molecular patterns during sepsis or 
damage-associated molecular patterns during tissue injury. These amplify complement 
and can lead to complement activation on bystander host cells. This forms the basis of a 
condition known as systemic inflammatory response syndrome. Secondary complement 
disease may also be induced by biomaterials such as implants, accumulating cell debris 
from ageing and oxidative stress and autoantibodies. It may also involve protein 
aggregates that lead to the maintenance of complement-induced inflammatory states such 
as those described in models for Alzheimer disease, other neurological and 
neurodegenerative diseases and atherosclerosis (Ricklin et al., 2016). Secondary 
complement disease does not involve genetic variations in complement genes. 
 
Primary deficiencies of or other altered functionalities within the complement 
system can disturb the balance of activators and regulators. These underlying genetic 
abnormalities in complement are often revealed after an immune trigger and the 
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manifestation of severe clinical symptoms. Primary deficiencies of complement represent 
~1-6% of all primary immunodeficiencies (Ricklin et al., 2016). All complement 
deficiencies are rare, which is defined as affecting either less than one in 2000 (0.05%) 
or less than one in 1500 (~0.07%) people in the European Union and the United States, 
respectively (Boycott et al., 2013). Early complement component deficiencies are 
associated with autoimmune and immune complex-mediated diseases as well as recurrent 
bacterial infections. Thus, impaired clearance of immune complexes and apoptotic cells 
by the classical pathway may trigger the generation of autoantibodies. For example, 
deficiencies in the C1 complex, C2 and C4 of the classical pathway are all associated with 
systemic lupus erythematosus (Walport, 2002). Interestingly, for patients deficient in 
either C1, C4, or C2, a lower prevalence of infection was shown, when compared to C3 
deficiency. This suggests that in the absence of classical pathway activation, an intact AP 
is able to activate some C3, which has been shown in patient serum experiments (Clark 
& Klebanoff, 1978; Frank & Sullivan, 2014). C3-deficient individuals have an increased 
susceptibility to infection by mainly encapsulated pyogenic bacteria such as 
meningococci, haemophilus influenzae and streptococci. For C3 deficiency, this can be 
caused by either reduced C3 expression or increased C3 consumption. The former can be 
caused by loss-of-function (LoF) mutation in C3 (Chapter 2, Section 2.4.3). The latter 
can be caused by the absence of C3 regulation, perhaps by either a gain-of-function (GoF) 
mutation in C3 or a LoF mutation in a C3 regulator. Thus, in vitro depletion of either FI 
or FH caused complete C3 consumption by the AP (Nicol & Lachmann, 1973). In patients 
with complete FI deficiency, exhaustive AP activation leads to both very low C3 and FB 
levels. FI deficiency is frequently associated with severe infections, glomerulonephritis 
and autoimmune diseases (Sadallah et al., 1999). For FH, previously known as 1H, a 
haemolytic uraemic syndrome (HUS) patient and his unaffected brother showed a very 
low level of functional FH that caused low levels of both C3 and haemolytic complement 
via the AP. Their C4 levels were normal. It was suggested that a genetic defect in CFH 
was inherited in homozygosity from both of their heterozygous parents, who had half-
normal CFH levels (Thompson & Winterborn, 1981). For the terminal complement 
components, C5 to C9, a deficiency increases the risk of meningococcal infection. In 
contrast, deficiencies in the classical pathway regulator C1-Inh form the basis of 
hereditary angioedema which is characterised by the accumulation of inflammation-
related fluid in tissues.  
 
24 
 
In complement, most primary deficiencies are inherited as autosomal recessive 
traits, except for those in either C1-Inh or properdin which are autosomal dominant and 
X-linked, respectively (Frank & Sullivan, 2014). In humans, autosomal recessive traits 
require two copies of the affected gene whereas autosomal dominant traits require only 
one copy of the affected gene. Individuals with only one copy of an autosomal recessive 
trait are known as carriers. X-linked traits are carried by genes on the X chromosome 
only, thus males that inherit the X-liked trait are always affected. On the other hand, 
females that inherit the X-linked trait are only carriers. In summary, each of the activator 
and regulator components of complement are vital to the functioning of either all of 
complement (C3) or their respective pathways. Genetic deficiencies in any of these 
complement components can result in a wide variety of rare, severe diseases. 
 
1.7.1 Atypical haemolytic uraemic syndrome 
 
HUS is a thrombotic microangiopathy. In thrombotic microangiopathy, small 
blood vessels in mainly the glomeruli of the kidney (Figure 1.6) and the brain are 
occluded by thrombus (blood clots) resulting from endothelial injury. As for most 
thrombotic microangiopathies, HUS is characterised by a triad of haemolytic anaemia, 
thrombocytopenia and acute organ failure (Ruggenenti et al., 2001). The most common 
form of HUS is typical HUS which is caused by gastrointestinal infection by Shiga toxin-
producing Escherichia coli. The Shiga toxin initiates the disease process by damaging 
endothelial cells (Jokiranta, 2017). Shiga toxin-producing Escherichia coli-HUS is 
thought to affect the kidneys the most due to the high expression of a receptor for the 
toxin on glomerular endothelium (Amaral et al., 2013). Low C3 levels are typical of HUS 
patients but not always seen. 
 
Atypical HUS (aHUS) is not caused by Shiga toxin-producing Escherichia coli 
infection but by dysregulated complement activation. aHUS is an ultra-rare disease that 
is reported to occur at an incidence of approximately 0.5 per million per year (Goodship 
et al., 2017). In aHUS, an immune insult triggers complement activation, primarily by the 
AP, which cannot be properly controlled due to underlying genetic defects (Chapter 2, 
Section 2.11). This leads to endothelial cell attack and microvasculature occlusion (Figure 
1.7) (Caprioli et al., 2006), which results in organ damage to the kidneys, gastrointestinal 
tract, liver, pancreas and brain. aHUS can occur at any age, and 10% of aHUS patients  
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Figure 1.6 Morphology of the kidney glomerulus. The major functions of the kidneys 
include removing waste products and excess fluid from the body and regulating the salt, 
potassium and acid concentrations of the blood. The kidneys also release hormones that 
regulate blood pressure and control the production of red blood cells. Each of the two 
kidneys consist of millions of nephrons. A nephron consists of a tuft of capillaries, known 
as the glomerulus, surrounded by the Bowman’s capsule. The glomerulus is a high-
pressure capillary bed. To form urine, blood passes through the glomerulus and a filtrate 
collects in the Bowman’s capsule via a filtration membrane. This filtration membrane is 
composed of the glomerular endothelial cells, the glomerular basement membrane, and 
the filtration slits between the podocytes. Sourced from (Alicic et al., 2017).
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Figure 1.7 Models for the complement-based pathophysiology of aHUS and C3G in the kidney glomerulus. Figure legend overleaf.
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Figure 1.7 (continued) Models for the complement-based pathophysiology of aHUS 
and C3G in the kidney glomerulus. 
(A) In a healthy glomerulus, the low level tick-over activation of C3 (green triangle) to 
C3b by the complement alternative pathway (AP) is stopped by regulators (purple 
rectangles) both in the fluid phase (factor I (FI), factor H (FH)) and membrane-attached 
(membrane cofactor protein (MCP)) to the capillary endothelium. By this, host-cell 
deposited or fluid-phase C3b (green triangle) is inactivated to iC3b (yellow triangle) and 
host cells are protected from complement. Platelets activation (small, pink ovals), red 
blood cells (large, red ovals) and endothelial cells are normal and healthy (blue ovals). 
(B) In atypical haemolytic uraemic syndrome (aHUS), dysregulation of the AP occurs 
due to loss-of-function (deficiency) in the regulators (FH, FI or MCP; purple rectangles 
with black cross), gain-of-function in the activators (C3, factor B; green triangles with 
black plus symbol) or acquired factors (auto-antibodies; not shown). This leads to 
impaired protection of host cell surfaces from AP activation of C3 to C3b (green triangles 
with black star), including membrane-attack complexes (MAC; dark green, double 
rectangles), inflammation and endothelial cell damage (orange ovals). By this, red blood 
cells are damaged (haemolytic anaemia; red, sickle-shaped ovals), platelets are activated 
(thrombocytopenia; small pink ovals) and the blood clots. For diacylglycerolkinase 
(DGKE)-associated aHUS, DGKE deficiency leads to a prothrombotic state (not shown).  
(C) For C3 glomerulopathy (C3G), which can be further categorised into dense deposit 
disease (DDD) and C3 glomerulopathy (C3GN), electron-dense deposits of mostly C3 
are seen in the glomerulus. These occur due to fluid phase AP dysregulation by either 
genetic or acquired factors. For C3G, the known predisposing genetic factors are low 
levels of FH or impaired FH cofactor activity (purple rectangle with black cross), and C3 
gain-of-function (green triangle with black plus symbol), which lead to massive activation 
of C3 to C3b (green triangles with black star). This leads to deposition of C3 activating 
products and MAC in the subendothelial space upon transfer through the fenestrated 
endothelium (Noris & Remuzzi, 2015). For DDD, the deposits occur in the glomerular 
basement membrane, and may also occur in the mesangium (mesangial matrix and cells; 
both green triangles and dark green double rectangles). The accumulation of iC3b along 
the glomerular basement membrane (not shown) may be critical for the development of 
DDD (Fakhouri et al., 2010). For C3GN, only mesangial deposits are seen (green triangles 
and dark green double rectangles). For complement factor H-related 5 nephropathy, 
which may lead to a loss-of-function for FH, histologic appearances include mesangial 
and/or capillary wall C3 deposits (Barbour et al., 2013) (green triangles).  
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are children. Despite multiple genetic or acquired risk factors (Esparza-Gordillo et al., 
2006), aHUS may not be manifested until the triggering stimulus occurs in middle age. 
For aHUS in childhood, the numbers of affected females and males are approximately 
equal (Sellier-Leclerc et al., 2007). However in adults, the literature suggests that more 
females than males are affected by aHUS (Sullivan et al., 2010). The occurrence of aHUS 
is either familial (<20%) or sporadic (Bu et al., 2012). Familial forms are defined as the 
presentation of aHUS in at least two members of the same family with individual 
diagnoses at least 6 months apart. For familial aHUS cases, the pattern of  inheritance is 
either autosomal recessive or dominant (Noris & Remuzzi, 2009). The role of the AP in 
aHUS was first suggested in 1974 (Kavanagh et al., 2008). The first discoveries of the 
role of complement genetic variants in aHUS were in CFH in 1981 (Thompson & 
Winterborn, 1981) and 1998 (Warwicker et al., 1998). Presently, in ~60% of aHUS 
patients, one or more genetic abnormalities in complement AP or related genes have been 
detected (Chapter 2, Section 2.11). For acquired factors of aHUS, anti-FH autoantibodies 
are involved in 5–13% of aHUS cases. These are typically associated with homozygosity 
for a CFHR3-CFHR1 genetic deletion. 
 
Up until recently, the prognosis of aHUS was poor with patients progressing to 
end-stage renal disease within 2 years of diagnosis. Recently, the humanized monoclonal 
antibody Eculizumab (Soliris; Alexion Pharmaceuticals Inc), which inhibits C5, was 
shown to reverse the exacerbation of aHUS and control microangiopathic haemolytic 
activity (Lapeyraque et al., 2011). For aHUS, guidelines for the application of eculizumab 
were established in 2012 (Zuber et al., 2012) and eculizumab has since been associated 
with significant time-dependent improvement in renal function (Legendre et al., 2013).  
 
Another form of HUS known as secondary HUS is caused by a co-existing disease 
or condition such as infection, transplantation, cancer, pregnancy, cytotoxic drugs or 
autoimmune diseases. These conditions can cause direct endothelial cell damage and 
promote complement activation (Jokiranta, 2017). Secondary HUS does not involve 
genetic abnormalities that affect complement regulation and is therefore a different 
condition to aHUS. 
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1.7.2 C3 glomerulopathy 
 
C3 glomerulopathy (C3G) describes a spectrum of renal diseases that involve 
either genetic or acquired AP dysregulation, and leads to kidney failure. C3G is also ultra-
rare with an incidence of approximately one per million per year (Goodship et al., 2017). 
However, unlike aHUS, C3G is not a thrombotic microangiopathy and C3G patients do 
not demonstrate anaemia, thrombocytopenia, or multisystem involvement (Bajwa et al., 
2018). In C3G, uncontrolled complement activation leads to deposits of C3 and its 
fragments within the kidney glomerulus and its damage (Figure 1.7). Approximately 20% 
of C3G cases are associated with predisposing rare variants (RVs) in the complement 
genes (Chapter 2, Section 2.11). For C3G, diagnosis requires a renal biopsy and the C3 
deposits are studied by electron microscopy (EM). Igs are absent from these deposits, 
which suggests that complement is activated independently of the classical pathway. 
Despite C3G and membranoproliferative glomerulonephritis (MPGN) sharing 
histopathological features, MPGN is caused by immune complex-mediated dysregulation 
of the classical pathway. C3G was classified in 2010 to reflect these differences (Fakhouri 
et al., 2010). C3G is further classified into either dense deposit disease if the C3 deposits 
are dense, osmiophilic and intramembraneous, or C3 glomerulonephritis if the deposits 
of C3 are a combination of light dense, mesangial, subendothelial or subepithelial (Figure 
1.7). Most dense deposit disease (80-85%) and many C3 glomerulonephritis patients 
(~50%) develop acquired autoantibodies to the AP C3 convertases which are known as 
C3 nephritic factors (Servais et al., 2012). C3 nephritic factor protects the AP C3 
convertase and leads to AP dysregulation (Appel et al., 2005). Anti-CFH autoantibodies 
are also acquired risk factors for C3G. An additional form of C3 glomerulonephritis, 
CFHR5 nephropathy, is characterised by the presence of abnormal FHR5 (Chapter 2, 
Section 2.11). Currently, the prognosis of C3G is poor with most C3G patients 
progressing to end stage renal disease within a decade. For renal allografts, the recurrence 
rate of C3G is 45-60%. For C3G patients, the response rate to eculizumab is 
heterogeneous and not as successful as for aHUS (Welte et al., 2018).  
 
Studies in mice have shown that the targeted deletion of CFH results in 
uncontrolled AP activation, very low circulating levels of C3, deposition of C3 on the 
glomerular basement membrane and MPGN-like characteristics of the glomerulus 
(Pickering et al., 2002). Further studies showed that mice with a transgenic CFH without 
the five C-terminal SCR domains were able to regulate the AP in the circulation but not 
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on the endothelial surface (Pickering et al., 2007). This lead to a renal thrombotic 
microangiopathy similar to aHUS (Cook, 2017).  
 
1.7.3 Age-related macular degeneration 
 
Age-related macular degeneration (AMD) is a common eye disease which affects 
~50 million people across the world and is the leading cause of blindness in developed 
countries (Clark et al., 2014). For AMD patients, the loss of central vision can have a 
significant impact on their quality of life. Age is a major risk factor for AMD, alongside 
genetics and environmental factors such as nutrition. In AMD, with age, more 
polymorphous debris known as drusen are deposited between the retinal pigment 
epithelium (RPE) and Bruch’s membrane (Figure 1.8). Also with age, the capability of 
the RPE to phagocytise debris likely decreases which adds to the accumulation of drusen. 
Under the RPE, drusen build-up is thought to activate complement and lead to 
inflammation and RPE damage. Drusen are classified by their size into small (<63 m), 
medium or large (>124 m) (Jager et al., 2008), which informs the grade of AMD. For 
example, medium-sized drusen in the absence of pigment abnormality are characteristic 
of early AMD for which there is a mild loss of vision. The molecular constituents of 
drusen include complement activators, components and regulators such as FH (Anderson 
et al., 2010). For the deposition of complement in drusen, photo-oxidised visual cycle 
products can activate complement. It has also been suggested that RPE cells might be 
prone to complement-mediated lysis (Ma et al., 2010). After the appearance of drusen, 
the development of AMD is subdivided into neovascular (wet) and atrophic (dry) forms. 
Similar to the complement-related diseases aHUS and C3G, complement genetic variants 
are thought to increase the risk of AMD by affecting the functionalities or circulating 
levels of the complement system. For AMD, this is expected to cause a hyperactive 
complement activation profile which, when combined with other factors, leads to 
excessive complement activation (Hecker et al., 2010; Heurich et al., 2011).
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Figure 1.8 Age-related macular degeneration. (A) In the human eye, the macular is affected by age-related macular degeneration (AMD). (B) In a 
healthy macular, no inflammation or deposits (drusen) are observed. (C) In early AMD, drusen form between Bruch’s membrane and the retinal pigment 
epithelium (RPE). Drusen contain the complement membrane attack complex and other complement components such as factor H. Macrophages are also 
present due to inflammatory processes. Slowly over time, the build-up of drusen increases loss of central vision. (D) In advanced AMD, severe sight loss 
is most commonly caused by either drusen (dry AMD) and less commonly by a combination of RPE cell death, geographic atrophy and the growth of 
new, abnormal and fragile blood vessels (wet AMD). In wet AMD, these vessels leak blood and fluid which damages the macula and makes central 
vision appear blurry. Adapted from (Apte, 2016) and an illustration provided by the National Library of Medicine (US) webpage 
[https://ghr.nlm.nih.gov/condition/age-related-macular-degeneration], accessed on 4 July 2018.
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Chapter Two 
 
Genetic variation 
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This introduction chapter describes the theory of genetic variation in humans, 
including how genetic variants can lead to disease phenotypes and how they are 
detected in the clinic by genetic sequencing. It provides a literature review of the 
role of complement genetic variants in the three diseases: atypical haemolytic 
uremic syndrome, C3 glomerulopathy and age-related macular degeneration. It 
describes bioinformatics methodologies for analysing the pathogenicity of these 
genetic variants, including allele frequencies, statistical analyses, web-databases 
and structural biology-based prediction tools. This chapter introduces my major 
research question for this PhD thesis, and outlines both the aims for my results 
Chapters 4, 5 and 6, and methodology for Chapters 4 and 6. 
 
 
2.1 From DNA to proteins 
 
One of the central goals of human biology and medicine is to understand the 
relationship between genotype and phenotype. For genetic diseases, the genotype-
phenotype relationship allows underlying and/or predisposing factors to be identified. For 
patients with genetic diseases, the identification of genetic predisposition factors is highly 
useful and in some cases essential for predicting the outcome, prescribing treatment and 
the development of new therapies. For example, for aHUS, the identification of a 
pathogenic genetic variant reinforces the diagnosis and accurately establishes the cause 
of the disease. Overall, this facilitates patient management, effective treatment, such as 
anti-complement treatments, and genetic counselling. In addition, genetic analysis is 
essential for carrying out related-living donor organ transplantation such as for the 
kidneys in aHUS and C3G. Thus, the donor must not carry any genetic or acquired factors 
that have been clearly identified as causative in the recipient with the disease (Goodship 
et al., 2017). 
 
In homo sapiens, or humans, the nucleus of every nucleated cell contains ~ 3 
billion base pairs of the hereditary molecule DNA. This is known as the human genome. 
The first model of the double-helix structure of DNA was published in 1953 by Watson 
and Crick (Watson & Crick, 1953). For DNA, each nucleotide comprises one of four 
nucleobases which are classified by their structures into either purines (adenine, A and 
guanine, G) or pyrimidines (cytosine, C and thymine, T). The two separate strands of 
DNA are bound together by specific base pairing between A and T or C and G only. 
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According to the central dogma of biology, in a cell, DNA is transcribed into messenger 
ribonucleic acid (mRNA) which is then translated into one or a number of proteins (Figure 
2.1). The translation of mRNA into a polypeptide of amino acids for protein folding is 
governed by a universal genetic code (Table 2.1). This genetic code shows degeneracy in 
that one amino acid can be encoded by more than one unique sequence of three DNA 
nucleotide bases. Overall, only ~1.5% of the genome corresponds to the ~20,000 genes 
that encode the human proteome. However, a further 80% of the genome is thought to be 
functional and may be transcribed, bind to regulatory proteins or be associated with other 
biochemical functions (Pennisi, 2012). In every cell, the proteome is different and 
constantly changes with time (Munoz & Heck, 2014). This is due to the differential 
expression of genes by different cell types. For the serum complement proteins, the main 
producers are hepatocytes in the liver. The only exceptions are FD, and factor properdin 
(FP) and C1q, which are primarily produced by adipocytes, and macrophages and other 
immune cells, respectively (Morgan & Gasque, 1997). Other cells such as endothelium 
and epithelium are also able to secrete various complement components, which may be 
essential for the localisation of complement at serum-restricted sites (Lubbers et al., 
2017). 
 
2.2       Genetic inheritance 
 
The human genome is diploid and arranged into 23 pairs of chromosomes. 
Humans also have one copy of maternally inherited mitochondrial DNA. For the 22 non-
sex chromosomes, also known as autosomes, two alleles or copies of the same gene are 
present at the same genomic position, or locus. Each one of these alleles is inherited from 
a parent. This mechanism of inheritance was first proposed by Gregor Mendel in 1865 in 
his principle of segregation, before DNA or genes were known to exist. Segregation refers 
to the separation of genes and their respective alleles during meiosis into daughter cells. 
Mendel also proposed the theory that one allele is dominant (A1) whilst another is 
recessive (A2). 
 
For the phenotype, recessive traits require two copies (homozygous) of the allele 
whereas dominant traits only require one copy (heterozygous) of the allele. This applies 
to both the autosomes and the female sex chromosomes (XX) only. Dominant traits are 
observed in every generation whereas recessive traits are absent from one generation but  
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Figure 2.1 The central dogma of biology for a eukaryotic gene. Genes contain non-
coding regulatory sequences such as the promoter (yellow) and the 5 and 3’ untranslated 
regions (blue). Mature mRNA is capped at the 5’ end and has a poly-adenine tail at the 
3’ end. Adapted from (Shafee & Lowe, 2017). 
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Table 2.1 The genetic code 
Second base 
T
h
ir
d
 b
a
se
 
F
ir
st
 b
a
se
 
 T C A G  
T 
TTT 
Phenylalanine 
TCT 
Serine 
TAT 
Tyrosine 
TGT 
Cysteine 
T 
TTC TCC TAC TGC C 
TTA 
Leucine 
TCA TAA Stop (Ochre) TGA Stop (Opal) A 
TTG TCG TAG Stop (Amber) TGG Tryptophan G 
C 
CTT CCT 
Proline 
CAT 
Histidine 
CGT 
Arginine 
T 
CTC CCC CAC CGC C 
CTA CCA CAA 
Glutamine 
CGA A 
CTG CCG CAG CGG G 
A 
ATT 
Isoleucine 
ACT 
Threonine 
AAT 
Asparagine 
AGT 
Serine 
T 
ATC ACC AAC AGC C 
ATA ACA AAA 
Lysine 
AGA 
Arginine 
A 
ATG Methionine ACG AAG AGG G 
G 
GTT 
Valine 
GCT 
Alanine 
GAT 
Aspartic acid 
GGT 
Glycine 
T 
GTC GCC GAC GGC C 
GTA GCA GAA 
Glutamic acid 
GGA A 
GTG GCG GAG GGG G 
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reappear in another. For heterozygotes, the phenotype can also be an intermediate state 
of the two heterozygous alleles, which is known as incomplete dominance, or an 
expression of both heterozygous traits in equal numbers, which is known as co-
dominance. For the pair of sex chromosomes, X-linked recessive traits are seen in many 
more males than females, because both parents of the female must carry the X-linked 
trait, compared to only one required for males. For X-linked dominant traits, affected 
males can pass them to daughters only and not sons (Griffiths, 2000). 
 
At any one locus, the composition of the two alleles is known as the genotype. At 
the population level, multiples alleles for one locus can exist. This forms the basis of 
genetic and phenotypic variation in a population. For two or more loci, the probability of 
their combined inheritance depends on the physical distance between them on one 
chromosome. For alleles at different loci, if the observed combination frequency is 
significantly greater than the expected frequency of random association, they are in 
linkage disequilibrium. By this, linkage disequilibrium refers to the non-random 
association of alleles at two or more loci (Robinson, 1998). For example, the human 
leukocyte antigen region displays strong linkage disequilibrium whereby certain human 
leukocyte antigen alleles are inherited together as a conserved haplotype. For CFH, 
haplotypes consisting of multiple polymorphisms are statistically associated with either 
susceptibility or protection for AMD (Li et al., 2006). 
 
A single gene can also contribute to multiple phenotypic traits in a phenomenon 
known as pleiotropy. Non-genetic factors, termed as the environment, can also affect 
genetic variation and the phenotypic outcome.  
 
2.3 Genetic variation and evolution 
 
Genetic variation is defined as the difference in DNA sequences between 
individuals within a population. For humans, the average amount of genetic variation 
between any two individuals has been estimated at ~0.1 - 0.4% of the genome (Jorde & 
Wooding, 2004; Karki et al., 2015). This equates to 3 – 12 million base pairs, on average. 
Between different species, the amount of genetic variation is even greater. The ultimate 
source of all genetic variation is DNA mutation, which is essential for the process of 
natural selection (Barton, 2010) that can drive biological evolution and eventual 
speciation (Nei & Nozawa, 2011). The theory of biological evolution was published by 
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Charles Darwin in his book “On the Origin of Species” in 1859 (Darwin, 1859). For 
evolution, the five mechanisms are: mutation, natural selection, random genetic drift, 
gene flow and recombination. Most of the human genome has been shaped primarily by 
both mutation and random genetic drift (Kimura, 1991). Evolution is defined as heritable 
changes in the frequency of alleles in a population over time.  
 
2.3.1  Allele frequency 
 
For a variant of interest in a population, genetic sequencing and subsequent 
analyses (Section 2.7) allow the number of reference and alternative alleles to be 
determined. Following this, the frequency of each allele can be calculated by dividing the 
number of alleles of interest (allele count) by the total number of alleles in the population 
(allele number). For example, in aHUS, the complement factor H (CFH) missense variant 
c.157C>T; p.Arg53Cys was identified in heterozygosity in two patients (two T alleles) 
and in homozygosity in two patients (four T alleles), out of a total of 3128 screened 
patients (6256 T or C alleles). The resulting AF for this variant (T allele) is thus 0.096% 
(Osborne et al., 2018a). For each family, the allele is only counted once. Because of this, 
it is important to record any relations between patients.  
 
Theoretically, without both evolutionary mechanisms such as new mutation and 
selection, and non-random mating, the allele and genotype frequencies of a population 
will remain constant between generations. This theory is described by the Hardy-
Weinberg equilibrium (HWE). The HWE corresponds to a mathematical equation and 
was formulated by G. H. Hardy and Wilhelm Weinberg in 1908 (Bacaër, 2011). For the 
HWE, two different alleles at an autosomal locus that segregate in a population are 
denoted A1 and A2. Their allele frequencies (AFs) are p and q, respectively: 
 
f(A1) + f(A2) = p + q = 1       (2.1) 
 
The expected frequencies of the three possible genotypes for the homozygotes 
(A1A1 and A2A2) and heterozygotes (A1A2), respectively, are then:  
 
f(A1A1) + f(A2A2) + f(A1A2) = p
2 + q2 + 2pq = 1    (2.2) 
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The total frequency of all alleles at a particular locus is equal to 1 or 100%. For a 
population, the HWE connects the frequency of an allele with the frequency of 
heterozygotes and homozygotes, as well as the genotype frequencies (Figure 2.2). For 
example, for the CFH single nucleotide polymorphism (SNP) rs800292 (c.184G>A; 
p.Val62Ile), for which the G allele was associated with AMD in an Iranian population, 
the observed genotype frequencies for the AMD group were 74% for GG homozygotes 
(A1A1), 22% for GA heterozygotes (A1A2) and 4% for AA homozygotes (A2A2) 
(Babanejad et al., 2016). The observed AFs for the G (p) and A (q) alleles are then: 
 
p = (A1A1) + ½(A1A2) = 0.74 + ½(0.22) = 0.85    (2.3) 
 
q = 1 – p = 1 – 0.85 = 0.15       (2.4) 
 
From these AFs, in order to test for HWE, the expected genotype frequencies can be 
calculated. For example, the expected number of heterozygotes (A1A2) is:  
 
(A1A2) = 2pq = 2(0.85)(0.15) = 0.255 = 26%     (2.5) 
  
Following this, the observed genotype frequencies are compared to the expected genotype 
frequencies by using a goodness-of-fit 𝜒2 test (Wittke-Thompson et al., 2005). If the 
difference is significant, the HWE is violated, and an evolutionary mechanism is inferred 
to have occurred in the population. For case-control studies (Section 2.8.2), in the case 
group, the HWE is often violated because a disease-associated allele is over-represented 
(Weiss & Scott, 2009). On the other hand, for the control or reference dataset, the HWE 
can typically be used as a quality control measure, whereby a major cause of HWE 
deviation is genotyping error among other causes. For other theoretical population 
studies, the HWE can also be used to detect cases of evolution, non-random mating and 
population stratification (Rousset & Raymond, 1995). For example, if the observed 
frequency of heterozygotes was significantly higher than expected, it may be associated 
with higher rates of survival than the homozygous genotype. In order to identify the 
evolutionary mechanism, further experiments can be planned.  
 
For multiple alleles at any one locus in a population, such as for the three A, B 
and O alleles which determine blood group in humans, the HWE can also be applied 
(Kumar et al., 2014). For three alleles, there will be six genotypes. For one locus, the 
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Figure 2.2 The Hardy-Weinberg equilibrium for two autosomal alleles. The 
relationship between genotype (A1A1, A1A2, A2A2) and allele (p, q) frequency. 
Heterozygotes (A1A2, green) increase rapidly as the values of p and q move away from 0 
or 1. For populations in which the frequencies of p and q are between 0.33 and 0.67, the 
frequency of heterozygotes (A1A2, green) is higher than for either homozygote (A1A1, 
yellow; A2A2, red). The highest proportion of the population that can be heterozygous is 
0.5 (green). Adapted from (Sanders & Bowman, 2012) and (Hedrick, 2005). 
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greater the number of alleles, the greater the heterozygosity, and the greater the genetic 
diversity (Rosenberg & Kang, 2015) (Figure 2.3). By this, the more variation that exists 
in a population, the better prepared the population will be for adaption to environmental 
change when it occurs. 
 
2.3.2 Natural selection, genetic drift and gene flow 
 
In natural selection, genotypes associated with high rates of survival and/or 
reproductive success are said to have high fitness, or genetic contribution, and are 
therefore selected for in the population. Positive selection maintains advantageous alleles 
whereas negative or purifying selection removes deleterious alleles. Selection can be 
weak or strong, depending on the magnitude of the advantage or disadvantage (Griffiths, 
2000). However, deleterious alleles could be maintained at moderate to high frequencies 
in a population by balancing selection if they influence two or more independent 
phenotypic traits (pleiotropic) and at least one of these is a beneficial trait. By this, for a 
recessive allele that is associated with a genetic disease, the selection against homozygous 
recessives can be counter-balanced by selection in favour of heterozygotes (Altshuler et 
al., 2008). This is known as the heterozygote advantage, or over-dominance, and is seen 
for sickle-cell anaemia and perhaps cystic fibrosis. Here, the recessive allele also provides 
a survival advantage (Gemmell & Slate, 2006). 
 
In genetic drift, the AFs of a population randomly change over generations in 
either direction. By this, a beneficial allele can become lost or a slightly harmful allele 
can become fixed (100%) in the population. These effects can significantly change the 
AFs and reduce genetic diversity. The smaller the population, the larger the effects of 
genetic drift. Two extreme examples of genetic drift are the bottleneck and the founder 
effect, both of which describe a severe reduction in the size of a population, due to either 
a catastrophe or isolation from the original population. Random genetic drift is thought 
to be responsible for most of the evolutionary changes at the molecular level, in the 
neutral theory of molecular evolution (Kimura, 1991).  
 
Gene flow is described as the transfer of genetic variation from one population to 
another by inter-mixing of populations. Gene flow can also cause a change in AF. 
 
 
42 
 
 
Figure 2.3 Punnett square showing the Hardy-Weinberg law for loci with three and 
four autosomal alleles in a population. (A) For one loci, the three alleles A, B and C 
are denoted p, q and r with example allele frequencies of 0.6, 0.3 and 0.1, respectively. 
For p2, q2, r2, pq, pr and qr, the genotype frequencies are thus 0.36, 0.90, 0.01, 0.18, 0.06 
and 0.03, respectively. (B) For another loci, the four alleles A, B, C and D are denoted as 
p, q, r and s, at example allele frequencies of 0.35, 0.3, 0.2 and 0.15, respectively. For p2, 
q2, r2, s2, pq, pr, ps, qr, qs and rs, the genotype frequencies are thus 0.12, 0.90, 0.04, 0.02, 
0.11, 0.07, 0.05, 0.02, 0.05, and 0.03, respectively. The white squares represent the 
homozygotes and the coloured squares represent the heterozygotes. Both the allele and 
the genotype frequencies add up to 1. Adapted from (Rosenberg & Kang, 2015). 
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2.3.3 Genetic recombination 
 
Genetic recombination or exchange occurs via the transfer or copying of DNA 
segments during the pairing of the two homologous chromosomes in meiosis. Genetic 
recombination facilitates the formation of a new combination of alleles. For the adaptive 
immune system, genetic recombination drives rapid diversification of receptors and is 
essential for the recognition of new pathogens. In the genome, a lack of genetic 
recombination between sites strengthens the linkage disequilibrium. 
 
2.3.4 Why do DNA mutations occur? 
 
The ultimate source of all genetic variation is DNA mutation. Mutations occur 
due to either the spontaneous chemical instability of the bases, errors during DNA 
replication or environmentally by ionising radiation. Most mutations are believed to be 
caused by replication errors. During DNA replication, despite the high efficiency of DNA 
polymerase enzymes, incorrect nucleotides are added at a rate of approximately 1 per 
every 100,000 nucleotides. Thus, for each human diploid cell of 6 billion base pairs in 
cell division, approximately 120,000 nucleotide errors are made. Most of these single 
nucleotide errors are rapidly corrected by the proofreading or mismatch repair 
mechanisms during replication. However, some are not corrected and become permanent  
after the next cell division (Pray, 2008). For multicellular organisms, mutations can be 
inherited from parents (germline) or acquired over the life of an individual (somatic). The 
latter is often seen for cancer. Mutations in germinal tissue such as gametes may be 
transmitted to some or all progeny whereas those in somatic tissue are not transmitted to 
progeny. Within an organism, the presence of a genetically distinct (in terms of genotype) 
population of cells is known as mosaicism. Mosaicism can occur in either or both somatic 
and germline cells, depending on when the mutation occurred. There are six elementary 
types of DNA mutation: substitution, deletion, insertion, duplication, inversion and 
translocation. Each of these can affect the protein and its expression. 
 
2.3.4.1 Substitution mutation 
 
Substitution or point mutations in DNA involve the exchange of one single base 
pair for another. Substitutions are categorised into two types. Transition changes are when 
either a purine changes to the alternative purine (A to G, or G to A) or a pyrimidine 
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changes to the alternative pyrimidine (C to T, or T to C). Transversion changes describe 
either a purine to a pyrimidine (A to C, A to T, G to C, or G to T) or vice versa (C to A, 
C to G, T to A, T to G). During DNA replication, both transition and transversion 
mutations can be caused by tautomeric shift of the nucleotides which results in a 
mispairing. They can also be caused by bases which are either in different non-tautomeric 
chemical forms or slightly shifted in space, which also results in mismatched base pairing. 
This phenomenon is known as wobble and is facilitated by the flexibility in the DNA 
double helix. Wobble also provides an explanation for the degeneracy of the genetic code 
(Crick, 1966). In terms of spontaneous mutations, transitions can result from hydrolytic 
deamination of the pyrimidine C and also 5-methlycytosine involved in gene 
transcription, which generates uracil (U) and T, respectively. These deamination reactions 
have been shown to account for many single-base mutations that lead to human disease. 
For example, in the tumour suppressor gene TP53 in carcinoma cells, C residues at CpG 
dinucleotides are mutational hotspots (Sassa et al., 2016). For the purines A and G, N-
glycosidic bond hydrolysis leads to depurination which can also induce transition or 
transversion mutagenesis if not repaired by the base excision repair pathway. In humans, 
it has been estimated that around 2,000 – 10,000 DNA purine bases are turned over every 
day due to hydrolytic depurination and subsequent repair (Lindahl, 1993). 
 
Theoretically, four transitions and eight transversions are possible. If the 
frequency of each nucleotide is the same, the expected transition to transversion ratio is 
1/2. However, in humans, the transition to transversion ratio is approximately 2.0-2.1 for 
the whole genome and 3.0-3.3 for exonic variation (DePristo et al., 2011). Thus, transition 
substitutions are more favoured than transversions, which is known as transition bias. 
One reason for transition bias is that for the eleven amino acids that have two alternative 
codon forms (Phe, Tyr, His, Gln, Asp, Lys, Asp, Glu, Cys, Ser, Arg; Table 2.1), the 
alternate codons differ by one base at the third position and are either both purines or both 
pyrimidines (Higgs & Attwood, 2013). By this, transitions often result in synonymous 
(silent) changes which do not affect the fitness of the host and are therefore more likely 
to be tolerated. Furthermore, at the first and second codon positions, transition mutations 
tend to cause changes that conserve the chemical properties of amino acids (Wakeley, 
1996). In addition, during replication, the generation of transversions requires greater 
distortion of the DNA helix than for transitions (Beamish, 2001). The transition to 
transversion ratio is a useful quality control parameter for genetic datasets. 
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For non-synonymous substitution mutations in the coding regions of DNA, the 
effect at the protein level is an amino acid substitution (missense mutation). A non-
synonymous substitution mutation can also lead to the gaining of a premature stop codon 
(nonsense mutation), the loss of a stop codon, or the loss of an initiator codon (Table 2.2). 
Non-synonymous substitution mutations can also occur in the non-coding regions of 
DNA, such as the 3’ and 5’ untranslated regions (3’UTR and 5’UTR), introns, and non-
coding transcript exons (Table 2.2). 
 
SNPs are a type of substitution mutation which occur at an AF of more than 1% 
in a population. In humans, approximately 90% of sequence variation among 
individuals is due to common variants which includes SNPs (Kruglyak & Nickerson, 
2001). SNPs are the most abundant form of genetic variation in the human genome and 
usually have a minimal impact on biological systems. However, SNPs can cause 
functional consequences such as changes to amino acids, mRNA transcript stability and 
transcription factor binding affinity. By this, SNPS can be risk factors for disease (Tabor 
et al., 2002). The frequency of a SNP is given in terms of the minor allele frequency 
(MAF), or the frequency of the second most frequent allele (Bush & Moore, 2012). 
For example, for the CFH SNP c.1204T>C which encodes the change p.Tyr402His, 
the MAF applies to the C allele and is reported to be 33% and 27% in each of the 
Exome Aggregation Consortium (ExAC) (Lek et al., 2016) and 1000 Genomes Project 
(1000GP) (Genomes Project et al., 2015) databases, respectively. 
 
2.3.4.2 Other types of mutation 
 
A deletion mutation can occur during DNA replication when the template strand 
slightly loops out and causes the deletion of one or several nucleotide bases from the 
newly synthesised DNA strand. This is known as strand slippage and is most often seen 
in regions of DNA with many copies of small repeated sequences (Pray, 2008). For a 
protein, a deletion of one or a few nucleotides could translate into either an in-frame or a 
frameshift mutation (Table 2.2), depending on the number of nucleotides involved. An 
in-frame mutation only results from nucleotides being in multiples of three. Otherwise, a 
frameshift mutation results.  
 
An insertion mutation describes the addition of one or more nucleotides. In DNA 
replication, insertion mutations can be caused by the template strand looping out which
46 
 
Table 2.2 Non-structural variant annotation 
Data sourced from the Exome Aggregation Consortium (ExAC) database. 
Annotation 
Description Example (for multiple 
genes) 
3' UTR 3’ untranslated region. c.*10C>T 
5' UTR 5’ untranslated region. c.-36G>C 
frameshift 
Any number of bases which are not a 
multiple of three are deleted or 
inserted which disrupts the reading 
frame from that point. 
c.3286_3287delTG;  
p.Trp1096AspfsTer20  
inframe 
deletion 
Any number of bases which are a 
multiple of three are deleted which 
deletes any number of residues. 
c.2422_2427delATACAA; 
p.Ile808_Gln809del 
inframe 
insertion 
Any number of bases which are a 
multiple of three are inserted which 
inserts any number of residues. 
c.196_207insCAG…AGG; 
p.Gln68_Arg69dup 
initiator 
codon 
At least one base in the initiator codon 
is changed. 
c.1A>G; 
p.Met1? 
intron 
At least one base in an intron is 
changed. 
c.1336+136T>G 
missense A substitution mutation. 
c.2465A>T; 
p.Asn822Ile 
non coding 
transcript 
exon 
A sequence variant that changes non-
coding exon sequence in a non-coding 
transcript. 
n.2587G>C 
splice 
acceptor 
A splice variant that changes the 2 
base region at the 3' end of an intron 
(LoF). 
c.2237-2A>G 
splice donor 
A splice variant that changes the 2 
base pair region at the 5' end of an 
intron (LoF). 
c.1519+5_1519+8delGT... 
splice region 
A splice variant that changes the 
region in between the two 2 base pair 
regions at the 3’ and 5' ends of an 
intron. 
c.1699A>C 
stop gained A nonsense mutation (LoF). 
c.3643C>T;  
p.Arg1215Ter 
stop lost 
At least one base in the terminator 
codon is changed which changes the 
terminator residue. 
c.1156T>C;  
p.Ter386ArgextTer69 
stop retained 
At least one base in the terminator 
codon is changed but the terminator 
remains. 
c.205G>A;  
p.Ter69Ter 
synonymous 
At least one base is changed which 
doesn’t affect the sequence but may 
affect the expression. 
c.903A>G;  
p.Ala301Ala 
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results in strand slippage. A duplication mutation is the abnormal copying of one or more 
nucleotides in the DNA strand. For a protein, a duplication or insertion could translate 
into either an in-frame or a frameshift mutation (Table 2.2). 
 
A complex mutation denotes a combination of two or more of the six different 
mutation types. One type of complex mutation combines an insertion and a deletion and 
is known as an indel. Thus, one or more nucleotides are deleted followed by the insertion 
of one or more different nucleotides. 
 
An inversion mutation is where a segment of two or more nucleotides is reversed 
end to end. The overall number of nucleotides is not changed. Two chromosomal 
breakpoints must occur for an inversion.  
 
A translocation mutation is where a segment of one or more nucleotides are 
moved to another genomic location between non-homologous chromosomes. 
 
Structural variation is defined as a region of DNA which is approximately 1 kb or 
greater in size (Freeman et al., 2006). Structural variations can include genomic insertions 
and deletions, which are also commonly referred to as copy number variants, and 
inversions and translocations. Thus, copy number variants are a type of mutation in which 
the gene is amplified or reduced through increased or decreased copy number of a 
particular locus-specific allele (Iafrate et al., 2004; Sebat et al., 2004). In addition to these 
types, segmental duplications are regions of DNA that are >1 kb in size and present more 
than once in the genome with >90% sequence identity (Sharp et al., 2005) and sometimes 
overlap with copy number variants. For structural variations, obtaining breakpoint 
resolution from sequencing is a major difficulty, and the events are highly variable. Thus, 
the Database of Genomic Structural Variation (dbVar) (Lappalainen et al., 2013) provides 
a database of human genomic structural variation to aid such analyses (Table 2.3). In non-
allelic homologous recombination, a recombination event occurs between two lengths of 
DNA that have high sequence similarity (95-97%) but are not alleles. These events can 
cause either large chromosomal deletions or hybrid gene products, which lead to deletions 
or hybrid versions of one or more proteins. Non-allelic homologous recombination often 
occurs between DNA sequences that have been duplicated throughout evolution. For 
example, the CFH and CFHR genomic region (Chapter 1, Section 1.6.1).  
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Table 2.3 Structural variant annotation in dbVar 
Variant Call Type Description Variant Region Type 
Sequence 
Ontology ID 
complex 
A structural sequence alteration or rearrangement encompassing 
one or more genome fragments. 
complex SO:0001784 
copy number 
gain/loss 
A sequence alteration whereby the copy number of a given 
region is greater/less than the reference sequence. 
copy number variation 
SO:0001742  
SO:0001743  
deletion The point of excision of one or more contiguous nucleotides. copy number variation SO:0000159  
duplication 
(copy number gain) A sequence alteration whereby the copy 
number of a given region is greater than the reference sequence. 
copy number variation SO:0001742  
insertion 
The sequence of one or more nucleotides added between two 
adjacent nucleotides in the sequence. 
insertion SO:0000667 
inter-chromosomal / 
intra-chromosomal 
breakpoint 
A rearrangement breakpoint between two different chromosomes 
/ within the same chromosome 
translocation or complex 
chromosomal mutation 
SO:0001873 
SO:0001874 
inversion 
A continuous nucleotide sequence is inverted in the same 
position. 
inversion SO:1000036 
mobile element 
insertion 
A kind of insertion where the inserted sequence is a mobile 
element. 
mobile element 
insertion 
SO:0001837 
novel sequence 
insertion 
An insertion the sequence of which cannot be mapped to the 
reference genome. 
novel sequence insertion SO:0001838 
sequence alteration 
A sequence alteration is a sequence feature whose extent is the 
deviation from another sequence. 
sequence alteration SO:0001059 
short tandem repeat 
variation 
A kind of sequence variant whereby a tandem repeat is expanded 
or contracted with regard to a reference. 
short tandem repeat 
variation 
SO:0002096 
tandem duplication A duplication consisting of 2 identical adjacent regions. tandem duplication SO:1000173 
translocation 
A region of nucleotide sequence that has translocated to a new 
position. 
translocation SO:0000199 
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2.4 How mutations affect proteins 
 
In order to fully understand how a mutation will affect the function of a protein, 
thus lead to an altered phenotype, its effects on the structure of the protein are typically 
studied (Chapter 3). For a protein, the amino acid sequence (primary structure) is 
considered to carry information about both the structure and the function of the protein. 
Here, a brief overview of protein structure and the importance of each residue in defining 
the protein structure is given. For the primary structure of a protein, peptide bonds 
between consecutive amino acids form a polypeptide chain. For the secondary structure 
of a protein, patterns of hydrogen bonds between the C=O and H-N groups along the 
peptide backbone lead to certain types of local fold. For secondary structure, the 
dictionary of Protein Secondary Structure (DSSP) detects eight types based on the 
hydrogen bonding patterns and the electrostatic model (Joosten et al., 2011; Kabsch & 
Sander, 1983). The most common types of secondary structure are alpha helices, turns 
and β-sheets in either anti-parallel or parallel form. For the formation of these secondary 
structure hydrogen bonds, the distance between the C=O and H-N groups is determined  
by the interaction of residue side chains with both the chemical environment and the 
polypeptide chain. For soluble proteins, the ‘Hydrophobicity’ and ‘Hydropathy Index’ 
properties of residue side chains (Table 2.4) drive the residues into positions which are 
either buried within the protein (hydrophobic) or on the protein surface in contact with 
water (hydrophilic). Thus, for soluble proteins, the global folding process is driven by the 
hydrophobic effect of water in the environment. For a transmembrane helix, the 
hydrophobic residues are typically in contact with the surrounding hydrophobic lipid 
bilayer. For residues, this allows both the solvent accessibility and associated secondary 
structure to be derived, e.g. residues from β-sheets are the most inaccessible to solvent, 
whereas random coils and turns are the most accessible to solvent. The residues in α-
helices are approximately 20% accessible (Lins et al., 2003). For a residue in a protein, 
the relative solvent accessibility measures the extent of burial or exposure of that residue 
in the 3-dimensional (3D) structure. It is defined as the solvent accessibility normalized 
by a suitable maximum value for that residue. For determining protein structure and 
function, the relative solvent accessibility of each residue is often used in the first 
predictive stages (Tien et al., 2013). 
 
For the polypeptide chain, both the size and chemistry of the residue side chains 
restrict the phi (φ) and psi (ψ) dihedral angles around the peptide bond due to steric clash.  
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Table 2.4 The 20 amino acids and their properties 
 
The data in this table was sourced from the PhD thesis of (Rallapalli, 2014). 
Symbol Code Name Type Cyclic 
Mass 
[Dalton] 
Size Hydrophobicity Charge Polarity 
Surface 
Area 
[A2] 
Residue 
Volume 
[A3] 
Hydropathy Index 
A  Ala  Alanine  Aliphatic  Acyclic  71.09 Small  Hydrophobic  Neutral  Nonpolar  115 88.6 1.8 
R  Arg  Arginine  Basic  Acyclic  156.19 Large  Hydrophilic  Positive  Polar  225 173.4 -4.5 
N  Asn  Asparagine  -  Acyclic  115.09 Medium  Hydrophilic  Neutral  Polar  150 111.1 -3.5 
D  Asp  Aspartic Acid  Acidic  Acyclic  114.11 Medium  Hydrophilic  Negative  Polar  160 114.1 -3.5 
C  Cys  Cysteine  -  Acyclic  103.15 Medium  Hydrophilic  Neutral  Polar  135 108.5 2.5 
E  Glu  Glutamic Acid  Acidic  Acyclic  129.12 Large  Hydrophilic  Negative  Polar  190 138.4 -3.5 
Q  Gln  Glutamine  -  Acyclic  128.14 Large  Hydrophilic  Neutral  Polar  180 143.8 -3.5 
G  Gly  Glycine  Aliphatic  Acyclic  57.05 Small  Hydrophobic  Neutral  Polar  75 60.1 -0.4 
H  His  Histidine  Aromatic/Basic  Cyclic  137.14 Large  Hydrophilic  Positive  Polar  195 153.2 -3.2 
I  Ile  Isoleucine  Aliphatic  Acyclic  113.16 Large  Hydrophobic  Neutral  Nonpolar  175 166.7 4.5 
L  Leu  Leucine  Aliphatic  Acyclic  113.16 Large  Hydrophobic  Neutral  Nonpolar  170 166.7 3.8 
K  Lys  Lysine  Basic  Acyclic  128.17 Large  Hydrophilic  Positive  Polar  200 168.6 -3.9 
M  Met  Methionine  -  Acyclic  131.19 Large  Hydrophobic  Neutral  Nonpolar  185 162.9 1.9 
F  Phe  Phenylalanine  Aromatic  Cyclic  147.18 Large  Hydrophobic  Neutral  Nonpolar  210 189.9 2.8 
P  Pro  Proline  -  Cyclic  97.12 Medium  Hydrophobic  Neutral  Nonpolar  145 112.7 -1.6 
S  Ser  Serine  -  Acyclic  87.08 Small  Hydrophilic  Neutral  Polar  115 89 -0.8 
T  Thr  Threonine  -  Acyclic  101.11 Medium  Hydrophilic  Neutral  Polar  140 116.1 -0.7 
W  Trp  Tryptophan  Aromatic  Cyclic  186.12 Large  Hydrophobic  Neutral  Nonpolar  255 227.8 -0.9 
Y  Tyr  Tyrosine  Aromatic  Cyclic  163.18 Large  Hydrophobic  Neutral  Polar  230 193.6 -1.3 
V  Val  Valine  Aliphatic  Acyclic  99.14 Medium  Hydrophobic  Neutral  Nonpolar  155 140 4.2 
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Thus, for each residue, only certain combinations of dihedral angles are permitted, 
and this influences the secondary structure of the protein. For example, large aromatic 
residues prefer β-strand conformations whereas the residues Met, Ala, Leu, Glu and Lys 
(“MALEK”) prefer helical conformations (Table 2.4) (Myers et al., 1997; Pace & Scholtz, 
1998). For α-helices or β-sheets, proline residues located internally can break the 
secondary structures and lead to protein destabilization because the amide proton is absent 
(Choi & Mayo, 2006). For a protein, the Ramachandran plot maps the dihedral angles of 
each residue onto an expected, empirically determined distribution of dihedral angles in 
order to detect any strained residues that are not likely to occur in a protein structure. Half 
of the regions of the Ramachandran plot are sterically inaccessible by residues (Haimov 
& Srebnik, 2016). The Ramachandran plot is useful for checking the quality of the 
secondary structure of a protein structure (Ramachandran & Sasisekharan, 1968). For the 
tertiary structure of a protein, one or more secondary structure formations can form 
independent stable functional domains (Branden & Tooze, 1999). Interactions between 
side chains such as disulphide bonds stabilise tertiary structure. In addition, the side 
chains of residues which are polar (Table 2.4) are able to either donate or accept a 
hydrogen bond with either other side chain or main chain atoms (Baker & Hubbard, 
1984). One type of tertiary structure includes the TIM (triosephosphate isomerase) barrel, 
which is a conserved fold that consists of eight α-helices and eight parallel β-strands in 
alternation along the protein backbone. Alternatively, some folds are all α-helical or all 
β-strands in their secondary structure. For the three enzymes triacylglcerol lipase, 
cholesterol esterase and serine carboxypeptidase, despite their different biochemical 
functions, each of their active-site catalytic triads are provided by an α/β hydrolase fold 
(Orengo et al., 2003). For FI in complement, its Trypsin-like serine protease functionality 
is provided by three catalytic triad residues (His362, Asp411, Ser507) in the serine 
protease domain (Chapter 1, Figure 1.4). These three residues are optimally arranged for 
reaction via a β-barrel fold which is composed of mainly β-strands (Dawson et al., 2017). 
For proteins, one particular structural fold may have many biochemical functions, and 
one particular function may have many structures. In summary, for a protein, the 
secondary and tertiary structures are not only essential for protein stabilisation but can 
also provide functional folds that mediate specific activities such as catalysis and ligand 
binding. Each residue of the polypeptide chain thus contributes to the overall protein 
structure and can dictate its function. 
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For a missense mutation in a coding region, the greater the difference between the 
properties of the wild-type and mutated residues (Table 2.4), the more likely the 
secondary and/or tertiary structure is altered or even destroyed. For a protein, such 
structural effects can lead to either degradation, aggregation or affect the ligand binding 
properties. Synonymous coding mutations can affect gene expression and alter the levels 
of the protein. For a mutation in a coding region which substitutes a non-stop codon to a 
stop codon (TAA, TAG or TGA; Table 2.1), a nonsense mutation results. For the 
polypeptide chain, nonsense mutations can occur at any point and lead to truncation. For 
a truncated transcript, the ability of the protein to fold and/or function may be 
compromised. This depends on the location of the nonsense mutation with respect to the 
structural and functional elements of the protein chain. With exceptions, the closer the 
nonsense mutation is towards the 3’ end of the polypeptide (the C terminus), the more 
likely the effects on the protein will be minimal as less of the protein is affected.  
 
For in-frame deletions or insertions, one or more residues in a row are deleted or 
inserted, respectively, in the polypeptide chain. Thus, after the deletion or insertion point, 
the rest of the residues in the polypeptide chain remain. On the other hand, for frameshift 
deletions or insertions, all of the residues after the deletion or insertion can be changed. 
This can lead to rapid degradation of the protein.  
 
For disorders of plasma proteins, a low level of protein with intact function is 
known as Type 1. By this, the protein was either not secreted or rapidly degraded. Type 
2 is defined when the protein level is normal but with less functional activity (Rodriguez 
et al., 2014). With the relevant clinical data, mutations can be associated with either Type 
1 or 2.  
 
2.4.1 Non-coding mutations 
  
 Non-coding mutations can either affect the expression of genes or cause aberrant 
splicing such as exon skipping or cryptic splice site utilisation. Splice sites are known as 
cryptic when they are either dormant or only used at low levels, unless activated by either 
mutation or nearby authentic splice sites (Kapustin et al., 2011). More than 90% of 
disease-associated SNPs are located in non-coding regions of the genome. These include 
promotor regions, enhancers and non-coding RNA genes (Hrdlickova et al., 2014). Such 
mutations located within either introns or splice sites can lead to abnormal transcripts 
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such as the retention of introns and additional residues, which can cause protein 
truncations. For example, the CFH splice donor site variant InterVening Sequence 
(intron) 6+1 G>A is located at the 5’ end of the sixth intron, and retention of this intron 
results in the addition of 30 amino acids to the protein before the stop codon. Thus, a 
truncated protein of 20% of the wild-type results (Wagner et al., 2016). 
 
2.4.2 Residue conservation 
 
Functional DNA sequences, such as those encoding proteins, tend to be actively 
conserved or inherited throughout evolution (Frazer et al., 2001). For any sequence, these 
conserved regions or blocks of residues are known as motifs. Motifs are biologically 
significant in terms of structure and/or function (Huang et al., 2013). Between two 
sequences, high sequence similarity of more than 30% identity over the entire length 
implies homology. This is because the probability of such similar sequences occurring 
independently due to chance is low. For two genes that are homologous, their separation 
occurred due to either speciation (orthologous), or genetic duplication (paralogous). In 
general, for two proteins, as their sequence identity (homology) decreases, both the 
topological differences of the protein backbones and the relative positions of 
corresponding side chains diverge (Hilbert et al., 1993). However, for proteins, large 
proportions can be structurally aligned despite their low sequence identity (e.g. <20%) 
(Chothia & Lesk, 1986). In order to predict the functional significance of a residue, a 
multiple sequence alignment of the sequence of interest (coding nucleotides or protein) 
and its homologs shows how conserved the residue is throughout evolution. Thus, highly 
conserved positions tend to be intolerant to substitution, due to their functional 
importance, whereas those with a low degree of conservation tolerate most substitutions. 
For the multiple sequence alignment, the chemical similarity of residues can also be taken 
into account. The homologous proteins compared could be from different species or in 
the same species. The DNA and protein sequences can be sourced from publicly 
accessible databases and tools (Section 2.7.1). 
 
2.4.3 Loss and gain of function mutations 
 
Mutations that diminish the function of the protein are known as LoF mutations. 
On the other hand, mutations that enhance the function of the protein are known as GoF 
mutations. For these terms, the loss or gain of function refers to the protein and not always 
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its corresponding biological system. For example, a LoF mutation in the C3 protein may 
increase the susceptibility of C3 for inhibition by complement regulators, thus decreasing 
complement activation. In the same way, a GoF mutation in FH may enhance its ability 
to regulate C3, thus also decreasing complement activation. For disease, either LoF or 
GoF mutations may increase either susceptibility or protection. 
 
Following a germline mutation, over generations, the evolutionary mechanisms 
of both genetic drift and natural selection push the mutated allele to be either lost from 
the population or increase in frequency and possibly become fixed. The likelihood of 
evolutionarily deleteriousness is more for LoF mutations than for mutations that either 
affect non-essential genes or only slightly alter protein function or expression (Henn 
et al., 2015). Therefore theoretically deleterious variants will be rare, which has been 
supported by observations of large proportions of deleterious variants that are indeed rare 
(Kryukov et al., 2007; Zhu et al., 2011). However, not all RVs will be deleterious. The 
average exome contains 7.6 rare non-synonymous variants with MAF < 0.1% in well-
characterised dominant disease genes, without disease (Lek et al., 2016). For deleterious 
RVs, their persistence at low frequencies in a population appear to be enabled by either 
the heterozygous advantage (Section 2.3.2), population bottlenecks (genetic drift) or rapid 
growth (Maher et al., 2012). 
 
2.5 In silico predictive tools 
 
In order to assess the functional impact of variants on proteins, a number of in 
silico predictive tools have been developed. Although experimental studies provide the 
most reliable variant functional analyses, in silico computational tools provide a quick 
and inexpensive theoretically-driven method of variant prediction. Thus, in silico tools 
are particularly useful for analysing large numbers of variants rapidly generated from new 
next generation sequencing methods. However, they do not always provide reliable and 
congruent evidence for variants of unknown significance (Ernst et al., 2018; Kerr et al., 
2017). PolyPhen-2 is a program which predicts the possible impact of an amino acid 
substitution on the structure and function of a human protein by using straightforward 
physical and comparative considerations. By this, PolyPhen-2 uses both sequence and 
structure-based predictions, including multiple sequence alignment, accessible surface 
area and hydrophobic propensity analyses, which feed into a machine-learning program 
known as a naïve Bayes classifier and result in a functional prediction. For PolyPhen-2 
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analyses, the user chooses either a HumVar or HumDiv trained dataset, which 
distinguishes either mutations with drastic effects (RVs in Mendelian diseases) from other 
human variation, or only mildly deleterious alleles (RVs in complex phenotypes and other 
uses) from other human variation, respectively (Adzhubei et al., 2010). 'Sorting Intolerant 
From Tolerant' (SIFT) is another algorithm which predicts whether an amino acid 
substitution affects protein function. For an amino acid substitution, SIFT uses sequence 
homology via protein sequence database searches and multiple sequence alignment to 
assess its conservation. The output is either ‘tolerated’ or ‘deleterious’ (Kumar et al., 
2009). One limitation of SIFT is that it does not analyse protein structure. For variants, 
both Polyphen-2 and SIFT were better at predicting those that were LoF than those that 
did not affect function or were GoF (Min et al., 2016). This difference in sensitivity may 
be due to LoF variants having more severe consequences than both GoF and benign 
variants, which likely increases the confidence with which the programs base their 
predictions for LoF variants. For example, a LoF variant that causes a large change in the 
physicochemical properties typically leads to protein misfolding. In contrast, GoF (and 
benign) variants may have a more subtle effect on protein structure thereby resulting in a 
prediction of lower confidence by the program. In addition, GoF variants are expected to 
be less common than LoF variants and this is reflected in the variant training datasets for 
the programs (Flanagan et al., 2010). Other similar in silico tools include PROVEAN 
(Protein Variation Effect Analyzer), Mutation Assessor, Panther, Combined Annotation 
Dependent Depletion (CADD), and Condel. 
 
2.6 Terminology of mutations, polymorphisms and variants 
 
For sequence variants in human DNA and protein sequences, the terms ‘mutation’ 
and ‘polymorphism’ were initiated by two papers in 1993 (Beaudet & Tsui, 1993; Beutler, 
1993). Mutation refers to any rare change in the nucleotide sequence which is usually but 
not always linked to a disease attribute. Mutation may or may not cause phenotypic 
changes. Polymorphism refers to a variation in DNA sequence that occurs in the general 
population with a frequency of 1% or higher. Thus, the threshold of 1% was established 
to distinguish common (polymorphism) from rare (mutation) variants (Brookes, 1999). 
For the general population, the more common the polymorphism, the more likely it has a 
neutral or beneficial effect. However, mutations that were thought to be rare have been 
found to exceed the 1% frequency threshold (Auer et al., 2012). In another study, alleles 
common in one population were frequently not common in another population. 
56 
 
Furthermore, a disease-associated mutation in one population was found to be harmless 
in another, and vice versa (Myles et al., 2008). Thus, the terms mutation and 
polymorphism can be independently used to describe the same event with different 
reference genetic datasets. The distinction between mutation and polymorphism on the 
basis of their disease-causing capacity is further complicated, e.g. for disease, common 
variants can be associated with either increased risk or increased protection. Overall, the 
terms mutation and polymorphism can lead to confusion. In order to resolve this issue, 
the American College of Medical Genetics and Genomics recommended the term 
‘variant’ be used instead with the modifiers: pathogenic, likely pathogenic, uncertain 
significance, likely benign, or benign (Richards et al., 2015; Karki et al., 2015).  
 
2.7 Sequencing methods 
 
For the investigation of genotype-phenotype relationships, a reference human 
genome sequence is required. The first human reference genome was assembled by The 
Human Genome Project in 2001 (Lander et al., 2001). The assembly was based on 
multiple genomes of anonymous donors in the US. Despite this human reference genome 
taking 10 years to sequence at first, the sequencing of entire genomes has now become 
routine in research and medicine and can take 1-2 days or even less. A combination of 
long-range sequencing and assembly technologies has made highly contiguous whole 
genome de novo (reference) assemblies possible. The current human reference genome 
assembly, GRCh38, has a total of 3,088,269,832 nucleotides and was constructed by 
using Sanger sequencing. Sanger sequencing (first generation) is based on the chain-
termination method of sequencing (Sanger et al., 1977) and can produce long, 1000 
nucleotide reads. This can make it 10 times more accurate than high throughput short read 
sequencing, such as next-generation sequencing (second generation) (Guo et al., 2017). 
Next generation sequencing encompasses a group of highly parallel DNA sequencing 
technologies that can produce hundreds of thousands or millions of short reads for a low 
cost and in a short time. When compared to Sanger sequencing, next generation 
sequencing is more sensitive to low frequency mutations (Arsenic et al., 2015). For CFH, 
due to its sequence homology with the five CFHRs, the longer reads obtained from Sanger 
sequencing are much more accurate than next generation sequencing. By using either 
Sanger or next generation sequencing methods, certain parts of the genome can be 
sequenced. Firstly, whole genome sequencing produces the most complete dataset for an 
individual’s genome, however both the costs and the time needed for computationally 
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analysing the massive amount of data are great. Despite being made quicker and less 
expensive by next generation sequencing technologies such as Illumina dye sequencing 
in 2005, whole genome sequencing still remained expensive. This prompted the 
development of targeted gene sequencing and whole exome sequencing. In targeted gene 
sequencing, only the genes of interest are sequenced. By this, the costs are much lower 
and the coverage is higher, but the detection of disease-associated variants will only 
succeed if the disease-causing gene is included in the panel (Sun et al., 2015). In contrast, 
whole exome sequencing captures only the protein-coding DNA. Whole exome 
sequencing is cheaper and provides an efficient strategy for the detection of disease-
causing variants in proteins, but can miss both major types and regions of disease-causing 
genomic variation such as structural and intronic variants. At present, the cost of whole 
genome sequencing and whole exome sequencing have each approached US$1000 and a 
few hundred US$, respectively. This has greatly accelerated the pace of individual human 
sequencing (Shendure et al., 2017).  
 
After the genomic DNA fragments are sequenced, they are aligned and merged 
based on overlapping nucleotides. This leads to contiguous segments or contigs of DNA 
for which the sequence of bases can be accurately calculated. Multiple contigs are then 
assembled to form a scaffold with gaps. Multiple scaffolds are then combined to form a 
chromosome. After this, genomic annotation involves predicting the features of the DNA, 
such as coding genes, pseudogenes, promoter and regulatory regions, untranslated regions 
and repeat regions (Reeves et al., 2009). Advanced computing methods and algorithms 
are required for these processes. For the detection of copy number variants, either 
multiplex ligation-dependent probe amplification or array based technologies are used 
to supplement whole genome sequence, whole exome sequencing and targeted gene 
sequencing (Dillon et al., 2018).  
 
Complete genome sequences for humans has led to the development of millions 
of polymorphic markers. For an individual, a whole genome-based SNP profile can be 
obtained by a SNP chip. Over the entire human genome, the International HapMap 
Project has mapped blocks of SNPs based on haplotype analyses (International HapMap 
et al., 2007). Haplotypes occur due to a lack of genetic recombination between sites, 
which strengthens the linkage disequilibrium. 
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2.7.1 Sequence databases and tools 
 
For nucleotide sequences, three publicly accessible databases hold both 
eukaryotic and prokaryotic data. These are the nucleotide sequence database of the 
European Molecular Biology Laboratory (EMBL) at the European Bioinformatics 
Institute (EBI) (Kanz et al., 2005), Genbank at The National Center for Biotechnology 
Information (NCBI) of the National Institutes of Health (NIH) (Benson et al., 2008) (US) 
and the DNA Database of Japan (DDJB) (Kodama et al., 2018) at the National Institute 
of Genetics in Mishima. For example, a total of 78 eukaryote and prokaryote reference 
genome sequences are provided by the EMBL Ensembl web-database. For conserved 
residue analyses via multiple sequence alignment, Ensembl and its tool Compara can be 
used to retrieve the DNA sequences of protein homologs from numerous different 
species. Ensembl also includes the prediction of genes, transcripts and peptides (Flicek et 
al., 2008). The EBI also provides tools such as Clustal Omega for the multiple sequence 
alignment of either DNA or protein sequences, and resources such as UniProt (The 
UniProt, 2017) for protein sequence and functional annotation. The Reference Sequence 
(RefSeq) collection by NCBI provides annotated, non-redundant sequences for genomic 
DNA, transcripts and proteins (Pruitt et al., 2007). RefSeq genomes are copies of selected 
assembled genomes from GenBank. As of Release 88, RefSeq contained over 132 million 
sequences, including 110 million protein sequences, which represented 79,448 organisms 
(O'Leary et al., 2016). The RefSeq transcript and protein records are generated by a 
combination of annotation pipelines, manual curation and other annotated genome 
resources. The NCBI also provides dbVar and the online version of the Online Mendelian 
Inheritance in Man database of human-inherited diseases and their associated genes. 
Online Mendelian Inheritance in Man contains about 18,000 entries and includes data on 
over 12,000 established gene loci and phenotypes. In addition, the NCBI provides a 
repository of tools which allows analyses to be performed for several types of gene, 
protein, and genomic data, such as the Basic Local Alignment Search Tool (BLAST) 
programs (Wheeler et al., 2008). The University of California Santa Cruz (USCS) 
genome browser displays genomic data for human, mouse and other organisms. USCS 
also provides genomic annotation which was either computed by USCS or contributed to 
by their collaborators. The genomic annotation is visualised as horizontal tracks (Kent et 
al., 2002). ClinVar is a public database of reports of the relationships between human 
variation and phenotype with supporting evidence. For variation calls in ClinVar, the 
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level of confidence in their accuracy depends on the supporting evidence, which is 
variable and provided by the resource (Landrum et al., 2018). 
 
2.8  Genetic variants and disease  
 
Single-gene or monogenic diseases run in families and can be either dominant or 
recessive, and either autosomal or sex-linked. For this reason they are known as 
Mendelian diseases and are usually rare. For monogenic diseases, pedigree analyses of 
large families with many affected individuals are used to determine the pattern of 
inheritance. However, sporadic cases of monogenic diseases are also seen. For 
monogenic disease, the affected gene will likely harbour a deleterious functional variant 
which increases disease susceptibility and is nearly fully penetrant. For the deleterious 
variant, the severity of the associated phenotypes and large reduction in fitness prevents 
it from rising to higher frequencies in populations. It is therefore kept at a very low AF 
in the population. However, in individual carriers, such a variant could be required but 
not sufficient to cause the Mendelian disease. By this, modifiers such as additional 
variants in the genetic background (Mitchell, 2012), as seen in Huntingdon’s disease 
(Kearney, 2011), or environmental triggers are required. The likelihood of the variant 
causing the disease by itself is known as penetrance. For a disease, the penetrance of the 
variant is calculated by dividing the number of patients that have the variant by the total 
number of patients. Variants that have lower penetrance might require additional 'hits' to 
result in the disease phenotype. However, highly penetrant monogenic diseases can still 
be modified by other genetic variants (Mitchell, 2012). Dominant variants occur largely 
as a result of sporadic mutation, whereas recessive variants are maintained at low 
frequencies by the process of natural selection against homozygotes. In total, 
approximately 7,000 rare, monogenic diseases are known. Collectively, monogenic 
diseases are common (Boycott et al., 2013) and may affect as many as 30 million 
Europeans (Dodge et al., 2011). The genetic basis is only known for around half of rare 
monogenic diseases (Boycott et al., 2013). 
 
A complex or multifactorial disease is thought to develop due to the combined 
effects of a large number of genetic variants in an affected individual. For complex 
disease, no single locus contains alleles that are necessary or sufficient for disease 
manifestation. This is distinct from a model of genetic heterogeneity in which many 
different genetic variants are involved in a disease across the whole population, but each 
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case is caused by a single or a few variants (Mitchell, 2012). Alongside genetics, non-
genetic environmental factors also influence the manifestation of complex disease. Thus, 
the multifactorial nature of complex diseases means that they do not usually follow 
Mendelian inheritance in familial segregation analyses. A small fraction (<1% - 7%) of 
complex diseases are associated with single mutant genes that were transmitted by 
Mendelian inheritance (Scheuner et al., 2004), but these cases often have an earlier age 
of onset with more severe clinical symptoms (Motulsky, 2006). For environmental 
factors, their importance in the emergence of disease phenotypes has been shown by the 
incomplete concordance of the phenotypes of monozygotic twins for many diseases. 
Many common diseases are complex, such as hypertension, diabetes, Alzheimer’s disease 
and AMD. Complex diseases often have late onset. For each of the multiple variants that 
contribute to the traits of a complex disease, the penetrance will be lower than for variants 
that contribute to Mendelian disease traits (Figure 2.4). For carriers of complex-trait 
variants, there is often little or no effect on their reproductive fitness. By this, in the 
population, the complex-trait variants may become more common due to random genetic 
drift (Wagner, 2013).  
 
For common complex diseases, the genetic architecture has been modelled by two 
hypotheses. The “common disease, common variant” hypothesis states that risk alleles 
for common complex diseases should be common (>5%) (Figure 2.4) and therefore old 
and found in multiple human populations rather than being population specific (Myles et 
al., 2008). This was coupled with the discovery of several susceptibility variants for 
common disease that had high MAF (Bush & Moore, 2012). In keeping with the 
“common disease, common variant” hypothesis, the “allelic spectrum of disease” is a 
theoretical perspective that includes low and high penetrance and common and RVs. On 
the other hand, the “common disease, RV” hypothesis focuses on RVs because, despite 
the total frequency of variant alleles that contribute to a trait at one locus being moderately 
high, the frequency of each of the individual variants can be much lower (i.e. rare). This 
theory was initially based on theoretical simulations of complex disease traits. Further 
evidence for the “common disease, RV” model was provided by a literature review of 
genetic association studies (Wagner, 2013). 
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Figure 2.4 Spectrum of disease allele effects. Allele frequency (AF) (x axis) and effect 
size (y axis) are often used to conceptualise disease associations. Alleles for Mendelian 
diseases are very rare and highly penetrant with high effect sizes (upper left). Most 
genome-wide association study (GWAS) findings are of common single nucleotide 
polymorphisms with low effect sizes (lower right). The bulk of discovered genetic 
associations lie within the diagonal dotted lines. Sourced from (Manolio et al., 2009). 
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2.8.1 Family-based studies 
 
In order to associate a genotype with a disease-related phenotype, either family-
based or population-based case-control studies are employed. Family-based studies are 
most efficient for analysing either rare monogenic diseases or rare sub-phenotypes of 
common conditions (Zondervan & Cardon, 2007). For family-based studies, the number 
of relatives studied can range from two family members to enormous pedigrees. The 
affected individual is known as the proband. In these families, both linkage and 
association studies directly evaluate genetic markers. In contrast, other family-based 
studies that use segregation, aggregation or twins evaluate the potential genetic basis of 
disease using patterns. For example, segregation analyses allow the mode of inheritance 
of the disease to be established.  
 
For rare monogenic diseases that have known inheritance patterns in families, 
linkage analyses are arguably the most powerful method. For linkage analyses, the 
inheritance of genetic markers spaced evenly throughout the entire genome, such as 
SNPs, with the disease is evaluated. If the markers and the disease trait co-segregate in 
families, the disease-causing variants are inferred to be near the markers. Model-based 
(parametric) linkage analyses are used for large pedigrees, whereas a model-free approach 
(non-parametric), which is less powerful and based on identity-by-descent estimates, is 
used for a pair of affected siblings. By these linkage methods, a priori pathophysiological 
hypotheses are not needed. Overall, linkage analyses do not aim to identify the casual 
gene but facilitate the process of directly identifying disease variants. An advantage of 
family-based studies is that population stratification issues are bypassed because of the 
common genetic background between individuals (Schnell & Witte, 2008). Furthermore, 
families with multiple disease cases are enriched for causal variants which leads to 
increased statistical power. A disadvantage is that it can be difficult to accumulate large 
enough samples of well-characterised families for analyses (Evangelou et al., 2006), and 
linkage analyses are not always applicable to small family sizes (Barc & Koopmann, 
2011). In addition, for sporadic cases of rare diseases, for which there is no previous 
family history of the disorder, family-based studies are limited. The power of linkage 
analyses is greatly reduced by incomplete penetrance. In order to overcome this loss of 
power, multiple families consisting of small numbers of affected individuals may be 
analysed via aggregation. However, in the presence of locus heterogeneity, the 
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aggregation may result in a further loss of power, because different families will have 
different genes associated with the disease (Guo et al., 2016). 
 
For complex and common diseases, family-based studies are not well suited 
unless the correlation between genotype and phenotype is very robust. Instead, 
population-based case-control studies are utilised. 
 
2.8.2 Population-based case-control studies 
 
For population-based case-control studies, individuals with the disease-associated 
trait (cases) and individuals without (controls) are selected from the population. In order 
to test whether a genetic variant of interest is associated with the trait, the variant AF is 
calculated for each group and subsequently compared. If the variant is significantly more 
frequent in cases than controls, the variant is statistically associated with the disease. This 
method can be applied to either rare or common variants. However, the sample sizes 
needed to detect RVs (AF < 1%) can be unfeasibly large (Zondervan & Cardon, 2004). 
In order to generate the genetic data for population-based case-control studies, all 
individuals in both populations should be sequenced by using the same method. This can 
be either targeted to specific genes, from a priori knowledge of the genes implicated in 
the disease (candidate gene method), or non-hypothesis based such as for genome-wide 
association studies (GWAS). Relative risk and odds ratio statistics can also be calculated. 
 
For these population-based case-control studies, despite the high statistical power 
from variant enrichment in cases, there is often an increased susceptibility to false 
positives due to the absence of data for the genetic backgrounds of cases and controls 
(Altshuler et al., 2008). Thus, spurious associations can be detected if cases and controls 
are sourced from different populations for which the AFs vary (Schnell & Witte, 2008). 
Such unaccounted population admixture can lead to confounding results. Ethnicity 
matching is thus very important in order to limit potential confounding by genetic 
ancestry. 
 
For GWAS, the aim is to correlate SNPs with a disease status or trait variation by 
comparing the AF of the variants between cases and controls (van der Sijde et al., 2014). 
Genotyping panels are typically used and can provide 300,000 – 1 million SNPs. The 
decreasing costs and increasing SNP density of standard genotyping panels has shifted 
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the focus of attention from candidate gene approaches towards whole genome based 
GWAS (International HapMap et al., 2007). In general, SNPs identified in GWAS that 
associate with a phenotype are unlikely to be causal variants but proxies. By this, they are 
likely to be associated via linkage disequilibrium with the true but currently unknown 
casual variants. GWAS can identify genes which would not have been considered a priori 
to be good candidates for the disease. For example, GWAS in humans have been 
successful for identifying genetic regions that are important in the development of 
complex and common diseases such as diabetes (Sladek et al., 2007), Crohn’s disease 
(Barrett et al., 2008) and other autoimmune and genetic diseases. One of the most 
successful applications of GWAS was for common variants in AMD in 2005 (Klein et 
al., 2005), which triggered numerous more detailed studies on AMD (Black & Clark, 
2016). One disadvantage of GWAS is that due to the number of independent tests 
performed, the statistical power is often low. 
 
However, for many complex common diseases, common variants identified by 
GWAS only explain a small proportion of the total genetic variance to the trait variance. 
For common diseases, this ‘missing heritability’ is thought to comprise either many 
common variants of small effect sizes (“common disease, common variant”) which are 
not fully identified by underpowered GWAS, RVs (“common disease, RV”) (Wagner, 
2013) or environmental factors. For AMD in 2011, a high-throughput GWAS using CFH 
genotyping identified a haplotype of high penetrance which lead to the association of a 
RV (c.3628C>T; p.Arg1210Cys) after statistical analyses. Following this, and with the 
use of functional data, it was concluded that AMD-risk is likely driven by rare CFH LoF 
alleles (Raychaudhuri et al., 2011), in addition to common variants. 
 
2.8.3 Allele frequency data for rare variants 
 
For rare Mendelian diseases, such as aHUS and C3G, candidate RVs are typically 
identified by family-based or small case-control studies. For the clinical interpretation of 
candidate variants, the rarity of a variant is a prerequisite for pathogenicity. For a variant, 
the pathogenicity generally decreases as the AF increases (Kobayashi et al., 2017) 
(Section 2.4.3). Thus, a variant expected to be causative for a rare Mendelian disease will 
not be frequent in unselected individuals (without the disease). The filtering of candidate 
variants by their AFs in unselected individuals is a key step in any pipeline for the 
discovery of causal variants (Lek et al., 2016). 
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 Next generation sequencing methods combined with the development of 
computer software have allowed a vast amount of sequence reads to be generated, 
processed, quality controlled and called. By this, RVs can be detected from datasets of 
sequences from thousands of individuals or more. An example of this is The 1000 
Genomes Project (1000GP) (Genomes Project et al., 2010), which sequenced more than 
2,500 healthy individuals from 26 populations by using low-depth whole genome 
sequencing combined with imputation methods for high-quality variant calls. Due to the 
difficulty in interpreting non-coding genomic DNA (98%), whole exome sequencing was 
developed in order to capture the exons only (Section 2.7). An example of whole exome 
sequencing for the identification of RVs is the National Heart, Lung and Blood Institute 
(NHBLI) Exome Sequence Project (ESP) Exome Variant Server (EVS) which sequenced 
the exomes of 6,515 individuals (Fu et al., 2013; Tennessen et al., 2012). Such whole 
exome sequencing has identified the genetic basis of many rare monogenic diseases 
(Gilissen et al., 2011). The ExAC is a large protein-coding human variation catalogue of 
aggregated sequence data from 60,706 individuals of different ethnicities (Table 2.5) and 
cohorts (Table 2.6). The ExAC study identified more than 7.4 million new genetic 
variants of high confidence. The ExAC is the first dataset with high enough power to 
identify very RV AFs in the range of 0.01% – 0.0001% (Walsh et al., 2016).  
 
The ExAC, 1000GP and EVS are large genetic variant datasets of unselected 
individuals without rare Mendelian diseases. By this, they can be used as reference 
datasets for the AF-based interpretation of candidate variants, with caveats such as 
differences between both the sequencing methods and ethnicity of participants. 
Population stratification can be used to overcome the latter. For a variant to be classified 
as “benign”, an “allele frequency greater than expected for disorder” in the reference 
dataset has been recommended as strong evidence by the American College of Medical 
Genetics and Genomics and the Association for Molecular Pathology in their joint 
consensus on the interpretation of sequence variants (Richards et al., 2015). The reference 
dataset AF cut-off for RVs is typically below 1% and differs depending on the disease of 
interest and the variant penetrance. Based on analyses of the ExAC data, it was concluded 
that a variant identified in ExAC with a global AF greater than 0.01% is too common for 
a disease of Mendelian inheritance. As an alternative to using theoretical incidence and 
penetrance methods, the AF cut-off for a disease can be determined by analysis of the 
pathogenic variant burden (Kobayashi et al., 2017).  
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Table 2.5 Cohorts represented in the ExAC data 
 
 
Table 2.6 Populations represented in the ExAC data 
Consortium/Cohort 
Number of 
Samples 
1000 Genomes 1,851 
Bulgarian Trios 461 
GoT2D (Type 2 diabetes) 2,502 
Inflammatory Bowel Disease 1,675 
Myocardial Infarction Genetics Consortium 14,622 
NHLBI-GO Exome Sequencing Project (ESP) 3,936 
National Institute of Mental Health (NIMH) Controls 364 
SIGMA-T2D (Type 2 diabetes) 3,845 
Sequencing in Suomi (SISu) 948 
Swedish Schizophrenia & Bipolar Studies 12,119 
T2D-GENES (Type 2 diabetes) 8,980 
Schizophrenia Trios from Taiwan 1,505 
The Cancer Genome Atlas (TCGA) 7,601 
Tourette Syndrome Association International Consortium for 
Genomics (TSAICG) 
297 
Total 60,706 
Population Male Samples Female Samples Total 
African/African American 1,888 3,315 5,203 
Latino 2,254 3,535 5,789 
East Asian 2,016 2,311 4,327 
Finnish 2,084 1,223 3,307 
Non-Finnish European 18,740 14,630 33,370 
South Asian 6,387 1,869 8,256 
Other 275 179 454 
Total 33,644 27,062 60,706 
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 Despite this, some recent studies have shown that the rarity of a variant in the 
reference dataset is not always a reliable indicator of pathogenicity for a Mendelian 
disease. In the ExAC dataset, which does not contain rare Mendelian disease cases (Table 
2.6), 192 variants reported to cause rare Mendelian disease were found at high 
frequencies. The ExAC also showed that the average participant had approximately 54 
variants that were previously classified as casual for rare disease (Lek et al., 2016). It has 
also been estimated that each healthy genome is heterozygous for 50-100 variants that 
have been classified as causing inherited disorders in the Human Gene Mutation 
Database. For the 1000GP, analyses found that each healthy genome contains 
approximately 100 high-confidence functional LoF variants, of which 20% were 
homozygous (MacArthur et al., 2012). These LoF variants include premature stop 
codons, splice site disruptions and frameshifts (Genomes Project et al., 2010). These LoF 
variants are mostly rare which indicates the act of negative selection (Wagner, 2013). 
These occurrences of deleterious LoF variants in healthy people implies that some 
functional variation may be tolerated by genes. By this, the genes most likely to influence 
disease are those that are the most intolerant of functional variation. In keeping with this, 
genes responsible for Mendelian diseases show significant intolerance (Petrovski et al., 
2013). For a gene, functional tolerance can be gained via a number of mechanisms. In 
summary, for analysing RV pathogenicity in disease, AF analyses are essential for 
support but cannot be used as the sole evidence. 
 
In GWAS, low-frequency (rare) variants are not tagged by conventional genome-
wide genotyping arrays (or chips). However, some specialised genotyping chips for RVs 
have recently been developed based on genomic co-ordinates that are identified by 
sequencing projects such as 1000GP and EVS. The chips can test many exonic variants 
at modest costs. Compared to sequencing, RV chips are computationally simpler to 
analyse but will miss a large amount of very rare genetic variation. Another drawback of 
RV chips is that they are based on European datasets and so may not reflect genetic 
variation in other populations (Auer & Lettre, 2015). 
 
2.9   Methods: rare variant assessment guidelines for rare genetic diseases 
 
For variant pathogenicity classification, the American College of Medical 
Genetics and Genomics recommends using criteria based on a combination of population, 
computational, functional and segregation data (Richards et al., 2015). Based on these 
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criteria, for aHUS and C3G, the categorisation of genetic variants has recently been 
standardised (Goodship et al., 2017) (Table 2.7). For variant pathogenicity for aHUS and 
C3G, a reference AF cut-off of <0.1% is recommended. Reference databases currently 
available include 1000GP, EVS and the ExAC. Overall, the variant is assessed by using 
these AF analyses in combination with the literature, supporting functional data, the 
zygosity, in silico predictions and the location of the variant within the protein. The 
opinion of an expert laboratory in aHUS or C3G is also required to determine the disease 
impact of particular genetic variants. A more stringent RV AF cut-off of <0.01% is also 
applicable to rare diseases of Mendelian inheritance (Kobayashi et al., 2017). Compared 
to <0.1%, the <0.01% AF cut-off restricts the pathogenicity inclusion criteria to rarer 
variants. This decreases the likelihood of incorrectly including a non-pathogenic variant 
(background variation), but may also exclude potentially pathogenic variants of less 
penetrance (not as rare). For describing genetic variants, a standard gene variant 
nomenclature is maintained by the Human Genome Variation Society. 
 
For clinical genetic testing of aHUS and C3G patients, the minimum set of genes 
that should be screened includes CFH, CD46, CFI, C3, CFB, THBD, CFHR1, CFHR5 
and DGKE. For aHUS only, genotyping for the risk haplotypes CFH-H3 and CD46ggaac 
is also carried out. In order to detect copy number variants, hybrid genes and other 
complex rearrangements in the CFH/CFHR genomic region, suitable technologies such 
as multiplex ligation-dependent probe amplification are used (Goodship et al., 2017). In 
addition to genetic analyses, plasma complement components, expression of CD46 on 
peripheral blood mononuclear cells and anti-FH autoantibodies are also measured. 
However, plasma FH level measurements may not allow detection of heterozygous FH 
deficiency states. 
 
2.10 Methods: rare variant burden tests  
 
For assessing the association of genes with a disease, RV burden tests can be used. 
RV burden tests allow the rare variation of a gene for a disease cohort to be compared 
with large reference datasets of many unselected individuals which represent background 
rare variation. By using large reference datasets, the power of the study is increased. 
However, this also depends on the size of the disease dataset. RV burden tests are useful 
for verifying the results of family-based and small-scale case-control studies for rare 
diseases, such as for aHUS and C3G. This is because these smaller-scale studies are  
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Table 2.7 Categorisation of the genetic variants for aHUS and C3G 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sourced from (Goodship et al., 2017) 
Category Criteria 
Pathogenic 
Novel or rare (MAF <0.1%) variant reported to cause disease in literature; supporting functional data 
indicating the variant affects protein function or expression; zygosity fits inheritance pattern. 
Likely pathogenic 
Novel or rare (MAF <0.1%) variants that change protein sequence or affect splicing and with highly 
deleterious effects by in silico predictions but without functional data; found in disease-related functional 
domains; zygosity fits inheritance pattern. 
Uncertain 
significance 
Novel or rare (MAF <0.1%) variants that change protein sequence or affect splicing with no known 
functional data; uncertain deleterious effects by in silico prediction.  
Likely benign 0.1% <MAF <1%; not in a mutational hotspot; no functional data; in silico predicted benign. 
Benign 
MAF >1%; variant reported as not-disease associated; functional data suggest benign; benign by in silico 
prediction.  
70 
 
limited by both genetic factors which are heterogeneous and incompletely penetrant, and 
diseases for which sporadic cases are often observed (Section 2.8.1). All of these limiting 
factors decrease the power of familial studies for detecting gene associations.  
 
For RV burden tests, RVs are collapsed into genetic scores and tested for 
association with the disease trait. For a gene, this determines whether the aggregated 
frequency of rare variation identified for the disease cohort is significantly different from 
that expected for individuals without disease. For the case individuals, RV burden tests 
are typically applied to unrelated probands. For the reference dataset, AF data from large 
population-based datasets such as the ExAC can be extracted. In a recent study, the use 
of population-based control subjects rather than disease-free control subjects showed 
negligible effects on power (Guo et al., 2016). 
 
Burden tests are powerful when a large proportion of the variants are causal and 
the effects are in the same direction. However, burden tests lose power when either a 
mixture of both trait-increasing and trait-decreasing variants are present, or if only a small 
fraction of the variants are casual (Lee et al., 2014). In the RV burden test, the qualifying 
variants in control subjects represent a background rate of variation for each gene. 
However, if there is incomplete penetrance, unaffected control individuals may also 
harbour pathogenic variants. By this, some of this background variation may correspond 
to incompletely penetrant pathogenic variants that have not yet manifested as disease, as 
well as potentially misclassified benign variants. Thus, the RV burden test is based on a 
simplifying assumption that the frequencies of rare benign variants in both cases and the 
reference dataset are equivalent, and that the frequency of pathogenic variants in the 
reference dataset is sufficiently low (Walsh et al., 2016). This is facilitated by including 
only protein-altering variants and applying the same AF filter to both cases and controls. 
In addition, in order to reduce false positives, the control cohort can be matched to the 
case samples for both ancestry and technical factors such as the depth of sequencing 
coverage in each gene (Guo et al., 2016). For a burden test, the data is presented in a 
contingency table and either the 𝜒2 or the Fisher’s exact test of independence can be used 
for significance testing. Both of these tests assess independence between two variables 
when the comparing groups are independent and not correlated. The 𝜒2 test applies an 
approximation which assumes the sample is large, whilst the Fisher's exact test runs an 
exact procedure which is more accurate for small-sized samples (Kim, 2017). 
 
71 
 
For statistically summarizing the evidence for association between a disease and 
a gene (or genetic variant), the most convenient method is significance testing with 
appropriate correction for multiple testing. For significance testing, the P value is defined 
as the probability of obtaining a value (T), which follows a known probability 
distribution, that is at least as extreme as that of the actual sample (t), when the null 
hypothesis (H0) is true (Fisher, 1925; Neyman & Pearson, 1933). If P is smaller than a 
pre-set “significance” threshold α then H0 is rejected and the result is considered to be 
significant. α can be corrected for multiple testing by using the Bonferroni correction. 
This divides α by the number of independent tests carried out (Armstrong, 2014). The 
range of values of the test statistic T that would lead to the rejection of H0 is known as the 
critical region of the test. For the test, the probability of rejecting H0 when it is actually 
true (a false negative) is known as a Type 1 error and is equal to α. Thus, the more relaxed 
(greater) the significance level, the more likely there will be a Type 1 error. The 
probability of failing to reject H0 when it is actually false (a false positive) is known as a 
Type 2 error and denoted as β. The statistical power of the test, (1 – β), is defined as the 
probability of correctly rejecting H0 when it is actually false (true negative) and a true 
association is present. For the study, the power calculation is used to ensure realistic and 
meaningful results are possible (Sham & Purcell, 2014) and is often set to 80%. This 
means that if a difference exists, there will be a 20% chance of a Type 2 error. The power 
of a study is increased by sample size. The Altman nomogram can be used to calculate 
the sample size needed for 80% power by inputting the standardized difference 
and α level (Columb & Atkinson, 2016). For categorical data expressed as proportions p1 
and p2 for two groups, the standardised difference is given by: 
 
Standardised difference =  
𝑝1 −  𝑝2
√𝑝(1 − 𝑝)
                                                                            (2.6) 
      
2.11 Overview of aHUS, C3G and AMD genetics 
 
aHUS and C3G are two ultra-rare diseases that both involve genetic predisposition 
for complement AP dysregulation and a triggering event. However, between aHUS and 
C3G, both the molecular mechanisms and clinical presentations differ (Chapter 1, 
Sections 1.7.1 and 1.7.2). For both aHUS and C3G, a number of predisposing genetic 
variants have been identified by familial and small-scale case-control cohort studies, with 
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subsequent functional analyses. For C3G, the genetic understanding is not yet comparable 
to that of aHUS (Goodship et al., 2017).  
 
For aHUS, some variants have strong links based on familial studies. For example, 
the screening of 25 individuals with aHUS within three families showed that all carry a 
pathogenic CFH variant (c.3643C>G; p. Arg1215Gly). However, the penetrance of this 
strongly linked variant in aHUS is ∼50% (incomplete) and is determined by the CFH and 
CD46 haplotype, additional RVs, age and a trigger (Sansbury et al., 2014). Overall, the 
investigation of individuals with aHUS for genetic susceptibility factors has become 
increasingly complex because both the number and nature of reported genetic defects has 
expanded (Goicoechea de Jorge & Pickering, 2010). Presently, in ~60% of aHUS 
patients, one or more genetic abnormalities in complement AP or related genes have been 
detected. These mostly drive AP dysregulation at the endothelial cell surface (Goodship 
et al., 2017). For genetic aHUS, most cases are heterozygous (Nester et al., 2015; 
Rodriguez et al., 2014), and are attributed to the genes CFH, followed by CD46, C3 and 
CFI, and CFB. In addition, rare copy number variation in the genomic region which 
encompasses the CFHRs are risk factors for aHUS. For example, the CFH/CFHR1 and 
CFH/CFHR3 hybrid genes. For aHUS, RVs in the thrombosis-related genes 
thrombomodulin (THBD) and plasminogen (PLG) have also been identified (Osborne et 
al., 2018a). For aHUS, in addition to the initial association of complement genes by using 
linkage and candidate gene analyses, whole exome sequencing followed by co-
segregation studies identified a highly significant association with recessive RVs in the 
non-complement gene DGKE (Lemaire et al., 2013). For rare diseases, this demonstrates 
the importance of genome and exome-wide methods in identifying genes for which an 
association could not have been predicted from previous immunological pathway data. 
 
For C3G, approximately 20% of cases are associated with predisposing RVs in 
the complement genes. Thus, the vast majority of cases are associated with C3 nephritic 
factor or autoantibodies. These genetic C3G cases are either sporadic or familial and can 
be inherited in either autosomal recessive or dominant forms. Familial C3G is most often 
linked to highly penetrant heterozygous copy number variation in CFHR1–5 genes, such 
as CFHR5 nephropathy (Gale et al., 2010), as well as homozygous CFH deficiency and 
heterozygous GoF mutation in C3 (Osborne et al., 2018a).  
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AMD is distinct from aHUS and C3G in that it is a common and complex disease, 
but similar to aHUS and C3G in that it is associated with both complement AP 
dysregulation and genetic variants. Thus, GWAS have revealed significant statistical 
associations between AMD and the complement genes CFH, CFHR1, CFHR3, CFB, C2 
and C3 (Anderson et al., 2010). As well as increasing the risk for AMD, common variants 
have also been associated with reduced activation of the AP thus reduced susceptibility 
to AMD for both CFB (Montes et al., 2009) and CFH (Tortajada et al., 2009). For AMD, 
one of the most significant statistical associations exists for the common CFH variant 
c.1204T>C which encodes the missense change p.Tyr402His. In FH, p.Tyr402His 
weakened the binding of FH SCR-7 to eye tissue-specific HS only (Clark et al., 2013), 
which is relevant to AMD. For common variants in complement, each individual has a 
functional ‘complotype’, which may influence susceptibility to AP-driven disease such 
as aHUS, C3G and AMD (Heurich et al., 2011). 
 
2.12 Methods: genetic variant web-databases 
 
Currently, the most reliable method of assessing whether a genetic variant is 
causative or a risk factor for disease consists of a combination of statistical association, 
by using case-control or family studies, functional assays and in silico-based conservation 
and predictive analyses. By this, large amounts of complex data may exist for each 
variant. Furthermore, for both rare and common diseases, one case may have multiple 
identified variants of different frequencies in multiple genes. At the population level, the 
disease may be associated with a number of different genes. For genetic variants within 
these contexts, databases allow the storage, organisation and analysis of the data and 
complex relationships. Databases provide critical resources for the clinical interpretation 
of variants identified in patients with rare diseases (Lek et al., 2016). For example, the 
interactive database for human coagulation factor IX assisted in making judgments about 
hemophilia B patient management, as well as providing insights into the molecular 
mechanisms of the disease (Rallapalli et al., 2013). 
 
Databases are organised collections of related data tables. A database server 
stores, retrieves and allows quick, simultaneous access to data from different users and 
web servers. Databases allow the management of complex relationships between related 
data tables including one-to-one, one-to-many, and many-to-many. In order to manage 
databases, a database management system provides a suite of specially designed 
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computer applications which enables the user, other databases and applications to interact 
with the data. The relational database management system is an improved version of the 
hierarchal and network models of database management systems that allows any table to 
be accessed directly and not via parent objects. For relational database management 
systems, an object-orientated system is where reusable chunks of applications (objects) 
are stored in the database, and instructions (commands) enable the object to be used. An 
object-relational database system thus combines the features of object-orientated storage 
and relational combinations of the data tables.  
 
Structured Query Language (SQL) was developed in the 1970s for the creation, 
manipulation and retrieval of data in databases. MySQL is a widely used database server 
or relational database management system which relies upon SQL. By the use of SQL, 
data in tables or whole databases can be defined, removed, modified, inserted, deleted, 
and retrieved, and administrative tasks such as user authorisation and monitoring, 
security, backup and recovery can be completed. Many application programming 
interfaces are able to interact with MySQL. SQL is compatible with web development 
languages such as the PHP: Hypertext Preprocessor (PHP) server-side scripting language 
thus allowing client/server interactions (Williams & Lane, 2002). Usually, PHP is 
embedded or combined with the Hypertext Markup Language (HTML) of a web page. 
When the page is requested, the web server executes the PHP script and the result is 
presented via substituting the webpage. By using PHP, dynamic pages can be created 
with content derived from either user input or a database. For PHP, many libraries exist 
for fast and customised access to relational database management systems. In order to 
query a MySQL server and produce the result in a HTML format for display in a web 
browser, many PHP scripting techniques are available (Table 2.8). 
 
When made into a web-database application, a database can become a scientific 
and medical community-based research tool and also securely connect to other web-
databases, analytical tools and APIs for in-depth analyses. In order to run dynamic 
database-driven websites, a stack of free software programs that include an Apache 
server, MySQL and PHP for either Windows or Linux-based operating systems are 
commonly used. For a database, a schema provides a complete overview or plan of the 
data table organisation and relationships. Thus a schema shows the tables with all of their 
columns, the primary (identifying column) and foreign (identifying column in another 
table) keys. In order to design a schema, an Enhanced Entity Relationship model is  
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 Table 2.8 PHP and SQL commands for a web-database application
Command Language Use example in web-database application Example command from my Complement database (Chapter 4) 
SELECT;  
FROM;  
WHERE 
SQL 
Select columns (* for all) from a table 
where certain conditions are fulfilled (e.g. 
column data must be equal to certain 
mutation ID). 
$q="SELECT * FROM mutations WHERE     
mut_id=\"".$line['mutid']."\""; 
COUNT;  
GROUP BY 
SQL 
Select the number of patients where two 
conditions are satisfied (e.g. patient ID 
equal to PHP variable $string). Count the 
number of patients for each different 
combination of the lab ID, zygosity, disease 
and source (by using GROUP BY). 
$q2="SELECT COUNT(pat_id) as countpatid, zygosity, 
pat_lab_id,    pat_cond_cat, source, ref_id_pat from patient  
            WHERE pat_id IN (".$string.") $pacond  
            GROUP BY pat_lab_id, zygosity, pat_cond_cat, source"; 
mysqli_connect PHP Connect to database. $link = mysqli_connect($db_host, $db_user, $db_pwd, $dbname); 
mysqli_query PHP Query database. $resultTotal = mysqli_query($link, $sql); 
mysqli_num_rows PHP Count the number of rows retrieved. $total_records = mysqli_num_rows($resultTotal); 
mysqli_error PHP If query fails, display error message. mysqli_error("Could not execute query"); 
mysqli_fetch_array PHP 
Fetch every row as an array, for which each 
column can then be specified. 
while($rowPatient=mysqli_fetch_array($resultPatient)){… 
round PHP 
Round a number up to a specified amount 
of decimal places. 
$exacmeanAN = round($rowmeanAN['suman']/$noexacanrows,0); 
pow PHP Exponential expression. $chisq = (pow((ABS($obs-$exp)-0.5),2))/$exp; 
ABS PHP Absolute value. $chisq = (pow((ABS($obs-$exp)-0.5),2))/$exp; 
for PHP 
For each variable (data) from each row of a 
column in one database table… 
for($t=0; $t<count($arraytype); $t++){… 
array_search PHP Search array for given value. $genematch = array_search($geneforsearch, $arrayallgenes); 
strlen PHP Return length of a string. if(strlen($geneforsearch) == strlen($arrallgenes [$countaa])){… 
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commonly used for the design and conceptual presentation. University College London 
provide secure web and MySQL (database) servers that can be accessed by Linux and the 
web, respectively.  
 
Database security against intruders must be prioritised, especially for databases 
that contain sensitive or patient identifiable data and are connected to the internet. Before 
being used in a web-database, sensitive or patient identifiable data must be anonymised 
in accordance with ethics procedures in order to reduce the risk of patient identification.  
In order to certify that the data has been anonymised and is safe for a web-database, an 
application can be submitted to the Information Technology support team for the School 
of Life and Medical Science at University College London. One type of malicious attack 
via the web is code injection, in which the attackers use vulnerabilities in the code to 
either redirect users to other web locations or inject new code that is harmful to the web-
database (Welling & Thomson, 2009). By this, the database may be destroyed, modified 
or copied. In order to prevent this sort of malicious behaviour, the programming of the 
web-database application is sanitised to eliminate any vulnerable (accessible) points. This 
can be checked by using the Python-based open source penetration testing tool sqlmap 
(http://sqlmap.org/), which automates and simulates the process of detecting and 
exploiting any SQL injection flaws in the database. Thus, using PHP, each query is only 
transmitted to the database if the variables correspond to pre-set known variables. One 
example of a vulnerability is the web address line which can be used to transmit variables 
(from PHP) for querying the MySQL database using SQL. 
 
2.12.1 Genetic variant web-databases for aHUS and C3G 
 
 For the analysis of genetic variants in aHUS and related diseases, an interactive 
FH-HUS web-database was set up at University College London in 2006 for both 
clinicians and researchers to use (Saunders et al., 2007; Saunders et al., 2006; Saunders 
& Perkins, 2006)(http://www.fh-hus.org). At first, the FH-HUS database contained data 
on published complement genetic variants in CFH only (Warwicker et al., 1998), and was 
then expanded to include the other complement genes CFI, C3, MCP and CFB following 
literature reports (Rodriguez et al., 2014). The FH-HUS database also includes genetic 
variant data for other diseases involved in complement AP dysregulation, such as MPGN 
and AMD. By 2014, there were 193 CFH, 130 CFI, 86 CD46 and 64 C3 variants for 
aHUS, C3G and other diseases. For each variant, the FH-HUS database features structural 
77 
 
analyses, based on whether it falls within a known ligand-binding region and the residue 
physicochemical differences. These structural analyses are facilitated by both side chain 
accessibility calculations and a three-dimensional view of the residue involved in the 
variant via a Jmol applet. For each of the four proteins, both a statistical analysis of the 
frequency of variants in each domain and the latest structural models are also provided.  
 
 For aHUS, C3G, AMD and other genetic diseases, the current challenge for 
researchers is to separate disease-associated genetic variants from the broader background 
of variants present in all human genomes that are rare, potentially functional, but not 
pathogenic for the disease (Vieira-Martins et al., 2016). This is one of the major research 
questions addressed in this PhD thesis. This background variation can now be well 
represented, with caveats, by the ExAC, the 1000GP and EVS datasets, which were 
generated by the recent onset of sequencing and computing advances. Thus, despite the 
extensive utility and high popularity of the FH-HUS database, a major omission was the 
inclusion of variant AF data from both reference and disease (aHUS and C3G) datasets. 
AF data is essential for assessing variant pathogenicity (Section 2.8.2 and 2.8.3) and can 
be used to verify disease-gene associations (Section 2.10). In addition, by 2014, the 
number of genes associated with aHUS and/or C3G increased to 13 (CFH, C3, CFI, 
CD46, CFB, DGKE, CFHR5, CFHR1, CFHR3, CFHR4, PLG, CFP, THBD), and many 
cases have more than one variant that requires analysis. Despite their AP regulatory 
activities, neither CR1 (Schramm et al., 2015) nor DAF (Kavanagh et al., 2007) are major 
susceptibility genes for aHUS or C3G. For CR1, this may be because it is not expressed 
on endothelial cells (Roumenina et al., 2009). Since the previous FH-HUS database, new 
methods for assessing variant pathogenicity, such as conservation analyses by using 
multiple sequence alignment and in silico tools, have also been developed. Overall, the 
FH-HUS database required an extensive update to include the latest genetic variant data 
for both aHUS and C3G and facilitate their pathogenicity analyses. This update included, 
for each gene, extracting the relevant AF data from large reference dataset web-servers 
and their subsequent presentation on the web-database for both pathogenicity and RV 
burden analyses (Chapter 4). It also included a new solution structure for FH (Chapter 5)  
in order to more accurately predict the functional impact of disease-associated CFH 
variants, such as the common AMD-risk variant p.Tyr402His and rare missense variants 
associated with aHUS and C3G (Chapter 6). 
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In order to calculate variant AFs for each of the aHUS and C3G populations, a 
substantial number of cases are required. For this, data from multiple clinical centres for 
aHUS and C3G can be aggregated. These data include the number of patients that had the 
variant, the zygosity and the number of patients screened for the gene in total. In order to 
provide these data for this PhD thesis, a collaboration with six clinical centres for aHUS 
and C3G was established. By this, new unpublished variant data was also obtained. Prior 
to this, the largest registry for aHUS was The Global aHUS Registry which was 
established in April 2012 and had 826 enrolled patients by June 2015. Thus, in Chapter 4 
of this PhD thesis, I created a new Database of Complement Gene Variants and used this 
to analyse AF data and verify the association of RVs in the complement and related genes 
with aHUS and C3G. These RV data were then used in Chapter 6 to assess whether the 
structural location of a rare missense variant in the complement proteins can predict the 
outcome of aHUS or C3G in patients.
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Chapter Three 
Protein structure and dynamics
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This chapter describes the theory, including the roles of amino acid residues, in 
protein structure, function and dynamics, and how these may be perturbed in 
disease. It describes methodologies for predicting the structures of flexible proteins 
in solution by using a combination of biophysics and bioinformatics, such as: low-
resolution small angle X-ray scattering, homology modelling, molecular dynamics 
and Monte Carlo-based modelling. These methods are either used or referred to in 
my results Chapter 5 for studying the structure of complement factor H and the 
effect of the disease-risk p.Tyr402His variant on its overall domain arrangement. 
The protein structure and function theory described here is also used in my results 
Chapter 6 to address whether the structural locations of rare missense variants in 
the complement proteins can predict complement disease phenotypes. 
 
3.1 Protein structure and function 
 
For a coding genetic variant that is statistically associated with a disease-related 
phenotype, the normal function of the encoded protein is expected to be dysfunctional. 
By this, the dysfunctional protein leads to an imbalance in the biochemical pathway and 
system. By causing an imbalance, certain components of the pathway will either increase 
or decrease, due to the inability of the dysfunctional protein to carry out its normal 
biochemical function. For example, in the complement AP, FB reacts with C3b to form 
the AP convertase C3bBb and also provides the C3bBb catalytic site for the proteolytic 
activation of C3 to C3b. For FB, the GoF variant p.Phe286Leu identified in aHUS was 
found to either increase the resistance of FB to regulation, or increase the formation of 
C3bBb. This is thought to be due to a decrease in the restriction of mobility for a residue 
at the C3b–Bb interface (Goicoechea de Jorge et al., 2007). By this, the levels of C3b 
increase, thereby predisposing for complement dysregulation and/or the abnormal 
deposition of complement activator components (Chapter 1, Sections 1.7.1 – 1.7.3). 
Predisposition is also driven by LoF variants in the AP regulators such as FH. For LoF 
variants in FH, the affected residues are often involved in binding to either host cell 
surfaces, C3b or FI, or involved in stabilising the FH SCR domains. For example, for FH, 
aHUS-associated missense variants often affect Cys residues that stabilise the SCR 
domain via disulphide bonds (Rodriguez et al., 2014) (Section 3.3.8). For aHUS and C3G, 
severe symptoms rapidly develop, and this is thought to be due to both strong 
predisposing variants that are rare in the general population and a triggering event. On 
the other hand, for the development of AMD, which is most common in the elderly 
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population, subtler age-related changes together with the presence of risk variants have 
been proposed to cause subtle symptoms that gradually worsen over a long period of time. 
For example, for AMD, the age-related decrease in the sulfation of the 
glycosaminoglycan HS structures combined with the FH p.Tyr402His risk variant have 
been proposed to reduce FH binding over time. Thus, p.Tyr402His was found to weaken 
the binding of FH SCR-7 to eye-specific HS at Bruch’s membrane, which leads to 
increased chronic local inflammation at the RPE/choroid interface (Clark et al., 2013) 
(Chapter 1, Section 1.7.3). This was concluded experimentally by comparing the 
distribution of fluorescently labelled FH Tyr402 and His402 along Bruch’s membrane 
(Clark et al., 2010). However, the full length structure of FH and how it is affected by 
p.Tyr402His is currently unknown. In order to study the molecular mechanisms of such 
disease susceptibility variants at the protein level, the physical properties of the protein, 
such as structure, stability, and dynamics, are typically characterised. 
 
3.1.1 Protein function 
 
Proteins are complex macromolecules that each execute a specific function at   
either the biochemical, cellular or phenotypic level. For many proteins, biochemical 
functions involve molecular interactions which can drive activities such as enzyme 
mechanisms, ligand binding, cell surface adhesion, membrane transport, the building of 
large structures (e.g. ribosomes), DNA reading and transcription control. Such 
biochemical functions are essential for life. The spatial arrangements of the residues in 
the protein structure provide optimal chemistry and configurational space for molecular 
interactions. For a protein, the relationship between structure and function is complex in 
that one protein-folding topology can support more than one function, and one function 
can be associated with more than one fold (Orengo et al., 2003). In addition, each domain 
type usually has one or more distinct biochemical function, and the majority of proteins 
are multi-domain, e.g. up to 80% in eukaryotes (Apic et al., 2001). Within genomes, 
protein domains have frequently been shuffled and recombined in different ways to give 
rise to subtly different functions (Todd et al., 2001). The cellular and phenotypic functions 
cannot be deduced directly from protein structure but can be predicted based on 
biochemical functions. Thus, a number of residues in the protein may be associated with 
function, and this can be predicted and/or studied experimentally (Chapter 2). Functional 
assays can also be used to measure the functional output of proteins. 
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3.1.2 Formation of protein structure 
 
A protein’s native structure is defined as the overall 3D organisation or fold of its 
polypeptide chain. Protein folding is a spontaneous process which is governed by 
interatomic forces that act among and on its amino acid sequence. These interatomic 
forces include covalent disulphide bridges, electrostatic interactions, water shells and 
charged surface residues, hydrogen bonds, hydrophobic interaction and Van der Waals 
forces (temporary electric dipoles) (Branden & Tooze, 1999). For a protein, both the 
conformational folding reaction and the formation of disulphide bonds take place within 
the cellular endoplasmic reticulum, which is an oxidative environment (Narayan, 2012). 
This process is known as oxidative protein folding and is facilitated by a series of 
chaperones, enzymes and sensors that detect the presence of misfolded or unfolded 
proteins. Such enzymes include endoplasmic reticulum oxidoreduction-1 and protein 
disulphide isomerases. Protein folding may also begin on the ribosome whilst its  
polypeptide chain is still being synthesised.  
 
For a protein, disulphide bonds, which form between the sulphur atoms of the 
thiol groups of two Cys residues, stabilise the structure and impose conformational 
rigidity. In general, proteins in the reduced environment of the cytoplasm contain free 
thiols (Trivedi et al., 2009). The length of a disulphide bond is typically 0.20 - 0.25 nm 
(2.0 - 2.5 Å) (Wiita et al., 2006).  
 
For two charges, the magnitude of the electrostatic force is inversely proportional 
to the square of their separation distance, and the product of the charges. This is given by 
Coulomb’s law. For electrostatic interactions, a type of ionic bond known as a salt bridge 
can form between spatially proximal pairs of oppositely charged residues. For proteins, a 
salt bridge can form between an anionic carboxylate (RCOOˉ) group of either Asp or Glu 
and either the cationic ammonium (RNH3
+) of Lys, the guanidinium (RNHC(NH2)2
+) of 
Arg, or nitrogen atom from His. To form the salt bridge, these charged-group atom 
centroids must lie within 0.4 nm (4 Å) of each other. Most stabilising salt bridges also 
contain at least one hydrogen bond between the side-chain charged-group atoms. For 
proteins, salt bridges are rarely found across segments joined by flexible linkers, which 
suggests that they constrain flexibility and motion. In contrast to salt bridges, nitrogen-
oxygen (N-O) bridges only require at least one pair of side-chain functional-group 
nitrogen and oxygen atoms within a 0.4 nm (4 Å) distance of each other (Kumar & 
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Nussinov, 2002a). Longer-range ion pairs are weaker and often destabilising for proteins 
(Kumar & Nussinov, 2002b). Water can screen (or lessen) electrostatic interactions and 
this is known as its dielectric property (Biedermannova & Schneider, 2015).  
 
Hydrogen bonds are formed between a hydrogen atom, which is covalently 
bonded to an electronegative atom (donor), and another electronegative atom (acceptor). 
For hydrogen bonds, the most frequently observed geometry corresponds to a distance of 
< 0.25 nm (2.5 Å) and a donor-hydrogen-acceptor angle of between 90° and 180°. For 
proteins, intramolecular hydrogen bonds are formed between main chain polar groups 
which lead to secondary structure elements (Hubbard & Kamran Haider, 2010). 
Hydrogen bonds are also formed between polar or charged residue side-chains and water, 
thus creating a protein surface network. For the surrounding hydration layer of a protein, 
each water molecule can simultaneously serve as an acceptor for up to two hydrogen 
bonds and a donor for an additional two hydrogen bonds (Biedermannova & Schneider, 
2015).   
 
For protein folding, both the hydrophobic interactions between hydrophobic side-
chains and the interactions of polar and charged residues with water molecules are 
essential. Hydrophobic interactions occur over long ranges of 0-10 nm and decay 
exponentially with distance (Israelachvili & Pashley, 1982). Polar water molecules also 
interact directly with the protein via either the protein backbone or the side-chains of 
residues in the protein interior, or form clusters in hydrophobic cavities (Ernst et al., 
1995). On average, for protein folding, 85% of non-polar side chains are buried (Lesser 
& Rose, 1990) and 1.1 hydrogen bonds per residue are formed (Baker & Hubbard, 
1984). Mutations can affect the number of structural water molecules within the core and 
disrupt essential main-chain-water interaction networks, resulting in destabilisation of the 
protein (Levy & Onuchic, 2004).  
 
Van der Waals or dispersion forces are weak interactions between temporary 
(induced) dipoles. These occur between the hydrophobic (non-polar) side chains of the 
residues Ala, Ile, Leu, Phe, Tyr, Val and Gly. For two non-bonding atoms, a mathematical 
model known as the Lennard-Jones potential describes the potential interaction energy as 
a function of the separation distance: 
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6
]                                                                                      (3.1) 
                                                                            
 By this, when the non-polar groups are at a distance, they do not interact, because 
they are not close enough to distort the other’s electron cloud and produce dipoles. As 
they approach each other more closely, and attract each other (long-range), the potential 
energy decreases until a minimum is reached. If the atoms are forced any closer (short-
range), there is a steep rise in energy from the electron clouds starting to overlap and 
repulsion results. 
 
Interatomic forces are dependent on both the pH and temperature of the 
surrounding environment. Thus, for proteins, variations in pH can alter the ionisation 
states of amino acid side chains and lead to different electrostatic forces and the disruption 
of hydrogen bonds. In addition, chemical denaturants such as ionic surfactants or high 
concentrations of urea or guanidinium chloride cause loss of native protein conformations 
and lead to complete unfolding. Proteins generally aggregate after heat denaturation. At 
temperatures higher than 80 °C, the heat denaturation of proteins is usually irreversible . 
However, naturally occurring hyper-thermostable proteins that can withstand very high 
temperatures also exist, such as the hsCutA1 protein in humans. This may be due to an 
unusually high content of charged residues (Matsuura et al., 2015). 
 
3.1.3 Protein stability 
 
The stability of a protein is defined as the tendency to maintain its native (folded) 
structure. Anfinsen’s classic experiment concluded from numerous denaturation-
renaturation experiments that the native state of a protein corresponds to the global 
minimum of free energy and is reached in a pathway-independent manner. This was 
called the thermodynamic hypothesis of protein folding (Anfinsen, 1973). In general, 
thermodynamics describes the stability of molecules between different states by using the 
free energy quantity and does not depend on time. On the other hand, kinetics describes 
how fast a reaction will reach equilibrium and overcome the activation energy quantity. 
Despite a reaction being thermodynamically favourable, it may be kinetically 
unfavourable. For a chemical reaction, the Gibbs free energy (G) is the maximum energy 
that can be spent and its change provides information on the spontaneity. If the change in 
Gibbs free energy (∆G) is negative, the reaction is thermodynamically favoured. For the 
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equilibrium between the native folded (N) and unfolded (U) states of a protein, the ratio 
of the folding (kf) and unfolding (ku) kinetic rate constants is known as the equilibrium 
constant Keq. The change in Gibbs free energy for a population of molecules is calculated 
from the equilibrium constant by: 
         
∆𝐺 =  −𝑅𝑇 ln 𝐾𝑒𝑞                                                                                                              (3.2) 
 
where R (J K-1mol-1) is the gas constant and T (K) is temperature. Thus, protein stability 
is proportional to the Gibbs free energy change. The Gibbs free energy change for a 
process at constant pressure is:  
         
∆𝐺 =  ∆𝐻 − 𝑇∆𝑆                                                                                                                 (3.3) 
 
where ∆H and ∆S are the changes in enthalpy and entropy, respectively, and T is the 
temperature. For the folding of a globular (roughly spherical and mostly water-soluble) 
protein, the enthalpy (∆H) is contributed by intra-molecular interactions whereas the 
configurational entropy (∆S) is determined by the number of accessible configurations. 
For protein folding, a net decrease in the Gibbs free energy occurs due to both the internal 
covalent bonds stabilising the structure and the hydrophobic effect which leads to a 
stabilising decrease in entropy. These override the folding-unfavourable decrease in 
configurational entropy which favours the unfolded, more random state. At a constant 
(biological) temperature of ~300K, both the effective potential energy (∆G) and the 
configurational entropy (∆S) decrease as the native folded state is approached (Karplus, 
2011). For globular proteins in physiological conditions, the Gibbs free energy change is 
typically small, of the order of 5-15 kcal/mol. Thus native proteins are only marginally 
stable entities.  
 
The protein folding process can be described as a free energy surface (or 
landscape) which is a rugged funnel shape (Figure 3.1). By this, the denatured state of the 
protein populates a large ensemble of structures (high entropy) whereas the native state 
populates one or few conformational states (Bartlett & Radford, 2009). Here, ‘ensemble’ 
refers to a collection of structures that have been sampled. For the native state to 
correspond to multiple conformational states, the potential energy surface is characterised 
by a large number of thermally accessibly minima close to that of the native 
structure(Elber & Karplus, 1987). For the native state, numerous folding pathways may 
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Figure 3.1 The folding funnel energy landscape for a globular protein. The top of the 
funnel (high potential energy) corresponds to unfolded proteins. As the protein folds, the 
entropy of the system, determined by the number of accessible configurations, is 
unfavourably decreased. However, a net decrease in potential energy (x-axis) occurs 
because the structure is stabilised by a combination of the formation of either internal 
interactions or intermolecular contacts and the hydrophobic effect. For native 
intramolecular contacts (x-axis, left), the native state has the lowest potential energy and 
may comprise a number of conformational substates (arrowed) around the local minima. 
For intermolecular contacts (x-axis, right), protein forms with the lowest potential 
energies include amorphous aggregates and amyloid fibrils. Adapted from (Raskatov & 
Teplow, 2017) and (Bartlett & Radford, 2009). 
Entropy 
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be present whereby multiple partially folded ensembles are populated en route (Onuchic 
& Wolynes, 2004). In addition, the protein may get trapped in local minima due to the 
formation of favourable but non-native (“wrong”) contacts, such as non-native 
hydrophobic contacts or hydrogen bonds which are favoured in terms of enthalpy. From 
the native to the unfolded state, the reversible thermal or melting transition of a protein 
can be determined by calorimetry methods. By this, the stabilising effect of disulphide 
bonds and other molecular interactions on proteins is manifested by an increase in the 
melting point of the protein.  
 
In order for a protein to fold into the native (functional) state, a random search 
through all of the possible folding routes would take a very long time. This is because the 
length of a typical polypeptide chain introduces many degrees of freedom. For example, 
in order to estimate the time required for folding, the number of configurations of the 
polypeptide chain can be multiplied by the time required to find one configuration. For a 
100 residue protein, this corresponds to 1070 configurations multiplied by 10-11 seconds 
which gives approximately 1052 years (Karplus, 1997). However, in nature, the speed of 
protein folding is rapid, being only a few seconds or less. This is known as Levinthal’s 
paradox (Levinthal, 1968). In order for a protein to achieve its native fold so rapidly, the 
native fold is thought to be favoured by local interactions of residues which limit the 
conformational space available for exploration. By this, protein folding is not an 
unbiased, random process. In contrast to Anfinsen, Levinthal postulated that a protein 
must follow a specific path that guides it to the native state under kinetic control, possibly 
to a local minimum. Thus, the native structure corresponds to a rapidly reachable 
minimum rather than the global one (Finkelstein, 2018). In order to resolve Levinthal’s 
paradox, a number of models have been developed including the nucleation-growth 
mechanism (Wetlaufer, 1973), the diffusion-collision model (Karplus & Weaver, 1994), 
the framework model (Kim & Baldwin, 1982) and the jigsaw-puzzle model (Harrison & 
Durbin, 1985). However, both thermodynamic and kinetic hypotheses are used for models 
of protein folding. Protein misfolding is seen in diseases such as Alzheimer’s disease, 
Creutzfeldt–Jakob disease, and bovine spongiform encephalopathy, and has been 
attributed to kinetic traps or folding to an alternate state of lower energy (Thomas et al., 
1995). For rigid globular proteins, mutations associated with diseases of protein 
deposition have been shown to destabilise the native structure thereby increasing the 
concentration of partially folded or disordered conformers (Uversky & Dunker, 2010). 
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For a bead model of a polypeptide chain in two dimensions, fast folding was 
shown to occur if the stabilising interactions corresponded to those present in the native 
state, by the use of Monte Carlo (MC) simulations (Go & Abe, 1981). For the folding 
reaction of a protein, the first full analysis of the effective energy, entropy and free energy 
surface was also modelled by a MC simulation of a 27-bead heteropolymer with random 
interactions (Sali et al., 1994). This found that, for at least 30 out of 200 random sequences 
folded on a lattice, less time steps were required when compared to sampling all 
configurations.  
 
Once folded, the structure of a protein can be described in terms of secondary 
structure elements and how they pack and connect together (topology) to form domains 
and tertiary and quaternary structures (Section 2.4). Proteins can have either single-
domain or multi-domain modular architectures. For protein domains, the ‘Class, 
Architecture, Topology/fold, Homologous superfamily’ (CATH) database has classified 
95 million protein domains into 6,119 superfamilies based on their evolution ancestries 
by using both structure and sequence (Sillitoe et al., 2015).  
 
3.1.4 Protein dynamics 
 
Proteins must be able to move in order to fulfil their biochemical functions in 
solution. By this, proteins are dynamic entities, and their motions are intrinsically 
encoded in the sequence of amino acids within the polypeptide chain (Frauenfelder et al., 
1991; Karplus & Kuriyan, 2005). Proteins and other biomolecules are thus inherently 
flexible systems that display a broad range of dynamics which occur on time-scales of 
femtoseconds to seconds (Markwick et al., 2008). Protein dynamics range from small 
atomic fluctuations around an average structure to large-scale reorganisations and often 
contribute to conformational changes. Such conformational changes include structural 
fluctuations, allosteric changes, domain motions, local folding to unfolding transitions, 
secondary structure element transitions, disorder to order transitions and other sidechain 
and backbone changes (Ruvinsky et al., 2012). In a dynamic equilibrium, proteins rapidly 
interconvert between conformational states. Most eukaryotic proteins are ordered thus 
possess a 3D structure which is relatively stable with Ramachandran angles that vary 
slightly around equilibrium positions due to thermal energy. They may also have 
occasional co-operative conformational switches. However, more than a third of 
eukaryotic proteins have been shown to contain intrinsically disordered regions of over 
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30 residues in length (Ward et al., 2004). For an intrinsically disordered protein, the atom 
positions and Ramachandran angles vary significantly over time without specific 
equilibrium values and hence the protein lacks a stable 3D structure. Such intrinsically 
disordered proteins exist as dynamic ensembles and typically undergo non-cooperative 
conformational changes (Uversky & Dunker, 2010). For FH, 19 unstructured and flexible 
linkers of three to eight residues length are situated between the 20 globular SCR 
domains. These linkers are defined as intrinsically disordered regions. For a protein, by 
knowing all conformational sub-states and their associated populations under 
physiological conditions, protein function and biological processes can be better 
understood. For ordered proteins, the relative probabilities of the conformational states 
(thermodynamics) and the energy barriers between them (kinetics) can be defined as an 
energy landscape (Henzler-Wildman & Kern, 2007).  
 
3.2 Methods for protein structure determination 
 
For experimentally determined atomic-level 3D structures of biological 
macromolecules such as proteins, the Protein Data Bank (PDB) is the only global archive. 
The PDB is managed by the Worldwide Protein Data Bank organisation which includes 
three data centres in Europe, the United States and Japan (Rose et al., 2017). However, 
for proteins, the number of sequences deposited in the UniProtKB database (Bairoch et 
al., 2005) greatly exceeds that of structures in the PDB (Berman et al., 2000). By this, in 
2015, there were approximately 90 million protein sequences compared to only about 
100, 000 protein structures. The reason behind this is that calculating the structure is much 
more demanding than determining the sequence, hence the importance of the work in this 
PhD thesis on determining the structure of FH. In order to elucidate the structure and/or 
dynamics of proteins, biophysical and structural biology techniques such as X-ray 
crystallography, small-angle scattering (SAS) of X-rays (SAXS) or neutrons, nuclear 
magnetic resonance (NMR) and cryo-electron microscopy (cryo-EM) can be employed. 
For protein sequences, the locations of structural domains can be predicted by using the 
CATH and Gene3D databases for bioinformatics-based analyses (Lees et al., 2012). By 
this, structure and function can be inferred from similar, well characterised proteins. For 
structures in the PDB in March 2017, 89% were determined by X-ray crystallography, 
9% by NMR, 1% by cryo-EM and <1% by other techniques (Gore et al., 2017). For highly 
dynamic and flexible systems in solution, both NMR and SAS are considered the most 
appropriate tools. These types of systems are often problematic for EM and X-ray 
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crystallography methods. In terms of protein size, for NMR, structure determination is 
limited to moderately sized macromolecules (e.g. <50 kDa). In contrast, SAS does not 
have any size limitations. In terms of resolution, SAS is a low resolution technique, 
whereas NMR, cryo-EM and X-ray crystallography are higher resolution. 
 
3.2.1 X-ray diffraction and scattering 
 
For the diffraction technique of X-ray crystallography, the electromagnetic 
radiation is composed of X-rays (of approximately 1 Å wavelength) in order to probe 
interatomic distances. For the scattering technique of SAS, X-rays or neutrons (of 
approximately 1 Å or 10 Å wavelength, respectively) are used to probe the overall shape 
of particles in solution. Conventionally, X-rays can be generated by decelerating electrons 
whereby a target such as Cu is bombarded with an electron beam in order to produce 
intense, monochromatic peaks of specific wavelength. A monochromator is used to 
further define the X-ray wavelength. Often, SAS experiments are performed at 
synchrotrons. 
 
During the X-ray scattering process, X-rays interact with electrons in the protein 
sample. By this, the electrons oscillate and become dipoles thereby emitting 
electromagnetic radiation of the frequency of the irradiated wavelength. From all of the 
oscillating electrons in the sample, an incident beam of X-rays thereby generates either 
scattered or diffracted X-rays, depending on the particle dynamics. Thus, for X-ray 
crystallography, the static crystal lattice arrangement of the particles produces a coherent 
diffraction pattern, whereas for SAS, the solution-based particles are tumbling in time 
which produces a less coherent scattering pattern. For the scattered X-rays, the intensity 
is proportional to the square of the charge/mass ratio of the particle. Particles with higher 
charge/mass ratios, such as electrons when compared to atomic nuclei or protons, are 
much more efficient at scattering. The relationship between scattering angle and inter-
planar or inter-atomic spacing is given by Bragg's law: 
 
n λ = 2 d sin θ         (3.4) 
 
where λ is the radiation wavelength, d is the inter-planar spacing, θ is the angle between 
either the incident or diffracted ray and the relevant planes and n is the order of diffraction. 
The scattered waves interfere which produces distinct spots at specific angles. For the 
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diffraction space, there is an inverse relationship between the spacing in the object and 
the angle of diffraction which is usually called "reciprocal space". Peaks in the intensity 
of scattered radiation will occur when rays from successive planes interfere constructively 
according to Bragg’s law. 
 
3.2.2 Small angle scattering  
 
For SAS, which was introduced in the 1930’s by André Guinier, a distinct 
advantage is the speed of both data collection (ms; millisecond) on a modern synchrotron 
and sample characterization. In addition, the protein can be analysed in native conditions, 
including its flexibility and dynamics. For structure determination, several overall 
parameters can be extracted from the resulting radially averaged scattering pattern. 
However, the major limitation of SAS is that only low resolution models can be obtained 
and there will be ambiguity in the modelling (many models may fit the data). SAS can be 
combined with higher resolution methods for model validation and refinement by using 
hybrid modelling techniques. In addition, SAS-driven rigid body modelling routines can 
refine or determine the positions and orientations of protein domains or stretches of 
nucleic acids (Mertens & Svergun, 2017). For SAS, milligram (typically 1 – 2 mg) 
amounts of highly pure, monodisperse protein that remains soluble at high concentration 
are required. This ensures that there is no interaction between the particles and the 
particles are free to move.  
 
For small angle neutron scattering, the excess scattering length density (contrast) 
is due to the nuclear scattering length density. Samples that highly absorb X-rays, such 
as solvents containing high salt, can be measured using small angle neutron scattering, 
and the samples will not suffer from radiation damage. For a protein, in order to study the 
structure and/or dynamics, hydrogen/deuterium (2H or D) exchange can be used. 
Deuterium is a heavy isotope of hydrogen. By this, labile hydrogen atoms from either the 
OH-, NH-, and SH- groups of polar amino acid side chains or the NH-group of peptide 
bonds are replaced by deuterium atoms in the solvent (Claesen & Burzykowski, 2017). 
In small angle neutron scattering only and not SAXS, hydrogen/deuterium exchange leads 
to contrast variation neutron scattering. A disadvantage of small angle neutron scattering 
is the high incoherent scattering of hydrogen due to its negative coherent scattering 
length. This can often make the buffer subtraction difficult. In order to minimise this 
92 
 
incoherent scattering, deuterium, which has a positive scattering length, is used instead 
of hydrogen. 
 
In SAXS, the sample is exposed to a collimated beam of incident radiation of a 
defined wavelength (typically 1 Å or 0.1 nm). Following Bragg’s law (equation 3.4), at 
smaller angles of 0.1° to 0.5° used in SAXS, distances of approximately 100 Å can be 
detected. Thus, the smaller the angle, the greater the inter-atomic distance resolved. By 
this, the dominant scattering process is elastic, for which net energy transfer between the 
incident wave and the sample is not observed and the wavelength and energy of the 
scattered wave does not change. Other scattering phenomena such as Compton and 
Raman scattering of X-rays contributes to the background of the experiment. In SAXS, 
the scattering of X-rays by a solution of biomolecules is dependent on the number of 
particles, the size of the particles, and the contrast with the solvent. By this, the scattering 
is dependent on the concentration of the solute, the square of the volume of the individual 
particle and the square of the excess scattering length density (Δρ(r)), respectively. The 
excess scattering length density refers to the difference in electron density (p(r)) between 
the solute and the solvent (contrast). For proteins, the electron density is approximately 
410 e/nm3 which is only slightly greater than that of water at 334 e/nm3. For dilute 
aqueous solutions of proteins or other macromolecules, an isotropic scattering intensity 
results (Mertens & Svergun, 2017). This scattering depends on the modulus of the 
momentum transfer (or vector/direction), s (or Q):  
 
  s = 4π sin(θ)/λ         (3.5) 
 
where 2θ is the angle between the incident and scattered beam. For s as a scattering vector: 
 
  𝑠 =   (𝑘𝑠⃗⃗ ⃗⃗  −  𝑘𝑖⃗⃗⃗⃗ )         (3.6) 
  
where ks and ki are the scattered and incident waves, respectively (Figure 3.2). For an 
atom, the scattering length density depends on the number of electrons, the distribution 
of the electrons and the atomic mass. Thus, the atomic scattering factor is a measurement 
of the scattering power of the atom and varies with X-ray wavelength. The atomic 
scattering factor is also the Fourier transform of the atom’s spatial distribution or electron 
density. The Fourier transform is a mathematical transformation which inverts the units 
of the input variable, e.g. between time and frequency (1/time), or between space 
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Figure 3.2 A schematic representation of a small angle scattering experiment (A) An 
incident beam of X-rays is scattered by the protein sample in solution. The 2D detector 
records the intensity I(Q) of the scattered radiation and the scattering vector Q, which 
corresponds to the angle 2θ between the incident (transmitted) and scattered X-ray beams. 
(B) The scattering pattern is radially averaged to a 1 dimensional scattering curve that 
represents the reciprocal space. The RG and RXS parameters are calculated from specific 
Q ranges. Sourced from the PhD thesis of Dr Orla Dunne (Dunne, 2015).
2D detector 
Reciprocal 
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(distance) and inverse-space (1/distance). The Fourier transform of the real space electron 
density profile probed by the X-rays is the observed scattering pattern (of constructive 
and destructive interference) in reciprocal-space. For a single scattering process, the 
scattering amplitudes of all atoms are summed up and the observed scattering intensity is 
given by an ensemble average of the intensity. The intensity at each Q is calculated by 
the Debye equation (Yang, 2014), which takes into account the differential orientations 
of the particles via rotational averaging in space: 
 
 
𝐼(𝑄) =  ∑ ∑ 𝑓𝑝𝑓𝑞
sin (𝑟𝑄)
𝑟𝑄
𝑞𝑝
                                                                                            (3.7) 
 
where fp and fq are the scattering lengths of the electrons at points p and q within the 
biomolecule, separated by a distance, r. For low concentrations of protein (approximately 
1 mg/ml), the interference of X-rays from within molecules dominates the scattering 
profiles thereby reflecting the molecular structure. In contrast, higher concentrations of 
protein (above 1 mg/ml) leads to a significant amount of interference between X-rays  
scattered from different molecules which is known as inter-particle interference 
(Goldenberg & Argyle, 2014) and particularly shows at low angles (Q < 1 nm-1). 
 
The scattered X-rays are detected by two-dimensional (2D) area detectors and 
radially averaged to one-dimensional (1D) SAXS profiles via integration for analysis. 
Experimentally, the detector can only measure an intensity, I(Q), which is proportional to 
the squared amplitude of the scattered radiation. The resulting profile corresponds to the 
intensity, I(Q), on the y-axis and the scattering angle, Q, on the x-axis. In order to account 
for variance in sampling distribution, multiple scattering curves are merged by averaging. 
After the solvent (buffer) scattering has been subtracted, the difference profiles are used 
for the direct extraction of important parameters for structural characterisation. These 
parameters provide information on the size, oligomeric state and overall shape of the 
molecules in solution. They include the molecular mass, radius of gyration (RG), hydrated 
particle volume (Vp) and maximum particle diameter (Dmax). For a protein, the RG (Å or 
nm) is defined as the root mean square distance from each atom to the protein’s centre of 
mass. The centre of mass is also known as the centre of gravity. The RG can be used as an 
indicator of compactness of the particle thereby the larger the RG, the less compact the 
structure (Mertens & Svergun, 2017).  
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3.2.3 Guinier analyses for small angle scattering 
 
 The RG can be determined at small angles for a monodisperse solution by using 
the Guinier approximation (Guinier et al., 1955) (valid when Q.RG < 1.3): 
 
  𝐼(𝑄) ~ 𝐼0𝑒
(
−𝑄2𝑅𝐺
2
3 )                                                                                                                  (3.8) 
        
  ln𝐼(𝑄) ~ ln𝐼0 −  
𝑄2𝑅𝐺
2
3
                                                                                                            (3.9) 
 
where I(Q) is the scattering intensity, I0 is the forward scattering intensity and Q (Å
-1 or 
nm-1) is equal to s (equations 3.5 and 3.6). From the Guinier plot of lnI(Q) vs. Q2, the 
values of I0 and RG can be determined from the y-axis intercept and the slope of the linear 
region, respectively (equation 3.9) (Mertens & Svergun, 2017). For the molar mass of the 
protein, I0 gives an independent estimation, being proportional to the number of electrons 
in the scattering particle. From the scattering curve, aggregation and inter-particle 
repulsion can also be identified via increased or decreased RG values. For macromolecules 
which have an elongated shape, it is possible to calculate the mean cross-sectional radius 
of gyration (RXS) from fitting a larger Q range (Figure 3.2) by using: 
 
ln[𝐼(𝑄)𝑄]  = ln[𝐼(𝑄)𝑄] 𝑄→0 −  
𝑅𝑋𝑆
2  𝑄2
2
                                                                   (3.10) 
 
The distance distribution function, P(r), shows the frequency of pair-wise 
interatomic distances in the sample. By this, particle shape characteristics can be 
identified, e.g. globular particles which yield bell-shaped profiles with a maximum of 
approximately Dmax/2 are spherical. In addition, multi-domain particles often yield P(r) 
profiles with multiple shoulders that correspond to intra- and inter- subunit distances. 
Theoretically, a Fourier transformation of the scattering intensity (in reciprocal space) 
yields the distance distribution function (in real space), P(r). However, in order to 
compute the P(r), the indirect Fourier transformation is used because a direct Fourier 
transformation is not possible using only the finite number of points available from the 
scattering curve. This is because at low Q, the data points close to the beam stop will be 
missing and at high Q, the data points are limited to the edge of the detector. The indirect 
Fourier transformation method was first proposed by Glatter (Glatter, 1977). The method 
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parameterizes P(r) in the range [0, Dmax], with Dmax being a user defined variable, and 
determines the coefficients as a smooth function which provides the best fit to the 
experimental data. For this, automated programs such as GNOM (Semenyuk & Svergun, 
1991) can be used: 
 
  dQ (Qr) Qr I(Q)  
2
1
 = P(r)
o
2
sin


       (3.11) 
 
In addition, I(0) and RG can be directly computed from the P(r), which is typically more 
accurate than using a Guinier analysis because it corresponds to real space (Mertens & 
Svergun, 2017). 
 
3.2.4 Other methods 
 
For X-ray crystallography, the diffraction of X-rays results in an electron density 
map which reflects the structural arrangement of atoms within the crystal. The signal to 
noise ratio is increased because a crystal arranges many molecules in the same orientation 
for the scattered waves to add up in phase. However, critical phase data is lost which 
prevents full retrieval of the real space 3D structure. This is known as the “phase 
problem”, and this can be overcome by methods such as molecular replacement. Overall, 
X-ray crystallography is a high resolution technique that has helped to elucidate the 
majority of protein structures in the PDB at the atomic level. However, a disadvantage of 
X-ray crystallography is that flexible and integral membrane proteins are very difficult to 
crystallise and purify. In vivo, many proteins are also glycosylated by flexible 
carbohydrate structures. Furthermore, proteins may not be able to be produced in 
sufficient quantities for crystallisation, and the method of crystallisation can introduce 
artefacts whereby the protein is forced into an unnatural frozen state, sometimes with the 
use of artificial ligands. The crystallisation of multiple functionally relevant states of 
proteins may also be difficult (Nogales & Scheres, 2015). The nature of the crystals such 
as size of the unit cell and lack of order may also make structural determination difficult.  
 
In cryo-EM, proteins can be observed directly in multiple conformations in their 
native environment at near atomic resolution (Murata & Wolf, 2018). A high-energy 
beam of electrons (wavelength ~ 1 nm or 10 Å), which are accelerated by an electrostatic 
potential, interacts with a sample and the elastic interactions are detected. By this, the 
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density of the sample results from the projected Coulomb potential or the 2D projection 
along the beam direction (Carroni & Saibil, 2016). For cryo-EM, biological specimens 
are solidified without ice formation by suspension in solid water via the use of liquid 
nitrogen. When kept at below -160°C, the protein sample is stable in the high vacuum 
and also more resistant to electron beam damage. Proteins are very weak at scattering 
electrons thus in order to see the (unstained) protein, a phase contrast effect is produced 
from using defocus and spherical aberration with a solvent such as dilute salt solution 
(Saibil, 1996). For the 3D protein, numerous 2D projections are obtained which are of 
random unknown directions and very noisy. In order to reconstruct the 3D volume, 
complicated post-processing involving classifying, aligning and averaging by using 
statistics is required. Compared to SAXS which is fast and easy but of lower resolution, 
a cryo-EM experiment yields a higher resolution 3D density map (Kim et al., 2017). 
Depending on instrumental limitations, cryo-EM can provide structural information in a 
resolution range of ∼3 Å to ∼30 Å (Hong‐Wei & Jia‐Wei, 2017). For heterogeneous 
samples, the division of particle images into more homogenous subsets can be carried out 
by using analyses such as eigenimage sorting (Villarreal & Stewart, 2014). 
 
For NMR, the resonating frequencies or chemical shifts of nuclei (such as 1H, 13C 
and 15N for proteins) are dependent on the local magnetic field thus reflect the local 
molecular environment. By this, the quantum mechanical properties of atoms, such as the 
nuclear spin, are exploited. NMR can be used to probe average inter-atomic distances of 
either 6 Å or less based on the Nuclear Overhauser Effect (Wüthrich, 1986) or longer-
range based on paramagnetic relaxation techniques (Iwahara & Clore, 2006). By 
combining these experimental NMR data with theoretical models or a library of short 
fragments of known 3D structure, a 3D protein structure can be determined (Markwick et 
al., 2008).  
 
3.3 Atomistic molecular modelling 
 
In order to elucidate the native structure of a protein, data collected from 
biophysical experiments are fitted to molecular models generated by computational 
methods. For molecular models in biology, the level of detail or resolution varies from 
atomistic-scale to overall shape. The process of moving up the scale at the cost of finer 
detail is known as coarse graining. In order to generate protein models, either ab initio or 
de novo (‘from scratch’) modelling, or homology or template-based modelling can be 
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used (Sali & Blundell, 1993). Both modelling methods require the sequence of the 
protein, but the latter method also requires a structure for a homologous protein to act as 
a structural template. 
 
3.3.1 Homology modelling 
 
 For homology modelling, the 3D structure of a given protein sequence (target) is 
predicted based primarily on its alignment to one or more proteins of known structure 
(templates) that are typically homologous (> 30%). By this, the folds are assigned, the 
target and templates are then aligned and finally the model is built and evaluated (Webb 
& Sali, 2016). For retrieval of homologous sequences with 3D structures, the multiple 
sequence alignment algorithm BLAST can be used to search the PDB database and the 
template structural PDB file can be downloaded. Multiple templates can also be used for 
the homology modelling. The quality of the resulting structure is highly dependent on the 
sequence alignment. At low sequence identity (30 - 35%) the chance of errors increases 
for both the alignment and the model. Thus, the alignment should be visually inspected 
to ensure that the most conserved residues are well aligned. Generally, the loop regions 
have low sequence similarity and can be highly variable in terms of length and dynamics. 
In order to optimise the sequence alignment, the CLUSTAL OMEGA (Sievers et al., 
2011) alignment program is used followed by manual checks. For the homology 
modelling, the MODELLER software (Webb & Sali, 2016) is one of the most widely 
used and can be accessed both as a webserver and as a Python library which can be 
customised. MODELLER also features a variable loop optimisation protocol and models 
can be selected based on their comparison to an atomic distance-dependent reference 
statistical potential (free energy function) known as the discrete optimised protein energy 
score. The most recent statistical potentials are determined by using statistics on the 
frequencies of pairwise residue contacts for proteins in the PDB and are based on the 
Boltzmann energy distribution. For the discrete optimised protein energy score, the sizes 
of the reference native proteins are also taken into account (Shen & Sali, 2006). In order 
to improve protein characterisation, the output homology model can be further refined, 
studied and verified by using a combination of molecular dynamics and experimental 
data.  
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3.3.2 Ab initio modelling 
 
For ab initio modelling, the native structure of the protein is computationally 
predicted from its amino acid sequence by using physicochemical principles. By this, ab 
initio modelling also helps address how and why a protein adopts a specific structure out 
of many possibilities. However, due to both physical and evolutionary constraints, the 
number of possible folds is limited, and predicted to be in the range of 1000 – 10,000 
folds (Grant et al., 2004). Thus, in order to quicken the ab initio method, possible folds 
are identified based on a comparison of the target sequence with a set of related protein 
structures, in a process known as threading. For ab initio modelling, the output depends 
on three main factors. Firstly, in order to identify the native structure from all possible 
structures, an accurate energy function is required to find the most thermodynamically 
stable state. For energy functions, either physics-based or knowledge-based functions are 
used which depend on whether they make use of existing structures in the PDB. An 
example of a knowledge-based function is the rule that proline residues are uncommon in 
α-helices. Secondly, the low-energy states must be identified quickly via an efficient 
conformational search method, and thirdly, near-native models need to be selected from 
a pool of non-native structures by using a certain strategy (Rigden, 2009) which may 
include statistical clustering and/or free-energy based methods. Ab initio-based programs 
for modelling include the ROSETTA (physics and knowledge-based) (Simons et al., 
1997) (Das et al., 2007) and I-TASSER (knowledge-based) (Roy et al., 2010) algorithms.  
 
In order to check the quality of protein structural models, a number of 
computational tools exist. For checking the residue torsion angles, Ramachandran plot 
analyses identify any outlier residues with very unusual backbone conformations 
(Ramachandran et al., 1963). For a high quality dataset, the number of outlier residues is 
less than 0.5% (Gore et al., 2017). Energy minimisation is effective in relaxing any high 
energy, strained inter-atomic interactions (Section 3.3.4). 
 
3.3.3 Molecular dynamics 
 
For a protein structure, molecular dynamics (MD) simulation can be used for both 
ab initio modelling, thus simulating folding directly from sequence (Section 3.3.2), and 
studying the physical movements of the folded state over time. However, normally, ab 
initio refers to quantum mechanics based modelling, and although quantum mechanics 
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based MD simulations are possible, they would be prohibitively expensive for molecules 
the size of a protein. Hence, usually classical MD simulations, based on Newtonian 
mechanics, are employed for large biomolecules. For a MD simulation of a system of 
interacting particles (atoms), the trajectories of molecules, thus the updated atomic 
positions, are determined by numerically solving Newton’s equations of motion (classical 
mechanics) and by using a force field. For the force field, for each atom, a mathematical 
formulation of the potential energy contains terms which are associated with bond 
lengths, angles, torsion angles, van der Waals and electrostatic interactions. By this, force 
fields are essentially huge databases of molecular properties which describe the detailed 
mathematical functions that account for the forces between atoms. They consist of both 
bonded components, which includes stretching, bending, torsion and improper 
interactions, and non-bonded components, which includes both electrostatic and Van der 
Waals. Stretching and bending interactions can be described by a harmonic potential. The 
force field treats atoms as point particles interacting through a defined potential form. The 
end result is a very large potential energy expression. Current computational resources do 
not allow the use of physics-based quantum mechanics. However, the parameters which 
govern inter-atomic interactions are obtained from comparisons of the force field with 
both experimental and quantum mechanical data (Hagler et al., 1974; Weiner et al., 1984). 
For all-atom physics-based force fields, well known examples include Assisted Model 
Building with Energy Refinement (AMBER) (Case et al., 2005), CHARMM (Brooks et 
al., 2009), and GROMOS (Reif et al., 2013). Between these force fields, the major 
differences correspond to both the selection of atom types and the interaction parameters.  
 
MD simulations are made possible by the multitude of algorithms and computer 
programs which are closely coupled to advances in both parallel computing and system 
hardware. Limitations to MD include very long simulations and very large systems, 
however present simulation times are close to biologically relevant timescales. MD 
simulations are highly sensitive to the parameters set by the user and can be performed in 
a large set of different conditions such as vacuum, implicit solvent, explicit water or saline 
solution of physiological salt strength and lipid membranes (Hospital et al., 2015). 
 
For the modelling of the environment surrounding proteins, which consists of 
water and ions, simulations are either explicit or implicit. For explicit models, both water 
molecules and ions are included, whereas for implicit models, only the mean force exerted 
by the external environment or media onto the protein is approximated. By this, implicit 
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models contribute either none or only a few degrees of freedom to the simulation thus 
speed up the computation time. However, important detailed features such as hydrogen 
bond fluctuations, conformational changes which reorient water dipoles and bridging 
water molecules are neglected (Kleinjung & Fraternali, 2014). 
 
By using MD for studying folded proteins, the dynamic evolution of the system 
resulting from atomic interactions in physiological conditions (such as solvent and 
temperature) over time is computationally simulated. By using MD, the energy surface is 
explored in order to find alternative configurations. The lower energy states are more 
probable than the higher energy ones, according to the Boltzmann distribution, but both 
may appear in the ensemble via thermal fluctuations. The Boltzmann distribution gives 
the probability of the system being in a certain state as a function of that state’s energy. 
MD is thus an important tool for studying the conformational ensembles of proteins. 
However, the true global minimum may not be found. For exploring the conformational 
space, the traditional approach of cumulating static experimental structures 
(“experimental ensembles”) allows only a partial view of flexibility and may be biased 
(Hospital et al., 2015). However, MD can be compared with experimental data, such as 
strength of binding characteristics, for verification purposes. MD simulation was first 
developed in the late 1950s within the field of theoretical physics (Alder & Wainwright, 
1959). The first biological system to be studied by MD was the folded globular protein 
bovine pancreatic trypsin inhibitor, for which the equations of motion were solved for the 
atoms with an empirical potential energy function (McCammon et al., 1977). In terms of 
timescales, the time-step (speed limit) of MD is of the order of femtosecond. If atomic 
vibration is slow, the time-step can be a few femtoseconds. In increasing order of time, 
typical biomolecular movements include bond stretching (femtosecond to picosecond), 
elastic vibrations, rotations of surface sidechains and hinge bending (picosecond to 
nanosecond), and allosteric transitions, local denaturation and rotation of buried side 
chains (microsecond to second). For MD simulation of large bimolecular systems, 
Nanoscale Molecular Dynamics (NAMD) is a parallel MD code which was developed by 
the Theoretical and Computational Biophysics Group in the Beckman Institute for 
Advanced Science and Technology at the University of Illinois at Urbana-Champaign 
(Phillips et al., 2005). NAMD produces output files that contain information about the 
co-ordinates, energies and velocities of each atom. The output DCD file contains the 
trajectory of the system. For running simulations in NAMD, a configuration file sets the 
parameters required such as how long-range electrostatic interactions are treated and the 
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dielectric variable for H2O. For force field parameter files, NAMD2 supports CHARMM. 
For NAMD, a protein structure file (PSF) contains information about the molecular 
structure such as the bonds, angles, dihedrals and impropers. PSF files can be built using 
topology files or generated by using the CHARMM-GUI online (Jo et al., 2008). By this, 
the structural PDB files are parameterised and compatible for CHARMM.  
 
Many proteins are glycosylated, such as FH with eight bi-antennary di-sialylated 
glycans which are Asn linked (Fenaille et al., 2007). In SAXS, glycan positons on proteins 
can be identified however their visualisation has been limited due to the similar scattering 
contrast of carbohydrate relative to protein (Hammel et al., 2002). Despite this, a 
reconstruction of the overall shape of the glycoprotein showed that the glycans appeared 
to either contribute bulk volume or just a bulge near the known glycan attachment site 
(Guttman et al., 2013). In order to prepare protein structural models with glycan chains, 
the program GlycanReader (Jo et al., 2011) can generate the CHARMM force field and 
PSF inputs required for MD and/or energy minimisation of the glycans in NAMD. 
Following this, energy-minimised glycans can be positioned onto structures by using 
PyMol scripting, and re-run through GlycanReader to generate a new set of input files. 
For the resulting PDB files, any nomenclature or numbering changes required for other 
modelling programs can be carried out by using bash scripting. 
 
3.3.4 Energy minimisation 
 
 Initial atomic coordinates of protein structures may have unphysical contacts 
which lead to high energies and forces. Thus, by energy minimising the whole system, 
the temperature is decreased to 0°C which decreases the kinetic energy. By this, the 
overall energy is decreased and any high energy interactions are relaxed. In terms of the 
energy landscape, a nearby local minimum is found, and further equilibration to nearby 
states is possible via low energy barriers. In order to access these other intermediate states 
in a timely manner in a MD simulation, steering forces such as random thermal 
fluctuations at physiological temperatures are required. NAMD can also be used for 
energy minimisation, before running an MD simulation.  
 
 
 
103 
 
3.3.5 Monte Carlo methods 
 
MD simulations can take a very long time and lots of computing power. In order 
to sample the configuration space or energy landscape more quickly, MC allows 
intermediate states to be sampled without solving the equations of motion for each step. 
By this, MC can be described as the “highlights” of an MD simulation and provides 
efficient sampling without considering time. As described by Boltzmann’s Ergodic 
hypothesis, the time-average of a quantity calculated by MD is equivalent to the 
ensemble-average of the same quantity calculated by MC. By this, points in configuration 
space are generated with a relative (to zero energy) probability that is proportional to the 
Boltzmann factor.  
 
For a given structure in an energy minimum, random perturbation using MC 
generates a trial structure. In order to generate the trial structure, the user defines both the 
flexible regions that will move and sets the degree to which those flexible regions will 
move. For proteins, the φ and/or ψ torsion angles around the peptide bond (protein 
backbone) are varied, in keeping with the physiochemical restraints of peptide bonds in 
the Ramachandran plot (Ramachandran et al., 1963). By this, in the MC simulations, these 
bonds can act as either hinges or they are twisted (torsion angle). For the peptide bond, 
the omega (ω) angle is always set to 180°.  
 
In order to determine systematically the acceptance of the trial structure over the 
first (starting) structure, the energy difference between them can be calculated by using 
the Metropolis algorithm (Rigden, 2009). By this, if the change of potential energy (∆E) 
associated with the displacement of atoms is less than zero (i.e. new structure is of a lower 
energy state), the new co-ordinates are accepted. If ∆E is equal to or greater than zero and 
the Boltzmann factor (probability of a state of energy E, relative to the state of zero 
energy) for the structure is less than a randomly generated number, the new coordinates 
are accepted. By this, some higher energy structures (which are less probable according 
to the Boltzmann distribution) are randomly accepted and may contribute to a high energy 
barrier being overcome to get to another local minima. This reflects the physiological 
random thermal fluctuations. The longer the MC simulation is run, the more likely this 
will happen. Otherwise, the new coordinates are discarded and the old coordinates are 
kept to start the process again. Structures with steric clashes are of high energy and will 
be discarded. MC simulations of the system are prone to becoming stuck in meta-stable 
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states. In order to prevent this from distorting the distribution of sampled states, the 
energy barriers can also be overcome by sampling states in a wide range of energies by 
changing the temperature.  
 
3.3.6 The SASSIE workflow 
 
For SAXS, in order to identify conformational ensembles of structures, the 
scattering curves can be compared to theoretical curves calculated for physically realistic 
atomistic-scale molecular models. Such models will have been obtained from rigorous 
energy minimisation, MD and/or MC simulations at physiological conditions. By this, 
although SAXS is typically limited to shape parameters due to both being a low resolution 
technique and loss of information from orientation averaging, atomistic-scale molecular 
models that produce very similar theoretical SAXS scattering patterns can be identified. 
Such models are then not only consistent with the scattering data but also with some of 
the known physical chemistry of the system.  
 
Traditional structural analyses for SAS make assumptions about the class of structure, 
such as radius and density/composition for a sphere, in order to fit the experimental data. 
By this, a large number of form factors for different shapes have been derived. However, 
these are restricted to shape classes with simple symmetry whereas biomaterials such as 
proteins have little or no symmetry. Thus, a method whereby experimental data is fitted 
to shape envelopes from spherical harmonics or assemblies of small spheres was 
developed by EMBL in the ATSAS suite of programs (Petoukhov et al., 2012). The first 
atomistic scale modelling was based on crystal structures but constrained by scattering 
curves and showed that only a limited number of antibody fragment conformations fitted 
the experimental scattering data. In order to automate this process, the SCT and SCTPL 
software tools (Perkins et al., 2011; Perkins et al., 2008) were developed by using a 
commercial MD package and applied to human antibody structures. This allowed the first 
atomistic scattering structure to be deposited in the PDB. However, these methods are not 
suitable for analysing the flexibility of proteins within a conformational ensemble. More 
recently, in order to facilitate the analysis of SAXS data by using atomistic-scale 
biomolecular modelling, the Collaborative Computational Project for SAS (CCP-SAS) 
has developed software, deployment infrastructure and a workflow framework. SASSIE-
web combines all of the necessary tools such as preparing protein structures, carrying out 
simulations, calculating theoretical scattering data and comparing the results with the 
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experimental data (Figure 3.3). A key feature of SASSIE is the dihedral angle MC 
simulation methods via Markov sampling of protein backbone torsion angles (Curtis et 
al., 2012). For MC, typically, around 10,000 to 50,000 structures are generated for 
analyses. In order to avoid steric overlap, a distance cut-off (typically 0.3 nm) is specified. 
Because MC is a coarse-grained method, further refinement of the structure is usually 
necessary. For MD and energy minimisation simulations, NAMD is used as the 
simulation engine. For the solvent, an implicit model with an efficient solvent-accessible 
surface area (Ferrara et al., 2002) that is applicable to proteins is used. For the models, in 
order to calculate the theoretical scattering curve from the atomic positions, the Debye 
equation is used. This requires atomistic pairwise distances to be calculated for every 
atom which is computationally demanding and time consuming. Both coarse graining of 
the original atomic structures and binning algorithms accelerate this process by reducing 
the number of scattering centres and number of distances to be processed, respectively. 
In SASSIE, the SasCalc module calculates scattering profiles from a structure file by 
using an exact all-atom expression for the scattering intensity. By this, the orientations of 
the Q vectors are taken from a quasi-uniform spherical grid generated by the golden ratio 
(Watson & Curtis, 2013). 
 
In order to identify the best-fitting structures, the theoretical scattering curves are 
compared to the experimental curves by using the R-factor metric: 
 
𝑅 =  ∑
‖(𝐼𝑒𝑥𝑝𝑡(𝑄𝑖)) − (𝐼𝑡ℎ𝑒𝑜𝑟(𝑄𝑖))‖
‖𝐼𝑒𝑥𝑝𝑡(𝑄𝑖)‖
𝑄𝑖
  × 100                                                  (3.12) 
     
where IExpt(Q) and ITheor(Q) are each the intensity at the Q value for the experimental and 
the theoretical scattering curves, respectively. By the use of data interpolation, the two 
scattering curves have equal Q spacing. The R-factor is a percentage, and models with 
lower R-factors show the best fits thus inferred to represent the average solution structure 
(Wright & Perkins, 2015). 
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Figure 3.3 The SASSIE workflow. A schematic representation of the inputs, modules 
and outputs for a typical modelling project in SASSIE. The decision (pink box) is 
determined by the amount of structures that well fit the experimental data. Sourced from 
(Perkins et al., 2016).    
107 
 
3.3.7 Methods for analysing conformational ensembles 
 
After filtering out theoretical scattering curves that are not well-fitted to the 
experimental data, by applying filters such as an R-factor <5% and RG within 5% of the 
experimental RG, a heterogenous ensemble of different best-fit structures may result.  
These best-fitting structures can be seen as corresponding to the co-existence of multiple 
conformational states for a flexible protein in solution. These structures will be encoded 
in a trajectory file, most commonly in either DCD or PDB format. In order to characterise 
the conformational ensemble of best-fit structures in the trajectory, each major 
conformational state must be identified and quantified. The program Visual Molecular 
Dynamics (VMD) (Humphrey et al., 1996) can be used to visualise and analyse trajectory 
files. By using the Tcl scripting facility in VMD, custom code can be developed and 
applied to the trajectory file in order to gain information on the structure and dynamics of 
each conformational state. By this, structural features of the protein such as inter-domain 
movements and organisations can be identified geometrically by calculating the distances 
between certain atoms and/or the centre of mass. For SAXS, the RG parameter cannot 
discriminate between two molecules that despite being similar in overall shape, thus 
appearing symmetrical, also show significant conformational differences. For example, 
for a long flexible protein such as complement factor H in solution, conformational states 
that correspond to either the N-terminal or C-terminal bending inwards are observed (Nan 
et al., 2010; Okemefuna et al., 2009).  
 
In order to calculate, visualise and compare inter-atomic and/or centre of mass  
distance distributions, the statistical program R provides a number of packages (R Core 
Team, 2013). By this, sampling distribution analyses can further be used to verify that the 
MC set up did not unexpectedly bias the simulation. If unexpected bias is present, a 
population of conformational states may have been ignored, and the simulation may need 
repeating with a different set of parameters to increase the sampling. Examples of such 
parameters include the length of the simulation, the maximum torsion angles and the 
definition of the flexible regions. For measuring the dynamics of the protein, thus the 
movement over time, the root mean square deviation of each atom when compared to the 
initial structure can probe protein flexibility and equilibration. In addition, the root mean 
square fluctuation, in which the reference is the mean structure over the trajectory, can be 
used to find conserved positions of C-α atoms in the models (Benson & Daggett, 2012). 
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 In order to gain a more detailed analysis of the different conformational states 
sampled in the trajectory, the statistical technique principal component analysis (PCA) 
can be employed (Hui et al., 2015). For PCA, a covariance matrix is used to characterise 
the variance between frames in the trajectory. During PCA, multi-dimensional patterns in 
the dataset are found and subsequently compressed by reducing the number of dimensions 
without losing much information. In order to do this, eigenvectors and eigenvalues are 
used. The eigenvector with the highest eigenvalue is the principle component (PC) of the 
dataset and represents the most significant relationship between the datasets 
(dimensions). Thus, for protein structures, the first principal component corresponds to 
the greatest variance between the structures. Overall, the greater the difference in 
displacement between two frames, the further away they will be from each other along 
the principal component line. This allows the best-fit structures to be clustered by their 
atomic co-ordinates, and the most variant regions to be mapped onto the structures. PCA 
has been used for the characterisation of a number of proteins (Gendoo & Harrison, 2012; 
Yang et al., 2009) and can be applied to datasets by using the Bio3D package in R (Grant 
et al., 2006). When combined with visualisation of the structural ensemble by using 
density plots, PCA can be used to identify the major structural conformations within 
ensembles.  
 
An alternative method for finding a combination of structures that fits the 
experimental scattering curve is the minimal ensemble search method. By this, the 
smallest possible number of structures that recapitulate the experimental scattering data 
is attempted to be found (Pelikan et al., 2009). In order to compute the theoretical multi-
conformational scattering from a minimal ensemble, the individual scattering patterns 
from the conformers are averaged. This is based on the ensemble optimization method 
which uses a genetic algorithm to select randomly generated models from a pool (Bernado 
et al., 2007). 
 
3.3.8 Application to the complement proteins 
 
 For complement, a diverse set of proteins with different functions are required 
(Chapter 1). For the proteins associated with aHUS and C3G, which are mostly 
complement AP but also thrombosis-related, many different protein domains are involved 
(Table 3.1). The complement proteins FB, FH, the FHRs and MCP are composed of SCR 
domains, also known as a sushi domains or complement control protein modules. SCR  
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Table 3.1 Complement and related protein domains 
a Protein name abbreviations include: DGKE, diacylglycerol kinase epsilon; FB, factor B; 
FH, factor H; FHR, factor-H related protein; FI, factor I; MCP, membrane cofactor 
protein; THBD, thrombomodulin.
Protein a Uniprot ID Domain type Amount  
C3 P01024 Anaphylatoxin-like (ANA)  1 
C3 P01024 Anchor 1 
C3 P01024 alpha N-terminal loop (a'NT)  1 
C3 P01024 C345C 1 
C3 P01024 C1r/C1s-Uegf-Bmp1 alpha (CUBa)  2 
C3 P01024 Macroglobulin (MG)  9 
C3 P01024 Thioester domain (TED)  1 
DGKE P52429 C1 2 
DGKE P52429 Kinase accessory domain (DAGKa)  1 
DGKE P52429 Kinase catalytic domain (DAGKc)  1 
FB P00751 Linker helix aL (aL)  1 
FB P00751 Short complement regulator (SCR)  3 
FB P00751 Serine protease  1 
FB P00751 von Willebrand factor type A (VWFA)  1 
FH P08603 Short complement regulator (SCR)  20 
FHR1 Q03591 Short complement regulator (SCR)  5 
FHR2 P36980 Short complement regulator (SCR)  4 
FHR3 Q02985 Short complement regulator (SCR)  5 
FHR4 Q92496 Short complement regulator (SCR)  9 
FHR5 Q9BXR6 Short complement regulator (SCR)  9 
FI P05156 FI membrane attack complex (FIMAC)  1 
FI P05156 
Low density lipoprotein-receptor class A 
(LDLR)  
2 
FI P05156 Serine protease 1 
FI P05156 Scavenger receptor cysteine-rich (SRCR)  1 
MCP P15529 Cytoplasmic tail (CT)  1 
MCP P15529 Linker and Ser/Thr rich region 1 
MCP P15529 Short complement regulator (SCR)  4 
MCP P15529 Transmembrane (TM) 1 
Plasminogen P00747 Kringle 5 
Plasminogen P00747 Plasminogen-apple-nemotode (PAN)  1 
Plasminogen P00747 Peptidase serine 1 (Peptidase S1) 1 
Properdin P27918 Thrombospondin type-1 (TSP type-1) 7 
THBD P07204 C-type lectin 1 
THBD P07204 Epidermal growth factor-like (EGF-like) 6 
THBD P07204 Integrin binding domain 1 
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domains are evolutionary conserved and based on a β-sandwich topology. A β-sandwich 
is composed of two opposing antiparallel β-sheets, and is one of the most common 
structural motifs in the proteins of multicellular organisms. It was first identified in the 
domains of Ig structures such as antibody and hence called the Ig-fold. For the SCR 
domain, its β-sandwich arrangement is typically composed of six β-strands which 
envelope a hydrophobic core. For each of SCR-11 and SCR-12 of FH, their six and five 
β-strand arrangements, respectively, are shown in Figure 3.4. For the SCR domains of 
FH, FHR1-5 and MCP, four conserved Cys residues co-ordinate two sets of disulphide 
bonds for stability (green, Figure 3.4). In addition, each SCR domain has one conserved 
Trp residue (purple, Figure 3.4). The SCR domain is associated with both heparin and 
complement C3b binding functions. 
 
For the complement AP and related proteins that are involved in aHUS and C3G, 
many have been structurally characterised to a certain extent by using a range of 
biophysical methods (Table 3.2). However, to date, full-length FH has proven too large, 
flexible and glycosylated for high resolution structural determination by X-ray 
crystallography or NMR. Preliminary molecular modelling of SAXS curves revealed that 
full-length FH in solution has a folded-back SCR structure that is affected by ionic 
strength (Aslam & Perkins, 2001; Nan et al., 2010; Okemefuna et al., 2009). The 
structures of each of DGKE, the FHRs 2 to 5 and plasminogen have not yet been solved.  
 
For this PhD thesis, in order to examine the overall domain arrangement of FH 
and how it is affected by the AMD-risk Tyr402His polymorphism and to better 
understand FH complement binding, the solution structures for both the His402 and 
Tyr402 FH allotypes were studied (Chapter 5). The resulting new models of FH in 
solution were used for my analyses in Chapter 6 which aimed to identify whether the 
structural location of a variant in FH complexes may predict the occurrence of aHUS or 
C3G in patients. Furthermore, my new FH models can also be deposited in the Database 
of Complement Gene Variants (Chapter 4) for better structural-based analyses of novel 
complement gene variants.  
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Figure 3.4 Structural arrangement of two short complement regulator domains of 
complement factor H. For each of the factor H short complement regulator (SCR) 11 
and 12 domains, the structural arrangement of the model with Protein Data Bank code 
4B2S is shown in cartoon style. The β-sheet structures are shown in yellow and numbered 
in black and red text, respectively. The green and purple ball and stick (CPK) style atomic 
representations show the four conserved Cys (two disulphide-bonded pairs) and one 
conserved Trp residue per domain. The cyan and grey coloured regions represent the turn 
and coil secondary structures, respectively.
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Table 3.2 Representative molecular structures for the complement proteins 
a Protein name abbreviations include: FB, factor B; FH, factor H; FHR1, factor-H related protein 1; FI, factor I; MCP, membrane cofactor protein; 
THBD, thrombomodulin.  
b Method abbreviations include: SAXS, small angle x-ray scattering; AUC, analytical ultra-centrifugation. 
c Protein Data Bank code 
Protein a Method b Code c Description Resolution (Å) Reference 
C3 X-ray crystallography 2A73 Full length C3 3.3 (Janssen et al., 2005) 
C3 X-ray crystallography 2I07 Full length C3b 4 (Janssen et al., 2005) 
C3 X-ray crystallography 5FO8 Complement C3b in complex with MCP SCR-1/4 2.4 (Forneris et al., 2016) 
C3 X-ray crystallography 5FO7 Complement C3b 2.8 (Forneris et al., 2016) 
C3 X-ray crystallography 5FO9 Complement C3b in complex with CR1 SCR-15/17 3.3 (Forneris et al., 2016) 
FB X-ray crystallography 1RRK Bb segment of FB 2 (Ponnuraj et al., 2004) 
FB X-ray crystallography 2OK5 Full length FB 2.3 (Milder et al., 2007) 
FH SAXS and AUC 3GAV Full length FH  - (Okemefuna et al., 2009) 
FH SAXS and AUC 3N0J Full length FH  - (Nan et al., 2010) 
FHR1 X-ray crystallography 3ZD2 The two N-terminal domains of FHR1 1.99 
(Goicoechea de Jorge et al., 
2013) 
FHR1 X-ray crystallography 4MUC The fourth and fifth C-terminal domains of FHR1 2.9 (Bhattacharjee et al., 2015) 
FI X-ray crystallography 2XRC Full length FI 2.6 (Roversi et al., 2011) 
MCP X-ray crystallography 3O8E 
Extracellular region of CD46 in complex with human 
adenovirus type 11 fiber knob 
2.8 (Persson et al., 2010) 
Properdin SAXS 1W0R Full length properdin - (Sun et al., 2004) 
Properdin SAXS 1W0S Full length properdin - (Sun et al., 2004) 
THBD X-ray crystallography 1DX5 THBD-thrombin complex 2.3 (Fuentes-Prior et al., 2000) 
THBD X-ray crystallography 3GIS Na-free thrombin in complex with THBD 2.4 (Adams et al., 2009) 
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Chapter Four 
 
Statistical validation of rare complement 
variants provides insights on the 
molecular basis of atypical haemolytic 
uraemic syndrome and C3 
glomerulopathy
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4.1 Summary 
 
Atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy (C3G) 
are associated with dysregulation and over-activation of the complement alternative 
pathway. Typically, gene analysis for aHUS and C3G is undertaken in small patient 
numbers, yet it is unclear which genes most frequently predispose to aHUS or C3G. 
Accordingly, a six-centre analysis of 610 rare genetic variants in 13 mostly complement 
genes (CFH, CFI, CD46, C3, CFB, CFHR1, CFHR3, CFHR4, CFHR5, CFP, PLG, 
DGKE, and THBD) from >3500 patients with aHUS and C3G was performed. There were 
371 novel rare variants for aHUS and 82 for C3G. A new interactive Database of 
Complement Gene Variants was used to extract allele frequency data for these 13 genes 
using the Exome Aggregation Consortium (ExAC) server as the reference genome. For 
aHUS, significantly more protein-altering rare variation was found in five genes CFH, 
CFI, CD46, C3 and DGKE than in ExAC (allele frequency <0.01%), thus correlating 
these with aHUS. For C3G, an association was only found for rare variants in C3 and the 
N-terminal C3b-binding or C-terminal non-surface-associated regions of CFH. In 
conclusion, the rare variant analyses showed non-random distributions over the affected 
proteins, and different distributions were observed between aHUS and C3G that clarify 
their phenotypes. 
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4.2 Introduction 
 
aHUS and C3G are two severe ultra-rare renal diseases that involve dysregulation 
of the AP in the complement system of innate immunity. In healthy individuals, the AP 
eliminates unwanted pathogens without compromising host cells due to the balance 
between AP activator and regulatory proteins. aHUS and C3G both feature host cell attack 
by the AP leading to end stage renal failure. However, aHUS is a thrombotic 
microangiopathy with an acute presentation, whereas C3G is not a thrombotic 
microangiopathy, but is characterised by an abundance of C3 deposition in the renal 
glomeruli with a mostly chronic presentation, with some exceptions (Goodship et al., 
2017). 
 
 Rare genetic abnormalities in AP and thrombosis-related genes are present in 
~60% of aHUS cases (Bu et al., 2012; Fakhouri et al., 2017; Warwicker et al., 1998). 
These mostly drive AP dysregulation at the endothelial cell surface (Goodship et al., 
2017). The penetrance of predisposing RVs in aHUS is ∼50% and is determined by the 
CFH and CD46 (MCP) haplotype, additional RVs, and a trigger (Bresin et al., 2013; 
Esparza-Gordillo et al., 2005; Noris & Remuzzi, 2015; Sansbury et al., 2014). As reported 
in the 2014 aHUS database (Rodriguez et al., 2014), most genetic aHUS cases are 
heterozygous (Nester et al., 2015) and are attributed to the genes CFH (25-30% of cases), 
followed by CD46 (8-10%), C3 and CFI (4-8% each) and CFB (1-4%) (Goicoechea de 
Jorge et al., 2007; Noris & Remuzzi, 2015). The C-terminal SCR-19/20 domains of FH 
are a well-known RV hotspot for aHUS, this being attributed to its functional binding 
sites for C3b, C3d and heparin (Noris & Remuzzi, 2017). In distinction to other genes, 
most RVs in CD46 lead to a quantitative decrease in the protein product and 
approximately a quarter are homozygous (Nester et al., 2015). Rare copy number 
variation leading to large genomic rearrangements in the CFHR-CFH region, such as the 
CFH/CFHR1 and CFH/CFHR3 hybrid genes, are risk factors for aHUS (Eyler et al., 
2013; Maga et al., 2011; Valoti et al., 2015; Venables et al., 2006). RVs in the non-
complement gene THBD account for 3-4% of genetic aHUS (Noris & Remuzzi, 2015), 
although no THBD variants were detected in the French aHUS cohort (Fremeaux-Bacchi 
et al., 2013). RVs in the non-complement gene DGKE account for ~27% of aHUS 
presenting under the age of one year and <4% under two years, respectively (Lemaire et 
al., 2013; Sanchez Chinchilla et al., 2014). 
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In C3G, complement gene RVs have been identified in ~20% of sporadic C3G 
cases (Bu et al., 2016; Iatropoulos et al., 2016; Noris & Remuzzi, 2015; Servais et al., 
2012). Familial C3G is most often linked to highly penetrant heterozygous copy number 
variation in the CFHR1-5 genes, such as CFHR5 nephropathy, as well as homozygous 
CFH deficiency and heterozygous GoF mutation in C3 (Athanasiou et al., 2011; Ault et 
al., 1997; Chauvet et al., 2016; Chen et al., 2014; Gale et al., 2010; Levy et al., 1986; 
Martinez-Barricarte et al., 2010; Tortajada et al., 2013). These frequently affect AP 
regulation in the fluid phase, with some exceptions (Noris & Remuzzi, 2017). As in 
aHUS, unaffected carriers of these genetic abnormalities are seen, indicating that the 
genetic variant only predisposes for the manifestation of C3G (Thomas et al., 2014). 
aHUS and C3G both also involve anti-CFH autoantibodies, known as acquired factors (5-
13% of cases) (Durey et al., 2016; Noris & Remuzzi, 2015). 
 
Genetic sequencing and multiple ligation-dependent probe assessment screening 
panels for aHUS and C3G typically include up to 10 complement (CFH, CFHR1, CFHR3, 
CFHR4, CFHR5, CFI, C3, CD46, CFB and complement factor properdin (CFP; FP) 
(Kouser et al., 2013)), two coagulation (THBD and PLG (Bu et al., 2014)) and one non-
complement (DGKE) genes (Goodship et al., 2017). RVs in six genes (CFH, CFI, C3, 
CD46, CFB and DGKE) are associated with aHUS, while RVs in CFH and C3 associate 
with C3G. These associations result from studies of many aHUS patients, and rather fewer 
C3G patients by linkage and familial segregation, case-control cohorts and functional 
studies. However, the associations of RVs in the four genes CFHR5, CFP, PLG and 
THBD with aHUS, and all 13 genes with C3G are less well defined (Goodship et al., 
2017). In addition, an increasing number of variants of unknown significance for aHUS 
and C3G are being identified amongst these 13 genes. These require rapid pathogenicity 
evaluations for clinical interpretation, e.g. almost a third of CFH variants have limited 
functional characterisation (Merinero et al., 2017). 
 
In order to clarify differences in the genetic and molecular basis of aHUS and 
C3G, I analysed the statistical AFs of RVs in multiple patient cohorts for comparison with 
reference datasets, and developed a new Database of Complement Gene Variants 
(http://www.complement-db.org). The AF provides the frequency of the variant in a given 
population. Variant pathogenicity can be identified by comparisons with genomic 
reference datasets such as the ExAC (Bennett et al., 2017). The database also provides 
structural biology and evolutionary tools to predict the effect of RVs on these proteins, 
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and present functional data from the literature and ClinVar. The database was used to 
analyse 610 rare genetic variants from >3500 patients in six renal centres, this being the 
largest dataset known to date for aHUS and C3G with 371 aHUS and 82 C3G novel RVs. 
Following comparisons with 60,706 genomic reference sequences from ExAC (Lek et al., 
2016) and 6,500 from the EVS, I confirmed the associations of six genes (above) with 
aHUS, and found that three genes CFHR5, PLG and THBD were not associated with 
aHUS. The statistical comparisons also confirmed that CFH and C3 were associated with 
C3G, and suggested the involvement of CFB and THBD with C3G. My results explain 
how changes in the same proteins result in the different pathologies observed with aHUS 
and C3G. Through the use of AFs and burden testing in my new database, this will inform 
patient management by enabling clinical immunologists to interpret new variants in terms 
of their associations with aHUS and C3G.   
 
4.3 Methods 
 
4.3.1 Data collection 
 
The aHUS and C3G phenotype and variant data was sourced from six centres 
(unpublished and published data) and literature searches. aHUS was diagnosed by the 
presence of one or more episodes of microangiopathic haemolytic anaemia and 
thrombocytopenia defined on the basis of hematocrit <30%, hemoglobin <10mg/dl, 
serum lactate dehydrogenase >460U/L, undetectable haptoglobin, fragmented 
erythrocytes in the peripheral blood smear, and platelet count <150,000/μl, associated 
with acute renal failure, together with a negative Coombs test, ADAMTS13 activity 
>10% and negative Shiga toxin (Goodship et al., 2017). C3G was diagnosed by the 
presence of C3 deposits by immunofluorescence in the absence, or comparatively reduced 
presence of immunoglobulins. The identification of dense deposits within the glomerular 
basement membrane by electron microscopy lead to the further classification of the C3G 
as dense deposit disease (Goodship et al., 2017). The database included variant data in 13 
genes (C3, CD46, CFB, CFH, CFHR1, CFHR3, CFHR4, CFHR5, CFI, CFP, DGKE, 
PLG, THBD) (Table 4.1). The estimated variant AFs in the aHUS and C3G datasets were 
based on data from the six centres only. Data from the three reference genome projects, 
namely ExAC (Version 0.3) (Lek et al., 2016), EVS (NHLBI GO Exome Sequencing 
Project, Seattle, WA (http://evs.gs.washington.edu/EVS), and 1000GP (Genomes Project 
et al., 2015), were downloaded and used as surrogate control reference datasets for all 
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Table 4.1 Summary of mRNA and protein identifiers for the 13 genes 
 
  
 
 
 
 
 
 
 
 
 
 
a The databases of annotated genomic, transcript and protein reference sequences are found at https://www.ncbi.nlm.nih.gov/refseq/ (RefSeq) and 
http://www.ensembl.org/index.html (Ensembl). 
Gene Protein 
RefSeq (NCBI)a Ensembla 
mRNA Protein Transcript ID Protein ID 
CFH FH NM_000186.3 NP_000177.2 ENST00000367429 ENSP00000356399 
CFI FI NM_000204.3 NP_000195.2 ENST00000394634 ENSP00000378130 
C3 C3 NM_000064.3 NP_000055.2 ENST00000245907 ENSP00000245907 
CD46 MCP NM_002389.4 NP_002380.3 ENST00000358170 ENSP00000350893 
CFB FB NM_001710.5 NP_001701.2 ENST00000425368 ENSP00000416561 
CFHR1 FHR1 NM_002113.2 NP_002104.2 ENST00000320493 ENSP00000314299 
CFHR3 FHR3 NM_021023.5 NP_066303.2 ENST00000367425 ENSP00000356395 
CFHR4 FHR4 NM_001201550.2 NP_001188479.1 ENST00000367416 ENSP00000356386 
CFHR5 FHR5 NM_030787.3 NP_110414.1 ENST00000256785 ENSP00000256785 
THBD THBD NM_000361.2 NP_000352.1 ENST00000377103 ENSP00000366307 
CFP FP NM_001145252.1 NP_001138724.1 ENST00000396992 ENSP00000380189 
DGKE DGKE NM_003647.2 NP_003638.1 ENST00000284061 ENSP00000284061 
PLG Plasminogen NM_000301 NP_000292 ENST00000308192 ENSP00000308938 
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genes apart from CFHR1, CFHR3 and CFHR4 that were involved in copy number 
variation only. These latter three genes were excluded because, at the time of writing, no 
copy number variation data were available from ExAC, EVS or 1000GP. These three 
reference datasets do not contain genomes from patients with rare renal disease 
phenotypes that include aHUS or C3G, however ExAC and EVS contain genomes from 
myocardial infarction studies. While this may affect the analyses of thrombosis-related 
genes such as THBD, a recent study found that the ExAC was not enriched in pathogenic 
RVs for these diseases (Song et al., 2016). In ExAC, only variants with “PASS” filter 
status were included in my analyses. The corresponding AF of each variant in ExAC, 
EVS and 1000GP was queried by using Human Genome Variation Society nucleotide 
level nomenclature (c.) and National Center for Biotechnology Information (NCBI) gene 
accession number. Published experimental data on each variant were sourced from 
literature searches using PubMed. Variants were described using DNA and protein level 
terms for both Human Genome Variation Society and legacy nomenclature.  
 
4.3.2 Data cleansing, duplications and maintenance 
 
Patient duplicate tests were carried out within and between datasets from the six 
renal centres, firstly by identifying potential duplicates using the patient’s variant profile, 
disease, gender and year of birth. Potential duplicates were investigated by requesting the 
full date of birth details from each renal centre and deleting as necessary. For maintenance 
of the database in the long term, each collaborating group will provide an annual data 
update as a spreadsheet that will be automatically uploaded to the database with 
automated duplication and error checks that are programmed into the MySQL backend. 
As an open resource, other clinical centres are invited to upload formatted data updates 
through the curator. To prevent against SQL injection attacks and related software 
vulnerabilities, the database inputs were sanitised and tested using the penetration testing 
tool SQLMAP. 
 
4.3.3 Web-database development 
 
The Database of Complement Gene Variants (http://www.complement-db.org) 
was constructed using a MySQL platform and its user interface was developed using a 
combination of PHP, JavaScript, jQuery, CSS and HTML. The design is based on the 
European Association for Haemophilia and Allied Disorders coagulation Factor IX web-
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database (http://www.factorix.org/) (Rallapalli et al., 2013). The database is mounted on 
a Linux server within the Information Services Division at University College London. 
 
4.3.4 Data retrieval 
 
Variant data were retrieved from the Database of Complement Gene Variants 
using simple or advanced search tools. The user first defined the data source and gene, 
and then the other search options, including protein domain, location, and variant type 
and effect. The advanced search tool featured a customisable default ExAC AF cut-off 
value of 1%, which was used to ensure that any variant with an ExAC AF >1% was not 
retrieved. Variants were mapped to their genomic location using the reference human 
genomes GRCh37 and GRCh38. The protein and transcript locations were identified 
using RefSeq and Ensembl (Table 4.1). The database provided protein structural views 
of each missense variant using the JSmol Java applet 
(https://sourceforge.net/projects/jsmol/). These views facilitated a structural 
understanding of the variant using the webpage ‘structure and function’ tab. For each 
disease dataset, the statistics page showed (i) the distribution of variants in genes by 
protein domain, exon/intron location, and variant type and effect; (ii) the RV burden per 
gene, and (iii) the number of RVs per case. The AF webpage summarised the number of 
variants in each gene using their reference genome AF, with links to their variant database 
entries, for each disease dataset. The world map webpage showed the number of 
laboratory-sourced cases that have citizenship in each country, where data were available. 
The new variants webpage predicted the effects of any theoretical missense variants using 
AF, structural and functional analyses. The structures webpage listed all known protein 
structural models with links to their PDB code. The amino acid alignments webpage 
showed the multiple sequence alignment of up to ten vertebrate species for each protein 
depending on sequence availability, this being calculated using the UniProt database and 
the Probabilistic Alignment Kit program (PRANK) (Loytynoja & Goldman, 2005). 
 
4.3.5 Rare variant burden 
 
The RV burden per gene was computed for the aHUS, C3G, ExAC and EVS 
datasets. The RV burden was defined as the proportion of screened cases with an 
identified RV per gene. For aHUS and C3G, the burden was calculated by dividing the 
number of cases with an identified RV by the total number of cases screened per gene. 
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For ExAC and EVS, this was calculated for each gene by dividing the total mean adjusted 
allele count, this being determined from the allele count minus the number of 
homozygous cases, by the total mean adjusted number of subjects screened (Walsh et al., 
2016). An AF cut-off value of 0.01% was used for all RV burden calculations, which is 
advised for a Mendelian disease (Kobayashi et al., 2017). The RV burden was calculated 
for all protein-altering RV only; truncating (nonsense, frameshift and splice) and non-
truncating (missense and in-frame). RVs classified as ‘benign’ and ‘likely benign’ (see 
next section) were not filtered out because these data were unavailable for the ExAC and 
EVS datasets.  
  
4.3.6 Rare variant assessment 
 
Each non-large genomic rearrangement RV was classified as ‘pathogenic’, ‘likely 
pathogenic’, ‘uncertain significance’, ‘benign’ or ‘likely benign’ using categorisation 
guidelines (Goodship et al., 2017) that followed the American College of Medical 
Genetics and Genomics and the Association for Molecular Pathology (Richards et al., 
2015). The following categories were also added to cover all RVs in the datasets:  
1. MAF <0.1%; likely benign by clinical testing (Illumina; ClinVar); in silico 
analyses predict: tolerated, neutral and benign. Categorised as ‘likely benign’ for all genes 
except for C3 and CFB which were ‘uncertain significance’ instead. 
2. MAF <0.1%; likely benign by clinical testing (Illumina; ClinVar); in silico 
analyses predict: uncertain deleterious effects. Categorised as ‘uncertain significance’. 
3. MAF <0.1%, predicted as loss-of-function (includes nonsense, frameshift and 
splice acceptor/donor variants) in C3 or CFB. Categorised as ‘uncertain significance’. C3 
or CFB loss-of-function is unlikely to over-activate complement and lead to aHUS or 
C3G. Since their effects on complement have not been experimentally proven, it was safer 
to categorise these as ‘uncertain significance’. 
4. MAF <0.1%; synonymous change; in silico analyses predict: tolerated, neutral 
and benign. Categorised as ‘likely benign’. 
5. 0.1% < MAF <1%; no functional data; in C3 or CFB. Categorised as ‘likely 
benign’. 
 
Loss-of-function RVs in all genes, except in those only involved in large genomic 
rearrangement variants or in the complement activators C3 and CFB, were classified as 
‘likely pathogenic’ for aHUS and C3G, unless functional data reported otherwise 
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(Goodship et al., 2017). The Ensembl Variant Effect Predictor tool (McLaren et al., 2016) 
was used for PolyPhen-2 (Adzhubei et al., 2010) and SIFT (Kumar et al., 2009) analyses 
and the results were used for combinatorial variant analyses. These classifications were 
made available for each variant identified in the aHUS and C3G datasets. 
 
4.3.7 Spatial distribution of missense rare variants in the proteins 
 
For each protein domain, the AFs of missense RVs in the aHUS and C3G datasets 
were summed, and then divided by the proportion of protein residues in the corresponding 
domain, in order to identify mutational hotspots. Missense RVs that were categorised as 
‘benign’ or ‘likely benign’ were excluded from these analyses. For FH, FI, C3, MCP and 
FB, where there were enough missense RVs to identify mutational hotspots, these were 
represented graphically as bar charts. For FH, FI, C3, MCP and FB, each unique missense 
RV was mapped onto the structural model for visualisation, but noting that these did not 
take the aHUS or C3G AF into account. The structural models for FH (PDB code 3N0J 
(Okemefuna et al., 2009)), C3 (PDB code 2A73 (Janssen et al., 2005)), FI (PDB code 
2XRC (Roversi et al., 2011)), MCP (PDB code 3O8E (Persson et al., 2010)) and FB (PDB 
code 2OK5 (Milder et al., 2007)) were sourced from the PDB. An alternative model for 
FH in which the C-terminal domains were extended and not the N-terminal domains was 
also used but not shown here (PDB code 3GAV) (Rodriguez et al., 2014). The R statistical 
package was used for statistical analyses and artwork (http://www.R-project.org/). PyMol 
was used for protein structural visualisation and artwork (Schrodinger, 2015). 
 
4.3.8 Statistical analyses  
 
The categorical variables shown in Tables 4.2 and 4.6, Appendix II, III and IV, 
and Figures 4.4 and 4.5 were examined using the two-tailed Chi-squared test (𝜒2) with 
Yates’ correction with a 0.05 significance level that was Bonferroni-corrected where 
applicable. For the common variants analyses in Table 4.2, the 0.05 significance level 
was Bonferroni-corrected by dividing by the 14 variants, to give 0.0036. For the patient 
gender analyses in Table 4.6, the 0.05 significance level was Bonferroni-corrected by 
dividing by 12 genes to give 0.0042 for aHUS, and by 11 genes to give 0.0045 for C3G. 
The ‘ALL’ genes category for both aHUS and C3G were each subjected to a 0.05 
significance level (no Bonferroni adjustment needed). For the RV burden analyses 
presented in Figure 4.4 and Appendix II and III, the 0.05 significance level was 
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Bonferroni-corrected by dividing by the 9 genes to give 0.0056. For the statistical 
analyses of CFH in Appendix IV and Figure 4.5, a 0.05 significance level was used. The 
categorical variables shown in Figure 4.2B and Table 4.3 were examined using the two-
tailed Fisher’s exact test with a significance level of 0.05.  
 
For each row of one independent t-test (protein-altering only) in Appendix II and 
III, I undertook a power calculation using the program PS Power and Sample Size 
Calculations (Version 3.0) (Dupont & Plummer, 1990). My calculations used expected 
differences of: ≥ 5% for CFH, C3 and CD46, ≥ 2.6% for DGKE in the aHUS and EVS 
groups, and ≥ 2.5% for DGKE in the other three groups, and ≥ 2% for all other genes, and 
took into account the unequal sizes of the experimental (aHUS or C3G) and control 
(ExAC or EVS) groups. If the true difference between the experimental and control 
groups was as expected, I was able to reject the null hypothesis that their frequencies were 
equal with a certain probability (power). The Type I error probability associated with all 
of these tests was 0.0056. The power was at least 80% in all tests apart from the following 
cases in Appendix II, with ExAC as the reference dataset, for aHUS: DGKE (74%), and 
for C3G: DGKE (55%) and PLG (32%), and also in Appendix III, with EVS as the 
reference dataset, for aHUS: DGKE (67%), and for C3G: DGKE (68%), PLG (10%), 
THBD (38%) and CFB (41%). 
 
4.3.9 Allele frequency (AF) analyses 
 
A two-tailed Chi-squared test (𝜒2) with Yates’ correction was used to assess the 
difference in protein-altering RV AF (ExAC AF < 0.1%) between the aHUS/C3G and 
reference datasets. Protein-altering variants included non-truncating and truncating 
variants only (Walsh et al., 2016). For each RV, the 0.05 significance level was 
Bonferroni-adjusted by dividing by the number of RVs identified in its gene for aHUS 
and ExAC (C3: 485, CD46: 191, CFB: 400, CFH: 469, CFHR5: 262, CFI: 215, DGKE: 
193, PLG: 263, THBD: 145), and for C3G and ExAC (C3: 452, CD46: 130, CFB: 391, 
CFH: 334, CFHR5: 261, CFI: 173, DGKE: 176, PLG: 263, THBD: 143) and rounding to 
4 decimal places to give significance levels of 0.0001, 0.0002, 0.0003 or 0.0004 
accordingly. The AF was not available in the aHUS dataset for the two CFP RVs so CFP 
was not analysed. CFHR1, CFHR3 and CFHR4 were not analysed because large genomic 
rearrangements were not included in ExAC at the time of writing. Related individuals 
were taken out the analyses by including familial alleles only once (twice for homozygous 
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cases). This procedure refers to the AF assessments that were displayed on the web 
database, and were also used to verify that none of the RVs were significantly more 
common in ExAC than in aHUS or C3G. 
 
4.4 Results 
 
4.4.1 Genetic variants in aHUS and C3G 
 
In order to perform the comparisons between aHUS and C3G using AF analyses, 
six Reference Centres from the United Kingdom, France, Italy, Spain, Holland and the 
United States of America provided phenotype and variant data sets for 3128 and 443 
patients from National and International Registries. The total of disease variants was 543 
for aHUS and 111 for C3G in 13 genes (Figure 4.1). The aHUS and C3G variants were 
analysed in terms of their reference AFs for these variants found in three reference 
datasets (1000GP, EVS and ExAC). First, 10, 10 and 8 common variants with AF > 1% 
were filtered out (red in Figure 4.1). The RVs that were retained were those with an AF 
of <1% in the reference datasets (light blue, green, dark blue, and pink, Figure 4.1), or 
were rare large genomic rearrangements not covered by the reference datasets. By this 
filtering, a total of 610 retained RVs (96-97% of the total) were identified in 13 genes 
(Table 4.1) for aHUS (542 variants) and C3G (110 variants), with 42 being shared by 
aHUS and C3G, including the large genomic rearrangements.  
 
For this PhD thesis chapter, only RVs were analysed for aHUS and C3G. The 
combined presence of multiple variants that are common in the general population can 
modify the risk for aHUS (Ermini et al., 2012), such as the SNP c.1204T>C p.Tyr402His 
(rs1061170) in the CFH-H3 haplotype (Pickering et al., 2007; Rodriguez de Cordoba & 
Goicoechea de Jorge, 2008). The CFH-H3 aHUS-risk haplotype also contains the SNPs 
−331C>T (rs3753394), c.184G>A Val62Ile (rs800292), c.2016A>G p.Gln672Gln 
(rs3753396), IVS15 −543G>A intron 15 (rs1410996) and c.2808G>T p.Glu936Asp 
(rs1065489), where the at-risk alleles are defined in bold. In contrast, the presence of one 
RV can predispose for genetic aHUS and C3G. Thus, the analyses of multiple common 
variants per case for aHUS and C3G are more complex and were beyond the scope of this 
PhD thesis. For the aHUS and C3G datasets, the remaining 3-4% of common variants 
with AF >1% in at least one of the reference datasets comprised 14 and four in aHUS and 
C3G respectively (Table 4.2). These 14 and four variants were only just over the 1% AF
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Figure 4.1 Stacked bar analyses showing the reference AF of the variants identified 
in the (A) aHUS and (B) C3G datasets. 
The total numbers of unique variants (nvar) are shown within the bars. A unique variant is 
defined as, when a variant is seen in more than one patient, the variant is only counted 
once. Unique variants (excluding the 13 aHUS and 3 C3G copy number variants) are 
categorised by their AF in each of the three reference datasets: the 1000 Genomes Project 
(1000GP) with an allele number (AN; total number of alleles screened for each gene) of 
3775-5008, the Exome Variant Server (EVS) with an AN of 8202-13005 and the Exome 
Aggregation Consortium (ExAC) with an AN of 14708-121412. The aHUS and C3G 
datasets each had ANs of 634-6256 and 208-886, respectively. The pink bars indicate a 
reference AF of 0%, dark blue bars indicate a reference AF of between 0% and 0.01% 
(non-inclusive), green bars indicate a reference AF of between 0.01% (inclusive) and 
0.1%, light blue bars indicate a reference AF of between 0.1% (inclusive) and 1%, and 
red bars indicate a reference AF ≥ 1%.
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Table 4.2 The 14 common genetic variants identified in at least one of the three 
reference datasets (1000GP, EVS and ExAC) at an AF of ≥1%. Bold text denotes 
statistical significancea,b. 
 
Gene 
Genetic 
Variant 
Protein 
Variant 
Dataset Allele Frequency (%) 
1000GP EVS ExAC 
aHUS 
(a) C3G (b) 
C3 c.1407G>C p.Glu469Asp 1.62a 1.41a 0.40 0.16 0 
CFB c.754G>A p.Gly252Ser 1.02a 2.82a 2.22a 0.43 0 
CFB c.1598A>G p.Lys533Arg 1.92a,b 0.44 1.05
a 0.20 0.26 
CFB c.1697A>C p.Glu566Ala 1.02 0.73 1.12a 0.53 0.13 
CFB c.1953T>G p.Asp651Glu 1.04a 0.94a 0.22 0.04 0 
CFH c.1652T>C p.Ile551Thr 1.91a 1.68a 0.50a 0.16 0 
CFH c.2669G>T p.Ser890Ile 6.23a 6.57a 1.99a 0.34 0 
CFH c.2808G>T p.Glu936Asp 20.33a 13.80a 19.55a 0.02 0 
CFHR5 c.136C>T p.Pro46Ser 0.90 1.13 0.70 0.63 0 
CFHR5 c.1067G>A p.Arg356His 1.04 2.09a 1.78a 1.42 0.12 
CFI c.884-7T>C - 2.56a 0 2.31a 0.02 0 
CFI c.1534+5G>T - 0.30 1.13 0.90 0.33 0.12 
CD46 c.1058C>T p.Ala353Val 0.40 1.25a 1.53a 0.60 0.24 
PLG c.1567C>T p.Arg523Trp 0.24 1.01 0.68 0.35 0 
 
a Determined to be significantly more common in ExAC than in aHUS using a two-tailed 
Chi-square test (𝜒2) with Yates’ correction and a Bonferroni-corrected significance level 
of 0.0036. 
b Determined to be significantly more common in ExAC than in C3G using a two-tailed 
Chi-square test (𝜒2) with Yates’ correction and a Bonferroni-corrected significance level 
of 0.0036. 
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threshold (for RVs) except for three (CFH p.Ser890Ile, CFH p.Glu936Asp and CFI 
c.884-7T>C. In the aHUS dataset, 14% (75), 19% (103), and 32% (174) of variants were 
found to have an AF between 0-1% (light blue/green/dark blue, Figure 4.1A) in the 
1000GP, EVS and ExAC reference datasets, respectively. In the C3G dataset, these 
proportions were significantly higher, being 31% (35), 46% (52) and 58% (65) 
respectively (light blue/green/dark blue, Figure 4.1B). In confirmation of this outcome, 
all three analyses gave p<0.0001 in the two-tailed Fisher’s exact test. This outcome was 
still true when the ‘benign’ and ‘likely benign’ RVs were excluded from the aHUS and 
C3G datasets (p<0.0001; Fisher’s exact test) (see below). The aHUS and C3G RV 
datasets were compared with the literature (Rodriguez et al., 2014)  in order to determine 
how many RVs were novel. Of the 542 aHUS and 110 C3G RVs, 56% (371) and 58% 
(82) respectively were not found in the literature and therefore novel (purple, Figure 
4.2A). The RVs that were reported in the literature but not in the six Reference Centres 
were not part of my current analyses because I could not calculate their aHUS and C3G 
AF values (green, Figure 4.2A). However, they are included in the updated database from 
this study.  
 
4.4.2 Rare variant frequencies in cases 
 
The frequencies of the RVs in the aHUS and C3G datasets were surveyed. First, 
I investigated differences in the screened cases with RVs for aHUS and C3G. The aHUS 
and C3G datasets comprised 3128 aHUS and 443 C3G patients respectively (Figure 4.2B; 
Table 4.3). Of these totals, 1231 (39%) aHUS and 116 (26%) C3G patients harboured 
542 and 110 unique RVs respectively, with an overlap of 42 unique variants between 
them. A significantly greater proportion of screened aHUS patients had at least one RV 
compared to C3G patients (p<0.0001; two-tailed Fisher’s exact test). There were 0.44 
unique RVs per case in aHUS, compared to 0.95 in C3G. This suggested that almost every 
C3G case had a different, unique RV, whereas aHUS cases were more likely to share the 
same RV. The proportion of aHUS patients with RV (1231/3128=39.3%) (Figure 4.2B) 
was low compared to literature reports of ~60%. This difference most likely arose from 
the omission in the AF analyses of the 119 literature-sourced aHUS RVs in the web-
database, for which no aHUS patient AF data from the six centres were available (green, 
Figure 4.2A).
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Figure 4.2 Summary of cases and variants in aHUS and C3G. 
(A) The source of the RV data in the database for aHUS and C3G. “Both” (yellow) 
indicates RVs that were identified both in the laboratory-sourced datasets (purple) and 
published in the literature (green). 
(B) The number of unique RVs (0 to 3) per patient case in the aHUS and C3G datasets, 
totalling 3127 patients. For aHUS, there is a further case with four RVs that is too small 
to be seen.  
(C) A matrix showing the genetic profiles of the 182 aHUS cases with compound 
heterozygous (in single or in two different genes) or homozygous RVs from panel (B). 
Their frequencies n are graded in colour (inset). 
(D) A matrix showing the genetic profiles of the 31 C3G cases with compound 
heterozygous (in single or in two different genes) or homozygous RVs from panel (B), 
graded in colour (inset). 
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Table 4.3 The total number of aHUS and C3G cases screened per gene 
 
Centre 1: Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, 
United Kingdom 
Centre 2: Clinical Research Center for Rare Diseases “Aldo e Cele Daccò”, IRCCS-
Istituto di Ricerche Farmacologiche “Mario Negri”, Ranica Bergamo, Italy 
Centre 3: Molecular Otolaryngology and Renal Research Laboratories, Carver College of 
Medicine, University of Iowa, Iowa City, Iowa, United States of America; 
Centre 4: Department of Cellular and Molecular Medicine, Center for Biological 
Research and Center for Biomedical Network Research on Rare Diseases, Madrid, Spain; 
Centre 5: Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges Pompidou, 
Service d’Immunologie Biologique, Paris, France; 
Centre 6: Department of Pediatric Nephrology, Radboud University Medical Center, 
Nijmegen, The Netherlands
 Gene Disease 
Total number of cases screened by the reference centres 1-6 
1 2 3 4 5 6 All 
C3 aHUS 410 480 286 252 409 618 2455 
CD46 aHUS 524 480 286 461 578 613 2942 
CFB aHUS 395 480 286 328 350 618 2457 
CFH aHUS 662 480 286 483 578 639 3128 
CFHR1 aHUS 7 250  442   699 
CFHR3 aHUS  250  348   598 
CFHR5 aHUS   286  31  317 
CFI aHUS 533 480 286 425 578 621 2923 
DGKE aHUS  76 286 191 150  703 
PLG aHUS   286    286 
THBD aHUS  480 286 348 214  1328 
C3 C3G 115 160 104    379 
CD46 C3G 142 160 104    406 
CFB C3G 115 160 104    379 
CFH C3G 179 160 104    443 
CFHR5 C3G   104    104 
CFI C3G 144 160 104    408 
DGKE C3G  23 104    127 
PLG C3G   104    104 
THBD C3G  160 104    264 
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4.4.3 Rare variant profiles of cases 
 
Next, I compared the genetic RV profiles of aHUS and C3G patients. Among the 
1231 aHUS and 116 C3G patients with RVs, 1024 (83%) and 82 (68%) respectively 
harboured a single RV in one of the 13 genes (Figure 4.2B). Two RVs were identified in 
182 (15%) aHUS and 31 (29%) C3G cases (light blue bars; Figure 4.2B), three in 24 (2%) 
and 3 (2%) respectively (red bars; Figure 4.2B), and four in 1 (<1%) and 0 (0%) 
respectively. However, the number of RVs per aHUS case in the dataset from Reference 
Centre 6 was unknown except for three homozygotes. All other RV occurrences in this 
dataset were analysed as one heterozygous aHUS case. When the 322 aHUS cases from 
Reference Centre 6 were excluded, 702/909 (77%) harboured a single RV, 182/909 (20%) 
had two, 24/909 (3%) had three, and 1 (<1%) had four RVs. Excluding Reference Centre 
6, no significant difference was seen between aHUS and C3G in the cases with two RVs 
(p=0.113; two-tailed Fisher’s exact test). For aHUS, cases with two RVs in CD46 (23 
cases including 19 homozygotes; 11% of all aHUS cases with CD46 RVs), were the most 
frequent, followed by CFH (37 cases, including 18 homozygotes; 9%) (Figure 4.2C; 
Table 4.4). For C3G, cases with two RVs in CFH (7 cases including 6 homozygotes; 
30%) were the most frequent, followed by C3 (6 cases including 2 homozygotes; 23%)  
(Figure 4.2D; Table 4.4). These analyses showed differences between aHUS and C3G, 
summarised in Figures 4.2C, 4.2D. No CFHR3 RVs were seen in any aHUS or C3G cases 
that had more than one RV. 
 
4.4.4 Gender analyses 
 
Finally, I examined gender dependences in aHUS and C3G cases. Of the 1231 
aHUS patients with at least one identified RV, 36% (440) were female, and 30% (363) 
were male (Table 4.5). In aHUS, assuming the remaining 34% of patients for which the 
gender was unknown showed a similar pattern, the bias towards females was significant 
(p=0.007). However, when CFH was removed from the analyses, the numbers of females 
(244) and males (225) was not significantly different (p=0.38) (Table 4.6). For the 116 
C3G patients, no significant difference in the number of females (53) and males (63) was 
seen (p=0.35) (Table 4.6). In terms of gender differences, the aHUS dataset (542 variants) 
showed a bias towards females in CFH, which is likely to be a reflection of potential 
triggering factors. For example, in pregnancy-aHUS, most patients harbour CFH variants 
(Bruel et al., 2017; Huerta et al., 2017). This trend was not observed for C3G.  
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Table 4.4 Homozygous RVs present in aHUS and C3G 
* Denotes a nonsense variant
Gene cDNA change Protein change Classification Disease Cases 
C3 c.3322_3333del p.1108_1111del Likely benign aHUS 1 
CD46 c.97G>C p.Asp33His Uncertain significance aHUS 2 
CD46 c.100G>A p.Ala34Thr Uncertain significance aHUS 1 
CD46 c.286+2T>G - Pathogenic aHUS 4 
CD46 c.286+1G>C - Pathogenic aHUS 1 
CD46 c.496T>C p.Cys157Arg Uncertain significance aHUS 1 
CD46 c.535G>C p.Glu179Gln Pathogenic aHUS 1 
CD46 c.565T>G p.Tyr189Asp Likely pathogenic aHUS 1 
CD46 c.718T>C p.Ser240Pro Pathogenic aHUS 2 
CD46 c.736T>A p.Phe246Ile Uncertain significance aHUS 1 
CD46 c.800_820del - Uncertain significance aHUS 1 
CD46 c.810T>G p.Cys270Trp Uncertain significance aHUS 1 
CD46 c.811_816delGACAGT p.Asp271_Ser272del Pathogenic aHUS 1 
CD46 c.881C>T p.Pro294Leu Uncertain significance aHUS 1 
CD46 c.1027+2T>C - Pathogenic aHUS 1 
CFH c.79_82delAGAA - Likely pathogenic aHUS 1 
CFH c.157C>T p.Arg53Cys Pathogenic aHUS 2 
CFH c.158G>A p.Arg53His Likely pathogenic aHUS 1 
CFH c.2697T>A p.Tyr899* Likely pathogenic aHUS 2 
CFH c.2880delT p.Phe960fs Likely pathogenic aHUS 1 
CFH c.2918G>A p.Cys973Tyr Uncertain significance aHUS 1 
CFH c.3048C>A p.Tyr1016* Likely pathogenic aHUS 2 
CFH c.3628C>T p.Arg1210Cys Pathogenic aHUS 1 
CFH [c.3674A>T; 3675_3699del] p.Tyr1225Tyrfs*38 Likely pathogenic aHUS 2 
CFH c.3693_3696 delATAG p.*1232Ilefs*38  Likely pathogenic aHUS 5 
CFI c.341T>C p.Val114Ala Uncertain significance aHUS 1 
CFI c.1357T>C p.Cys453Arg Uncertain significance aHUS 1 
CFI c.1456T>C p.Trp486Arg Uncertain significance aHUS 1 
CFI c.1642G>C p.Glu548Gln Uncertain significance aHUS 2 
DGKE c.889-1G>A p.IVS5-1 Likely pathogenic aHUS 1 
DGKE c.966G>A p.Trp322* Likely pathogenic aHUS 4 
DGKE c.1000C>T p.Gln334* Likely pathogenic aHUS 1 
DGKE c.1608_1609del p.His536Glnfs*16 Likely pathogenic aHUS 1 
PLG c.1481C>T p.Ala494Val Likely benign aHUS 1 
C3 c.168_169delTG p.Thr56Thrfs*16 Uncertain significance C3G 1 
C3 c.1682G>A p.Gly561Asp Uncertain significance C3G 1 
CFB c.2035C>T p.Arg679Trp Uncertain significance C3G 1 
CFH c.232A>G p.Arg78Gly Pathogenic C3G 1 
CFH c.262C>A p.Pro88Thr Uncertain significance C3G 1 
CFH c.694C>T p.Arg232* Likely pathogenic C3G 1 
CFH c.3286T>A p.Trp1096Arg Uncertain significance C3G 3 
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Table 4.5 Demographics of the 1231 aHUS and 116 C3G cases showing an identified 
RV 
 
 
a Born in or before 1997 
b Born after 1997 
c Year of birth
Disease Gender 
Number of 
cases aged 
18+ years a 
Number of 
cases aged 
<18 years b 
YOB c 
unknown 
Total 
aHUS Female 328 (27%) 84 (7%) 28 (2%) 440 (36%) 
aHUS Male 254 (20%) 84 (7%) 25 (2%) 363 (29%) 
aHUS Unknown 2 (<1%) 1 (<1%) 425 (34%) 428 (35%) 
aHUS ALL 584 (48%) 169 (14%) 478 (38%) 1231 
C3G Female 34 (29%) 12 (10%) 7 (6%) 53 (46%) 
C3G Male 40 (35%) 16 (14%) 7 (6%) 63 (54%) 
C3G Unknown 0 0 0 0 
C3G ALL 74 (64%) 28 (24%) 14 (12%) 116 
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Table 4.6 Gender of the 1231 aHUS and 116 C3G cases with an identified RV 
 
Disease Gene Female Male Unknown 
Proportion of 
females (known) 
(%) 
P a 
aHUS C3 76 61 99 55 0.20 
aHUS CD46 77 91 67 46 0.28 
aHUS CFB 13 11 11 54 0.68 
aHUS CFH 196 138 196 59 0.002 
aHUS CFHR1 8 13 1 38 0.28 
aHUS CFHR3 1 1 0 50 1.00 
aHUS CFHR5 4 3 0 57 0.71 
aHUS CFI 80 60 54 57 0.09 
aHUS CFP 1 1 0 50 1.00 
aHUS DGKE 16 9 0 64 0.16 
aHUS PLG 7 5 0 58 0.56 
aHUS THBD 16 8 10 67 0.10 
aHUS ALL b 440 363 428 55 0.007 
C3G C3 23 20 0 53 0.65 
C3G CD46 1 1 0 50 1.00 
C3G CFB 4 4 0 50 1.00 
C3G CFH 19 24 0 44 0.45 
C3G CFHR1 0 1 0 0 0.32 
C3G CFHR3 0 1 0 0 0.32 
C3G CFHR5 0 4 0 0 0.05 
C3G CFI 5 6 0 45 0.76 
C3G DGKE 1 2 0 33 0.56 
C3G PLG 2 5 0 29 0.26 
C3G THBD 2 7 0 22 0.10 
C3G ALL b 53 63 0 46 0.35 
 
a P value from a two-tailed Chi-square test (𝜒2) with Yates’ correction using a Bonferroni-
corrected significance level of 0.0042 for aHUS and 0.0045 for C3G. The ‘ALL’ genes 
category was subject to a significance level of 0.05 (no Bonferroni correction). Bold text 
denotes a P level less than the Bonferroni-corrected significance level. 
b ‘ALL’ is not equal to the gene sum, because some patients possessed RVs in more than 
one unique gene.
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4.4.5 Rare variant pathogenicity classification 
 
RVs were categorised for their pathogenicity using published experimental 
evidence, reference AFs and in silico predictive analyses, in accordance with genetic 
variant guidelines (Goodship et al., 2017) (Figure 4.3A). The average healthy genome 
also contains benign RVs that occur at similar AFs to disease-related RVs, therefore AF 
analyses alone cannot be used as evidence for pathogenicity (Kobayashi et al., 2017). In 
terms of pathogenicity, only gain-of-function RVs in the activators C3 and CFB are 
expected to predispose for aHUS or C3G disease; here gain-of-function results from the 
loss of ability to interact with an inhibitory complement regulator. The predictive tools 
PolyPhen-2 and SIFT were unable to predict gain-of-function phenotypes, thus many C3 
and CFB RVs without experimental data could only be classified as ‘uncertain 
significance’ (green bars; Figure 4.3A). For example, the C3 RV p.Arg161Trp was 
predicted to be damaging and deleterious, while functional studies showed a C3 gain-of-
function (Roumenina et al., 2012). The number of ‘pathogenic’ or ‘likely pathogenic’ 
RVs in C3 and CFB were therefore lower than for the other genes. In aHUS, the majority 
of RVs in CFH, CFI, CD46 and DGKE were either ‘pathogenic’ or ‘likely pathogenic’ 
(red and light blue bars; Figure 4.3A), this being attributed to their loss-of-function 
phenotypes. In C3G, the majority of RVs in all genes were of ‘uncertain significance’ 
(green bars; Figure 4.3A) except for CFH. In terms of the non-pathogenic RVs in the 
aHUS and C3G datasets, a survey of all 542 RVs in aHUS and 110 in C3G showed that 
43 (8%) and 27 (25%) RVs respectively were categorised as ‘benign’ and ‘likely benign’, 
and these were filtered out (Appendix I). This suggested that the RVs in the C3G dataset 
may be less pathogenic compared to aHUS overall; this observation reinforced the 
importance of using classification guidelines prior to the protein domain hotspot analyses 
below. I also note that ‘likely pathogenic’ RVs still require further functional studies to 
confirm or disprove the predicted effects and disease relevance of the variants. 
 
4.4.6 Rare variant abundance in genes 
 
In order to identify differences in the frequency of unique RVs per gene between 
aHUS and C3G, and therefore the molecular pathogenesis of both diseases, the 
abundances of RVs in each gene were analysed. I stress that only those RVs that were not 
classified as ‘benign’ or ‘likely benign’ were analysed (red, light blue, green and grey 
bars; Figure 4.3A). The CFHR1-CFHR4 genes were subject to multiple 
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Figure 4.3 RV effects and classifications in aHUS and C3G. The colour coding of each 
RV effect and its classification is shown in the insets. 
(A) In terms of pathogenicity, the total number of unique RVs for each gene and their 
classification, based on the pathology guidelines (Methods), are shown for the aHUS and 
C3G datasets, and for both datasets, in three panels. 
(B) In terms of functional annotation (such as that used in ExAC), the total number of 
unique RVs for each gene and their effect on each protein are shown for the aHUS and 
C3G datasets, and for both datasets in three panels. 
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ligation-dependent probe assessment only, and were not sequenced, thus only large 
genomic rearrangements were identified. In aHUS, CFH showed the most RVs (204 
variants; 41%) (Figure 4.3A), followed by CFI (82; 17%), CD46 (79; 16%), and C3 (68; 
14%). This outcome confirmed the 2014 analyses for CFH, CFI, CD46 and C3 
(Rodriguez et al., 2014). Lesser abundances for aHUS were seen for CFB (20; 4%), 
DGKE (20; 4%); THBD (11; 2%), PLG (4; 1%), CFHR5 (3; 1%), CFHR1 (4; 1%), 
CFHR3 (2; <1%) and CFP (2; <1%). Only one unique variant in CFHR4, a 
CFHR1/CFHR4 deletion, was seen in three heterozygous and one homozygous aHUS 
cases. This was classified under the CFHR1 gene in the database. In C3G, C3 (31 variants; 
37%) and CFH (25 variants; 28%) showed the most RVs (red, light blue, green and grey 
bars; Figure 4.3A). Lesser abundances for C3G were seen for CFI (5; 6%), CD46 (1; 1%), 
CFB (8; 10%), DGKE (2; 2%); THBD (2; 2%), PLG (2; 2%), CFHR5 (1; 1%), CFHR1 
(1; 1%), CFHR3 (1; 1%) and CFP (0; 0%). It was concluded that RVs in CFI and CD46 
were substantially reduced in C3G compared to aHUS (p=0.0121 and p<0.0001, 
respectively; two-tailed Fisher’s exact test). When analysed in terms of genetic effect for 
both aHUS and C3G, most RVs were non-truncating (yellow; Figure 4.3B), except for 
the aHUS variants in DGKE that were mostly truncating, and the large genomic 
rearrangements in CFHR1 and CFHR3. The most frequent RV in the aHUS dataset was 
C3 p.Arg161Trp, seen at an AF of 1.16% in 52 aHUS cases. However in C3G, none of 
the RVs were notably more frequent than others. Data on RVs found in the complement 
inhibitor vitronectin and clusterin genes in the aHUS and C3G datasets were not available 
for analysis at the time of writing (Stahl et al., 2009; van den Heuvel et al., 2018). 
 
4.4.7 Gene-based rare variant burden 
 
In order to confirm that the amount of rare variation seen in the genes of aHUS 
and C3G patients was greater than in the genes of individuals without these diseases, I 
determined the burden of protein-altering rare variation (ExAC MAF<0.01%) per gene 
for each dataset (Methods). These were compared to the ExAC and EVS reference 
datasets (Figure 4.4; Appendix II and III). Because ExAC and EVS did not contain data 
on large genomic rearrangements, CFHR1-4 were not analysed. No aHUS or C3G AF 
data were available for CFP. This left nine out of 13 genes (CFH, CFI, CD46, C3, DGKE, 
CFB, CFHR5, PLG, THBD) for analysis. For the aHUS dataset, a significantly greater 
burden of rare variation was revealed in patients than in the ExAC and EVS datasets for 
five genes, namely CFH, CFI, CD46, C3 and DGKE (Chi-square test (𝜒2) with Yates’ 
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Figure 4.4 The RV burden (%) per gene for the nine relevant genes in the four aHUS (Allele number (AN): 634-6256), ExAC (AN: 74194-
121246), EVS (AN: 8202-13005) and C3G (AN: 208-886) datasets. These were based on an ExAC MAF cut-off of 0.01%. *** denotes p<0.0001. * 
denotes p=0.0052.
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correction using a Bonferroni-corrected significance level of 0.0056; the five genes each 
gave p<0.0001), and also for CFB when compared with the EVS dataset only (also with 
p<0.0001) (Figure 4.4; Appendix II and III). No association with aHUS was observed 
with RVs in THBD, PLG and CFHR5. The tests for these three genes showed a power 
>80% thus their false negative rates were expected to be very low. In the C3G dataset, 
C3 (p<0.0001; p<0.0001) and CFH (p<0.0001; p<0.0001) showed a significantly greater 
burden of protein-altering rare variation in patients than in the ExAC and EVS datasets 
(Chi-square test (𝜒2) with Yates’ correction using a Bonferroni-corrected significance 
level of 0.0056) (Figure 4.4; Appendix II and III). C3G was also associated with RVs in 
CFB (p<0.0001) and THBD (p=0.0052) when only EVS was used as the reference dataset 
(green bar, Figure 4.4; Appendix III), despite both tests showing a lack of power (CFB: 
41% and THBD: 38%). The lack of association of DGKE and PLG with C3G may also 
relate to lack of power (DGKE: 55% ExAC and 68% EVS, and PLG: 32% ExAC and 
10% EVS) shown in the tests for these genes.  
 
4.4.8 Distribution of aHUS and C3G RVs in FH 
 
The aHUS and C3G location and AF of the missense RVs for each gene resulted 
in the identification of mutational hotspots in each protein structure. For FH, as seen in 
the 2014 study (Rodriguez et al., 2014), most aHUS missense RVs (78) occurred in the 
C-terminal ten domains, compared to the N-terminal ten domains (47; p=0.0042) (Figure 
4.5A; Appendix IV). In aHUS, the total frequency of CFH alleles with a missense RV in 
the C-terminal ten domains (3.2%) was significantly greater than for the N-terminal ten 
domains (1.2%; Chi-square test with Yates’ correction using a significance level of 0.05; 
p<0.0001). In SCR-20, the total missense RV aHUS AF of 2.03% (Appendix IV) was the 
highest for all 20 domains. These non-random distributions supported the functional 
association of SCR-20 with cell surface dysregulation in aHUS, although laboratory 
experimentation and functional characterization will be required to validate this result. 
This was still the case when normalised for the size of the FH domain (62/1231 residues; 
5.5%), giving 37.2% (Figure 4.5A; Appendix IV). Most of the six FH domains (SCR-2, 
SCR-5, SCR-8, SCR-12, and SCR-13) with the least number of aHUS RVs did not 
correspond to known FH binding sites. For C3G, in contrast to aHUS, the C3G missense 
RVs in FH were clustered at the N-terminal C3b binding site, with comparatively few at 
the non-surface associated C-terminal domains such as SCR-15 (Figure 4.5A). No C3G 
clusters were seen in the heparin binding regions of FH. The only three unique C3G
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Figure 4.5 The distribution and disease allele frequencies (AFs) of non-benign missense RVs in the domains of FH, C3, FI, MCP, and FB in the 
aHUS and C3G datasets. Figure legend overleaf.
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Figure 4.5 (continued) The distribution and disease allele frequencies (AFs) of non-
benign missense RVs in the domains of FH, C3, FI, MCP, and FB in the aHUS and 
C3G datasets. The largest bars correspond to missense RV hotspots (e.g. FH SCR-20 for 
aHUS; SCR-18 for C3G). Each domain missense RV AF is normalised for its size by 
dividing it by the proportion of residues in the protein domain. In each of (A-E), red 
represents the total AF missense RVs identified in the aHUS dataset, and likewise dark 
blue for C3G. For those missense RVs identified in both the aHUS and C3G datasets, 
pink represents the AF for aHUS and light blue for C3G. On the x-axes, the domain names 
are shown. 
(A) The total AF of missense RVs in each of the 20 SCR domains in FH. Beneath the x-
axis, the functional binding sites associated with each SCR domain are shown by coloured 
arrows (identified in the inset).  
(B) The total AF of missense RVs in each C3 domain. Beneath the x-axis, the functional 
binding sites associated with each C3 domain are shown by arrows to correspond to the 
SCR domains in FH (pink) or other sites in FI or on the cell surface. The C3d binding site 
on SCR-19/20 corresponds to the TED domain, however this is not shown.   
(C) The total AF of missense RVs in each FI domain.  
(D) The total AF of missense RVs in each MCP domain.  
(E) The total AF of missense RVs in each FB domain.
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missense RVs found in SCR-7 (p.Cys431Tyr; C3G AF: 0.2%) and SCR-20 
(p.Arg1210Cys, 0.1%; p.Cys1218Arg, 0.1%) in the heparin binding regions were also 
seen in aHUS at similar AFs of 0.01%, 0.4%, and 0.01% respectively, suggesting an 
overlap in phenotypes. The C3G missense RVs in FH were also not found in eleven SCR 
domains (SCR-4/6, SCR-8/9, SCR-11/13, SCR-16/17 and SCR-19). There was a C3G 
missense RV cluster at the N-terminal SCR-1/3 C3b binding region (Thomas et al., 2014) 
(Figure 4.5A; Appendix IV); I infer that SCR-1/3 may be a mutational hotspot for C3G. 
In summary, the distribution of FH hotspots between aHUS and C3G showed clear 
differences between the two diseases. 
 
4.4.9 Distribution of aHUS and C3G rare variants in C3 
 
For C3, the 67 aHUS C3 missense RVs occurred in 12 of the 16 C3 domains 
(Figure 4.5B; Appendix IV). Macroglobulin (MG)-2 showed the highest missense RV AF 
for C3 (1.3%), normalised by the proportion of domain residues (21.7%), followed by 
MG-6b (0.5%; 18.5%) (Figure 4.5B). Both the MG-2 and MG-6b domains were thus 
inferred to be aHUS hotspots. The 29 C3G missense RVs occurred in 13 of the 16 C3 
domains (Appendix IV). In contrast to aHUS, these were spread more evenly throughout 
C3 and no hotspots were inferred (Figure 4.5B). No aHUS or C3G variants involved the 
key C3 thioester residues (Glu991, Cys998, His1104 and Glu1106), or the anaphylatoxin 
(ANA), aNT, and beta-sheet (CUB)-a domains. Again the distribution of C3 missense 
RVs between aHUS and C3G showed clear differences between the two diseases. 
 
4.4.10 Distribution of aHUS and C3G rare variants in FI, CD46, FB and others  
 
For FI, the 65 missense RVs in aHUS were distributed across all five domains of 
FI (Figure 4.5C). For MCP, the 45 aHUS rare missense variants were distributed across 
the four MCP domains (Figure 4.5D). For FB, there were no aHUS or C3G missense RVS 
in SCR-1 or SCR-3 (Figure 4.5E). In FB, most aHUS missense RVs occurred in the 
VWFA domain, whereas the C3G missense RVs were spread across the SCR-2, VWFA 
and serine protease domains. No mutational hotspots were evident for either aHUS or 
C3G in FI, MCP or FB. 
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4.4.11 Minor allele frequency analyses  
 
The AFs of each of the protein-altering RVs per gene in the aHUS and C3G 
datasets were compared with the corresponding AF in ExAC. The two CFP RVs in aHUS 
were not analysed because there were no available patient AF data. CFHR1, CFHR3 and 
CFHR4 were not analysed because large genomic rearrangements were not included in 
ExAC at the time of writing. There were no variants that were rare in ExAC 
(MAF<0.01%) yet were significantly more common in ExAC, than in aHUS or C3G. The 
AFs and their significance are shown on the database for users.  
 
4.5 Discussion 
 
4.5.1 Summary of rare variants in aHUS and C3G  
  
Compared to a 2014 study (Rodriguez et al., 2014) in which 324 aHUS- and C3G-
associated genetic variants in CFI, CFH, C3 and CD46 were used to identify variant 
hotspots in these four proteins (www.fh-hus.org), my more detailed study now reports 
610 RVs in 13 genes from 3128 aHUS and 443 C3G patients, together with their 
associated AFs. The expansion to 13 genes reflects new candidate genes for potential 
association with these diseases, and clarifies the extent to which they are indeed 
associated. To my knowledge, this is the largest study of aHUS and C3G patients to date. 
The much increased totals of RVs and cases now make possible for the first time AF 
analyses and RV burden analyses of the aHUS and C3G datasets, including comparisons 
to three reference genome datasets. In turn, the AF analyses provided more detailed 
statistical analyses of the RV distributions in both diseases. The analyses of distinct 
protein domain hotspots for aHUS and C3G clarify molecular differences that rationalise 
the occurrence of their two different phenotypes, the involvement of the RVs that are 
present, and the molecular mechanisms involved in both diseases. In particular, this study 
has reduced the earlier knowledge gap in the genetics and genotype-phenotype 
correlations of C3G to bring these closer to that of aHUS (Goodship et al., 2017).  
 
4.5.2 Differences between aHUS and C3G using allele frequency analyses  
 
The AF analyses revealed three new insights into the individual RVs associated 
with aHUS and C3G (and not the full genes). My analyses raised the question of what AF 
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cut-off to employ. Firstly, my AF analyses verified the rarity of 97% of the aHUS and 
C3G variants when compared to the ExAC reference (Figure 4.1), especially given the 
ability of ExAC to resolve ultra-RV AFs as low as 1×10-5 (0.001%) (Walsh et al., 2016). 
Such disease-predisposing alleles in aHUS and C3G are by definition deleterious. In 
theory, evolutionary pressures will maintain these alleles at very rare frequencies in the 
general population through negative selection (Gibson, 2011; Rallapalli et al., 2014; Zuk 
et al., 2014). Other studies report a histogram of variants in which pathogenicity increases 
with rarity and low AF (Kobayashi et al., 2017). These results therefore justify my focus 
on RVs with AF<1% in the reference datasets. A more stringent RV AF cut-off of 0.01% 
is applicable to rare diseases of Mendelian inheritance (Kobayashi et al., 2017). This 
0.01% cut-off was used for the RV burden calculations in order to restrict them to RVs 
with a higher confidence of pathogenicity (Figure 4.4; Appendix II and III). However, 
RVs observed in both aHUS and C3G have reduced penetrance, where disease-free 
individuals also harbour these pathogenic RVs, and the onset of aHUS or C3G disease 
depends upon a trigger and other factors. To enable my hotspot analyses, a less stringent 
reference AF cut-off of <0.1% was thus used, but accompanied alongside experimental 
data and prediction tools, as specified in genetic variant classification guidelines1. Some 
variants show AFs of >1% (Table 4.2). While these may be risk factors for aHUS (e.g. 
CFH p.Val62Ile) (Noris & Remuzzi, 2017), their analysis was beyond the scope of this 
study. All the variants are available to view in the Database of Complement Gene Variants 
by adjusting the value of the ExAC AF filter. 
  
The second insight involved AF differences between aHUS and C3G that relate 
to their different phenotypes. Significantly greater proportions of C3G RVs were 
identified in the reference datasets, with AFs between 0-1% rather than 0%, unlike aHUS 
(Figure 4.1). This meant that the C3G RVs occurred more frequently in individuals 
without C3G (the reference datasets) than the aHUS RVs. This result may explain the 
mostly chronic presentation of C3G that accumulates over time, in distinction to the 
mostly acute presentation of aHUS. 
 
Thirdly, the AF analyses of the disease datasets (i.e. not the reference datasets) 
revealed differences between the most common RVs in the aHUS and C3G datasets that 
were likely to reflect their different phenotypes. In the aHUS dataset, while CFH had the 
most RVs, the most frequent RV was p.Arg161Trp in C3, corresponding to an AF of 
1.16% of 3128 aHUS cases, i.e. 52 aHUS cases. C3 p.Arg161Trp has a surface exposed 
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position in the MG2 domain and forms a hyperactive C3 convertase with an increased 
affinity for factor B, thus leading to over-activation of the AP. C3 p.Arg161Trp was not 
seen in the reference datasets, and classification guidelines confirmed its pathogenicity 
(Goodship et al., 2017). In the C3G dataset, C3 had the most RVs. Further analyses 
(below) reveal distinct domain hotspots for aHUS and C3G.    
 
4.5.3 Rare variant burden testing  
 
The RV burden is the proportion of screened cases with an identified protein-
altering RV for which the ExAC AF was <0.01%. As opposed to the AF analyses that 
look at each variant one-by-one, the RV burden now provides insight into all the RVs 
associated with each gene. In general, RV burden tests assume that all tested RVs 
influence the phenotype in the same direction (Auer & Lettre, 2015). I therefore separated 
RVs into ‘truncating’ (loss-of-function) and ‘non-truncating’ (either loss- or gain-of-
function, or neutral) in order to aid interpretations. RV burden tests showed clear 
differences between aHUS and C3G when compared to reference datasets, and this 
clarified the molecular mechanisms of the two diseases. Previous knowledge of 
experimental functional characterization of some of the RVs collectively support that 
aHUS is more related to surface AP dysregulation, while C3G is more related to fluid 
phase AP dysregulation. Here I now extend these earlier functional results: 
 
(i) For aHUS, my RV burden analyses confirmed the association of rare variation in the 
six genes CFH, CFI, CD46, DGKE (Azzi et al., 1992; Lemaire et al., 2013), C3 and CFB. 
For the five genes of the AP, CFH, CFI, C3 and CFB are involved in both cell surface 
and fluid phase regulation, but CD46 is only involved in cell surface regulation. 
Therefore, my RV burden analyses suggest that aHUS involves defects that result in both 
cell surface and fluid phase dysregulation. Different domains of C3 and FH are involved 
in cell surface dysregulation compared to fluid phase dysregulation, and this is explored 
in terms of the aHUS and C3G RV distributions in the next section (Section 4.5.4). The 
protein encoded by the sixth gene, DGKE, is found in endothelium, platelets and 
podocytes, and normally inactivates the signalling of arachidonic acid-containing 
diacylglycerols which activate protein kinase C (PKC) and promote thrombosis. Loss of 
DGKE function may thus result in a prothrombotic state and lead to microangiopathic 
haemolytic anaemia seen in aHUS outside the complement system (Lemaire et al., 2013). 
For three more genes CFHR5, PLG and THBD, no association of RVs in these with aHUS 
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was observed. Each of their tests showed a high power of >80%. This is unexpected from 
their known function, where FHR5 is likely to compete with FH for regulation (Csincsi 
et al., 2015; Goicoechea de Jorge et al., 2013), while PLG and THBD are inhibitors of 
thrombosis, and THBD also regulates complement (Conway, 2012; Delvaeye et al., 2009; 
Heurich et al., 2016; Wang et al., 2012). 
 
(ii) For C3G in contrast, the RV burden analyses showed that the four genes C3, CFH, 
CFB and THBD were associated with C3G, while the two genes CD46 and CFI were not 
associated with C3G. This outcome suggested that C3G is not caused by defects in cell 
surface regulation by CD46 or defects in cell surface or fluid phase regulation by FI. My 
results also suggested that non-large genomic rearrangement RVs in CFHR5 and PLG are 
not causative for C3G. I did not analyse large genomic rearrangements in CFHR5 such 
as those identified in CFHR5 glomerulopathy. Despite pathogenic RVs in known cardiac 
genes not being overrepresented in ExAC (Song et al., 2016), THBD is involved in cardiac 
disease cases. Furthermore, the prevalence of RVs may differ across different centres, 
especially for genes such as CFHR5 and PLG in aHUS, and CFHR5, PLG and DGKE in 
C3G that are less mutated and/or were sequenced by one or two centres only. This 
outcome is potentially affected by sampling bias, thus being difficult to interpret, and the 
results for these genes should be considered as preliminary only. In addition, the lack of 
association of DGKE and PLG with C3G may also be related to a lack of power (10% - 
68%) shown by their tests. 
 
4.5.4 Hotspots for missense rare variants 
 
The 2014 identification of hotspots in four complement proteins (Rodriguez et al., 
2014) can now be expanded to examine clusters of missense RVs in each of aHUS and 
C3G. Based on the RVs with 0.1% reference AF cut-offs, clear differences were seen 
between the phenotypes of aHUS and C3G at the molecular level. In particular, RV 
‘hotspots’ were identified in FH and C3 that could be rationalised on the basis of their 
importance in protein-protein interactions. For example, FH is involved in both fluid 
phase and cell surface regulation by (i) being a cofactor for FI, (ii) possessing C3 
convertase DAA, and (iii) blocking the formation of the C3 convertase. Despite the FH 
N-terminal SCR-1/4 and C-terminal SCR-19/20 domains both binding to C3b, required 
for both fluid phase and cell surface regulation, the C-terminal region of FH is critical for 
cell surface regulation and is not required for fluid phase regulation (Rodriguez de 
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Cordoba et al., 2004). Thus surface-exposed missense RVs in CFH that map to individual 
SCR domains can be correlated with FH function. Other variants predicted to affect FH 
stability may lead to FH aggregation, making this unable to perform fluid or cell surface 
phase regulation. In the fluid phase, FH is the only AP complement regulator that has 
cofactor activity for FI, however at the cell surface, both FH and MCP can act as the FI 
cofactor. Thus, if the FH C-terminal SCR-19/20 domains are compromised, wild-type 
MCP may save cell surface regulation. An additional scenario is that if the FH variant is 
heterozygous, this would affect only half of the FH in plasma, thus altering the resulting 
phenotype. Overall, the consequence of each RV on FH function can be complex to 
interpret. 
 
 Different FH SCR domains were identified as hotspots in aHUS and C3G:  
(i) For aHUS, the AF analyses confirmed that SCR-20 with 31 RVs and a RV density of 
37.2% was a notable missense hotspot (Figures 4.5A; Appendix IV). SCR-20 is 
functionally important for FH binding to C3b, C3d, heparin-like oligosaccharides and 
sialic acid (Blaum et al., 2015; Rodriguez et al., 2014; Saunders et al., 2006; Schmidt et 
al., 2008). The occurrence of SCR-20 as a RV hotspot is well explained by the disruption 
of FH binding to surfaces, leading to host cell damage from excess complement activation 
caused by unregulated C3b. aHUS missense RVs were also identified in the remaining 
19 SCR domains in FH (Appendix IV). Four of the five FH domains (SCR-2, SCR-5, 
SCR-8, SCR-12, and SCR-13) do not correspond to known FH binding sites and have 
only single missense RVs. The distribution (Figure 4.5A) suggested that the aHUS 
missense RVs affect mainly FH cell surface binding. 
(ii) In contrast, for C3G, the missense RVs were clustered at the N-terminal C3b binding 
site (SCR-2/3) (Figure 4.5A). No missense RVs in C3G were now clustered at cell surface 
heparin binding sites in SCR-6/7 or SCR-20. The SCR-2/3 domains were identified as 
C3G hotspots, likely attributed to its binding to MG-2 and MG-6 in C3b (Figure 4.5A) 
(Schmidt et al., 2008; Wu et al., 2009). This different clustering best correlates the C3G 
variants with dysregulation of the complement AP in the fluid phase (C3, FH) and not at 
the cell surface (CD46). 
 
Different C3 domains were likewise identified as hotspots in aHUS and C3G:  
(i) For aHUS, the MG-2 and MG-6b domains with the highest RV density (Appendix IV) 
were deduced to be RV hotspots (Figure 4.5B). Both MG domains interact with FH SCR-
2 and SCR-3 to enable C3 regulation by FH in both the fluid phase and on the cell surface 
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(Wu et al., 2009). The disruption of the MG-2 and MG-6b domains would reduce C3 
regulation by FH. It is not clear if these two C3 domains also bind MCP thus affecting 
cell surface regulation further (Schramm et al., 2015). While the TED domain contained 
22 RVs, its RV density, which takes into account the number of residues in the domain 
(300), was not as high as might be expected from its functionally important thioester 
group and its binding to cell surfaces.  
(ii) In distinction, for C3G, too few missense RVs in C3 have been reported for a clear 
outcome. The RVs were distributed in 11 of its 13 domains with no clustering seen to 
date. 
 
4.5.5 Utility of the Database 
 
The new Database of Complement Gene Variants enhances the understanding of 
rare genetic variants in aHUS and C3G for clinical applications. Improvements include 
the use of AFs, predictive comparisons of wild-type and mutant amino acids, in silico 
analyses using PolyPhen-2 and SIFT, examination of evolution-conserved residues across 
species, and correlations with functional binding sites. These tools enable clinicians to 
assess RVs in disease, for example, to investigate which variants within these genes 
conferred predisposition to aHUS and C3G, and to identify mutational hotspots within 
these protein structure. This is especially useful for variants of uncertain significance for 
which no experimental data exists.  
 
Ethnicity data was only recorded for less than 50% of the aHUS and C3G patients 
in the datasets. The RVs are displayed on the database in comparison with ExAC ethnicity 
data with a full record of ethnicity. While the disease datasets are incomplete in this 
regard, the new web-database has the capacity to capture new ethnicity data for aHUS 
and C3G cases for future AF comparisons. Because the six renal clinics of this study are 
based in Western Europe and the United States, which are also the source of much of the 
ExAC dataset, the effect of ethnicity are expected to be minimal on the aHUS and C3G 
analyses.
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Chapter Five 
 
Two distinct conformations of factor H 
regulate discrete complement-binding 
functions in the fluid phase and at cell 
surfaces
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5.1 Summary 
 
Factor H (FH) is the major regulator of C3b in the alternative pathway of the 
complement system in immunity. FH comprises 20 short complement regulator (SCR) 
domains, including eight glycans, and its Tyr402His polymorphism predisposes those 
who carry it for age-related macular degeneration. To better understand FH complement 
binding, the solution structures of both the His402 and Tyr402 FH allotypes were studied. 
In prior work, analytical ultracentrifugation revealed that up to 12% of both FH allotypes 
self-associate, and this was confirmed by small angle X-ray scattering (SAXS), mass 
spectrometry and surface plasmon resonance analyses. Here, starting from known 
structures for the SCR domains and glycans, the SAXS data were fitted using Monte 
Carlo methods to determine atomistic structures for monomeric FH. The analysis of 
29,715 physically realistic but randomised FH conformations resulted in 100 similar best-
fit FH structures for each allotype. Two distinct molecular structures resulted that showed 
either an extended N-terminal domain arrangement with a folded-back C-terminus, or an 
extended C-terminus and folded-back N-terminus. These two molecular structures are the 
most accurate to date for glycosylated full-length FH. To clarify FH functional roles in 
host protection, crystal structures for the FH complexes with C3b and C3dg revealed that 
the extended N-terminal conformation accounted for C3b fluid phase regulation, the 
extended C-terminal conformation accounted for C3d binding, and both conformations 
accounted for bivalent FH binding to anionic glycosaminoglycans on the target cell 
surface. 
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5.2 Introduction 
 
The alternative pathway of complement is activated by the spontaneous hydrolysis 
of C3 into C3u, also known as C3(H2O). This leads to a positive-feedback amplification 
of C3 cleavage to form activated C3b that opsonises pathogenic cells. To prevent 
unwanted C3b-mediated host cell damage, FH regulates complement by acting as a 
cofactor for FI to cleave C3b (Law & Reid, 1995; Pangburn et al., 1977; Whaley & 
Ruddy, 1976), competing with FB to interfere with the formation of the C3 convertase 
C3bBb (Farries et al., 1990), and accelerating the decay of the C3bBb complex (Weiler 
et al., 1976; Whaley & Ruddy, 1976). These activities occur in the fluid phase and less 
effectively at the host cell surface (Liszewski et al., 1996).  
 
Disrupted complement regulation is associated with AMD, the most common 
cause of blindness in the West (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 
2005; Klein et al., 2005), and also with aHUS, C3G, and Alzheimer's disease (Osborne et 
al., 2018a; Saunders et al., 2007; Strohmeyer et al., 2002; Zetterberg et al., 2008). In early 
stage AMD, sub-retinal pigment epithelial deposits known as drusen develop within 
Bruch’s membrane which is an extracellular matrix layer interposed between the RPE 
and the choroidal vasculature (Bird, 2010). Drusen contain oxidized lipids, carbohydrates, 
cellular materials and over 200 proteins including FH and other complement components 
(Bok, 2005; Crabb et al., 2002; Hageman et al., 2005).  
 
FH is composed of 20 SCR domains of size ~61 residues connected by linkers of 
lengths 3-8 residues (Figure 5.1) (Lambris & Morikis, 2005). Eight out of nine potential 
N-glycosylation sites in FH are occupied by biantennary disialylated glycans (Fenaille et 
al., 2007). Functionally, FH has multiple binding sites for its major ligands C3b, the C3d 
fragment, C-reactive protein and two host-cell markers heparin, which is an analogue of 
the natural ligand HS, and sialic acid (Perkins et al., 2012; Perkins et al., 2010a; Perkins 
et al., 2010b). Each ligand binds to FH weakly with μM KD values (Perkins et al., 2014) 
at specific SCR domains summarised in Figure 5.1. For example, FH has two binding 
sites for heparin at SCR-7 and SCR-20 (Blackmore et al., 1998; Blackmore et al., 1996; 
Okemefuna et al., 2009; Ormsby et al., 2006; Perkins et al., 2014), and weak independent 
interactions with heparin at SCR-7 and SCR-20 result in bivalent binding with an overall 
greater affinity than either site on their own (Khan et al., 2012; Perkins et al., 2012). The 
dimerization of FH at high concentrations was first reported by X-ray and neutron 
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Figure 5.1 Cartoon of the 20 SCR domains in FH. Each SCR domain is represented by an ellipse colour-coded to indicate the starting atomistic 
structure (green, X-ray crystallography; purple, NMR; orange, homology modelling). Ribbon views of the seven SCR structures used to model FH are 
shown above the cartoon, together with their PDB codes. The asterisks signify newer SCR structural models that became available after the previous 
full-length FH models were published. Beneath the cartoon, the FH functional binding sites are denoted by horizontal bars for each of C3b, C3d, factor 
I, heparan sulphate and sialic acid. 
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scattering (Perkins et al., 1991). FH also self-associates at each of SCR-6/8 and SCR-
16/20 with μM KD values; the sequential daisy-chaining of these two dimer sites leads to 
FH oligomers (Fernando et al., 2007; Nan et al., 2008a; Okemefuna et al., 2008; 
Okemefuna et al., 2009). The formation of dimers and tetramers of FH may also be 
involved in host cell recognition essential for complement regulation (Pangburn et al., 
2009). However it is often presumed that FH is monomeric (DiScipio, 1992). 
 
Genetic variants in FH are associated with disease (Osborne et al., 2018a). In 
AMD, FH SCR-7 harbours the AMD-risk polymorphism Tyr402His (Edwards et al., 
2005; Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005). Individuals 
homozygous for His402 have a 6-fold increased risk of developing AMD compared to 
2.5-fold for His402 heterozygotes (Thakkinstian et al., 2006). The presence of His402 
weakened FH-heparin binding to both FH SCR-6/8 and full length FH (Herbert et al., 
2007a; Skerka et al., 2007), FH binding to C-reactive protein (Laine et al., 2007; Ormsby 
et al., 2008), and full length FH binding to HS in Bruch's membrane (Langford-Smith et 
al., 2014). For the development of AMD, age-related changes in glycosaminoglycan 
structures such as a decrease in the sulfation of HS, together with the presence of FH 
His402, have been proposed to reduce FH binding over time. At host cell surfaces, FH 
His402 showed weaker SCR-7 binding to eye tissue-specific HS only (Clark et al., 2013). 
In opposition to these observations of weaker HS binding for the His402 allotype, His402 
in SCR-6/8 was seen to be bound to the highly-sulphated glycosaminoglycan analogue 
sucrose octasulfate using X-ray crystallography while no such crystals were reported for 
the Tyr402 allotype (Prosser et al., 2007b). Although the statistical association of 
Tyr402His with AMD is one of the strongest, many other complement variants in CFH 
and other complement genes associate also with AMD, suggesting that AMD is caused 
by several different molecular mechanisms. For example, at the other heparin binding site 
on FH, SCR-20 harbours the AMD-risk RV Arg1210Cys (Raychaudhuri et al., 2011). 
AMD is associated with another 12 RVs in FH in its signal peptide or in SCR-1, SCR-
3/5, SCR-8, SCR-16 or SCR-18 (Geerlings et al., 2017). AMD is also associated with the 
protective polymorphism Val62Ile in SCR-1 (Hageman et al., 2005; Hocking et al., 
2008), common synonymous and non-coding variants in a region overlapping the CFH 
gene (Herbert et al., 2007b; Li et al., 2006; Maller et al., 2006), and genetic variants in 
complement C3, FI, FB and C9 (Geerlings et al., 2017; Hecker et al., 2010).  
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Additional insights into molecular mechanisms for AMD may be gained by 
studying both the self-association and overall solution structure of FH in the context of 
the Tyr402His polymorphism. To date, full-length FH has proven too large, flexible and 
glycosylated for high resolution structural determination by crystallography or NMR. 
Preliminary molecular modelling of SAXS curves revealed that full-length FH in solution 
has a folded-back SCR structure that is affected by ionic strength (Aslam & Perkins, 2001; 
Nan et al., 2010; Okemefuna et al., 2009). This preliminary FH modelling was based on 
just 11-14 high resolution SCR structures and an initial molecular dynamics approach to 
model the inter-SCR linkers (Nan et al., 2010; Okemefuna et al., 2009). In prior work, 
homozygous FH Tyr402 and His402 were submitted to analytical ultracentrifugation 
(AUC), SAXS, mass spectrometry and surface plasmon resonance studies, which found 
that both FH allotypes self-associate to form oligomers (Osborne et al., 2018b). Here, in 
order to examine the effect of the Tyr402His polymorphism on the solution structure of 
FH, SAXS curve extrapolation to zero concentration showed that both FH allotypes 
exhibited similar overall structures. The SAXS curves for both FH allotypes were 
modelled by starting from 17 high resolution SCR structures (Figure 5.1; Table 5.1) 
(Hocking et al., 2008; Okemefuna et al., 2009; Schmidt et al., 2010; Wu et al., 2009) and 
utilising a much improved Monte Carlo atomistic modelling method for the full-length 
FH structure, including the eight FH glycan chains (Perkins et al., 2016). The resulting 
SAXS best-fit structural ensembles corresponded to the most accurate FH models 
determined to date. These ensembles revealed two different extended and folded-back FH 
domain arrangements that favour two different modes of FH binding to either C3b or C3d. 
Both arrangements accounted for the bivalent binding of FH to HS-coated cell surfaces. 
The outcome of two different FH conformations provides new insights into the way in 
which FH regulates complement C3b activity. 
 
5.3 Methods 
 
5.3.1 Homology modelling of SCR-9, SCR-14 and SCR-17  
 
The first scattering modelling of the 20 SCR domains in FH used NMR structures 
for three SCR domains and homology models for the remaining 17 SCR domains (Figure 
5.1) (Aslam & Perkins, 2001). The second modelling used NMR and crystal structures 
for 11-14 SCR domains, and homology models for the remaining 9 SCR domains (Nan 
et al., 2010; Okemefuna et al., 2009). Here, a combination of MODELLER v9.14  
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Table 5.1 Sources of molecular SCR structures in FH. 
FH domain(s) PDB code Reference Method Used in previous FH model 
SCR-1/4 2WII (Wu et al., 2009) X-ray crystallography (Nan et al., 2010) 
SCR-1/3 2RLP/2RLQ (Hocking et al., 2008) NMR (Okemefuna et al., 2009). 
SCR-4  (Saunders et al., 2006) Homology (Okemefuna et al., 2009). 
SCR-5  (Barlow et al., 1992) NMR (Okemefuna et al., 2009); (Nan et al., 2010) 
SCR-6/8 2V8E (Prosser et al., 2007a) X-ray crystallography (Okemefuna et al., 2009); (Nan et al., 2010)  
SCR-9 b  (Saunders et al., 2006) Homology (Okemefuna et al., 2009); (Nan et al., 2010)  
SCR-10/11 a 4B2R (Makou et al., 2012) NMR - 
SCR-10/13  (Saunders et al., 2006) Homology (Okemefuna et al., 2009). 
SCR-11/12 a 4B2S (Makou et al., 2012) X-ray crystallography - 
SCR-12/13 2KMS (Schmidt et al., 2010) NMR (Nan et al., 2010)  
SCR-14 b  (Saunders et al., 2006) Homology (Okemefuna et al., 2009); (Nan et al., 2010)  
SCR-15/16 1HFH (Barlow et al., 1993) NMR (Okemefuna et al., 2009); (Nan et al., 2010)  
SCR-17 b  (Saunders et al., 2006) Homology (Okemefuna et al., 2009); (Nan et al., 2010)  
SCR-18  (Saunders et al., 2006) Homology (Okemefuna et al., 2009). 
SCR-18/20 a 3SW0 (Morgan et al., 2012) X-ray crystallography - 
SCR-19/20 2G7I (Jokiranta et al., 2006) X-ray crystallography (Okemefuna et al., 2009); (Nan et al., 2010) 
a Newer SCR structural models published after the previous full-length FH models were published. 
b Only homology models are available for this (Figure 5.1).
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(Sali & Blundell, 1993) and monomer Monte Carlo (SASSIE-web) (Curtis et al., 2012) 
was used to build a starting FH model from NMR and crystal structures for 17 SCR 
domains and three improved SCR homology models for SCR-9, SCR-14 and SCR-17 
(Tables 5.1 and 5.2). For the homology modelling, a template SCR structure without 
linker residues was identified using the basic local alignment search tool to search the 
PDB server (BLAST-PDB) (Altschul et al., 1990) (Table 5.2), and its sequence was 
aligned to the template sequence using Clustal Omega multiple sequence alignment 
(Sievers et al., 2011). By this, low sequence identity was mostly confined to the loop 
regions, and the secondary structure was conserved. These loop regions were modelled 
using the loop optimisation protocol in MODELLER. The best SCR model was selected 
from a final dataset of 100 generated models using the normalised discrete optimised 
protein energy score (Shen & Sali, 2006). For the SCR-9, SCR-14 and SCR-17 homology 
models and the NMR-based SCR-5 model (Barlow et al., 1992), strained high energy 
bonds were relaxed to give physically stable models by energy minimisation (500,000 
steps) and molecular dynamics simulations (1,000,000 steps) in the simulation engine 
NAMD v2.9 (Phillips et al., 2005). The PDB Reader input generator tool (Jo et al., 2014; 
Jo et al., 2008) converted the PDB file into CHARMM readable format, generated a PSF 
including the disulphide bonds, and provided the CHARMM36 force-field files (Brooks 
et al., 2009; Lee et al., 2016). The quality of the secondary structure was verified using 
Ramachandran plots on the RAMPAGE server (Lovell et al., 2003), the DSSP program 
(Joosten et al., 2011; Kabsch & Sander, 1983) and visual comparison with other SCR 
domains. As required, the Ramachandran plots showed a minimal number of outliers in 
these four SCR models.  
 
5.3.2 Building of initial FH model with eight glycans 
 
In order to create the initial full-length FH structure (Figure 5.1), the 11 SCR 
fragment models (SCR-1/4, SCR-5, SCR-6/8(His402), SCR-9, SCR-10/11, SCR-11/12, 
SCR-12/13, SCR-14, SCR-15/16, SCR-17, SCR-18/20) were aligned to the FH sequence 
sequentially using MODELLER. Each of SCR-1/5, SCR-6/13, SCR-14/16 and SCR-
17/20 were assembled first, before their simultaneous alignment to the full-length FH 
sequence. The best FH model was selected based on the normalised discrete optimised 
protein energy score, then refined in NAMD to give the final FH initial structure. FH was 
numbered from the N-terminus of the 18-residue signal peptide to follow Human Genome 
Variation Society convention. Eight biantennary disialylated glycans
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Table 5.2 Homology modelling of the SCR-9, SCR-14, and SCR-17 domains. 
 
Target 
domain 
Template domain PDB code Residues  Maximum score Total 
Query 
cover 
E value a Residue identities 
SCR-9 SCR-4 2UWN 148-186  40.1 41.2 68% 0.0004 44% 
SCR-14 SCR-15 3ZD1 5-59  37.5 37.5 100% 0.002 36% 
SCR-17 SCR-18 3SW0 3-59  42.2 77.6 100% 0.00007 37% 
 
a Expect value. This is a parameter that describes the number of hits one can expect to see by chance.
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(Fenaille et al., 2007) were added to Asn511 in SCR-9, Asn700 in SCR-12, Asn784 in 
SCR-13, Asn804 in SCR-14, Asn864 and Asn892 in SCR-15, Asn1011 in SCR-17 and 
Asn1077 in SCR-19 (Figure 5.1). For each glycan-Asn PDB files, GlycanReader was 
used to generate the CHARMM force field and PSF inputs for energy minimisation in 
NAMD. The resulting energy-minimised glycans were positioned onto FH by 
superimposing the Asn residues in PyMol, then deleting the Asn residue in the glycan 
PDB. Once all eight glycans had been added to FH and accepted by GlycanReader, bash 
scripts were used to convert the nomenclature and numbering of the glycan and protein 
atoms to the format required for the Torsion Angle Monte Carlo module in SASSIE-web. 
In this, the glycans were moved with their attached protein segment as a single entity and 
not varied independently.   
 
5.3.3 Building of FH model library using Monte Carlo 
 
The model library of physically realistic FH structural conformations was 
generated by subjecting the inter-SCR linkers to the Torsion Angle Monte Carlo module 
in SASSIE-web (Zhang et al., 2017). Eleven of the 19 linkers were defined by high 
resolution structures and were therefore held fixed. The remaining eight linkers at SCR-
4/5, SCR-5/6, SCR-8/9, SCR-9/10, SCR-13/14, SCR-14/15, SCR-16/17, and SCR-17/18 
were moved (arrowed, Figure 5.1). For each of these linker residues, the backbone φ and 
ψ torsion angles were varied in steps of up to either 30o or 180o, except for the torsion 
angles involving the conserved Cys residues at the start and end of each linker. In order 
to maximise the sampling, four simulations were run as follows: (i) 200,000 steps with 
up to 30o moves using the FH initial model, (ii) 200,000 steps with up to 180o moves 
using the FH initial model, (iii) 100,000 steps with up to 30o moves using a FH model 
from simulations (i, ii) with its CT bent inwards, and (iv) 10,000 steps with up to 30o 
moves using the best-fit FH model from simulations (i-iii). In a Monte Carlo simulation, 
many moves result in structures with steric clashes, and were discarded as physically 
unrealistic. In the present case, the 510,000 attempted moves resulted in 15,136 (8%), 
3720 (1%), 10,316 (10%) and 543 (5%) physically-realistic, acceptable models 
respectively. These were combined into a library of 29,715 models for SAXS curve 
fitting.  
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5.3.4 Fitting FH models to experimental scattering data 
 
Prior to the work carried out for this PhD thesis, experimental SAXS data for two 
FH Tyr402 and two FH His402 homozygous allotypes were acquired at five 
concentrations between 0.4 mg/ml (2.6 μM) and 3.3 mg/ml (21.4 μM) (Table 5.3) 
(Osborne et al., 2018b). Before these SAXS experiments, the Tyr402His and Ile62Val 
polymorphisms were identified by direct DNA sequencing of their PCR product (Osborne 
et al., 2018b). Here, in this PhD thesis chapter, a theoretical scattering curve was 
generated from each of the 29,715 FH models by using SasCalc. SasCalc calculates the 
scattering curve using an exact all-atom expression for the scattering intensity in which 
the orientations of the Q vectors are taken from a quasi-uniform spherical grid generated 
by the golden ratio (Watson & Curtis, 2013). For each of the Tyr402 and His402 
allotypes, the experimental scattering curve with 221 data points was extrapolated to zero 
concentration to eliminate the contribution of self-association. These were compared to 
the theoretical curves using the R-factor: 
 
 
    𝑅 =  ∑
‖(𝐼𝑒𝑥𝑝𝑡(𝑄𝑖)) − (𝐼𝑡ℎ𝑒𝑜𝑟(𝑄𝑖))‖
‖𝐼𝑒𝑥𝑝𝑡(𝑄𝑖)‖
𝑄𝑖
× 100                                                              (5.1) 
  
 
where Qi is the Q value of the i-th data point, Iexp(Qi) is the experimental scattering 
intensity and Imodel(Qi) is the theoretical modelled scattering intensity (Wright & Perkins, 
2015). For SasCalc, the lowest Q values before the Guinier RG region in the extrapolated 
scattering curves were interpolated to zero Q using MATLAB. After interpolation, the 
original 221 I(Q) values between Q of 0.0-1.5 nm-1 were retained, to define the Q spacing 
for SasCalc. The R-factor vs RG graphs were similar for the extrapolated and 0.4 mg/ml 
curves, while those from curve fitting at 0.7, 1.1 and 2.2 mg/ml gave worse R-factors 
(data not shown), as expected. For each of the four Tyr402 and His402 curves, the 29,715 
models were filtered on both RG and R-factor. Models were accepted if their RG values 
were within ±5% of the experimental RG values (Table 5.3), and their R-factor was ≤5%. 
The best-fit 100 models were identified by ranking the filtered models by their R-factors. 
The Tyr402His polymorphism had no effect on the curve fits, leading to an R-factor 
difference of only 0.0003%. In order to analyse the flexibility of FH, normalised Kratky 
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Table 5.3 Experimental X-ray and analytical ultracentrifugation data for FH Tyr402/Val62 and His402/Val62 and their modelling fits 
 Filter Models RG (nm) RXS-1 (nm) RXS-2 (nm) Dmax (nm) R factor (%) s
0
20,w (S) 
Experimental data (Osborne et al., 2018b)        
FH Tyr402/Val62    7.39 ± 0.25 
7.35 ± 0.13 
2.21 ± 0.06 
2.27 ± 0.06 
1.77 ± 0.01 
1.77 ± 0.01 
25 
 
5.66 ± 0.08 
7.61 ± 0.01 a 
FH His402/Val62    7.77 ± 0.27 
7.22 ± 0.15 
2.02 ± 0.06 
2.15 ± 0.06 
1.76 ± 0.01 
1.75 ± 0.01 
25 
 
5.69 ± 0.02 
7.54 ± 0.01 a 
Atomistic Modelling        
Library of 29,715 FH 
models 
None 29,715 5.61 - 11.08 n.a n.a n.a 2.8 - 25.3 n.a. 
FH Tyr402/Val62 
 (sample 1) 
RG and R-factor 1,240 7.02 – 7.75 n.a n.a n.a. 2.3 – 4.9 n.a. 
Best fit 100 7.02 – 7.57 2.34 – 2.98 1.85 – 2.10 n.a. 2.3 – 3.2 5.35 – 5.77 
 PCA group 2 (NT out) 49 7.34 – 7.57 2.34 – 2.62 1.95 – 2.10 n.a. 2.7 – 3.2 5.38 – 5.77 
   centroid 1 7.41 2.50 2.03 n.a. 3.1 5.52 
FH Tyr402/Val62 b 
 (sample 2; data not 
RG and R-factor 2,678 6.98 – 7.72 n.a n.a n.a. 1.9 – 4.9 n.a. 
Best fit 100 7.03 – 7.47 2.71 – 3.05 1.81 – 2.04 n.a. 1.9 – 2.7 5.33 – 5.70 
  shown) PCA group 14 (NT in) 48 7.11 – 7.43 2.71 – 2.98 1.81 – 1.99 n.a. 1.9 – 2.7 5.36 – 5.70 
   centroid 1 7.32 2.84 1.95 n.a. 2.2 5.49 
FH His402/Val62 
(sample 1) 
RG and R-factor 1,219 7.38 – 8.16 n.a n.a n.a. 2.3 – 4.9 n.a. 
Best fit  100 7.39 – 8.13 2.32 – 3.15 1.48 – 1.97 n.a. 2.4 – 3.6 5.21 – 5.61 
 PCA group 5 (NT in) 79 7.39 – 7.95 2.67 – 3.07 1.64 – 1.94 n.a. 2.5 – 3.6 5.21 – 5.55 
   centroid 1 7.48 2.92 1.87 n.a. 3.2 5.44 
FH His402/Val62 
 (sample 2; data not 
RG and R-factor 310 6.86 – 7.58 n.a n.a n.a. 2.7 – 4.9 n.a. 
Best fit  100 6.86 – 7.57 2.09 – 2.93 1.82 – 2.10 n.a. 2.7 – 4.0 5.38 – 5.88 
  shown) PCA group 19 (NT out) 84 6.86 – 7.57 2.28 – 2.82 1.89 – 2.10 n.a. 2.7 – 4.0 5.38 – 5.78 
   centroid 1 7.40 2.48 2.03 n.a. 3.8 5.51 
a Both the RG and RXS values correspond to the SAXS curve extrapolated to zero concentration. The first RG value corresponds to the Guinier fits; the 
second corresponds to the P(r) analyses. 
b In this instance Ile62Val was heterozygous; the other three were homozygous for Val62.  
n.a, not available
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analyses of (Q/RG)
2.I(Q)/I(0) vs Q/RG were calculated for the four FH experimental 
curves (Receveur-Brechot & Durand, 2012). 
 
5.3.5 Parameterisation of the FH domain arrangement  
 
The SCR domain arrangement in the 29,715 FH models was parametrised using 
the separations between the FH centre of mass (COM) and the N-terminal (NT) and C-
terminal (CT) α-carbon atoms. Separations were calculated using Tcl scripting within 
Visual Molecular Dynamics (VMD) software (Humphrey et al., 1996), and their 
frequencies were displayed as histograms using R (R Core Team, 2013) for statistical 
analyses. In order to assess the normality of the separation distributions, Quantile-
Quantile (Q-Q) plots and two-tailed Kolmorogov-Smirnov tests were employed using the 
ks.test statistical function in R (Grant et al., 2006; R Core Team, 2013). Here, the null 
hypothesis stated that the distribution was consistent with the normal distribution, and a 
Bonferroni-corrected significance level of 0.05 divided by 2 (0.025) was set. The 
Kolmorogov-Smirnov test calculated the maximum vertical deviation between the two 
curves as the test statistic D and the probability of D occurring due to chance (p-value). 
In order to compare the distributions for all 29,715 models, the 310-2,678 filtered models, 
and the best-fit 100 models of the two allotypes, their distributions were converted to 
cumulative density frequencies and compared using the two-tailed Kolmorogov-Smirnov 
test in R with the ks.test statistical function. Here, for each comparison, the null 
hypothesis stated that the distributions were the same and a Bonferroni-corrected 
significance level of 0.05 divided by 12 (0.00417) was set. In order to visualise the 
resulting conformations after applying the RG and R-factor filters, the filtered models were 
superimposed with the reference FH model using SCR-10/13, and visualised as density 
plots using SASSIE-web.  
 
5.3.6 Principal component analyses (PCA) 
 
PCA provided by the Bio3d package in R (Grant et al., 2006) identified four major 
conformational states in the best-fit 100 models. For both allotypes, PCA satisfactorily 
accounted for >80% of the variance between the models. The average FH structure for 
each PCA group was identified using a centroid model computed using R. The SCR 
domain arrangement of each PCA group was identified by a density plot using SASSIE-
web. In order to assess the conformational differences between the two allotypes, the 
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frequencies of the two major SCR domain arrangements were compared by using the two-
tailed Fisher’s test for a 2×2 contingency table in GraphPad QuickCalcs 
(https://www.graphpad.com/quickcalcs/). Here, the null hypothesis stated that the 
proportion of FH models with an inwardly-bent NT and extended CT, compared to an 
extended NT and inwardly-bent CT, were the same. The significance level was set as 0.05 
and the probability of the difference occurring due to chance (p-value) was computed. To 
see whether these two conformations could be distinguished by their SAXS curves, the 
difference in scattering intensity between their best fitting centroid model curves was 
calculated and visualised using R. The FH models were assessed by superimposing the 
centroid model for each of the largest ensembles with crystal structures for the FH-ligand 
complexes of SCR-1/4 with C3b and SCR-19/20 with C3d using PyMol (PDB codes: 
2wii and 5nbq) (Kolodziejczyk et al., 2017; Wu et al., 2009). 
 
5.3.7 Theoretical sedimentation co-efficient values 
 
Prior to the work carried out for this PhD thesis, AUC sedimentation velocity 
experiments were conducted on five homozygous FH Tyr402 and five homozygous FH 
His402/Val62 samples (Osborne et al., 2018b). Here, in this PhD thesis, for the AUC 
modelling, the theoretical sº20,w values for the FH models were calculated directly from 
the atomic coordinates with the default value of 0.31 nm for the atomic element radius 
for all atoms to represent the hydration shell by using the HYDROPRO shell modelling 
program (Garcia-de la Torre et al., 2000). The molecular weight and partial specific 
volume for FH used followed that used previously (Okemefuna et al., 2009; Ortega et al., 
2011). FH glycosylation was considered by using the compiled partial specific volumes 
for saccharides (Perkins, 1986). 
 
5.3.8 Links to web servers and tools 
 
BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi),  
Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/),  
SASSIE-web (https://sassie-web.chem.utk.edu/sassie2/),  
CHARMM-GUI Glycan Reader (http://charmm-gui.org/?doc=input/glycan),  
CHARMM-GUI PDB Reader (http://www.charmm-gui.org/?doc=input/pdbreader), 
RAMPAGE (http://mordred.bioc.cam.ac.uk/~rapper/rampage.php),  
DSSP (http://swift.cmbi.ru.nl/gv/dssp/),  
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GraphPad QuickCalcs (https://www.graphpad.com/quickcalcs/contingency1/). 
 
5.4 Results 
  
5.4.1 FH models for the Tyr402 and His402 allotypes  
 
The atomistic modelling of the two FH Tyr402 and two His402 scattering curves 
was initiated using 17 high-resolution SCR structures, three SCR homology models and 
eight glycan chains to construct an energy-minimised initial FH model (Figure 5.1, Tables 
5.1 and 5.2; Section 5.3). By varying the torsion angles at eight inter-SCR linkers, 
510,000 FH models were created in four Monte Carlo simulations, from which 29,715 
models were retained for analysis as being physically realistic without steric clashes. 
Comparison of the four extrapolated experimental scattering curves with the 29,715 
theoretical curves gave an R-factor vs. RG distribution with a minimum close to the 
experimental extrapolated RG value (Figure 5.2). An RG filter of ±5% of the experimental 
value and an R-factor filter of >5% gave 1,240/2,678 and 1,219/310 best-fit models for 
the two Tyr402 and two His402 allotypes respectively, these being 1-9% of the 29,715 
trial models (blue/red, Figure 5.2). The best-fit 100 FH models were selected on the basis 
of the lowest R-factors (orange, Figure 5.2) of 2.3-3.2% and 2.3-3.6%, respectively (Table 
5.3).  
 
The sº20,w values of the best-fit 100 FH models were calculated using 
HYDROPRO to be 5.35-5.77 S and 5.21-5.61, and for the centroid models to be 5.49-
5.52 S and 5.44-5.51 S, both for FH Tyr402 and FH His402 respectively (Table 5.3). 
These values agreed well with the previously obtained experimental values of 5.66-5.69 
S (Table 5.3) (Osborne et al., 2018b), and confirmed the outcome of the atomistic 
modelling, given that the mean difference between the modelled and experimental values 
should be ± 0.21 S for related macromolecules including antibodies (Perkins et al., 2009). 
Like antibodies which are also considered to be flexible molecules, HYDROPRO was 
effective in calculating the sº20,w values, this being attributed to the use of the averaged 
best-fit solution structures. The calculations were much improved to those of the 2009 
FH modelling which gave 4.91-5.01 S from older scattering models that in retrospect 
were too elongated (Okemefuna et al., 2009). 
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Figure 5.2 Atomistic modelling searches for the FH solution structure.  The 29,715 
FH models were fitted to one experimental scattering curve for each of A, homozygous 
FH Tyr402/Val62 and B, FH His402/Val62, each extrapolated to zero concentration. Grey 
corresponds to all FH models. The blue/red subsets corresponds to FH models that passed 
two filters, namely RG within ± 5% of the experimental RG, and an R-factor of < 5%. 
Orange corresponds to the 100 best-fit FH models (see inset). The vertical black lines 
represent the experimental RG for FH Tyr402 (7.39 nm) and FH His402 (7.77 nm). The 
dashed lines represent the ±5% upper and lower boundaries of these RG values.
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5.4.2 The NT-COM and CT-COM separation distributions  
 
The best-fit SCR arrangements within the 29,715 trial FH models were shown to 
be bimodal using histograms of their N-terminal α-carbon (NT) and C-terminal α-carbon  
 (CT) to centre of mass (COM) separations (Figure 5.3). Longer separations corresponded 
to extended SCR arrangements in FH; shorter separations corresponded to a folded-back  
bent one. 
 
(i) For all 29,715 models, the NT-COM and CT-COM separations corresponded 
to similar ranges of 0.5-21.8 nm and 0.8-22.4 nm respectively (Figure 5.3A,D). However, 
the most populated NT-COM separations were short ones (3-5 nm) that tailed off after 
>16 nm. In distinction, the most populated CT-COM separations were long ones (14-16 
nm) followed by short ones (~ 5 nm) (Figure 5.3A,D). The NT-COM separations were 
right skewed with a skewness coefficient of 0.53, whereas the CT-COM separations were 
left skewed and bimodal with a skewness coefficient of -0.55. Overall, the separation 
distributions were uneven and not normally distributed. This unexpected outcome was 
attributed to the seven glycans in SCR-12/18 that perturbed the random generation of 
physically-realistic FH structures (Figure 5.1) and the asymmetric distribution of the 
longest inter-SCR linkers in FH (Okemefuna et al., 2009). 
 
(ii) For the 1219-1240 filtered FH models, both the NT-COM and CT-COM 
distance distributions corresponded to small subsets of those for all 29,715 models 
(Figure 5.3B,E). Density plots showed that these models occupied limited conformations 
when compared to all 29,715 models (insets, Figure 5.3B,E). The separations for both 
allotypes were bimodal, being left-skewed for the NT-COM distances, and right-skewed 
for the CT-COM distances. Overall, no differences were seen between the two allotypes. 
 
(iii) For the two sets of 100 best-fit FH models, the two NT-COM and CT-COM 
distance distributions were again largely bimodal distributions (Figure 5.3C,F). Similar 
bimodal results were obtained for the fits with the other pair of FH Tyr402 and FH His402 
experimental curves (distributions not shown). 
 
For the filtered and top 100 models, statistical analyses were performed to confirm 
that the separation distance distributions (Figure 5.3) were unaffected by sampling bias. 
The best-fit 100 models were not necessarily a converged subset of the filtered models as
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Figure 5.3 The centre-of-mass separation frequencies in the FH Tyr402 and FH His402 models. A, D, The top two panels (grey) show the separations 
(NT-COM, CT-COM) between the N-terminal α-carbon (NT) and C-terminal α-carbon (CT) to the centre of mass (COM) for all 29,715 FH models.  
B, The separations are shown for the filtered 1,240 and 1,219 FH models (see Figure 5.2). C, F, The separations are shown for the 100 best-fit FH models. 
For each set of FH models, the density plot shows the N-terminal half in blue, the C-terminal half in red, and the best-fit model as a cartoon.
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seen in other modelling (Fung et al., 2016). A non-parametric (i.e. no underlying 
assumption) Kolmogorov-Smirnov test (not shown) was used to indicate that the best-fit 
distances for NT-COM and CT-COM were either short or long, and were independent of 
any sampling bias observed in all 29,715 models. This suggested that FH existed in two 
conformations. In order to check that the distance parameters for the filtered models were 
independent of sampling bias, each distance distribution (Figure 5.3) was converted to a 
cumulative density distribution (Figure 5.4A-D). For both allotypes, the cumulative 
distributions for each of the filtered and best-fit 100 models (red, blue, orange) were 
significantly different from that (in grey) for all 29,715 models (each p< 2.2×10-16; two-
tailed Kolmogorov-Smirnov test; arrowed as A, B, C, D and G, H, I, J in Figure 5.4A-D). 
This was as expected because only a small subset of the starting models would fit the 
scattering curves. This also indicated that the results for the filtered and best-fit 100 
models were independent of any sampling bias seen in all 29,715 models. A significant 
difference was also seen between the filtered and top 100 models in three of the four cases 
(p=2.5×10-12 or p=1.31×10-7; two-tailed Kolmogorov-Smirnov test; excepting that for 
CT-COM distance for His402 (p=0.327); E, F, K, L in Figure 5.4A-D). Overall, because 
the best-fit 100 models were not necessarily a converged subset of the filtered models as 
seen in other modelling (Fung et al., 2016), it was concluded that the best-fit distances 
for NT-COM and CT-COM were either short or long, suggesting that FH existed in two 
conformations.  
 
The full FH SCR domain arrangement was examined using pairs of NT-COM and 
CT-COM distances. The 29,715 separations were non-randomly distributed between 1-
25 nm, showing that a broad range of FH conformations had been generated as desired 
(Figure 5.4E,F). The most sampled best-fit NT-COM and CT-COM separations occurred 
at 1-10 nm and 12-17 nm respectively at the top left hand corner. The second most 
sampled best-fit separations occurred as a broad cluster at 5-17 nm and 2-8 nm 
respectively. For the filtered Tyr402 models, two structural regions were visible as two 
dense clusters in blue, in which the top 100 Tyr402 models were shown in orange (Figure 
5.4E). For the filtered His402 models, the same two clusters were seen in red and orange 
respectively (Figure 5.4F). In contrast, FH models with long NT-COM and CT-COM 
separations (>15 nm) showed large radii of gyration and poor fits with R-factors >5% 
(grey, Figure 5.4E,F). This analysis showed that FH either has a bent-inwards N-terminal 
region and an extended C-terminal region, or vice versa.  
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Figure 5.4 The separation densities in the FH Tyr402 and FH His402 models. For 
each of the Tyr402 (A, B) and His402 (C, D) allotypes, the cumulative densities of the 
individual NT-COM and CT-COM separations are shown for all 29,715 FH models (grey 
lines), the filtered FH models and the 100 best-fit FH models (orange lines). The double-
headed arrows labelled A-L) indicate the maximum vertical deviation of the densities 
compared with each other using a combination of quantile-quantile plots and the 
Kolmogorov-Smirnov statistical test, of which L denoted by * is non-significant. (E,F), 
The joint NT-COM and CT-COM separations for the FH Tyr402 and FH His402 models 
are compared with each other. Blue/red corresponds to the filtered FH models and orange 
corresponds to the 100 best-fit FH.
A B 
C D 
E F 
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5.4.3 Best-fit conformations for FH Tyr402 and His402 
  
After superimposition of the top 100 Tyr402 and His402 FH structures, visual 
inspection showed multiple conformers. To understand these conformers, they were 
clustered into conformational families using principal component analysis (PCA) (Figure 
5.5) (Hui et al., 2015). PCA determines the correlated motions of protein residues as 
linearly uncorrelated variables termed principal components (David & Jacobs, 2014). 
These “essential motions” are extracted from a covariance matrix of the atomic 
coordinates of the frames in the trajectory. The eigenvectors of this matrix each have an 
associated eigenvalue that characterises a mode of the motion, or variance.  
 
The PCA analyses confirmed that two families of FH structures with either a bent-
inwards N-terminal region and an extended C-terminal region, or vice versa, were seen. 
Four PCA groups accounted for 98.5% and 86.9% of the variances in the top 100 models 
of each of Tyr402 and His402 respectively (Figure 5.5C,G). For each PCA group, the 
combined NT-COM and CT-COM separation distances were plotted (Figure 5.5D,H). 
The conformational density of each group was represented as either blue (NT) or red (CT) 
density, with the centroid FH model depicted as a black cartoon (Figure 5.6). The 60 
Tyr402 models in PCA groups 2, 3 and 4 corresponded to an extended N-terminus and a 
bent inwards C-terminus (red, green and blue, Figure 5.5D; Figure 5.6B-D). The 40 
Tyr402 models in PCA group 1 corresponded to a bent inwards N-terminus and an 
extended C-terminus (black, Figure 5.5D; Figure 5.6A). The 79 His402 models in PCA 
group 5 corresponded to a bent inwards N-terminus and an extended C-terminus (black, 
Figure 5.5H; Figure 5.6E). The 21 His402 models in PCA groups 6, 7 and 8 corresponded 
to a bent inwards C-terminus and an extended N-terminus (red, green and blue, Figure 
5.5H; Figure 5.6F-H).  
 
Each of the PCA groups 1-8 gave FH structures whose theoretical scattering 
curves I(Q) fitted well with the experimental Tyr402 or His402 curves with low R-factors 
between 2.4%-3.8% (Figure 5.6). The visual agreement was good out to at least Q = 1.0 
nm-1. The centroid models with an extended N-terminus and a bent inwards C-terminus 
(Figure 5.6B,C,D,F) gave fits similar to those with a bent inwards N-terminus and an 
extended C-terminus (Figure 5.6A,E,G,H). The theoretical distance distribution curves 
P(r) also showed good agreements with those of the experimental curves obtained 
previously (Osborne et al., 2018b).  
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Figure 5.5 Principal component analyses of the 100 best-fit models for FH Tyr402 
and FH His402. Figure legend overleaf.
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Figure 5.5 (continued) Principal component analyses of the 100 best-fit models for 
FH Tyr402 and FH His402.  For each of A, B, FH Tyr402 and E, F, FH His402, the 100 
best-fit models were grouped by principal component analysis (PCA) into four groups 1-
4 (black, red, green and blue, respectively) as exemplified by the first three principal 
components (PC2 vs. PC1 and PC3 vs. PC2). C, G, The first three eigenvalue rankings 
(PC1 to PC3) accounted for variances of 98.5% and 86.9% in the 100 best-fit FH models. 
D, H, The black, red, green and blue triangles correspond to the PCA groups 1-4 and 5-8 
in each set of best-fit 100 models. The four arrowed diamonds corresponds to the average 
(centroid) model for each PCA group.
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Figure 5.6 Scattering curve fits for the centroid PCA models for FH. Figure legend 
overleaf.
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Figure 5.6 (continued) Scattering curve fits for the centroid PCA models for FH. For 
each of A-D, FH Tyr402 and E-H, FH His402, the four panels display the centroid FH 
model for the PCA groups 1-4 and 5-8 respectively in density plots. The number of FH 
models in each PCA group is displayed. The experimental curve is denoted by black 
circles and the theoretical curve is denoted as solid blue/red lines. The inset shows the 
P(r) curves for the experimental data (black line) and modelled curve (blue/red line). For 
each PCA group, the conformational space is represented as blue (NT), white or red (CT) 
density. The average (centroid) model of each PCA group is depicted as a black cartoon 
in which SCR-1 and SCR-20 are arrowed. 
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Thus, the eight centroid FH models gave very similar M1 peak values that agreed with 
the experimental P(r) curves obtained previously where M1 was 4.7-5.0 nm (Osborne et 
al., 2018b). Their intensities were comparable although these showed oscillations around 
the experimental P(r) curves. Of note, the experimental P(r) curves generally appeared 
smoother than the theoretical curves. This is likely due to both the lower resolution and 
the fluctuation between the alternative conformations of the solution structure studied by 
the experimental curves. Only eight of the 200 best-fit structures had conformations in 
which both the N-terminal and C-terminal regions were inwardly bent, and none showed 
that both regions were extended in any structure. The same PCA analyses for the other 
pair of available Tyr402 and His402 curves gave similar structural outcomes (not shown). 
The normalised Kratky analyses for the modelled best-fit curves (Figure 5.7) showed that, 
as for the experimental analyses in prior work (Osborne et al., 2018b), a clear peak was 
obtained that tailed off at large Q/RG values, thus validating that FH is a multi-domain 
protein whose domains were connected by linkers (Receveur-Brechot & Durand, 2012). 
 
5.5 Discussion 
 
FH is an essential regulatory glycoprotein that protects host cells from 
complement activation both at the cell surface and in the fluid phase. In this present study, 
the most accurate molecular models to date have been produced for full-length FH, and 
these suggest that FH exists in two distinct conformations that enable its complement 
regulatory functions. Common and rare genetic variants in FH are associated with major 
and rare inflammatory diseases including AMD, Alzheimer’s, aHUS and C3G (Osborne 
et al., 2018a). For AMD, each of the Tyr402His and Val62Ile variants are associated with 
increased and decreased risk, respectively. In order to perform its regulatory activities, 
FH binds to multiple physiological ligands, including to itself, with weak KD values in 
the μM range, and has a highly glycosylated 20-domain structure (Figure 5.1). Up to now, 
the only FH molecular structures had been determined by preliminary modelling of X-
ray scattering curves of heterozygous FH, resulting in two different folded-back structures 
whose significance was unclear (Nan et al., 2010; Okemefuna et al., 2009; Rodriguez et 
al., 2014). Here, by utilising a much-improved atomistic modelling procedure based on 
molecular dynamics and Monte Carlo procedures and statistical assessments of the 
outcome, similar detailed molecular models for both the Tyr402 and His402 allotypes of 
homozygous full-length FH, including its eight FH glycans, were determined. The 
statistical validation of two alternative FH conformations significantly  
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Figure 5.7 Normalised Kratky plot for the experimental and best-fit FH curves. For 
both allotypes, the theoretical curves for the most representative N-terminus extended and 
C-terminus extended FH models are shown as black solid and dashed lines, respectively. 
These correspond to the centroid models shown in Figures 5.6B and 5.6E respectively. 
The experimental curves are shown as blue and red open circles for the Tyr402 and 
His402 allotypes, respectively.
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improves the understanding of ligand binding to FH and how this may be perturbed in its 
function. 
 
5.5.1 Self-association of FH 
 
Characterisation of FH self-association is important for both determining its 
conformational solution states and investigating the development of drusen in AMD. FH 
self-association is important for FH function because this will increase the local 
concentration of its ligand-binding sites. Biologically, given that the plasma concentration 
of FH is around 0.7 mg/ml (Perkins et al., 2010a), reversible dimers and trimers are 
expected to form in vivo (Osborne et al., 2018b). The resulting clustering of FH on cell 
surfaces, when bound to surface markers and C3b/C3d, is likely to enable broader surface 
protection, thus being functionally significant (Ferreira et al., 2010). However, the 
accumulation of FH by clustering may also relate to the formation of soft drusen in AMD 
via chronic inflammation, in particular if FH oligomer formation becomes irreversible 
(Hageman et al., 2001). Consistent with this, studies with full-length FH showed that its 
affinity for both heparin and HS were not altered by the Tyr402His polymorphism (Kelly 
et al., 2010; Ormsby et al., 2008; Toomey et al., 2018). It was also found that FH multimer 
formation is enchanced in the presence of zinc, which inhibits FH function (Nan et al., 
2008b). In work conducted prior to this PhD thesis, it was shown using four independent 
methods that wild-type FH Tyr402 and AMD risk-associated FH His402 both 
significantly self-associate (Osborne et al., 2018b). These FH preparations were also 
genotyped for the AMD-protective Val62Ile polymorphism, which has a subtly better 
capacity to bind C3b, inhibit proconvertase formation and catalyse inactivation of C3b, 
by a minor structural rearrangement within SCR-1 (Hocking et al., 2008; Tortajada et al., 
2009). SAXS analyses of the Guinier I(0)/c, RG and RXS-1 parameters also showed clear 
concentration effects attributable to self-association (Osborne et al., 2018b). In order to 
model the monomeric FH structure for this thesis chapter, one immediate consequence of 
this was the need to allow for self-association effects in the SAXS structural studies. Thus, 
it was necessary to extrapolate the scattering curves to zero concentration. 
 
5.5.2 Atomistic modelling of two FH conformations 
 
The new molecular modelling of the FH scattering curves has benefitted from five 
improvements (Perkins et al., 2016): (i) the application of molecular dynamics to generate 
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an initial full FH structure; (ii) the use of 17 high resolution SCR structures, in distinction 
to up to 11-14 SCR structures previously; (iii) the inclusion of eight energy-refined glycan 
chains in FH; (iv) the use of rapid Monte Carlo simulations with the inter-SCR linkers to 
generate a large number of 29,715 physically realistic trial FH structures; (v) statistical 
analyses of the resulting ensemble of best-fit structures. Interestingly, two previous 
modelling studies in 2008 yielded alternative folded-back FH structures with either the 
N-terminal or C-terminal SCR domains in an extended conformation (Nan et al., 2010; 
Okemefuna et al., 2009; Rodriguez et al., 2014), yet their significance was unclear. Here, 
the statistical analysis of the 29,715 curve fits showed that both alternative FH 
conformations were valid outcomes from the SAXS modelling (Figure 5.8A,B). In the 
200 best-fit structures, some 81 and 119 structures respectively corresponded to (i) an 
extended N-terminus and a bent inwards C-terminus, and (ii) a bent inwards N-terminus 
and an extended C-terminus. In principal, either of these two FH structures may be the 
actual solution structure, or both FH structures may co-exist as an equilibrium in solution. 
Consideration of C3b and C3d binding (below) suggested both FH conformations exist. 
Further statistical analyses of the 200 best-fit structures showed that the two FH Tyr402 
and His402 allotypes displayed the same solution structures.  
 
5.5.3 Biological significance of the FH Tyr402 and His402 models 
 
To summarise FH activity, SCR-1/5 is involved in both cofactor and decay-
acceleration activities (Kuhn & Zipfel, 1996; Sharma & Pangburn, 1996) whereas SCR-
19/20 is involved in the recognition of host cell surfaces (Pangburn, 2000). These two 
functions are mediated by N-terminal SCR-1/4 binding to both C3b and FI, and C-
terminal SCR-19/20 binding to C3d, heparin and sialic acid. C3dg and C3d, being two 
fragments of C3 that each contain the thioester domain (TED) for host-surface binding, 
are formed by the breakdown of C3b by FI and/or serum proteases and both bind to 
complement receptor 2 in order to trigger immune complex clearance and stimulate the 
immune response (Law & Reid, 1995). C3d is also an autologous helper T-cell target 
(Knopf et al., 2008). During complement regulation at host cell surfaces, an increase in 
the number of C3d binding sites for SCR-19/20 would enable more FH to be recruited at 
the host cell surface for a more rapid breakdown of C3b (Kajander et al., 2011). For cell 
surface attachment of FH, an optimal combination of affinities for each of C3b and 
polyanion ligand is essential for C-terminal FH binding (Ferreira et al., 2010), for which 
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Figure 5.8 Best-fit FH centroid models superimposed onto C3b and C3dg. For both allotypes, the most representative A, N-terminus extended and 
B, C-terminal extended FH models are shown as blue ribbon traces (left). These correspond to the centroid models shown in Figures 5.12B and 5.12E 
respectively. The coordinates are available for download in Supplementary Materials. These models were superimposed onto the SCR-1/4-C3b and SCR-
19/20-C3d crystal structures, in which C3b is shown as a yellow surface and C3dg is shown as a green surface (right; PDB codes: 2WII, 5NBQ). The 
eight glycans are shown in magenta. The cyan arrow indicates Tyr402/His402. Black arrows indicate steric clashes of FH with C3b or C3dg.
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both SCR-7 and SCR-19/20 bind bivalently via heparin (Khan et al., 2012; Perkins et al., 
2012).  
  
The functions of FH were clarified by superimposing the two alternative best-fit 
conformations of FH with crystal structures for the SCR-1/4-C3b complex and the SCR-
19/20-C3dg complex (PDB codes: 2WII, 5NBQ) (Kolodziejczyk et al., 2017; Wu et al., 
2009). 
 (i) The N-terminal extended FH conformation accounted for binding to C3b at 
SCR-1/4, and to heparin and sialic acid, but less so for C3dg. The binding of C3b to SCR-
1/4 showed minimal steric clashes with the rest of FH (black arrow, Figure 5.8A). 
Likewise, for binding to fluid phase FI, the SCR-1/3 domains were accessible, including 
the FH residues 101, 106, 112 and 119 that were important for this interaction (Wu et al., 
2009). For bivalent SCR-7 and SCR-19/20 binding to heparin and/or sialic acid on cell 
surfaces, the essential residues in each of SCR-7 (Tyr/His402) and SCR-19/20 (FH 
residues 1181-1183, 1191, 1195, 1196, 1198 and 1199) were solvent-accessible. 
However, C3dg binding to SCR-19 resulted in significant steric clashes with SCR-9, 
SCR-12/15 and the glycans (black arrows, Figure 5.8A), implying that some structural 
rearrangement will be required for C3dg binding. During complement regulation at host 
cell surfaces, an increase in the number of C3d binding sites for SCR-19/20 would enable 
more FH to be recruited at the host cell surface for a more rapid breakdown of C3b 
(Kajander et al., 2011). This N-terminal extended FH conformation did not favour cell 
surface binding via C3d (and heparin), which may restrict it to the fluid phase for cofactor 
and DAA. 
 (ii) In contrast, the C-terminal extended FH model accounted for binding to C3dg 
at SCR-19 or SCR-20, and to heparin and/or sialic acid on cell surfaces, but not to C3b at 
SCR-1/4. Thus, the binding of C3b to SCR-1/4 resulted in large steric clashes with the 
SCR-6/8 domains (black arrows, Figure 5.8B). For binding to fluid phase FI, the SCR-
1/3 domains were accessible. In order to bind C3 via SCR-1/4, potential steric hindrance 
from SCR-6/8 would need to be removed, most likely by moving the flexible linkers 
between SCR-4/5 and SCR-5/6 (Wu et al., 2009). Such large conformational changes in 
other complement proteins have already been reported for the TED domain in C3b, and 
the Bb fragment from C3b within the C3 convertase (Wu et al., 2009). The accessibility 
of the Tyr/His402 residue in SCR-7 was not compromised. For bivalent binding to 
heparin and/or sialic acid on cell surfaces, each of SCR-7 and the essential residues in 
SCR-19/20 (above) were accessible. For C3dg binding to SCR-19 or SCR-20 (Morgan et 
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al., 2011), no steric clash was seen (Figure 5.8B). The shortest distance between the SCR-
1/4 and SCR-6/9 domains was ~6 nm between Arg78 in SCR-1 and Asp538 in SCR-9. 
These residues bear opposite charges (Armstrong et al., 2016). I speculate that these 
domains may electrostatically attract each other; indeed conformational changes in FH 
with increase in ionic strength have been reported (Okemefuna et al., 2009). Further 
studies are required to investigate such a proposed mechanism. 
 
The existence of two FH conformations with different C3b and C3d binding 
strengths accounts for previously-reported KD values for each of SCR-1/4 binding to C3b 
(10-14 µM) and SCR-19/20 binding to C3b or C3d (1-5 µM and 0.2-8 µM respectively). 
These KD values are similar to the KD value of full-length FH binding to C3b (0.6-3 µM) 
(Perkins et al., 2012), indicating no synergy between the two binding sites at SCR-1/4 
and SCR-19/20, and meaning that these two C3b and C3d sites are independent of each 
other. This outcome is in concord with N-terminal extended and C-terminal extended FH 
models which bind to C3b or C3d separately, but not both together. In summary, FH is 
seen with an N-terminal extended conformation that is able to both dismantle fluid phase 
C3 convertases and perform cofactor activity, and also with a distinct C-terminal extended 
conformation that has increased affinity for binding to cell surfaces via both heparin and 
deposited C3d for enhanced local protection from complement activation. This is because 
the presence of C3d on the cell surface may increase the affinity of FH in the correct 
conformation for cell surface binding (Kajander et al., 2011). For the C-terminal extended 
FH structure, following its binding to cell surfaces, a conformational change involving 
the flexible linkers between SCR-4/5 and SCR-5/6 would allow SCR-1/4 to bind C3b. By 
this, C3b can either be inactivated to iC3b at host cell surfaces (cofactor activity) or 
separated from Bb in the C3 convertase (DAA). Overall, both alternative conformations 
are able to bind to glycosaminoglycans at the host cell surface, thus protecting this against 
excess C3b activity. However, the second structure with an extended C-terminus is more 
likely to be recruited to cell surfaces by the proposed increased affinity for C3d. In 
summary, the SAXS data modelling has resulted in the proposal of two distinct FH 
conformations that would enable FH to perform separate C3b or C3d binding functions 
in either the fluid-phase or at host cell surfaces respectively. 
180 
 
Chapter Six 
 
Structural analyses rationalise the 
distribution of aHUS and C3G rare 
variants in complement factor H
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6.1 Summary 
 
Atypical haemolytic uraemic syndrome and C3 glomerulopathy (aHUS, C3G) are 
two severe rare diseases associated with complement dysregulation. The most common 
variants were missense changes in the regulators factor H, factor I and membrane cofactor 
protein (FH, FI and MCP), and the activators C3 and factor B (FB). Their molecular 
correlations with aHUS and C3G were assessed by mapping the variants onto three-
dimensional structures for the FH-C3b-FI, FH-C3dg and C3b-FB complexes and full-
length FH. The 128 aHUS rare missense variants in FH mostly affected three types of 
residues, namely 13 case alleles in 42 buried residues (31%), followed by 290 case alleles 
in 1045 non-binding surface-accessible residues (28%), and finally 12 case alleles in 92 
residues at C3b-binding interfaces (13%), but none were found at the FI interfaces. In 
contrast, for 19 C3G variants in FH, these three types of residues totalled 2% (one case 
allele), 3% (26 case alleles) and 5% (five case alleles) respectively, and two case alleles 
(6%) within the FI binding interface were now involved. Another prominent group of 
variants involve Cys residues involved in disulphide bridges. Only those in the regulators 
FH, MCP and FI were associated with aHUS, while only those in FH and C3 were 
associated with C3G, when these were compared to the ExAC reference dataset. In 
conclusion, these differences between aHUS and C3G reflect their different pathologies, 
and importantly indicate that the structural location of a newly-discovered variant may 
predict the occurrence of aHUS or C3G in patients.
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6.2 Introduction 
 
In the complement AP, aHUS is associated with defects in cell surface regulation 
that lead to TMA, whereas C3G is associated with fluid phase dysregulation which leads 
to abnormal complement deposition in glomeruli (Goodship et al., 2017). aHUS was 
associated with rare genetic variation in FH, MCP, FI, C3 and FB, while C3G was 
associated with rare variation in FH and C3 only (Osborne et al., 2018a). For both aHUS 
and C3G, predisposing RVs lead to either a LoF in the regulators (FH, MCP or FI), or a 
GoF in the activator proteins (C3 or FB), and AP dysregulation. Protein three-dimensional 
structures are known for many of the AP proteins. This includes crystal structures for FH 
SCR-1/4-C3b (Wu et al., 2009), FH SCR-1/4-FI-C3b (Xue et al., 2017) and FH SCR-
19/20-C3dg (Kolodziejczyk et al., 2017), a solution structure for glycosylated full length 
FH (Osborne et al., 2018b), and a crystal structure for C3b-FB (Forneris et al., 2010). In 
terms of general protein function and structure, residues involved in molecular 
interactions are surface-associated whereas residues involved in structural stabilisation 
are buried or surface-associated. In order to predict these structural residue types, residue 
positions can be determined by submitting protein structural co-ordinates to surface 
accessibility or “accessible surface area” calculations (Lee & Richards, 1971). In order 
to predict which surface-accessible residues are involved in binding interfaces, such as 
for the regulatory C3b-FH-FI or activating C3b-FB complement complexes, the buried 
surface area can also be calculated. 
 
The SCR is the most abundant domain in the complement proteins and occurs in 
FH, MCP and FB. SCR domains generally contain about 60 residues arranged as six to 
eight β-strands numbered β1 to β8 with a hypervariable sequence loop between strands 
β2 and β3. SCR domains are structurally stabilised by two disulphide bridges formed by 
two pairs of conserved Cys residues (Chapter 3, Section 3.3.8). SCR domains also contain 
one conserved Trp residue. In all proteins, disulphide bonds are the second most common 
covalent link between amino acids and are estimated to be present in ~10% of mammalian 
proteins. Disulphide bonds form in the oxidising environment of the endoplasmic 
reticulum. In addition to structural stability, disulphide bonds can mediate thiol-
disulphate interchange reactions in substrate proteins (catalytic) and control protein 
function by triggering a conformational change upon being broken or formed (allosteric) 
(Schmidt et al., 2006). For any protein, the disruption of a structural disulphide bond often 
leads to LoF via protein misfolding. In genetic disease, these LoF events can be predicted 
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by the presence of predisposing rare missense variants in disulphide bond-forming Cys 
residues. For FB, an additional five disulphide bonds are present in the aL, von 
Willebrand Factor A and serine protease domains (Forneris et al., 2010). For C3 and FI, 
there are ten and 20 structural disulphide bonds present, respectively (Xue et al., 2017). 
Previously for FH and MCP, SCR consensus domain analyses associated missense 
variants in disulphide bridge-forming Cys residues with aHUS and AMD (Rodriguez et 
al., 2014). For example, the two Cys-affecting FH variants (p.Cys518Arg and 
p.Cys914Tyr) were identified in a FH-deficient patient with a C3G-like phenotype for 
which FH was synthesised but retained in the endoplasmic reticulum (Ault et al., 1997; 
Schmidt et al., 1999).  
 
The aim of this thesis chapter was to bring together the aHUS and C3G RV 
analyses from Chapter 4 and the FH modelling from Chapter 5 in order to identify whether 
the structural location of a variant in FH complexes may predict the occurrence of aHUS 
or C3G in patients. Here, the structural basis for the effect of RVs that predispose for 
aHUS and C3G were reviewed by predicting their functional impacts such as binding 
sites or protein stability. Firstly, the RV distributions in the complexes of both FH SCR-
1/4-C3b (Wu et al., 2009) and FH SCR-19/20-C3dg (Kolodziejczyk et al., 2017), with 
improved structural models for glycosylated full length FH (Chapter 5) (Osborne et al., 
2018b), and crystal structures for FH SCR-1/4-FI-C3b (Xue et al., 2017), and C3b-FB 
(Forneris et al., 2010) were analysed. Secondly, in order to analyse the abundances of the 
aHUS and C3G RVs in the functional regions of complement SCR domains, an SCR 
consensus domain was defined based on averaging the known structures of SCR domains 
(Rodriguez et al., 2014). This consensus was here updated for FH and MCP. For both 
aHUS and C3G, the frequencies of RVs in the so-called hypervariable loop were not 
significantly greater than for the rest of the SCR domain. For FH, the aHUS variants 
mostly affected FH residues which were surface-inaccessible (or buried), followed by 
non-binding surface-accessible residues and finally those at the C3b-binding interfaces. 
In contrast, for C3G, in addition to these three types all at similar frequencies to each 
other, those within the FI binding interface were now involved. Thirdly, for the SCR 
domains in FH and MCP, the frequency of missense rare variation in the four conserved 
Cys residues that mediate disulphide bridges was significantly greater for aHUS than for 
the ExAC reference genomic dataset (Lek et al., 2016). This result was also observed for 
aHUS for Cys residues involved in disulphide bridges in FI, but not for C3 or FB. For 
C3G, this was only observed for FH and interestingly, for C3. Overall, disulphide bridge 
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disruption was associated with aHUS in the AP regulators FH, MCP and FI, and, in 
contrast, with C3G for FH and C3. In summary, these three considerations suggest that 
the structural locations of complement variants may predict the occurrence of aHUS or 
C3G in patients. 
 
6.3 Methods 
 
For the aHUS, C3G and ExAC datasets, rare missense variants in the five genes 
CFH, C3, CFI, CD46 and CFB were filtered and extracted from the Database of 
Complement Gene Variants by using SQL commands as previous (Osborne et al., 2018a).  
 
6.3.1 Rare variant distributions in FH, C3, FI and FB complexes 
 
For the filtering, the rare missense variants for the aHUS and C3G datasets were 
only included if they were classified as pathogenic, likely pathogenic or uncertain 
significance (Chapter 4, Section 4.3.6) and were not located in the signal peptide. The 
total numbers of variants correspond to those previously analysed (Osborne et al., 2018a). 
 
The N-terminal extended and C-terminal extended FH structures were aligned 
with C3b-FH SCR-1/4 (PDB code: 2WII) (Wu et al., 2009) and FI-C3b-SCR-1/4 (PDB 
code: 5O32) (Xue et al., 2017), and C3dg-FH SCR-19/20 (PDB code: 5NBQ) 
(Kolodziejczyk et al., 2017), respectively, by using PyMol commands (Chapter 5, Section 
5.5.2). For the C3b and FB convertase complex, the crystal structure (PDB code: 2XWJ) 
(Forneris et al., 2010), was used. All the sequences were converted to HGVS numbering 
using PyMol commands. The rare missense variants extracted for aHUS, C3G and both 
aHUS and C3G were then mapped to their respective α-carbon atoms as red, yellow and 
black spheres, respectively, onto the structures for FH, C3, FI and FB by using PyMol 
commands. 
 
6.3.2 Consensus SCR domain analyses 
 
The consensus sequence from 124 human complement SCR sequences was 
computed as previous (Rodriguez et al., 2014) (Figure 6.1). This included the averaged 
side-chain accessibilities of the 27 experimental SCR structures aligned to the consensus 
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structure which were computed from DSSP software for secondary structure assignments 
and side-chain surface accessibilities (Kabsch & Sander, 1983).  
 
For aHUS and C3G, rare missense variants were only included if they were 
classified as pathogenic, likely pathogenic or uncertain significance (Chapter 4, Section 
4.3.6) and were not located in the signal peptide. The total numbers of variants 
corresponded to those previously analysed (Osborne et al., 2018a).  
 
The frequency of affected (and unaffected) residues was calculated by dividing 
the numbers of affected (and unaffected) residues by all residues (Table 6.1). In order to 
compare the frequencies of the aHUS and C3G rare missense variants between regions, 
the Fisher’s two-tailed exact test for a 2×2 contingency table was used. The null 
hypothesis stated that there was no difference in frequency and the alternative stated that 
there was a difference in frequency. The significance level was 0.05. GraphPad 
QuickCalcs (https://www.graphpad.com/quickcalcs/) was used. 
 
In order to consider how many times each variant had been seen in aHUS and how 
many patients were screened in total, these analyses were repeated with AF data (Table 
6.2). By this, both the total allele count and the total AF of aHUS rare missense variants 
was calculated for each region of interest (Table 6.2). The aHUS AF takes into account 
the total number of alleles screened (i.e. two per patient) for each gene, this being 6256 
CFH alleles and 5884 CD46 (MCP) alleles. In order to normalise these total allele counts 
and AFs by the size of the region (i.e. size), they were divided by the number of residues 
in the region. These analyses were not performed for C3G because there were too few 
variants thus the frequencies were too low to give reliable results. 
 
6.3.3 Surface-accessibility analyses of FH residues 
  
 For full-length FH in complex with FI and C3b, in order to determine whether the 
FH residues become buried, remain surface-exposed or are involved in binding interfaces, 
the residue surface accessibilities were calculated. This was done by using the crystal 
structures of C3b-FH SCR-1/4 (PDB code: 2WII) and FI-C3b-SCR-1/4 (PDB code: 
5O32) (Figure 6.1B) and the software Protein Interfaces, Surfaces and Assemblies (PISA) 
at the PDBePISA server (http://www.ebi.ac.uk/pdbe/pisa/) (Krissinel & Henrick, 2007). 
By this, only the interactions and macromolecular contacts already present in the crystal 
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structures were analysed. These contacts were superimposed with full-length FH as part 
of FH SCR-1/4. PISA calculates the accessible surface area by rolling a water probe of 
1.4Å in diameter over the surface of the protein and summing up all sampled points in 
contact with this probe, which then represents the surface area, normalised by the 
precision of the element analysis. For two residues, the interface between them or buried 
surface area is calculated from their accessible surface areas. For each FH residue, the 
aHUS and C3G rare missense variant allele counts and frequencies were calculated by 
using the Database of Complement Gene Variants with SQL commands, as previous 
(Osborne et al., 2018a) (Table 6.3). 
 
6.3.4 Frequencies of rare variants in structural disulphide bridges 
 
For each of the five proteins (FH, FI, MCP, FB and C3), rare missense variants 
for the aHUS, C3G and ExAC buried Cys datasets were only included if they affected 
disulphide bond forming-Cys residues and had an ExAC AF < 0.01%. By using the ExAC 
AF filter for all of the aHUS, C3G and ExAC datasets, a potential bias was introduced 
whereby common variants in aHUS and C3G were included but common variants in 
ExAC were excluded. However, for these analyses, there were no common variants 
affecting Cys residues for ExAC (all Cys variants were rare), and the variants affecting 
Cys residues that were the most common in the aHUS and C3G datasets were also rare. 
Overall, it was concluded that the effects of this potential bias were minimal.  
 
For the SCR domains in FH, MCP and FB, all their Cys residues were involved 
in disulphide bridges. Thus, SCR domains account for all of FH, 70% of MCP (SCR-1/4; 
251/358 residues) and 26% of the activator FB (SCR-1/3; 195/764 residues). For the 
remaining non-SCR domain residues of C3, FB and FI, the number of disulphide bridge-
forming Cys residues was extracted from their structural co-ordinate files (PDB codes: 
2XWJ and 5O32). Thus, for FB, an additional five disulphide bonds were present in the 
aL, von Willebrand Factor A and serine protease domains (Forneris et al., 2010). For C3 
and FI, ten and 20 structural disulphide bonds were present, respectively (Xue et al., 
2017). 
 
For each protein, for each of the aHUS and C3G datasets, the total AF of rare 
missense variants that affected disulphide bridge-forming Cys residues was calculated 
(Table 6.4). This was calculated by dividing the total allele count for the variants by the 
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total number of alleles screened for the gene. For ExAC, this was calculated by summing 
the allele count and dividing this by the mean allele number, as previous (Chapter 4). 
 
In order to compare the frequencies of rare missense variants that affected 
disulphide bridge-forming Cys residues in aHUS and C3G with those for the reference 
ExAC dataset, the Chi-square test (𝜒2) with Yates’ correction for a 2×2 contingency table 
was used. The null hypothesis stated that there was no difference in AF. The alternative 
stated that there was a difference in frequency. The significance level was 0.05. GraphPad 
QuickCalcs (https://www.graphpad.com/quickcalcs/) was used. Prior to each test, the 
power was calculated by using the program PS Power and Sample Size Calculations 
(Version 3.0) (Dupont & Plummer, 1990). The tests for FH and MCP showed powers of 
at least 80%.  
 
6.4 Results 
 
6.4.1 Frequency of aHUS and C3G rare variants in hypervariable loop 
 
In order to appreciate the impact of the rare missense variants on the SCR domain, 
the updated SCR consensus domain for FH and MCP is shown in Figure 6.1 for aHUS 
and C3G. The averaged side-chain accessibility of the 27 experimental SCR structures 
aligned to the SCR consensus structure is also shown (Rodriguez et al., 2014). In this 
present study, a total of 170 rare missense variants for aHUS and C3G were mapped to 
their positions within the consensus sequence. These variants corresponded to totals of 
115 FH and 37 MCP for aHUS (red and blue texts, respectively), ten FH for C3G (yellow 
text), and eight FH that were identified in both aHUS and C3G patients (black text) 
(Figure 6.3).  
 
For aHUS, while the rare missense variants were randomly distributed throughout 
the consensus SCR domain, the five conserved Cys and Trp residues were the most 
populated with 40 occurrences out of 160 (25%). The loss of any of these residues appears 
to impact the stability of the SCR domain. For C3G, the distribution of the rare missense 
variants also appeared to be random. However, out of the four conserved Cys residues, 
only the third conserved Cys residue was affected by C3G variants (three; p.Cys431Tyr, 
p.Cys915Ser, p.Cys1218Arg) and all of these were also identified in aHUS patients (black  
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Figure 6.1 Location of aHUS and C3G rare missense variants on a SCR consensus sequence. Figure legend overleaf.
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Figure 6.1 (continued) Location of aHUS and C3G rare missense variants on a SCR 
consensus sequence. The consensus SCR sequence for FH and MCP shows the most 
commonly occurring residue at each position. Mapped to their positions within the 
consensus sequence are the total of 170 rare missense variants for aHUS and C3G. These 
correspond to 115 FH and 37 MCP for aHUS (red and blue, respectively), 10 FH for C3G 
(yellow), and 8 FH that were identified in both aHUS and C3G patients (black). On the 
SCR consensus sequence, the residues corresponding to the six main β-strands β2 to β7 in 
SCR domains are shown in yellow. For the hypervariable loop between β2 and β3 which 
corresponds to five residues 12–16, the 27 aHUS, 1 C3G and 1 identified in both aHUS 
and C3G rare missense variants are displayed against a green background. The consensus 
solvent side-chain accessibilities computed by DSSP are numbered from 0 to 9, where 0 
denotes 0–9% accessibility, 1 denotes 10–19% accessibility, etc. Residues with values of 
0 and 1 are considered to be buried in the protein structure.
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text, Figure 6.1). This suggested an overlap in aHUS and C3G phenotypes at this Cys 
residue. In addition for C3G, the conserved Trp residue was affected by one variant. 
 
For aHUS, 28 of the 160 rare missense variants (for FH and MCP), which 
corresponded to 24 distinct residues, occurred in the five consensus residues 12-16 of the 
hypervariable loop between β-strands β2 and β3 (blue, red and black text in green boxes, 
Figure 6.3) These five consensus residues of the hypervariable loop corresponded to 192 
FH and MCP distinct residues in SCR domains. For the hypervariable loop, the frequency 
of residues affected by aHUS rare missense variants was 13% (Table 6.1). When this was 
compared to the frequency of 9% for the non-hypervariable loop regions, there was no 
significant difference (p=0.1494). However, for the four conserved Cys residues (96 
residues in total), which were included in the ‘non-hypervariable loop’ region, the 
frequency of aHUS-affected residues (29; 30%) was significantly greater than for the 
remaining ‘non-Cys’ residues (8%; p<0.0001). For the non-hypervariable loop residues, 
when these four conserved Cys residues were taken out, the frequency of aHUS-affected 
residues was also 8% (last row, Table 6.1). The frequency of hypervariable loop residues, 
13%, was now significantly greater than the frequency for both the non-hypervariable 
loop and non-Cys residues (8%; p=0.0230), but not as significant as for the four conserved 
Cys residues. This statistical analysis shows that alterations in the four Cys residues were 
indeed a major factor leading to aHUS.  
 
In order to consider how many times each variant was observed in aHUS and how 
many patients were screened in total for CFH and CD46 variants, these analyses were 
repeated with aHUS AF data (Table 6.2). By this, both the total allele count and the total 
AF of aHUS rare missense variants were calculated for the hypervariable loop residues, 
the four conserved Cys residues, and those residues not in either the hypervariable loop 
nor the four Cys residues (Table 6.2). These were then normalised by the size of each 
region by dividing by the number of residues for that region. For aHUS, the total allele 
counts were 52, 62 and 284 for the hypervariable loop, the four conserved Cys residues 
and neither the hypervariable loop nor the Cys residues, respectively. These corresponded 
to total AFs of 0.84%, 1.00% and 4.61%, respectively. After normalisation, the AFs were 
0.0044%, 0.0104% and 0.0039%, respectively. Overall, the four conserved Cys residues 
had the highest normalised allele count and AF of 65% and 0.0104%, respectively. The 
other residues had very similar aHUS AFs ranging from 0.0039% to 0.0044% (Table 6.2). 
In summary, as noted above, the four conserved Cys residues (0.0104%) were  
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Table 6.1 Frequencies of aHUS and C3G affected residues in the consensus SCR 
a  “Total residues” was calculated by adding up the number of residues for each of the four 
SCRs in MCP and 20 SCRs in FH, including the linker residues. 
b The frequency of affected (or unaffected) residues was calculated by dividing the 
numbers of affected (or unaffected) residues by all residues. 
 
 
Table 6.2 Allele frequencies of aHUS affected residues in the consensus SCR 
Location of 
residues 
Total 
residues a 
aHUS 
allele 
count 
aHUS allele 
count by 
residues (%) b   
aHUS 
allele 
frequency 
(%) 
aHUS allele 
frequency c 
by residues b 
(%) 
Hypervariable loop 192 52 27 0.84 0.0044 
Cys 96 62 65 1.00 0.0104 
Non-hypervariable   
  loop and non-Cys 
1176 284 24 4.61 0.0039 
All 1464 398 27 6.45 0.0044 
Non-hypervariable  
  loop 
1272 346 27 5.61 0.0044 
a  “Total residues” was calculated by adding up the number of residues for each of the four 
SCRs in MCP and 20 SCRs in FH, including the linker residues. 
b  Divided by the total number of residues in each region (second column). 
c The aHUS allele frequency takes into account the total number of alleles screened (i.e. 
two per patient) for each gene, this being 6256 CFH alleles and 5884 CD46 alleles.
Location of residues 
Total 
residues a 
Affected residues 
(frequency b) 
 Unaffected residues 
(frequency  b) 
aHUS C3G  aHUS C3G 
Hypervariable loop 192 24 (13%) 2 (1%)  168 (87%) 189 (99%) 
Non-hypervariable    
  loop 
1272 117 (9%) 17 (1%) 
 
1155 (91%) 1249 (99%) 
     Cys 96 29 (30%) 3 (3%)  67 (70%) 93 (97%) 
    Non Cys 1368 112 (8%) 16 (1%)  1256 (92%) 1345 (99%) 
All 1464 141 (10%) 19 (1%)  1323 (90%) 1438 (99%) 
Non-hypervariable   
  loop and non-Cys 
1176 88 (8%) 14 (1%) 
 
1088 (92%) 1156 (99%) 
192 
 
significantly more affected by aHUS rare missense variants, but the hypervariable loop 
residues (0.0044%) were not. For C3G, there were too few C3G variants giving very low 
frequencies (1% to 3%), thus the power was too low for these analyses. 
 
6.4.2 Distributions of aHUS and C3G rare variants in complement complexes 
 
  For each of the five proteins (FH, FI, MCP, FB, C3), datasets of aHUS and C3G 
rare missense variants that were classified as pathogenic, likely pathogenic or uncertain 
significance (Chapter 4, Section 4.3.6) and not located in the signal peptide were extracted 
from the Database of Complement Gene Variants. These variants were categorised as 
either aHUS, C3G or both aHUS and C3G, and were mapped onto the protein structures 
by using red, yellow and black spheres, respectively (Figure 6.2). 
 
Only rare missense variants that were classified as pathogenic, likely pathogenic 
or uncertain significance and were not located in the signal peptide were included. Thus, 
for FH, there were 128 aHUS (109 unique residues) and 19 C3G (18 unique residues) rare 
missense variants, of which eight in each dataset were common to both aHUS and C3G 
(8 unique residues). These are taken from column 1 of Figure 4.3B. For C3, there were 
61 aHUS (56 unique residues) and 24 C3G (24 unique residues) rare missense variants, 
of which five in each dataset were common to both aHUS and C3G (five unique residues). 
These are taken from the fourth protein of Figure 4.3B. These affected residues were 
mapped onto the N-terminus extended FH model (Chapter 5, Section 5.5.2) in complex 
with C3b (Wu et al., 2009) (Figure 6.1A) and the C-terminus extended FH model in 
complex with C3dg (Kolodziejczyk et al., 2017) (Figure 6.1B). As previously observed 
(Chapter 4, Section 4.5.4), the aHUS rare missense variants (red and black spheres, 
Figures 6.2A, B and C) were clustered at SCR-20 and also distributed throughout the 
other SCR domains. For SCR-20, these variants likely affect heparin binding required for 
host-cell surface protection. For SCR-7, the three rare missense variants may also affect 
heparin binding. For the N-terminal domains, despite there being fewer aHUS variants 
than in the C-terminal domains (Chapter 4, Section 4.4.8) the aHUS variants within SCR-
1/4 appeared to cluster at the interfaces between FH SCR-3 and C3b MG2/CUB, and FH 
SCR-4 and C3b TED/MG1 (red and black spheres, Figure 6.2A and B). For C3b, within 
the FH SCR-3/C3b MG2 interface, the MG2 variant p.Arg161Trp (red arrow, Figure 6.2A 
and B) had the greatest aHUS AF (1.1%) in the aHUS dataset, being identified in 52 
aHUS cases in heterozygous form. For the FH SCR-3/C3b CUB interface 
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Figure 6.2 Rare missense variants mapped onto models for FH in complex with C3b 
and FI. Figure legend overleaf.
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Figure 6.2 Rare missense variants mapped onto models for FH in complex with C3b 
and FI. Rare missense variants for aHUS, C3G and both aHUS and C3G mapped as red, 
yellow and black spheres, respectively, onto structural models shown in cartoon style by 
using PyMol. For FH, there were 128 aHUS (109 unique residues) and 19 C3G (18 unique 
residues) rare missense variants, of which eight in each dataset were common to both 
aHUS and C3G (eight unique residues). For C3, there were 61 aHUS (56 unique residues) 
and 24 C3G (24 unique residues) rare missense variants, of which five in each dataset 
were common to both aHUS and C3G (five unique residues). The N-terminal extended 
FH model was aligned with each of (A) C3b (tan) and FH SCR-1/4 (cyan) (PDB code: 
2WII), and (B) FI (green), C3b (tan) and SCR-1/4 (cyan) (PDB code: 5O32). The variant 
p.Arg161Trp (red arrow) had the greatest aHUS allele frequency (1.1%) in the aHUS 
dataset. The hypervariable loop in FH SCR-3 is labelled as hpv (blue text). (C) The C-
terminal extended FH structure was aligned with C3dg (green) and FH SCR-19/20 (not 
shown) (PDB code: 5NBQ). 
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(Wu et al., 2009), the FH hypervariable loop (hpv; residues 157 to 163) harboured the 
four aHUS missense variants p.Val158Ile, p.Ser159Asn, p.Ala161Ser, p.Met162Val, 
with aHUS AFs of 0.05%, 0.02%, 0.08% and 0.02% respectively. Interestingly, 
p.Ser159Asn was also seen in one C3G patient, suggesting an overlap in phenotypes at 
this position. The mutational frequency of the hypervariable loop in aHUS and C3G was 
further analysed using statistics in Section 6.4.3. 
 
For C3G, for FH and C3b, the rare missense variants were distributed mainly in 
C3 and in FH SCR-1/3 (yellow and black spheres, Figure 6.2A, B and C). This appeared 
to include the FH SCR-3 and C3b MG2/CUB binding interfaces. However, in contrast to 
aHUS, were no C3G rare missense variants in FH SCR-4 or the interfaces between FH 
SCR-4 and C3b TED or MG1. Also in contrast to aHUS, few C3G rare missense variants 
were seen in the middle and C-terminal SCR domains, as noted previously (Osborne et 
al., 2018a). For the SCR-7 and SCR-20 domains involved in binding heparin, the one 
C3G variant in SCR-7 and two C3G variants in SCR-20 were also seen in aHUS patients 
(black spheres, Figure 6.2A, B and C). For C3b, the two C3G variants p.Arg1303His and 
p.Arg1320Gln were located in the first and second cleavage sites thus were predicted to 
provide resistance against C3b cleavage by FI and a cofactor. 
 
For FI, there were 65 aHUS (61 unique residues) and five C3G (five unique 
residues) rare missense variants, with four (four unique residues) common to both aHUS 
and C3G. The affected FI, FH and C3b residues were mapped onto the structure of FI 
complexed with C3b (Xue et al., 2017) and the N-terminus extended FH model (Chapter 
5, Section 5.5.2) (green, Figure 6.2B). In contrast to FH and C3b, the aHUS affected 
residues for FI were randomly distributed over the whole structure, as observed 
previously (Chapter 4, Section 4.4.10).  
 
For FB, there were 19 aHUS (19 unique residues) and seven (seven unique 
residues) C3G rare missense variants, with one variant common to both aHUS and C3G. 
The affected FB and C3 residues were mapped onto the structure of FB complexed with 
C3b (Figure 6.3). No clustering of variants was observed in the binding sites for the C3 
convertase complex. However, interestingly, one C3G variant (p.Cys1518Arg) affected a 
disulphide bond-forming Cys residue in the C3 C345C domain (cyan sphere, Figure 6.3).
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Figure 6.3 Rare missense variants mapped onto the crystal model for the C3 convertase. Rare missense variants for aHUS, C3G and both aHUS 
and C3G are mapped as red, yellow and black spheres, respectively, onto the structural model for the C3b and factor B convertase complex (PDB code: 
2XWJ). For C3, there were 61 aHUS (56 unique residues) and 24 C3G (24 unique residues) rare missense variants, of which five in each dataset were 
common to both aHUS and C3G (five unique residues). For FB, there were 19 aHUS (19 unique residues) and seven (seven unique residues) C3G rare 
missense variants, with one variant common to both aHUS and C3G. The models are shown in cartoon style and the disulphide bonds are shown in cyan 
stick style by using PyMol. The single rare missense variants affecting a Cys residue is shown as a cyan sphere. 
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6.4.3 Structural locations of aHUS and C3G rare variants in FH 
 
For the complex of N-terminal extended FH with C3b and FI (Figure 6.2B), the 
molecular views were quantified using the program PISA to assess the surface- 
accessibility of the FH residues (Table 6.3). Mature FH contains 1213 residues. For free 
FH, 42 out of the 1213 FH residues were predicted to be surface-inaccessible (4%), and 
1171 were accessible. For the complex, overlaps were found between three residue types 
of (i) surface-accessible FH, (ii) surface-inaccessible FH, or (iii) C3b or FI binding 
interface FH (bracketed numbers, Table 6.3). For example, 126 of the 1171 surface-
accessible residues (10%) were found to lie within the C3b and FI binding interfaces with 
a buried surface area greater than 0 Å². Of these 126 residues, 50 were involved in the 
binding interface with C3b (α-chain) (4%), 56 with C3b (β-chain) (5%), and 36 with FI 
(3%), with overlaps between them. 
 
For both aHUS and C3G, the vast majority of rare missense variants affected 
surface-accessible residues in FH (92% and 94%, respectively) given its large size (third 
column, Table 6.3), and the FH-FI-C3b crystal structure will be uninformative as to how 
these leads to disease. However, in order to take the number of residues in the three types 
into account (top row Table 6.3), the proportion of residues for each residue type were 
now considered. For aHUS, surface-inaccessible residues within FH were most affected 
by aHUS (21%; 9 out of 42 surface-inaccessible residues) (last column, Table 6.3). This 
implies that a misfolded FH caused the phenotype. The 1171 FH residues that were 
surface-accessible were affected by aHUS at a frequency of 8% (third column, Table 6.3). 
Thus, the surface-inaccessible residue frequency (21%) was significantly greater than the 
surface-accessible frequency (8%; p=0.0086) only, the latter including the 7 and 6 variant 
residues involved with C3b. Altered FH residues at the interface can also contribute to 
disease. In contrast, for C3G, the type of residues most affected by C3G were the surface-
accessible residues in the C3b binding interface (β-chain) (5%) (Table 6.3).  However, 
this frequency was not significantly greater than for any of the other types, these being 
all similar in frequency for C3G. In addition, there were fewer C3G variants than aHUS 
variants in the dataset, which reduces the power of these results.  
 
These analyses above were based on the numbers of aHUS and C3G affected 
residues only. In order to consider how many times each residue was mutated in aHUS 
and C3G, the analyses were repeated with allele count data for aHUS and C3G (Table 
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Table 6.3 FH residue surface-accessibility analyses for aHUS and C3G 
 
Residue type 
Total 
residues 
Surface-
accessible 
residues a 
Surface-accessible binding 
interface residues b (unique) 
Surface- 
inaccessible 
residues c C3b α C3b β FI 
FH all 
   of FH all (%) 
1213 
100 
1171 (1045) 
97 
50 (42) 
4 
56 (50) 
5 
36 (34) 
3 
42 
4 
FH aHUS 
  of FH aHUS (%) 
   of FH all (%)d 
   allele count 
   of FH aHUS (%) 
107 
100 
9 
311 
100 
98 (89) 
92 
8 
308 (290) 
99 
7 (5) 
7 
14 
12 (8) 
4 
6 (4) 
6 
11 
8 (4) 
3 
0 
- 
- 
0 
- 
9 
8 
21 
13 
4 
   of FH all (%) 26 26 (28) 24 (19) 11 (16) - 31 
FH C3G 17 16 (12) 1 (1) 3 (3) 1 (1) 1 
   of FH C3G (%) 100 94 6 18 6 6 
   of FH all (%) 1 1 2 5 3 2 
allele count 27 26 (26) 2 (2) 3 (3) 2 (2) 1 
   of FH C3G (%) 100 96 7 11 7 4 
   of FH all (%) 2 2 (3) 4 (5) 5 (6) 6 (6) 2 
 
a Residues with accessible surface area greater than 0 Å2, calculated by PISA, followed 
by the number of unique residues in brackets. 
b Solvent accessible residues with buried surface area greater than 0 Å2, calculated by 
PISA. 
c Residues with accessible surface area of 0 Å2, calculated by PISA. 
d The frequency of all FH residues for that residue type. For example, for the surface-
accessible residues (third column), 98 out of 1171 were affected by aHUS, giving a 
frequency of 8%. 
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6.3). The 128 aHUS rare missense variants in FH mostly affected three types of residues: 
nine of the 42 surface-inaccessible (or buried) in 13 case alleles (31%), followed by 89 
of the 1045 non-binding surface-accessible residues (290 case alleles; 28%) and finally 
nine of the 92 residues at the two C3b-binding interfaces (12 case alleles; 13%), but none 
at the interfaces with FI. In contrast, for 19 C3G variants, in addition to these three types 
totalling 2% (one case allele), 3% (26 case alleles) and 5% (five case alleles) respectively, 
two case alleles (6%) within the FI binding interface were now involved.  
 
For the 36 surface-accessible FH residues at the FI binding interface, none were 
affected by aHUS, but one was affected by C3G in the rare missense variant datasets 
(sixth column, Table 6.3). However, this one C3G residue corresponded to two C3G 
variant alleles: p.Arg127Cys and p.Arg127His (Table 6.3). In addition, an additional RV 
p.Arg127Leu was reported in the literature for C3G in two MPGN patients, both in 
homozygous form (four extra alleles in total) (Dragon-Durey et al., 2004). In the C3b-
FH-FI complex, p.Arg127 was predicted by PISA software to form a salt bridge and a 
hydrogen bond with FI p.Asp438 (interatomic distance: 2.88 Å). For aHUS, for the FI 
binding interface, one variant p.Arg166Leu, of only one allele count, was also reported 
in the literature (Chaudhary et al., 2014). Overall, rare missense variants in FH that 
occurred in the FI binding interface appeared to be more frequent in C3G (either two or 
six alleles; 6% or 18%) than in aHUS (either zero or one allele; 0% or 3%), but more 
studies are required to verify this. 
 
6.4.4 Frequency of aHUS and C3G rare variants in protein disulphides                         
 
In order to test that the disruption of disulphides was significant in causing aHUS 
and C3G, each of the aHUS, C3G and genomic reference ExAC datasets were used to 
calculate the AF of rare missense variation that affected disulphide bridge-forming Cys 
residues in each of FH, MCP, C3, FI and FB (Table 6.4). These type of variants are 
associated with a LoF in the protein. 
 
For FH, all 80 Cys residues are involved in 40 essential disulphide bonds that 
stabilise the SCR domains (Figure 6.1). For FH in aHUS, the 21 affected Cys residues 
(24 variants; red and black text, Figure 6.1) were randomly distributed in FH at a total 
aHUS AF of 0.512% (Table 6.4). For FH in C3G, three rare missense variants affected 
Cys at a total AF of 0.451% and all of these three were also seen in the aHUS dataset  
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Table 6.4 The frequency of rare variation in Cys residues that affected protein disulphide bonds for aHUS, C3G and ExAC 
Gene 
aHUS  C3G  ExAC 
Number of 
rare missense 
variants 
(residues) 
Allele 
count 
Allele 
number 
Allele 
frequency 
(%) 
 
Number of 
rare 
missense 
variants 
(residues) 
Allele 
count 
Allele 
number 
Allele 
frequency 
(%) 
 
Number of 
rare 
missense 
variants 
(residues) 
Allele 
count 
Allele 
number 
Allele 
frequency 
(%) 
CD46 9 (8) 30 5884 0.510  0 (0) 0 812 0.000  0 (0) 0 116676 0.000 
CFB 0 (0) 0 4914 0.000  0 (0) 0 758 0.000  1 (1) 1 117464 0.001 
CFH 24 (21) 32 6256 0.512  3 (3) 4 886 0.451  9 (9) 10 118326 0.009 
C3 0 (0) 0 4910 0.000  1 (1) 1 758 0.132  0 (0) 0 119090 0.000 
CFI 5 (5) 6 5846 0.103  0 (0) 0 816 0.000  9 (9) 12 120578 0.010 
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(p.Cys431Tyr, p.Cys915Ser, p.Cys1218Arg) (black text, Figure 6.1). For FH in ExAC, 
only nine out of 118,326 total mean FH alleles (0.009%) harboured a Cys-affecting rare 
missense variant in FH (Table 6.4). The total mean alleles were calculated as previous for 
the RV burden calculations (Osborne et al., 2018a). These nine ExAC alleles 
corresponded to nine RVs and these were distributed in SCR-1, SCR-3, SCR-5, SCR-7, 
SCR-9 and SCR-19. For FH, the AF of Cys-affecting rare missense variation for both 
aHUS (0.512%) and C3G (0.451%) was significantly greater than for ExAC (0.009%; 
both p<0.0001). 
 
For MCP, rare missense variants in disulphide bridge-forming Cys residues were 
only seen for aHUS. None were seen for C3G. Thus, for MCP in aHUS, nine variants 
affected eight different Cys residues and these were all located in the four SCR domains 
(blue text, Figure 6.1). Their total aHUS AF of 0.510% was significantly greater than for 
ExAC (0%; p<0.0001) (Table 6.4).  
 
For FI, the total AF of rare missense variation in disulphide bridge-forming Cys 
residues was significantly greater for aHUS (0.103%) than for ExAC (0.010%; p<0.0001) 
(Table 6.4). None were observed for C3G. 
 
For C3, only the C3G dataset contained a rare missense variant that affected a 
disulphide bond-forming Cys residue. This variant, p.Cys1518Arg, occurred in the 
C345C domain (cyan sphere, Figure 6.3). The C3 Cys1518 residue is conserved in ten 
vertebrates (Database of Complement Gene Variants, AA Alignments webpage). When 
compared to ExAC (0%), the total AF of these C3G variants (0.132%) was significantly 
greater (p<0.0001) (Table 6.4). This was not the case for aHUS. 
 
For FB, the AF of rare missense variation in disulphide bridge-forming Cys 
residues was zero for both aHUS and C3G, and 0.001% for ExAC (Table 6.4).   
 
6.5 Discussion 
 
It is unknown whether the structural locations of rare missense variants in the 
complement proteins differ between aHUS and C3G. This is important for the prediction 
of aHUS or C3G in patients. In this chapter, for the structural locations of complement 
variants, a number of differences were seen between aHUS and C3G, which indicated 
202 
 
their potential use for the prediction of aHUS or C3G. Firstly, the aHUS rare missense 
variants appeared to cluster at either the regulatory FH SCR-3/4 and C3b MG2/CUB or 
TED/MG1, or cell surface SCR-20 associated regions, whereas the C3G variants 
appeared to cluster in regions associated with decay acceleration activity (SCR-1/2), some 
cofactor activity (SCR-1/3) and FI-mediated cleavage. Secondly, for rare missense 
variants in FH, those that occurred in the FI binding interface residues appeared to be 
more frequent in C3G (either two or six alleles; 6% or 18%) than in aHUS (either zero or 
one allele; 0% or 3%). However, more statistical based analyses are required to verify 
this. Thirdly, for Cys residues involved in disulphide bonds, only those in the regulators 
FH, MCP and FI were associated with aHUS, while only those in FH and, interestingly, 
C3 were associated with C3G, when compared to the ExAC reference dataset. 
 
6.5.1 Consensus SCR domain updated for aHUS and C3G 
 
The SCR consensus domain has proved useful in earlier analyses of genetic 
variants in complement (Rodriguez et al., 2014; Saunders et al., 2007). Here, it was found 
useful to analyse the abundances of the aHUS and C3G RVs in the functional regions of 
complement SCR domains, following an update for FH and MCP (Figure 6.1). Overall, 
the four conserved Cys residues showed the highest normalised both allele count and AF 
of 65% and 0.0104%, respectively (Table 6.2). For the locations of residues in either the 
hypervariable loop, not in the hypervariable loop nor the Cys residues, or all locations, 
the aHUS AFs were very similar, ranging from 0.0039% to 0.0044% (Table 6.2). In 
summary, the four conserved Cys residues with a total aHUS AF of 0.0104% were more 
affected by aHUS rare missense variants than the rest of the consensus SCR domain. The 
hypervariable loop residues were not significantly more affected by aHUS than the rest 
of the consensus SCR domain residues. For aHUS, this outcome suggested that the 
hypervariable loop did not have greater functional importance when compared to the 
other residues of the consensus SCR domain which were not involved in disulphide 
bridges (Cys). Previously, the consensus SCR hypervariable loop was associated with 
disease variants for AMD, aHUS and C3G, for which the analyses included the AMD-
risk variant p.His402Tyr (Rodriguez et al., 2014). For aHUS, p.Tyr402His (rs1061170) 
is part of the protective CFHCATAGG haplotype for aHUS. For dense deposit disease, a sub-
category of C3G, p.Tyr402His is a risk allele, and the presence of two or more risk alleles 
increased the odds ratio of developing the disease (Abrera-Abeleda et al., 2011; Smith et 
al., 2011). Thus, by itself, p.His402Tyr does not predispose for either aHUS or C3G. The 
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analyses of common risk or protective haplotypes for aHUS and C3G was beyond the 
scope of this thesis. 
 
6.5.2 aHUS variants cluster in regulatory FH-C3b regions 
 
Three-dimensional views assist with the interpretations of the variants. Firstly, 
aHUS and C3G rare missense variants were mapped onto the complexes of FH-C3b-FI 
(Wu et al., 2009; Xue et al., 2017) and FH-C3dg (Kolodziejczyk et al., 2017) with 
improved structural models for glycosylated full length FH (Chapter 5), and the C3b-FB 
convertase (Forneris et al., 2010). Compared with previous analyses of their distributions 
in each of FH, C3, FI, MCP and FB separately (Chapter 4), this chapter focusses on the 
protein complexes with FH in its two major conformations (Chapter 5). This permitted a 
more detailed understanding of the variant distributions and their associations with the 
functional binding regions of FH. For aHUS and FH, the rare missense variants were 
clustered at SCR-20 and distributed non-randomly throughout the other SCR domains 
(red and black spheres, Figures 6.2A, B and C), as previously observed at the genetic 
level (Chapter 4, Section 4.5.4). In addition, for the FH-C3b complex, clusters of aHUS 
variants were observed at the interfaces between FH SCR-3 and C3b MG2/CUB, and also 
between FH SCR-4 and C3b TED/MG1 (red and black spheres, Figure 6.2A and B). This 
indicated the association of aHUS with disrupted FH-C3b binding, which leads to a LoF 
for FH. For the FH SCR-4 and TED/MG1 interface, this region had previously been 
associated with individual aHUS variants e.g. C3 p.Gln1139Lys in TED introduces a 
positive charge that may lead to formation of a salt bridge between p.Lys1139 and the 
preceding p.Asp1138, thereby modifying the C3b-FH interaction (Wu et al., 2009). For 
both SCR-3 and SCR-4, their binding to residues within the C3b domains MG1, MG2, 
CUB and TED holds C3b in place for cleavage by FI. Thus, both SCR-3 and SCR-4 are 
important for the regulation of C3b by FH cofactor activity and decay acceleration 
activity. Overall, for FH and C3b, the aHUS rare missense variants appeared to be 
clustered at both the regulatory (SCR-3 and C3b MG2/CUB, and SCR-4 and C3b 
TED/MG1) and cell surface (SCR-20) associated regions. 
 
For C3G, the rare missense variants were distributed mainly in C3 and in FH SCR-
1/3 (yellow and black spheres, Figure 6.2A, B and C). FH SCR-1/2 are required for 
displacing Bb in decay acceleration activity. Interestingly, in contrast to aHUS, there were 
no C3G rare missense variants in SCR-4 or the interfaces between SCR-4 and TED or 
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MG1. This implied that C3G is not associated with the disruption of C3b regulation by 
FH via these SCR-4 interfaces. Few C3G rare missense variants were seen in the middle 
and C-terminal SCR domains. By this, the C3G variants appeared to cluster in regions 
associated with decay acceleration activity (SCR-1/2) and some cofactor activity (SCR-
1/3) only, and not in regions required for cell surface regulation (SCR-19/20) (Chapter 4, 
Section 4.5.4). As discussed in Chapter 4, this reflects the role of fluid-phase and surface-
associated activities in the C3G and aHUS phenotypes. For C3b, two C3G variants were 
located in the first and second cleavage sites thus prevent cleavage of C3 by FI and a 
cofactor. These represent GoF variants in C3 that may lead to an over-active C3 and thus 
its consumption. In contrast, in aHUS, none of these C3 cleavage sites were affected.  
 
6.5.3 Structural locations of FH variants differ between aHUS and C3G 
 
For a protein, the change of a surface-associated residue involved in a binding 
interface generally affects the activity of the protein only, and not its amounts or levels. 
On the other hand, buried residues are involved in structural stabilisation, and their 
disruptions via missense variants can lead to reduced levels of the protein due to protein 
misfolding. Thus, the locations of rare missense variants can account for their effects on 
protein structure, function and the associated biochemical pathway. For aHUS and C3G, 
their occurrences in individuals may be predicted from complement genetic variant data, 
by analysing the structural locations of the complement variants. For N-terminal extended 
FH in complex with C3b and FI (Figure 6.2B), the program PISA was used to assess the 
surface-accessibility of the FH residues (Table 6.3). By this, 97% FH residues were 
surface-associated and of these, 4%, 5% and 3% were involved in molecular interactions 
with C3b (α-chain), C3b (β -chain) and FI, at SCR-1/4, respectively. In addition, 4% 
residues were buried, and were thus predicted to be involved in structural stabilisation for 
FH. For the FH residues involved in interactions, only those that interact with C3b and FI 
at the N-terminal SCR-1/4 were analysed here. For FH, the 128 aHUS rare missense 
variants mostly affected three types of residues; nine of the 42 surface-inaccessible (or 
buried) residues in 13 case alleles (31%), followed by 89 of the 1045 non-binding surface-
accessible residues (290 case alleles; 28%) and finally nine of the 92 residues at the C3b-
binding interfaces (12 case alleles; 13%). None of the residues at the FI binding interfaces 
were affected. In contrast, for the 19 C3G variants, in addition to these three types 
totalling 2% (one case allele), 3% (26 case alleles) and 5% (five case alleles) respectively, 
two case alleles (6%) within the FI binding interface were now involved. For the C3G 
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dataset of rare missense variants analysed for this chapter, this corresponded to two alleles 
for p.Arg127Cys and p.Arg127His. However, in the literature, a further four alleles for 
C3G were reported for the variant p.Arg127Leu (Dragon-Durey et al., 2004), and this 
may increase the frequency to 18%. In the C3b-FH-FI complex, p.Arg127 was predicted 
by PISA software to form a salt bridge and a hydrogen bond with FI p.Asp438 
(interatomic distance: 2.88 Å). Thus, in the C3b-FH-FI complex, mutation of the FH 
Arg127 residue may lead to decreased FI binding and cofactor activity. This may lead to 
an over-active complement phenotype, which is usually observed for C3G. For the aHUS 
dataset analysed for this thesis chapter, no alleles for the FI binding region of FH were 
reported. However, one aHUS variant (p.Arg166Leu) in this region was reported in the 
literature, for one aHUS allele (Chaudhary et al., 2014). Overall, rare missense variants 
in FH that occurred in the FI binding interface appeared to be more frequent in C3G 
(either two or six alleles; 6% or 18%) than in aHUS (either zero or one allele; 0% or 3%), 
however more statistical analyses are required to verify this. 
 
6.5.4 Disulphide bond disruption is associated with aHUS and C3G 
 
For proteins, the disruption of a structural disulphide bond often leads to LoF via 
protein misfolding and lower levels of the protein in plasma. For the SCR domains in FH, 
MCP and FB, all the Cys residues were involved in disulphide bridges. Thus, for FH, 80 
Cys residues are involved in 40 essential disulphide bonds that stabilise the SCR domains 
(Figure 6.1).  
 
For FH, the frequency of Cys-affecting rare missense variation for both aHUS 
(0.512%) and C3G (0.451%) was significantly greater than for ExAC (0.009%; both 
p<0.0001) (Table 6.4). For aHUS, the 21 affected Cys residues were randomly distributed 
in FH. For C3G, the three affected Cys FH residues were also affected by aHUS (residues 
431, 915 and 1218) which suggested that the structural defect of disulphide bridge 
disruption in FH in SCR-7, SCR-15 and SCR-20 was common to both the aHUS and C3G 
phenotypes. For FH, such disulphide bond disruption would lead to misfolding of the 
SCR domain, which causes poor secretion or a short half-life (Wagner et al., 2016). 
Interestingly, for ExAC, nine FH alleles harboured a Cys-affecting missense rare variant, 
however the overall frequency of these for the dataset (0.009%) was very low. For these 
ExAC variants, the individuals harbouring them must possess a combination of genetic 
or environmental factors that had so far protected them from aHUS or C3G, which lowers 
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their penetrance (Chen et al., 2016). An example of such genetic factors is the complotype 
(Heurich et al., 2011). 
 
For C3, ten structural disulphide bonds were present in its most recent structure 
(Xue et al., 2017). Of interest for C3, only the C3G dataset contained rare missense 
variation that affected disulphide bond-forming Cys residues. This corresponded to the 
variant p.Cys1518Arg, which was predicted to disrupt the disulphide bond with 
p.Cys1590 in the C345C domain. The variant p.Cys1518Arg was previously found in a 
patient with severe C3 deficiency and predicted to cause a LoF for C3. This may lead to 
either the retention of C3 in the ER or C3 with a misfolded C345C domain. However, 
C3G is associated with over-activation of complement and therefore a GoF phenotype in 
the activator C3. Thus, either p.Cys1518Arg is not truly associated with C3G, or the 
breaking of the disulphide bridge with p.Cys1590 is beneficial for a catalytic or 
allosteric C3 event which enhances C3 function. This may be related to the formation 
of the C3 convertase which is mediated by C3 C345C binding to FB (Forneris et al., 
2010). By this, despite that p.Cys1518Arg does not map to the C3b-FB binding site, it 
may enable greater flexibility within the C345C domain for FB binding (Figure 6.3). 
For the C345C domain, this may indicate a novel structural mechanism that enables 
C3b-FB binding for the formation of C3 convertase complexes. aHUS was not 
associated with disulphide bridge disruption in C3 (Table 6.4), as expected. 
 
207 
 
Chapter Seven 
 
Conclusions – new findings on 
complement genetics and protein 
structures
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7.1 Prologue 
 
7.1.1 Overview of complement function and the role of FH 
 
Complement is an evolutionarily ancient inflammatory pathway that provides 
rapid protection from pathogens. The AP of complement is spontaneously activated at 
low levels in order to provide a tick-over mechanism of protection. Due to the broad 
specificity of activated C3b for any nucleophilic surface, host cell surfaces require 
continuous protection from complement activation, whilst pathogens remain targeted. In 
healthy individuals, this is achieved by a fine balance between the activator and regulator 
components which includes host cell-bound regulators (Chapter 1, Section 1.6). For the 
AP, factor H (FH) is the main inhibitor of C3 activation (Rodriguez de Cordoba et al., 
2004) and works with or alongside the two other regulators FI and MCP to regulate the 
activators FB and properdin. Specifically, FH regulates the AP by providing cofactor 
activity for the FI-mediated degradation of C3b, DAA for the dissociation of the C3 and 
C5 convertases and by blocking the formation of the C3 convertases. In order to provide 
such regulation at host cell surfaces, FH recognises surface poly-anions such as sialic acid 
and glycosaminoglycans. The N-terminal SCR-1/4 domains interact with C3b and FI 
for decay-accelerating and cofactor activity. The last two C-terminal domains, SCR-
19 and SCR-20, interact with the C3b TED and the host surface thereby mediating self-
recognition and protection. This self-cell specificity depends on the simultaneous 
binding of SCR-19/20 to host cell surface polyanionic markers and C3b (Schmidt et al., 
2013). In addition, the FHR 1-5 proteins support FH cofactor activity as well as additional 
complement regulatory activities, but can also compete with FH for C3b binding (Chapter 
1, Section 1.6.1). 
 
7.1.2 Complement genetic variants in disease 
 
Genetic variants in the complement AP can lead to a range of disease phenotypes, 
from ultra-rare, sudden and severe, to more common, chronic and progressive. Such 
variants affect the levels and/or the biochemical function of the complement proteins. For 
genetic variants that lead to changes in the protein, their locations in different types of 
functional sites will typically have different consequences. For example, residues 
involved in molecular interactions are mainly surface-associated whereas residues 
involved in structural stabilisation are typically buried or surface-associated (Chapter 2, 
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Section 2.4). For genetic diseases, characterisation of the genotype-phenotype 
relationship allows predisposing, risk and protective factors to be identified. When the 
structure of a protein is known, the impact of the genetic variant on protein function and 
the genotype-phenotype relationship can be much better understood. For patients with 
genetic disease, this can be essential for predicting the disease outcome, prescribing 
treatments and developing new therapies. 
 
aHUS and C3G are two ultra-rare severe diseases that are associated with 
dysregulation and over-activation of the complement AP. In aHUS, an immune insult 
triggers complement activation, primarily by the AP, which cannot be properly controlled 
due to either underlying genetic defects (~60% aHUS cases) or acquired factors such as 
FH auto-antibodies (5-13% aHUS cases) (Chapter 2, Section 2.11). This leads to 
endothelial cell attack and microvasculature occlusion (Caprioli et al., 2006), which 
results in organ damage to the kidneys, gastrointestinal tract, liver, pancreas and brain. In 
C3G, uncontrolled complement activation, from either underlying genetic complement 
variants (~20%) or acquired auto-antibodies such as C3Nef (~80%), leads to deposits of 
C3 and its fragments within the kidney glomerulus and its damage (Chapter 2, Section 
2.11). In contrast, AMD is a common, progressive eye disease which affects ~50 million 
people across the world and is the leading cause of blindness in developed countries 
(Clark et al., 2014). In AMD, polymorphous debris known as drusen are deposited 
between the RPE and Bruch’s membrane. Similar to aHUS and C3G, complement genetic 
variants are thought to increase AMD risk by affecting the functionalities or circulating 
levels of the complement system, such as FH (Chapter 1, Section 1.7.3). 
 
For patients with genetic disease, new genetic variants are continuously being 
identified due to the onset of more rapid next generation sequencing and advanced 
computing methods. The current challenge for researchers of genetic diseases is to 
separate disease-associated genetic variants from the broader background of variants 
present in all human genomes that are rare, potentially functional, but not pathogenic for 
the disease (Vieira-Martins et al., 2016). This was one major question addressed in this 
thesis (Chapters 4, 5 and 6). For each variant, this may be achieved by using a 
combination of familial segregation analyses, statistical analyses, which are based on the 
frequencies of variants in disease and reference populations, functional assays, structural 
biology and in silico predictive analyses. Background variation can be well represented, 
with caveats, by reference datasets sourced from large sequencing projects such as the 
210 
 
ExAC (Lek et al., 2016), the 1000GP (Genomes Project et al., 2010) and the EVS (Fu et 
al., 2013; Tennessen et al., 2012). For genetic variants, as their (allele) frequency in the 
general (reference) population increases, their pathogenicity generally decreases 
(Kobayashi et al., 2017) (Section 2.4.3). Thus, a variant expected to be causative for a 
rare disease, such as aHUS or C3G, will not be frequent in unselected individuals without 
the disease. On the other hand, disease-risk alleles that are common in the general 
population, such as CFH p.Tyr402His, often show minimal effects on overall 
reproductive fitness. Common diseases such as AMD are often complex, and are thought 
to comprise either many common variants of small effect sizes which are not fully 
identified by underpowered GWAS (“common disease, common variant”), rare variants 
(“common disease, rare variant”) (Wagner, 2013) and/or further environmental factors. 
Overall, AF data is essential for assessing variant pathogenicity, especially for rare 
diseases (Sections 2.8.2, 2.8.3 and 2.9), and can be used to statistically verify disease-
gene associations such as for statistical burden testing (Section 2.10).  
 
Prior to the work presented in this PhD thesis, in order to analyse genetic variants 
identified in aHUS and other complement diseases, an interactive FH-HUS web-database 
(http://www.fh-hus.org) was set up at University College London in 2006 for both 
clinicians and researchers (Saunders et al., 2007; Saunders et al., 2006; Saunders & 
Perkins, 2006) (http://www.fh-hus.org). By 2014, there were 193 CFH, 130 CFI, 86 
CD46 and 64 C3 variants for aHUS and other complement diseases (Rodriguez et al., 
2014). However, major omissions from the 2006 FH-HUS database included not only 
new complement genes and variants associated with aHUS and related complement 
diseases, but also the inclusion of variant AF data. Thus, I created a new Database of 
Complement Gene Variants (Chapter 4) which incorporated these new variant and AF 
data, and used this to verify the association of RVs in the complement and related genes 
with aHUS and C3G. 
 
7.2 Statistical validation of rare complement variants provides insights on the 
molecular basis of atypical haemolytic uraemic syndrome and C3 glomerulopathy 
 
aHUS and C3G are two ultra-rare severe diseases that are associated with 
dysregulation and over-activation of the complement alternative pathway. Typically, 
gene analysis for aHUS and C3G is undertaken in small patient numbers, yet it is unclear 
which genes most frequently predispose to aHUS or C3G. Accordingly, in this PhD thesis 
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(Chapter 4), I performed a six-centre analysis of 610 rare genetic variants in 13 mostly 
complement genes (CFH, CFI, CD46, C3, CFB, CFHR1, CFHR3, CFHR4, CFHR5, 
CFP, PLG, DGKE, and THBD) from >3500 patients with aHUS and C3G. This reported 
371 novel rare variants for aHUS and 82 for C3G. My new interactive Database of 
Complement Gene Variants (http://www.complement-db.org) was used to extract allele 
frequency data for these 13 genes using the ExAC server as the reference genome. For 
aHUS, significantly more protein-altering rare variation was found in five genes CFH, 
CFI, CD46, C3 and DGKE than in ExAC (allele frequency <0.01%), thus correlating 
these with aHUS. For C3G, an association was only found for rare variants in C3 and the 
N-terminal C3b-binding or C-terminal non-surface-associated regions of CFH. In 
conclusion, the RV analyses showed non-random distributions over the affected proteins, 
and different distributions were observed between aHUS and C3G that clarify their 
phenotypes. Importantly, these results were able to explain how changes in the same 
biochemical pathway and/or proteins result in the different pathologies observed with 
aHUS and C3G, which was not clear before. Furthermore, this work has reduced the 
earlier knowledge gap in the genetics and genotype-phenotype correlations of C3G to 
bring these closer to that of aHUS (Goodship et al., 2017). 
 
7.2.1 The Database of Complement Gene Variants and future work 
 
In summary, the new Database of Complement Gene Variants 
(http://www.complement-db.org) enhances understanding of rare genetic variants in 
aHUS and C3G for clinical applications (Figure 7.1). Improvements include the use of an 
ExAC AF cut-off in the search tools (Figure 7.2), the display of AF data for the disease 
and references datasets (Figure 7.3), predictive comparisons of wild-type and mutant 
amino acids, in silico analyses using PolyPhen-2 and SIFT (Figure 7.4), examination of 
evolution-conserved residues across species, and correlations with functional binding 
sites. These tools enable clinicians to assess RVs in disease, for example, to investigate 
which variants within these genes conferred predisposition to aHUS and C3G, and to 
identify mutational hotspots within these protein structures. This can be especially useful 
for variants of uncertain significance for which no experimental data currently exists. 
Through the use of AFs and burden testing in the database, the new database informs 
patient management by enabling clinical immunologists to interpret new variants in terms 
of their associations with aHUS and C3G (Chapter 4). 
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Figure 7.1 Screenshot of the Database of Complement Gene Variants homepage. The 
design is based on the European Association for Haemophilia and Allied Disorders 
coagulation Factor IX web-database (http://www.factorix.org/) (Rallapalli et al., 2013).
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Figure 7.2 Screenshot of the Advanced Search tools in the Database of Complement 
Gene Variants. For searching the database for variant data, the search terms can now 
include the type of condition, the number of variants per case and the Exome Aggregation 
Consortium (ExAC) allele frequency cut-off value for filtering based on a reference allele 
frequency. 
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Figure 7.3 Screenshot of the Search Results web-page in the Database of 
Complement Gene Variants. For the complement factor H (CFH) variant, c.1949G>T 
p.650Val, its allele frequency for each of atypical haemolytic uraemic syndrome (aHUS), 
C3 glomerulopathy (C3G), The 1000 Genomes Project (1000GP), Exome Aggregation 
Consortium (ExAC) and Exome Variant Server (EVS) are displayed. For the ExAC, these 
allele frequencies are further categorised by ethnicity. Also provided are links to the 
variant in the databases of single nucleotide polymorphisms (dbSNP) and ClinVar.
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Figure 7.4 Screenshot of the In-Depth Variant Analysis web-page in the Database of 
Complement Gene Variants. In order to assess the structural and functional implications 
of a genetic variant in the database, this web-page does the following: the wild-type and 
mutated residue properties are compared, results from the in silico predictive tools 
PolyPhen-2, SIFT and Provean are displayed, and the variant is mapped onto the protein 
structure. This is shown for the complement factor H (CFH) variant, c.1949G>T 
p.650Val.
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For the maintenance of the database in the long term, each collaborating group 
will provide an annual data update as a spreadsheet that will be automatically uploaded 
to the database with automated duplication and error checks that are programmed into the 
MySQL backend. As an open resource, other clinical centres are invited to upload 
formatted data updates through the curator. This will allow the continuing addition of new 
variants seen in the 13 complement and related genes of the original study (Chapter 4).  
 
In addition, these clinical data can be extended to include other diseases of the 
complement system, most notably AMD, in order to better predict the outcome of disease 
variants. For example, a new sequencing study this year based on 866 aHUS/C3G and 
697 AMD patients from the Nijmegen clinical centre (Geerlings et al., 2018) shows that 
the extension to AMD patients is feasible.  
 
Reference genomic data, such as the ExAC, provide the baseline for assessing the 
significance of the genetic variants by referencing these to normal populations of variants. 
In the future, new variant data from the UK’s ongoing 100,000 Genomes Project, for both 
reference and renal disease datasets, may be incorporated into the database in order to 
monitor the statistical associations of variants with aHUS and C3G. These analyses may 
also be extended to other complement diseases such as AMD.  
 
For clinicians, in order to improve the understanding of the molecular basis of the 
complement protein defects, more accurate computational predictive tools that 
incorporate molecular dynamics simulations can be developed. This will provide 
clinicians with a rapid, informative and explorative view of the effect of missense variants 
on the complement proteins, and output the result in terms of a loss or a gain of function 
prediction.  
 
7.3 Two distinct conformations of factor H regulate discrete complement-
binding functions in the fluid phase and at cell surfaces 
 
FH is the major regulator of C3b in the alternative pathway of the complement 
system in immunity. FH comprises 20 SCR domains, including eight glycans, and its 
Tyr402His polymorphism predisposes those who carry it for AMD. Biologically, given 
that the plasma concentration of FH is around 0.7 mg/ml (Perkins et al., 2010a), and AUC 
had demonstrated that FH forms oligomers (Nan et al., 2008a), reversible dimers and 
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trimers of FH are expected to form in vivo (Osborne et al., 2018b). The resulting 
clustering of FH on cell surfaces, when bound to surface markers and C3b/C3d, is likely 
to enable broader surface protection, thus being functionally significant (Ferreira et al., 
2010). However, the accumulation of FH by clustering may also relate to the formation 
of soft drusen in AMD via chronic inflammation. In this PhD thesis, to better understand 
FH complement binding and self-association, the atomistic solution structures of both the 
His402 and Tyr402 FH allotypes were determined (Chapter 5).  
 
Previously, in prior experimental work (Osborne et al., 2018b), analytical 
ultracentrifugation revealed that up to 12% of both FH allotypes self-associate, and this 
was confirmed by SAXS, mass spectrometry and SPR analyses. SAXS showed that 
monomeric FH has a radius of gyration Rg of 7.2-7.8 nm and a length of 25 nm. Thus, 
for this thesis, in order to model the monomeric FH structure, it was necessary for me to 
firstly extrapolate the scattering curves to zero concentration (Chapter 5). 
 
Prior to this PhD thesis, preliminary molecular modelling of SAXS curves using 
an older technology based on conformational randomisation of the inter-SCR linkers 
revealed that full-length FH in solution has a folded-back SCR structure that is affected 
by ionic strength (Aslam & Perkins, 2001; Nan et al., 2010; Okemefuna et al., 2009).  
 
For my work for this PhD thesis, starting from known structures for 17 SCR 
domains and eight glycans, the SAXS data were fitted using Monte Carlo methods to 
generate physically-realistic atomistic structures for monomeric FH (Chapter 5). 
Compared to previous, the FH modelling here is much improved by starting from 17 high 
resolution SCR structures (Figure 5.1; Table 5.1) (Hocking et al., 2008; Okemefuna et 
al., 2009; Schmidt et al., 2010; Wu et al., 2009) and utilising a much improved Monte 
Carlo and energy minimisation atomistic modelling method for the full-length FH 
structure (Perkins et al., 2016), including the eight FH glycan chains. The analysis of 
29,715 physically realistic but randomised FH conformations resulted in 100 similar best-
fit FH structures for each allotype. Two distinct molecular structures resulted that showed 
either an extended N-terminal domain arrangement with a folded-back C-terminus, or an 
extended C-terminus and folded-back N-terminus. These two molecular structures are the 
most accurate to date for glycosylated full-length FH. To clarify FH functional roles in 
host protection, crystal structures for the FH complexes with C3b and C3dg suggested 
that the extended N-terminal conformation accounted for C3b fluid phase regulation, the 
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extended C-terminal conformation accounted for C3d binding, and both conformations 
accounted for bivalent FH binding to anionic glycosaminoglycans on the target cell 
surface (Chapter 5, Figure 5.8). By this, FH with an N-terminal extended conformation 
appeared to be able to both dismantle fluid phase C3 convertases and perform cofactor 
activity. On the other hand, FH with a distinct C-terminal extended conformation will 
have increased affinity for binding to cell surfaces via both heparin (SCR-20) and 
deposited C3d (SCR-19) for enhanced local protection from complement activation. This 
is because the presence of C3d on the cell surface may increase the affinity of FH in the 
correct conformation for cell surface binding (Kajander et al., 2011). For this C-terminal 
extended FH structure, following its binding to cell surfaces, a conformational change 
involving the flexible linkers between SCR-4/5 and SCR-5/6 would allow SCR-1/4 to 
bind C3b. By this, FH attached to host cell surfaces can then also perform either cofactor 
activity (inactivation of C3b to iC3b) or DAA (separate C3b from Bb in the C3 convertase 
complex). Overall, by elucidating the conformational states of full-length FH and its 
structural interactions with C3b, FI and C3dg, the molecular basis for inflammatory 
processes has become better understood. This is relevant for the interpretation of 
complement genetic variants identified in inflammatory diseases such as AMD, and also 
aHUS and C3G. In addition, for the AMD-risk p.Tyr402His variant, the two FH Tyr402 
and His402 allotypes displayed the same solution structures, thus the overall domain 
arrangement of FH was unaffected (Chapter 5, Section 5.4.3). This result is consistent 
with its common AF, and also the common frequency of AMD, for which only a subtle 
effect is expected. 
 
7.3.1 Stoichiometry of FH and C3b complexes and future FH work 
 
For the modelling of FH undertaken for this PhD thesis (Chapter 5), both of the 
resulting full-length solution-state FH models showed that SCR-1/4 and SCR-19 were too 
far apart to bind the same C3b molecule. This section (7.3.1) aims to put this result into 
context with the literature. In 2008, by using functional site mapping studies, FH SCR-
1/4 and SCR-19/20 were proposed to bind either the same C3b or two different C3b 
molecules (Schmidt et al., 2008). Following this, two structural studies concluded that 
they bind to either the same C3b molecule (Morgan et al., 2011) or two different C3b and 
C3d molecules (Kajander et al., 2011). The first study involved merging their C3d:SCR-
19/20 crystal complex (PDB code: 3OXU) with an existing C3b:SCR-1/4 structure (Wu 
et al., 2009) and its concatenation to SCR-6/8 and SAXS-derived envelopes (Morgan et 
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al., 2011). The resulting full-length FH model was constructed by juxtaposition or 
superposition of the structures of SCR-5 and SCR-6/8 and the SAXS-shape envelopes of 
SCR-8/15 and SCR-15/19. This FH model was not subject to molecular dynamics or 
energy minimisation procedures. For the latter study, the crystal structure of SCR-
19/20:C3d2 showed that FH binding to two C3b molecules was sterically impossible, but 
that SCR-19/20 can simultaneously bind to C3b (the C3d part) and C3d (Kajander et al., 
2011). The bidentate binding of C3b by SCR-19 (C3d part) and SCR-1/4 (via aNT, MG7, 
MG6, MG2, CUB, TED or C3d) (Wu et al., 2009) was proposed to enhance both the 
avidity and activity of FH, and SCR-20 was able to bind an earlier deposited C3d 
(Kajander et al., 2011). In 2017, another study of the crystal structure of the SCR-19/20, 
C3dg and OspE complex showed SCR-19 binding to C3dg (of either C3b or C3d) and 
SCR-20 binding to OspE. For SCR-20, in the absence of OspE, it may also bind another 
C3d (Kajander et al., 2011). Following these studies, both X-ray crystallography and 
SAXS were employed for the structural characterisation of SCR-18/20. The SAXS 
concluded that under solution conditions SCR-18/20 adopts multiple conformations 
mediated by the flexible linker between SCR-18 and SCR-19 (Morgan et al., 2012) (PDB 
code: 3SW0). In 2013, a mini-FH construct consisting of SCR-1/4 and SCR-19/20 bound 
together by a 12 glycine residue linker was engineered as a novel therapeutic agent 
(Schmidt et al., 2013). The structural model of the C3b:mini-FH complex was 
computationally constructed by superimposing the TED/C3d domain of the C3b:FH1-4 
(PDB code: 2WII) (Wu et al., 2009) and C3d:FH19-20 (PDB code: 3OXU) (Morgan et 
al., 2011) complex structures via alignment of the common TED in C3b and C3d. The 
resulting model of the tertiary complex revealed that the two FH fragments were in a 
close proximity (Schmidt et al., 2013). In 2017, in another study, this mini-FH construct 
(SCR-1/4 and SCR-19/20) was co-crystallised with one C3b molecule and FI. The 
resulting mini-FH-FI-C3b complex revealed how FI generates the late-stage opsonins 
iC3b or C3dg by its cleavage activities. In this model of FH, SCR-19 binds to the TED of 
the shared C3b molecule (Xue et al., 2017) (PDB code: 5O32). 
 
In summary, most crystal structures of FH in complex with C3b show both SCR-
1/4 and SCR-19 binding to the same C3b molecule. Despite the high-resolution of X-ray 
crystallography for the structures of the FH fragments, the binding of glycosylated full-
length FH to C3b had not been considered. Thus, the 1:1 C3b:FH model deduced from 
X-ray crystallography studies above may lack physiological relevance. In addition, the 
resulting full–length FH models do not use molecular dynamics or energy minimisation 
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procedures to either find physically plausible structures or statistically validate their 
modelling results. Furthermore, in the two most recent studies using the mini-FH 
construct, the ends of the modelled FH SCR-1/4 and SCR-19/20 fragments are artificially 
held together by 12 glycine residues.  
 
In this PhD thesis, for both of the resulting full-length solution-state FH models, 
SCR-1/4 and SCR-19 are too far apart to bind the same C3b molecule (Chapter 5, Figure 
5.8). By capturing full-length glycosylated FH in solution, the experimental conditions of 
the previous SAXS set up are more physiologically relevant. Thus, despite the lower 
resolution of SAXS when compared to X-ray crystallography, when combined with 
atomistic molecular modelling in this thesis, this allowed the flexibility of FH to be 
studied, and the molecular modelling identified an ensemble of physically plausible, 
energetically stable models that well fitted the SAXS data. However, further experimental 
studies are required to validate the outcome of the two major structural conformations of 
FH. 
 
Overall, in order to verify the full-length structures of FH and the stoichiometry 
of the FH:C3b complex, further experiments using solution-based techniques such as SPR 
are required. For example, by using SPR, the binding of FH to C3b can be monitored, and 
the resulting data can be fitted to a binding model. In addition, the use of cryo-EM 
techniques may allow FH-C3b complexes, with full-length and glycosylated FH, to be 
observed directly in multiple conformations in their native environment at near atomic 
resolution. For cryo-EM, in order to reconstruct the 3D volume, complicated post-
processing involving classifying, aligning and averaging by using statistics is required. 
However, compared to SAXS which is fast and easy but of lower resolution, a cryo-EM 
experiment yields a higher resolution 3D density map (Kim et al., 2017), which will help 
to verify the stoichiometry of the FH-C3b complex. These future projects will help to 
elucidate the impact of disease variants on the functioning of the FH-C3b complex, and 
facilitate the development of disease therapies that target the disease variants.  
 
7.4 Structural analyses rationalise the distribution of aHUS and C3G rare 
variants in complement factor H 
 
The aim of Chapter 6 was to bring together the aHUS and C3G RV analyses from 
Chapter 4 and the FH modelling from Chapter 5 in order to identify whether the structural 
221 
 
location of a complement variant may predict the occurrence of aHUS or C3G in patients. 
For genetic variants that lead to changes in the protein, their locations in different types 
of functional sites will typically have different consequences. Thus, residues involved in 
molecular interactions are mainly surface-associated whereas residues involved in 
structural stabilisation are typically buried or surface-associated (Chapter 2, Section 2.4). 
The disruption of a structural disulphide bond often leads to LoF via protein misfolding. 
These LoF events can be predicted by the presence of rare missense variants in disulphide 
bond-forming Cys residues. The SCR domain is one of the most abundant domains in the 
complement proteins, occurring in FH, MCP and FB, and is structurally stabilised by two 
disulphide bridges formed by two pairs of conserved Cys residues (Chapter 3, Section 
3.3.8). Previously, for the SCR consensus domain for FH and MCP, the hypervariable 
loop was suggested to have an association with AMD, aHUS and C3G disease variants 
(Rodriguez et al., 2014). 
 
For Chapter 6, the structural basis for the effect of predisposing variants for aHUS 
and C3G were reviewed by predicting their structural and functional impacts. For aHUS 
and C3G, the most common variants were non-truncating, missense changes in the 
regulators FH, FI and MCP, and the activators C3 and FB (Chapter 4, Figure 4.3). In 
Chapter 6, their molecular correlations with aHUS and C3G were assessed by mapping 
the variants onto three-dimensional structures for the FH-C3b-FI, FH-C3dg and C3b-FB 
complexes and full-length FH. The 128 aHUS rare missense variants in FH mostly 
affected three types of residues, namely 13 case alleles in the 42 buried residues (31%), 
followed by 290 case alleles in the 1045 non-binding surface-accessible residues (28%), 
and finally 12 case alleles in the 92 residues at C3b-binding interfaces (13%), but none 
were found at the FI interfaces. In contrast, for 19 C3G variants in FH, these three types 
of residues totalled 2% (one case allele), 3% (26 case alleles) and 5% (five case alleles) 
respectively, and two case alleles (6%) within the FI binding interface were now involved. 
Another prominent group of variants involve Cys residues involved in disulphide bridges. 
Only those in the regulators FH, MCP and FI were associated with aHUS, while only 
those in FH and C3 were associated with C3G, when these were compared to the ExAC 
reference dataset. In conclusion, these differences between aHUS and C3G reflect their 
different pathologies, and importantly indicate that the structural location of a newly-
discovered variant may predict the occurrence of aHUS or C3G in patients. 
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7.4.1 Future work 
 
In future work, these residue type analyses could be extended to the other 
complement proteins that have high frequencies of rare missense variants for aHUS and 
C3G. These are C3, FI, MCP and FB, in their respective regulatory or activating 
complement complexes. In order to correlate rare missense variants that predispose for 
aHUS and C3G with different structural functions, their effects on protein stability could 
be analysed in more detail by using free energy change calculations and statistics. These 
analyses could also be extended to new rare missense variant data for AMD patients. 
Following comparisons with aHUS and C3G, novel insights into the differences between 
the molecular bases of the three inflammatory diseases may be identified.
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Appendix I. Rare variants classified as ‘benign’ or ‘likely benign’ with their allele frequency and functional details (continues overleaf) 
Gene Variant Protein level 
 Allele frequency (%)  
Function reference In silico: PolyPhen-2 In silico: SIFT Class 
 aHUS C3G  ExAC 1000GP EVS  
C3 c.-3_-2dupAC -  0.02 0.13 0.88 0.22 0  - - - Likely benign 
C3 c.463A>C p.Lys155Gln  0.37 0.13 0.34 0.04 0.29  - Benign, neutral Tolerated, neutral Likely benign 
C3 c.696C>T p.Phe232Phe  0.02 0 0 0 0  - - Tolerated, neutral Likely benign 
C3 c.975C>T p.Tyr325Tyr  0.02 0 0 0 0  - - Tolerated, neutral Likely benign 
C3 c.1146T>C p.Ser382Ser  0 0.26 0.001 0 0  - - Tolerated, neutral Likely benign 
C3 c.1650C>T p.Ser550Ser  0 0.13 0.01 0 0.02  - - Tolerated, neutral Likely benign 
C3 c.1758G>A p.Glu586Glu  0.02 0 0 0 0  - - Tolerated, neutral Likely benign 
C3 c.2190C>T p.Tyr730Tyr  0 0.26 0.04 0.04 0.05  - - Tolerated, neutral Likely benign 
C3 c.2203C>T p.Arg735Trp  0.22 0.26 0.21 0.08 0.26  Fremeaux-Bacchi et al, 2008 Probably damaging, deleterious Damaging, deleterious Benign 
C3 c.2901C>T p.Leu967Leu  0.02 0 0.20 0.08 0.19  Clinvar - Tolerated, neutral Likely benign 
C3 c.3671G>A p.Gly1224Asp  0.04 0 0.18 0.76 0.70  Clinvar Benign, neutral Tolerated, deleterious Likely benign 
C3 c.4645C>A p.Leu1549Met  0.02 0 0.12 0.40 0.34  Clinvar Possibly damaging, deleterious Damaging, neutral Likely benign 
C3 c.4827C>T p.Ser1609Ser  0.02 0 0.01 0 0.01  - - Tolerated, neutral Likely benign 
C3 c.4855A>C p.Ser1619Arg  0.20 0.13 0.11 0.04 0.22  Clinvar Possibly damaging, deleterious Tolerated, neutral Likely benign 
CD46 c.38C>T p.Ser13Phe  0.09 0 0.50 0.86 0.15  - Probably damaging, deleterious Tolerated, neutral Likely benign 
CD46 c.66G>A p.Ala22Ala  0 0.12 0 0 0  - - Tolerated, neutral Likely benign 
CD46 c.796G>A p.Asp266Asn  0.03 0 0.12 0.44 0.42  - Benign, neutral Tolerated, neutral Likely benign 
CFB c.1524C>T p.His508His  0.04 0 0.31 0.18 0.20  - - Tolerated, neutral Likely benign 
CFH c.172T>G p.Ser58Ala  0.06 0 0.01 0.02 0.02  Merinero et al, 2017 Benign, neutral Tolerated, neutral Benign 
CFH c.849A>G p.Lys283Lys  0.02 0 0 0 0  - - Tolerated, neutral Likely benign 
CFH c.1707C>T p.Cys569Cys  0.02 0 0.04 0.06 0.19  - - Tolerated, neutral Likely benign 
CFH c.1824C>T p.Ser608Ser  0.02 0 0.01 0.02 0.01  - - Tolerated, neutral Likely benign 
CFH c.1949G>T p.Gly650Val  0.02 0.11 0.02 0.04 0.02  - Benign, neutral Tolerated, neutral Likely benign 
CFH c.2468T>C p.Met823Thr  0.02 0 0 0 0  Merinero et al, 2017 Possibly damaging, deleterious Damaging, deleterious Benign 
CFH c.2509G>A p.Val837Ile  0.02 0 0.13 0.34 0  Clinvar Benign, neutral Tolerated, neutral Likely benign 
CFH c.2850G>T p.Gln950His  0.37 0.45 0.36 0.16 0.44  Clinvar Possibly damaging, deleterious Damaging, deleterious Likely benign 
CFH c.2867C>T p.Thr956Met  0.14 0.56 0.12 0.12 0.12  Merinero et al, 2017 Probably damaging, deleterious Tolerated, neutral Benign 
CFH c.3050C>T p.Thr1017Ile  0.03 0.34 0.12 0.30 0.52  Clinvar Possibly damaging, deleterious Damaging, neutral Likely benign 
CFH c.3172T>C p.Tyr1058His  0.29 0.11 0 0.14 0  - Benign, neutral Tolerated, neutral Likely benign 
CFH c.3178G>C p.Val1060Leu  0.26 0 0 0 0  - Benign, neutral Tolerated, neutral Likely benign 
CFH c.3207T>C p.Ser1069Ser  0 0.11 0.10 0.18 0.17  - - Tolerated, neutral Likely benign 
CFHR5 c.329T>C p.Val110Ala  0.16 0 0.21 0.38 0.01  - - Damaging, deleterious Likely benign 
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Appendix I. (continued) Rare variants classified as ‘benign’ or ‘likely benign’ with their allele frequency and functional details 
Gene Variant Protein level 
 Allele frequency (%)  
Function reference In silico: PolyPhen-2 In silico: SIFT Class 
 aHUS C3G  ExAC 1000GP EVS  
CFHR5 c.432A>T p.Lys144Asn  0.16 0 0.12 0.12 0.07  - - Tolerated, neutral Likely benign 
CFHR5 c.832G>A p.Gly278Ser  0.32 0.48 0.73 0.36 0.69  - - Damaging, deleterious Likely benign 
CFHR5 c.1586T>G p.Leu529Arg  0 0.96 0.11 0.26 0.51  - - Tolerated, deleterious Likely benign 
CFI c.608C>T p.Thr203Ile  0.05 0.12 0.05 0.04 0.05  - Benign, neutral Tolerated, neutral Likely benign 
CFI c.782G>A p.Gly261Asp  0.22 0 0.13 0.04 0.17  Fremeaux-Bacchi et al, 2013 Benign, neutral Tolerated, neutral Likely benign 
CFI c.916A>G p.Ile306Val  0.03 0 0.05 0.12 0.15  - Benign, neutral Tolerated, neutral Likely benign 
CFI c.1322A>G p.Lys441Arg  0.21 0.37 0.34 0.12 0.36  Clinvar Benign, neutral Tolerated, neutral Likely benign 
CFI c.1657C>T p.Pro553Ser  0.15 0.12 0.13 0.04 0.14  Fremeaux-Bacchi et al, 2013 Benign, neutral Tolerated, deleterious Likely benign 
CFI c.*144T>C -  0.02 0 0.27 0 0  Clinvar - - Likely benign 
CFI c.*7G>T -  0 0.12 0.27 0 0.78  - - - Likely benign 
DGKE c.35C>T p.Pro12Leu  0.21 0 0.49 0.20 0.56  - Benign, neutral Damaging, neutral Likely benign 
DGKE c.1679A>G p.Gln560Arg  0 0.39 0.20 0.08 0.18  - Benign, neutral Tolerated, neutral Likely benign 
PLG c.112A>G p.Lys38Glu  0 0.48 0.33 0.22 0.43  - - Damaging, neutral Likely benign 
PLG c.266G>A p.Arg89Lys  0.35 0.48 0.66 0.18 0.80  - Benign, neutral Tolerated, neutral Likely benign 
PLG c.1259G>A p.Gly420Asp  0 0.96 0.19 0.08 0.15  - - Tolerated, neutral Likely benign 
PLG c.1469G>A p.Arg490Gln  0.52 0.48 0.12 0.08 0.19  - Probably damaging, deleterious Damaging, deleterious Likely benign 
PLG c.1481C>T p.Ala494Val  0.70 0 0.82 0.90 0.85  - Probably damaging, deleterious Damaging, neutral Likely benign 
THBD c.40G>A p.Gly14Ser  0.04 0.19 0.22 0.68 0.37  Clinvar Benign, neutral Tolerated, neutral Likely benign 
THBD c.939C>A p.Gly313Gly  0 0.19 0 0.02 0  - - Tolerated, neutral Likely benign 
THBD c.1437C>T p.Asp479Asp  0.04 0 0 0 0  - - Tolerated, neutral Likely benign 
THBD c.1504G>C p.Gly502Arg  0.04 0 0.23 0.76 0.62  - Possibly damaging, deleterious Tolerated, neutral Likely benign 
THBD c.1536C>G p.Leu512Leu  0.04 0 0 0 0  - - Tolerated, neutral Likely benign 
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Appendix II. The frequency of individuals with a rare variant (RV) out of all individuals screened per gene in the aHUS, C3G and ExAC datasets 
using an AF cut off of 0.01% 
Gene Variant effect 
aHUS  ExAC  C3G 
RVs RV cases All cases Frequency (%) P a RVs RV cases All cases Frequency (%) P b RVs RV cases All cases Frequency (%) 
CFH Protein-altering 193 411 3128 13.14 <0.0001c 342 734 59163 1.24 <0.0001c 22 23 443 5.19 
C3 Protein-altering 64 177 2455 7.21 <0.0001c 448 923 59545 1.55 <0.0001c 24 26 379 6.86 
CD46 Protein-altering 74 219 2942 7.44 <0.0001c 136 240 58338 0.41 0.18 0 0 406 0.00 
CFI Protein-altering 68 98 2923 3.35 <0.0001c 197 382 60289 0.63 0.48 2 2 408 0.49 
DGKE Protein-altering 19 21 703 2.99 <0.0001c 174 273 58439 0.47 0.45 0 0 127 0.00 
THBD Protein-altering 6 7 1328 0.53 0.37 144 247 38602 0.64 0.09 3 4 264 1.52 
CFB Protein-altering 15 22 2457 0.90 0.09 215 382 58732 0.65 0.10 6 5 379 1.32 
PLG Protein-altering 2 2 286 0.70 0.49 251 536 60619 0.88 0.28 2 2 104 1.92 
CFHR5 Protein-altering 2 2 317 0.63 0.42 254 535 59751 0.90 0.50 1 1 104 0.96 
CFH Non-truncating e 129 318 3128 10.17 <0.0001c 334 725 59286 1.22 <0.0001c 17 19 443 4.29 
C3 Non-truncating 59 171 2455 6.97 <0.0001c 436 901 59566 1.51 <0.0001c 20 21 379 5.54 
CFI Non-truncating 55 83 2923 2.84 <0.0001c 179 353 60259 0.59 0.50 2 2 408 0.49 
CD46 Non-truncating 43 99 2942 3.37 <0.0001c 124 214 58634 0.37 0.21 0 0 406 0.00 
DGKE Non-truncating 7 9 703 1.28 <0.006 c 159 247 58385 0.42 0.48 0 0 127 0.00 
CFHR5 Non-truncating 1 1 317 0.32 0.30 211 438 59650 0.73 0.50 1 1 104 0.96 
THBD Non-truncating 6 7 1328 0.53 0.39 138 239 37880 0.63 0.08 3 4 264 1.52 
CFB Non-truncating 15 22 2457 0.90 0.06 197 364 58710 0.62 0.23 5 4 379 1.06 
PLG Non-truncating 2 2 286 0.70 0.50 236 519 60632 0.86 0.26 2 2 104 1.92 
CD46 Truncating f 31 125 2942 4.25 <0.0001c 12 26 55275 0.05 0.50 0 0 406 0.00 
CFH Truncating 64 98 3128 3.13 <0.0001c 8 9 54027 0.02 <0.0001c 5 5 443 1.13 
DGKE Truncating 12 18 703 2.56 <0.0001c 15 26 59004 0.04 0.50 0 0 127 0.00 
CFI Truncating 13 16 2923 0.55 <0.0001c 18 29 60583 0.05 0.50 0 0 408 0.00 
C3 Truncating 5 6 2455 0.24 <0.0001c 12 22 58798 0.04 <0.0001c 4 5 379 1.32 
THBD Truncating 0 0 1328 0.00 0.50 6 8 55211 0.02 0.50 0 0 264 0.00 
CFB Truncating 0 0 2457 0.00 0.40 18 18 58973 0.03 <0.0001c 1 1 379 0.26 
PLG Truncating 0 0 286 0.00 0.50 15 17 60408 0.03 0.50 0 0 104 0.00 
CFHR5 Truncating 1 1 317 0.32 0.50 43 97 60244 0.16 0.50 0 0 104 0.00 
a p value after the Chi-Square test (𝜒2) with Yates’ correction (p<0.05 after Bonferroni correction) for aHUS and ExAC 
b p value after the Chi-Square test (𝜒2) with Yates’ correction (p<0.05 after Bonferroni correction) for C3G and ExAC 
c Denotes aHUS or C3G dataset frequency significantly greater than ExAC frequency 
d Denotes ExAC frequency significantly greater than aHUS or C3G dataset frequency 
e Defined as missense or in-frame variant 
f Defined as nonsense, frameshift, or splice acceptor/donor variant
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Appendix III. The frequency of individuals with a rare variant (RVs) out of all individuals screened per gene in the aHUS, C3G and EVS datasets 
using an AF cut off of 0.01% 
Gene Variant effect 
aHUS  EVS  C3G 
RVs RVs cases All cases Frequency (%) P a RVs RVs cases All cases Frequency (%) P b RVs RVs cases All cases Frequency (%) 
CFH Protein-altering 193 411 3128 13.14 <0.0001c 55 55 6503 0.08 <0.0001c 22 23 443 5.19 
C3 Protein-altering 64 177 2455 7.21 <0.0001c 71 71 6503 1.09 <0.0001c 24 26 379 6.86 
CD46 Protein-altering 74 219 2942 7.44 <0.0001c 95 95 6502 1.46 0.18 0 0 406 0.00 
CFI Protein-altering 68 98 2923 3.35 <0.0001c 29 29 6494 0.45 0.48 2 2 408 0.49 
DGKE Protein-altering 19 21 703 2.99 <0.0001c 24 24 6501 0.37 0.45 0 0 127 0.00 
THBD Protein-altering 6 7 1328 0.53 0.28 19 19 6457 0.29 0.0052 3 4 264 1.52 
CFB Protein-altering 15 22 2457 0.90 <0.0001c 5 5 6503 0.08 <0.0001c 6 5 379 1.32 
PLG Protein-altering 2 2 286 0.70 0.89 30 30 6503 0.46 0.16 2 2 104 1.92 
CFHR5 Protein-altering 2 2 317 0.63 0.94 39 39 6502 0.60 0.64 1 1 104 0.96 
CFH Non-truncating e 129 318 3128 10.17 <0.0001c 55 55 6503 0.85 <0.0001c 17 19 443 4.29 
C3 Non-truncating 59 171 2455 6.97 <0.0001c 70 70 6503 1.08 <0.0001c 20 21 379 5.54 
CFI Non-truncating 55 83 2923 2.84 <0.0001c 26 26 6503 0.40 0.78 2 2 408 0.49 
CD46 Non-truncating 43 99 2942 3.37 <0.0001c 92 92 6502 1.41 0.03 0 0 406 0.00 
DGKE Non-truncating 7 9 703 1.28 <0.002c 24 24 6501 0.37 0.49 0 0 127 0.00 
CFHR5 Non-truncating 1 1 317 0.32 0.86 36 36 6503 0.55 0.58 1 1 104 0.96 
THBD Non-truncating 6 7 1328 0.53 0.19 17 17 6467 0.26 0.0026 3 4 264 1.52 
CFB Non-truncating 15 22 2457 0.90 <0.0001c 4 4 6503 0.06 <0.0001c 5 4 379 1.06 
PLG Non-truncating 2 2 286 0.70 0.8934 30 30 6503 0.46 0.1561 2 2 104 1.92 
CD46 Truncating f 31 125 2942 4.25 <0.0001c 3 3 6503 0.05 0.50 0 0 406 0.00 
CFH Truncating 64 98 3128 3.13 <0.0001c 0 0 6503 0 <0.0001c 5 5 443 1.13 
DGKE Truncating 12 18 703 2.56 <0.0001c 0 0 6501 0 0.50 0 0 127 0.00 
CFI Truncating 13 16 2923 0.55 <0.0001c 3 3 6422 0.05 0.50 0 0 408 0.00 
C3 Truncating 5 6 2455 0.24 0.0024 c 1 1 6503 0.02 <0.0001c 4 5 379 1.32 
THBD Truncating 0 0 1328 0.00 0.52 2 2 6373 0.03 0.77 0 0 264 0.00 
CFB Truncating 0 0 2457 0.00 0.54 1 1 6503 0.02 0.23 1 1 379 0.26 
PLG Truncating 0 0 286 0.00 0.84 0 0 6503 0 0.90 0 0 104 0.00 
CFHR5 Truncating 1 1 317 0.32 0.46 3 3 6502 0.05 0.83 0 0 104 0.00 
a p value after the Chi-Square test (𝜒2) with Yates’ correction (p<0.05 after Bonferroni correction) for aHUS and EVS 
b p value after the Chi-Square test (𝜒2) with Yates’ correction (p<0.05 after Bonferroni correction) for C3G and EVS 
c Denotes aHUS or C3G dataset frequency significantly greater than ExAC frequency 
d Denotes EVS frequency significantly greater than aHUS or C3G dataset frequency 
e Defined as missense or in-frame variant 
f Defined as nonsense, frameshift, or splice acceptor/donor variant
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Appendix IV. The total missense rare variant allele frequency for each protein domain, normalised by the proportion of domain residues (continues 
overleaf) 
Protein Domain 
Residues 
(% of total in 
protein) 
aHUS only 
 
C3G only 
RVs common to both aHUS and C3G 
 
Missense 
RVs 
aHUS  C3G 
Missense 
RVs a 
Sum AF b (%) 
Sum AF/ 
residue 
proportion c 
 
Missense 
RVs 
Sum AF 
(%) 
Sum AF/ 
residue 
proportion 
Sum AF 
(%) 
Sum AF/ residue 
proportion 
 
Sum AF 
(%) 
Sum AF/ residue 
proportion 
C3 Signal peptide 22 (1.3) 2 0.08 6.1  0 - - 0 - -  - - 
C3 MG1 103 (6.2) 4 0.35 5.6  0 - - 1 0.02 0.3  0.13 2.1 
C3 MG2 103 (6.2) 10 1.34 21.7  1 0.13 2.1 0 - -  - - 
C3 MG3 122 (7.3) 1 0.02 0.3  2 0.26 3.6 0 - -  - - 
C3 MG4 98 (5.9) 0 - -  1 0.13 2.2 0 - -  - - 
C3 MG5 108 (6.5) 3 0.06 0.9  3 0.40 6.1 0 - -  - - 
C3 MG6b 42 (2.5) 4 0.47 18.5  1 0.26 10.4 0 - -  - - 
C3 LNK 65 (3.9) 0 - -  1 0.26 6.8 2 0.22 5.7  0.40 10.1 
C3 ANA 86 (5.2) 0 - -  0 - - 0 - -  - - 
C3 aNT 17 (1) 0 - -  0 - - 0 - -  - - 
C3 MG6a 59 (3.5) 1 0.06 1.7  2 0.26 7.4 0 - -  - - 
C3 MG7 107 (6.4) 0 - -  1 0.13 2.1 0 - -  - - 
C3 CUBa 54 (3.2) 0 - -  0 - - 0 - -  - - 
C3 TED 302 (18.2) 22 0.73 4.0  2 0.26 1.5 4 0.08 0.4  0.13 0.7 
C3 CUBb 65 (3.9) 2 0.04 1.0  2 0.26 6.8 0 - -  - - 
C3 MG8 139 (8.4) 7 0.14 1.7  2 0.26 3.2 3 0.06 0.7  0.13 1.6 
C3 Anchor 22 (1.3) 1 0.02 1.5  0 - - 0 - -  - - 
C3 C345C 148 (8.9) 0 - -  1 0.13 1.5 0 - -  - - 
MCP Signal peptide 34 (8.9) 3 0.10 1.1  0 - - 0 - -  - - 
MCP SCR1 62 (16.2) 3 0.31 1.9  1 0.12 0.8 0 - -  - - 
MCP SCR2 63 (16.4) 10 0.31 1.9  0 - - 0 - -  - - 
MCP SCR3 66 (17.2) 13 0.49 2.9  0 - - 0 - -  - - 
MCP SCR4 60 (15.7) 11 0.37 2.4  0 - - 0 - -  - - 
MCP Linker 59 (15.4) 4 0.09 0.6  0 - - 0 - -  - - 
MCP TM 23 (6) 0 - -  0 - - 0 - -  - - 
MCP CT 16 (4.2) 1 0.07 1.6  0 - - 0 - -  - - 
FB Signal peptide 25 (3.3) 0 - -  0 - - 0 - -  - - 
FB SCR1 66 (8.8) 0 - -  0 - - 0 - -  - - 
FB SCR2 60 (8) 1 0.02 0.3  1 0.13 1.7 0 - -  - - 
FB SCR3 58 (7.7) 0 - -  0 - - 0 - -  - - 
FB aL 49 (6.5) 0 - -  0 - - 5 0.10 1.5  0.26 4.0 
FB VWFA 200 (26.6) 13 0.43 1.6  2 0.26 1.0 0 - -  - - 
FB SP 295 (39.2) 4 0.08 0.2  3 0.53 1.3 0 - -  - - 
FH Signal peptide 18 (1.6) 2 0.03 2.0  1 0.11 7.1 0 - -  - - 
FH SCR1 60 (5.3) 8 0.29 5.5  1 0.11 2.1 1 0.02 0.3  0.11 2.1 
FH SCR2 57 (5) 1 0.02 0.3  4 0.57 11.3 0 - -  - - 
FH SCR3 60 (5.3) 8 0.21 3.9  2 0.23 4.3 1 0.02 0.3  0.11 2.1 
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Appendix IV. (continued) The total missense rare variant allele frequency for each protein domain, normalised by the proportion of 
domain residues (also continues overleaf) 
Protein Domain 
Residues 
(% of total in 
protein) 
aHUS only 
 
C3G only 
RVs common to both aHUS and C3G 
 
Missense 
RVs 
aHUS  C3G 
Missense 
RVs 
Sum AF b (%) 
Sum AF/ 
residue 
proportion c 
 
Missense 
RVs 
Sum AF 
b (%) 
Sum AF/ 
residue 
proportion c 
Sum AF 
(%) 
Sum AF/ residue 
proportion 
 
Sum AF 
(%) 
Sum AF/ residue 
proportion 
FH SCR4 53 (4.7) 6 0.11 2.4  0 - - 0 - -  - - 
FH SCR5 54 (4.7) 1 0.02 0.3  0 - - 0 - -  - - 
FH SCR6 61 (5.4) 4 0.06 1.2  0 - - 0 - -  - - 
FH SCR7 54 (4.7) 3 0.14 3  0 - - 1 0.02 0.3  0.23 4.8 
FH SCR8 58 (5.1) 1 0.02 0.3  0 - - 0 - -  - - 
FH SCR9 56 (4.9) 6 0.27 5.5  0 - - 0 - -  - - 
FH SCR10 55 (4.8) 5 0.1 2  0 - - 1 0.06 1.3  0.23 4.7 
FH SCR11 55 (4.8) 6 0.14 3  0 - - 0 - -  - - 
FH SCR12 54 (4.7) 1 0.02 0.3  0 - - 0 - -  - - 
FH SCR13 51 (4.5) 1 0.02 0.4  0 - - 0 - -  - - 
FH SCR14 53 (4.7) 8 0.19 4.1  0 - - 1 0.02 0.3  0.11 2.4 
FH SCR15 57 (5) 7 0.13 2.6  1 0.11 2.3 1 0.02 0.3  0.11 2.3 
FH SCR16 54 (4.7) 3 0.10 2.0  0 - - 0 - -  - - 
FH SCR17 55 (4.8) 3 0.06 1.3  0 - - 0 - -  - - 
FH SCR18 55 (4.8) 6 0.30 6.3  2 0.33 4.6 0 - -  - - 
FH SCR19 55 (4.8) 8 0.21 4.3  0 - - 0 - -  - - 
FH SCR20 62 (5.5) 31 2.03 37.2  0 - - 2 0.38 7.1  0.23 4.2 
FHR5 Signal peptide 19 (3.3) 0 - -  0 - - 0 - -  - - 
FHR5 SCR1 61 (10.7) 0 - -  0 - - 0 - -  - - 
FHR5 SCR2 58 (10.2) 0 - -  0 - - 0 - -  - - 
FHR5 SCR3 59 (10.4) 0 - -  0 - - 0 - -  - - 
FHR5 SCR4 59 (10.4) 0 - -  0 - - 0 - -  - - 
FHR5 SCR5 58 (10.2) 0 - -  0 - - 0 - -  - - 
FHR5 SCR6 55 (9.7) 0 - -  0 - - 0 - -  - - 
FHR5 SCR7 58 (10.2) 1 0.16 1.6  1 0.48 4.7 0 - -  - - 
FHR5 SCR8 59 (10.4) 1 0.16 1.5  0 - - 0 - -  - - 
FHR5 SCR9 63 (11.1) 0 - -  0 - - 0 - -  - - 
FI Signal peptide 18 (3.1) 0 - -  0 - - 0 - -  - - 
FI Linker 1 23 (4) 1 0.02 0.4  0 - - 0 - -  - - 
FI FIMAC 66 (11.4) 9 0.24 2.1  1 0.12 1.1 0 - -  - - 
FI SRCR 103 (17.8) 13 0.68 3.8  0 - - 0 - -  - - 
FI LDLR 1 44 (7.6) 6 0.12 1.6  0 - - 0 - -  - - 
FI LDLR 2 36 (6.2) 2 0.07 1.1  0 - - 0 - -  - - 
FI Linker 2 46 (7.9) 4 0.17 2.2  0 - - 1 0.02 0.2  0.12 1.7 
FI SP 244 (43) 28 1.09 2.5  0 - - 1 0.05 0.1  0.12 0.3 
DGKE Signal peptide 34 (6) 1 0.07 1.2  0 - - 0 - -  - - 
DGKE DAGKa 155 (27.3) 0 - -  1 - - 0 - -  - - 
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Appendix IV. (continued) The total missense rare variant allele frequency for each protein domain, normalised by the proportion of 
domain residues 
Protein Domain 
Residues 
(% of total in 
protein) 
aHUS only 
 
C3G only 
RVs common to both aHUS and C3G 
 
Missense 
RVs 
aHUS  C3G 
Missense 
RVs 
Sum AF b (%) 
Sum AF/ 
residue 
proportion c 
 
Missense 
RVs 
Sum AF 
b (%) 
Sum AF/ 
residue 
proportion c 
Sum AF 
(%) 
Sum AF/ residue 
proportion 
 
Sum AF 
(%) 
Sum AF/ residue 
proportion 
DGKE DAGKc 141 (24.9) 3 0.28 1.1  0 - - 0 - -  - - 
DGKE C1 51 (9) 2 0.14 1.6  1 0.39 4.4 0 - -  - - 
DGKE C2 53 (9.3) 0 - -  0 - - 0 - -  - - 
DGKE Linker 43 (7.6) 1 0.07 0.9  0 - - 0 - -  - - 
PLG Signal peptide 19 (2.3) 0 - -  0 - - 0 - -  - - 
PLG PAN 79 (9.8) 0 - -  0 - - 0 - -  - - 
PLG Kringle 1 79 (9.8) 1 0.18 1.8  2 0.96 9.9 0 - -  - - 
PLG Kringle 2 79 (9.8) 1 0.18 1.8  0 - - 0 - -  - - 
PLG Kringle 3 78 (9.6) 0 - -  0 - - 0 - -  - - 
PLG Kringle 4 78 (9.6) 0 - -  0 - - 0 - -  - - 
PLG Kringle 5 80 (9.9) 1 0.18 1.8  0 - - 0 - -  - - 
PLG Peptidase S1 228 (28.1) 0 - -  0 - - 0 - -  - - 
PLG Linker 25 (3.1) 1 0.18 5.7  0 - - 0 - -  - - 
THBD C-type lectin 139 (24.2) 7 0.57 2.3  0 - - 0 - -  - - 
THBD EGF-like 6 41 (7.1) 1 0.04 0.5  0 - - 2 0.34 4.8  0.57 8.0 
THBD EGF-like 1 41 (7.1) 0 - -  0 - - 0 - -  - - 
THBD EGF-like 3 39 (6.8) 0 - -  0 - - 0 - -  - - 
THBD EGF-like 2 41 (7.1) 0 - -  1 0.19 2.7 0 - -  - - 
THBD EGF-like 5 37 (6.4) 0 - -  0 - - 0 - -  - - 
THBD EGF-like 4 41 (7.1) 0 - -  0 - - 0 - -  - - 
THBD 
Integrin 
binding 
33 (5.7) 0 - -  1 0.38 6.6 1 0.15 2.6  0.19 3.3 
 
a Number of missense RVs classified as ‘pathogenic’, likely pathogenic’, or ‘uncertain significance’ 
b The sum of missense RV allele frequencies for each protein domain 
c The sum of missense RV allele frequencies divided by the proportion of protein residues attributed to the protein domain 
